Ticker,Price,Drug,Indication,Stage,Date,Catalyst,Shares_Millions,Market_Cap,Volatility,Share_Price_D-1,Share_Price_D1,Share_Price_D5,Perc_Return_D1,Perc_Return_D5,XBI_Return_D1,XBI_Return_D5,Short_Interest_Pct,Year_Beta,Daily_Volum_Traded
SNDX,21.86,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD)Â ,BLA Filing,1/2/2024,"BLA submitteed to the FDA, noted January 2, 2024.",86,1853.94083,47.8089,21.61,21.86,22.64,0.011502312,0.046562083,0.012282537,-0.047140884,12.18667,0.3223,27.4223
INCY,65.45,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD)Â ,BLA Filing,1/2/2024,"BLA submitteed to the FDA, noted January 2, 2024.",195,14667.94963,26.2121,62.79,65.45,64.38,0.041490667,0.025007201,0.012282537,-0.047140884,3.11092,0.29539,95.47892
LBPH,25.1,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs)Â ,Phase 1/2,1/2/2024,"Phase 1b/2a top-line data reported a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population, noted January 2, 2024.",39,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.012282537,-0.047140884,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
ATAI,1.69,EMP-01,Post-Traumatic Stress Disorder (PTSD)Â ,Phase 1,1/2/2024,"Phase 1 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose-dependent, noted on January 2, 2024.",214,280.5577,76.7738,1.41,1.69,2.19,0.181138825,0.440311839,0.012282537,-0.047140884,2.72094,0.19038,5.22094
AVXL,6.05,ANAVEX 2-73-RS-003 - (EXCELLENCE),Pediatric Rett SyndromeÂ ,Phase 2/3,1/2/2024,"Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.",85,496.21296,88.6481,9.31,6.045,6.41,-0.431857607,-0.37322982,0.012282537,-0.047140884,22.07637,0.2929,56.00573
ATXI,12,AJ201,Spinal and bulbar muscular atrophy (SBMA)Â ,Phase 1/2,1/2/2024,"Phase 1b/2 enrollment completed, noted January 2, 2024.",3,2.11961,106.4138,12.07503,12.00003,14.13754,-0.006230534,0.157693987,0.012282537,-0.047140884,1.7293,0,0.16552
SPRO,1.52,Tebipenem HBr (SPR994) - (PIVOT-PO),"Complicated urinary tract infection (cUTI), including acute pyelonephritis (AP)Â ",Phase 3,1/2/2024,"Phase 3 dosing initiated, noted January 2, 2024.",56,80.55896,48.2975,1.47,1.52,1.46,0.033447934,-0.006825965,0.012282537,-0.047140884,1.84249,0.13337,0.65182
CTXR,0.81,Mino-Lok,Catheter related blood stream infection (CRBSI)Â ,Phase 3,1/2/2024,"Phase 3 enrollment was completed, noted January 2, 2024.",17,128.55627,58.412,18.9125,20.2175,18.6625,0.066725487,-0.013306916,0.012282537,-0.047140884,8.46801,0.03937,0.5833
NVS,â€”,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD)Â ,Phase 1b,1/2/2024,"Phase 1b third cohort completed, noted January 2, 2024.",,1411.16675,47.7725,4.52,4.4,4.45,-0.026907453,-0.015607898,0.012282537,-0.047140884,0,0.01319,0.03078
AGIO,24.02,PYRUKYND (Mitapivat) - (ENERGIZE),ThalassemiaÂ ,Phase 3,1/3/2024,"Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.",58,1342.50864,35.5535,22.83,24.02,23.4,0.050811356,0.024660562,0.008682156,-0.02517095,12.29495,0.42335,64.6156
TEVA,10.95,AVT06 - (EYLEA biosimilar),Eye disordersÂ ,Phase 3,1/3/2024,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",,12274.63466,37.7228,10.67,10.95,11.49,0.025903391,0.074041027,0.008682156,-0.02517095,1.25926,0.10705,159.06765
ALVO,11.68,AVT06 - (EYLEA biosimilar),Eye disordersÂ ,Phase 3,1/3/2024,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",301,3101.38715,40.855,11.36,11.68,12.21,0.027779564,0.072156875,0.008682156,-0.02517095,0.02756,0.03281,0.63091
DYN,14.77,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1)Â ,Phase 1/2,1/3/2024,"Phase 1/2 MAD data reported a dose-dependent splicing correction and increase in muscle delivery and DMPK knockdown while also showing functional improvement in myotonia, noted January 3, 2024.",142,906.63648,83.4003,13.06,14.77,17.34,0.123043973,0.283461848,0.008682156,-0.02517095,15.85134,0.17516,309.23751
DYN,14.77,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,1/3/2024,"Phase 1/2 initial data reported a mean absolute dystrophin level of 0.88% of normal and a 0.28% change from baseline at 6 months, noted January 3, 2024.",142,906.63648,83.4003,13.06,14.77,17.34,0.123043973,0.283461848,0.008682156,-0.02517095,15.85134,0.17516,309.23751
ATHA,3.03,Fosgonimeton (ATH-1017) - (LIFT-AD),Alzheimerâ€™s diseaseÂ ,Phase 2/3,1/3/2024,"Phase 2/3 trial enrollment completed, noted January 3, 2024.",3,115.30538,69.7535,28.9,30.3,28.8,0.047306117,-0.003466208,0.008682156,-0.02517095,1.29185,0.13226,2.42009
APLM,0.96,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Â ,Phase 3,1/3/2024,"Phase 3 enrollment completed, noted January 3, 2024.",1,85.50182,138.9394,91.93,95.5,94.7399,0.03809883,0.030107824,0.008682156,-0.02517095,0.08805,0.08805,0.65609
GLYC,3.03,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Â ,Phase 3,1/3/2024,"Phase 3 enrollment completed, noted January 3, 2024.",13,195.1114,0,0,0,0,#DIV/0!,#DIV/0!,0.008682156,-0.02517095,0,0,0
CMMB,0.53,nebokitug (CM-101) - (SPRING),Primary Sclerosing CholangitisÂ ,Phase 2,1/3/2024,"Phase 2 early enrollment completed, noted January 3, 2023.",5,6.32064,82.6604,2.1512,2.1388,2.18,-0.005780902,0.013299051,0.008682156,-0.02517095,0.1516,0.11831,0.08527
SLRX,0.64,Seclidemstat,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)Â ,Phase 1/2,1/3/2024,"Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a",,2.51585,77.5817,76.81196,76.65596,79.07996,-0.002032999,0.029099135,0.008682156,-0.02517095,0.17692,0.00028,0.01679
INTS,7.99,INT230-6,Advanced Soft Tissue SarcomaÂ ,Phase 3,1/3/2024,"FDA provided ""Study May Proceed"" letter, noted January 3, 2024.",47,109.53792,139.0833,8.67,7.99,6,-0.081678031,-0.368109322,0.008682156,-0.02517095,0.6222,0.00328,0.44293
ENVB,1.32,EB-003 (EVM301 series),Mental health disordersÂ ,Preclinical,1/3/2024,"Preclinical development to commence in early 2024, with IND submission planned in 2024, noted January 3, 2024.",3,3.06413,88.0568,18.89999,19.79999,19.34999,0.04652004,0.02353051,0.008682156,-0.02517095,0.51747,0.0259,0.07766
IFRX,1.83,INF904,Chronic Autoimmune and Inflammatory DiseasesÂ ,Phase 1,1/4/2024,Phase 1 MAD results from 24 healthy volunteers showed that study was well tolerated in participants over the entire dose range and resulted in no safety signals of concern. The overall percentage of A,59,107.75639,81.2025,1.6,1.83,1.75,0.134312338,0.089612159,-0.012394525,-0.025411341,1.07199,0.00094,1.89428
GLYC,3,GMI-1687,Healthy volunteersÂ ,Phase 1a,1/4/2024,"Phase 1a Initial results demonstrated that subcutaneous dosing achieved target therapeutic plasma concentration and linear pharmacokinetics with rapid renal clearance across all dosing levels, noted",13,193.1796,0,0,0,0,#DIV/0!,#DIV/0!,-0.012394525,-0.025411341,0,0,0
ADCT,1.88,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC)Â ",Phase 1b,1/4/2024,"Preliminary Phase 1 data shows the maximum-tolerated dose has been reached, and the study is currently in dose optimization, noted Janaury 4, 2024.",112,151.86847,138.0034,1.66,1.88,2.07,0.124454174,0.220731005,-0.012394525,-0.025411341,5.01402,0.04643,2.46834
ADCT,1.88,ADCT-901,Solid tumorsÂ ,Phase 1,1/4/2024,"Program discontinued due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs, noted January 4, 2024.",112,151.86847,138.0034,1.66,1.88,2.07,0.124454174,0.220731005,-0.012394525,-0.025411341,5.01402,0.04643,2.46834
ALDX,3.34,ADX-629,SjÃ¶gren-Larsson Syndrome (SLS)Â ,Phase 1/2,1/4/2024,Phase 2 biomarker results observed in adult cohort proposed expansion to include pediatric patients expected to be submitted to the FDA in the 1H 2024.,59,196.46576,180.3384,3.35,3.34,3.2,-0.002989539,-0.045809536,-0.012394525,-0.025411341,6.04079,0.25004,1.83975
ALDX,3.34,ADX-246,Systemic Immune-Mediated Diseases and atopic dermatitisÂ ,Phase 1,1/4/2024,"Phase 1 expanded to include patients with atopic dermatitis, noted Janaury 4, 2024.",59,196.46576,180.3384,3.35,3.34,3.2,-0.002989539,-0.045809536,-0.012394525,-0.025411341,6.04079,0.25004,1.83975
KNSA,19.13,Abiprubart (KPL-404),Rheumatoid arthritisÂ ,Phase 2,1/4/2024,"Phase 2 trial met its primary endpoint, noted January 4, 2024.",74,1345.22102,58.665,19.98,19.125,19.28,-0.043735394,-0.035663484,-0.012394525,-0.025411341,4.65689,0.02271,26.4366
RYTM,43.31,Bivamelagon (LB54640),Healthy overweight adultsÂ ,Phase 1,1/4/2024,"Phase 1 has shown targeted effect on MC4 receptor without hyperpigmentation, noted January 4, 2024.",66,2559.46742,63.5507,43.88,43.31,41.51,-0.01307508,-0.055524273,-0.012394525,-0.025411341,14.61566,0.13496,58.38885
SNGX,0.91,SGX302/hypericin sodium,PsoriasisÂ ,Phase 2a,1/4/2024,"Phase 2a data reported that two patients reached a disease status of ""Almost Clear"" represented by an Investigator Global Assessment (IGA) score of 1, noted January 4, 2024.",4,9.41616,145.0268,14.68,14.5168,13.8608,-0.011179424,-0.057421311,-0.012394525,-0.025411341,0.38244,0.0002,2.15457
PRTG,1.35,IMM60 - (PORT-2),Refractory NSCLC & MelanomaÂ ,Phase 1,1/4/2024,"Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.",2,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.012394525,-0.025411341,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
MRK,116.27,IMM60 - (PORT-2),Refractory NSCLC & MelanomaÂ ,Phase 1,1/4/2024,"Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.",,296506.0411,18.1863,114.77,117.01,118.43,0.019329276,0.031391943,-0.012394525,-0.025411341,0.53146,0.00786,1344.70361
IMMP,2.41,Eftilagimod alpha - INSIGHT-004,Solid tumorsÂ ,Phase 1,1/4/2024,"Phase 1 dosing initiated, noted January 4, 2024.",145,398.25958,47.012,2.31,2.41,2.56,0.042379223,0.102759734,-0.012394525,-0.025411341,0,0,0.38981
APLT,3.79,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM)Â ,Phase 3,1/4/2024,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",144,292.6987,115.7805,3.59,3.79,2.44,0.054213817,-0.386154163,-0.012394525,-0.025411341,2.77586,0.02185,15.36482
APLT,3.79,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM)Â ,Phase 3,1/4/2024,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",144,292.6987,115.7805,3.59,3.79,2.44,0.054213817,-0.386154163,-0.012394525,-0.025411341,2.77586,0.02185,15.36482
TBPH,10.37,YUPELRI (revefenacin) - (PIFR-2),Chronic obstructive pulmonary disease (COPD)Â ,Phase 3,1/5/2024,"Phase 4 data reported that the trial did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, noted January 5, 2024.",50,516.40387,33.7589,11.52,10.37,9.83,-0.105167633,-0.158645721,-0.043425645,-0.010785672,18.72446,0.07479,14.80076
CVAC,4.34,CV0601,COVID-19 vaccineÂ ,Phase 2,1/5/2024,"Phase 2 data reported a meaningful immune responses and favorable reactogenicity profiles across all tested doses, including the lowest tested dose, noted January 5, 2024.",224,971.82889,66.8964,4.22,4.34,3.88,0.02803922,-0.083999974,-0.043425645,-0.010785672,1.6726,0.08841,8.8193
GSK,38.51,XMT-2056,HER2-Expressing TumorsÂ ,Phase 1,1/5/2024,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",,62822.05247,17.5791,15.398,15.412,15.73,0.000908796,0.021332086,-0.043425645,-0.010785672,0,0.00274,97.31924
MRSN,2.27,XMT-2056,HER2-Expressing TumorsÂ ,Phase 1,1/5/2024,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",4,273.72137,200.1738,57.75,56.75,75.5,-0.017467693,0.268009307,-0.043425645,-0.010785672,7.01236,0.01324,2.06218
FBIO,2.42,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,NDA Filing,1/5/2024,"NDA submitted to the FDA, noted January 5, 2024.",29,44.47174,153.9349,2.5,2.42,1.92,-0.032523192,-0.263965546,-0.043425645,-0.010785672,4.93768,0.11582,1.86287
DERM,5.05,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular RosaceaÂ ,NDA Filing,1/5/2024,"NDA submitted to the FDA, noted January 5, 2024.",24,93.46767,107.6582,4.97,5.05,4.82,0.015968403,-0.030645912,-0.043425645,-0.010785672,0.94107,0.0194,1.55421
NOVN,0,ZELSUVMI (berdazimer topical gel),Molluscum ContagiosumÂ ,Approved,1/5/2024,"FDA Approved on January 5, 2023.",28,185834.1823,17.9254,89.84,90.41,91.43,0.00632457,0.017543342,-0.043425645,-0.010785672,0,0.03559,239.20642
LGND,70.83,ZELSUVMI (berdazimer topical gel),Molluscum ContagiosumÂ ,Approved,1/5/2024,"FDA Approved on January 5, 2023.",19,1234.98891,29.5135,70.36,70.83,72.6,0.00665772,0.031340002,-0.043425645,-0.010785672,5.12487,0.4139,9.88709
PTHS,â€”,ZELSUVMI (berdazimer topical gel),Molluscum ContagiosumÂ ,Approved,1/5/2024,"FDA Approved on January 5, 2023.",3,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.043425645,-0.010785672,0,0,0
VINC,1.36,VIP236,Solid tumorsÂ ,Phase 1,1/8/2024,"Phase 1 update observed that 15 patients have been treated, showing a promising safety profile and preliminary evidence of clinical activity with once every 3-week dosing, noted January 8, 2024.",5,29.07756,95.4296,23.6,27.2,27.4,0.141970261,0.149296301,-0.047028896,-0.012463994,0.57629,0.02201,31.69311
VINC,1.36,VIP943 (anti-CD123),Hematologic malignanciesÂ ,Phase 1,1/8/2024,"Phase 1 enrollment in the second cohort of the VIP943 trial is nearly complete. Preliminary pharmacokinetic results from the first cohort trial showed very little free payload in circulation, consiste",5,29.07756,95.4296,23.6,27.2,27.4,0.141970261,0.149296301,-0.047028896,-0.012463994,0.57629,0.02201,31.69311
VINC,1.36,Enitociclib (VIP152) in combination with venetoclax and prednisone - (NIH trial),Peripheral T-cell lymphoma (PTCL) and 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL)Â ,Phase 1,1/8/2024,"Phase 1 preliminary data from investigators from the National Institutes of Health (NIH) reported 2 partial responses (PR) in 3 PTCL patients and 1 PR in DH-DLBCL in ongoing dose-escalation trial, not",5,29.07756,95.4296,23.6,27.2,27.4,0.141970261,0.149296301,-0.047028896,-0.012463994,0.57629,0.02201,31.69311
ARGX,413.29,Empasiprubart (ARGX-117) - (ARDA),Multifocal motor neuropathy (MMN)Â ,Phase 2,1/8/2024,"Phase 2 topline data reported that treatment demonstrated a 91% reduction in the need for IVIg rescue compared to placebo, noted January 8, 2024.",60,21610.92518,66.0046,353,365.8,348,0.035618679,-0.014265577,-0.047028896,-0.012463994,0,0.00064,21.21896
ABSI,4.18,ABS-101,Inflammatory bowel disease (IBD)Â ,Preclinical,1/8/2024,"Preclinical data support profile for development of a potential best-in-class drug. IND submission expected in 1Q 2025; Phase 1 trials anticipated to initiate shortly after, noted January 8, 2024.",149,388.48283,99.6955,3.62,4.18,3.99,0.143837221,0.097317205,-0.047028896,-0.012463994,2.20066,0.22448,6.27638
VERU,0.56,Enobosarm with semaglutide (Wegovy) - (PLATEAU),ObesityÂ ,IND-Enabling,1/8/2024,"IND submitted to the FDA, noted January 8, 2024.",14,77.84445,90.1866,5.86,5.58,4.592,-0.048960827,-0.243833945,-0.047028896,-0.012463994,9.00548,0.00894,1.07315
BIOR,1.28,BT-600 + NaviCap Platform,Ulcerative Colitis (UC)Â ,Phase 1,1/8/2024,"Phase 1 dosing initiated, noted January 8, 2024.",4,13.205,0,0,0,0,#DIV/0!,#DIV/0!,-0.047028896,-0.012463994,0,0,0
ALT,11.39,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,1/8/2024,"Phase 2 results presented at NASH-TAG Conference reported that treatment resulted in reductions of up to 76.4% in relative LFC, 15.2 IU/L in serum ALT, and 149.7ms in cT1 at 24 weeks January 6, 2024.",88,611.97184,100.7755,11.19,11.39,12,0.017715255,0.069886127,-0.047028896,-0.012463994,20.64737,0.03152,93.50513
CLRB,3.2,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstromâ€™s macroglobulinemiaÂ ,Phase 2b,1/8/2024,"Phase 2b trial met its primary endpoint, noted January 8, 2024.",3,39.3226,83.7134,81.30008,96.0001,105.30011,0.166202233,0.258667463,-0.047028896,-0.012463994,4.88196,0.06612,99.21629
ITOS,11.14,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM)Â ,Phase 1/2,1/8/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",44,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.047028896,-0.012463994,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
BMY,51.19,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM)Â ,Phase 1/2,1/8/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",,105380.1035,21.5968,52.23,51.79,50.31,-0.008459962,-0.037453178,-0.047028896,-0.012463994,1.18445,0.11643,970.84887
GSK,38.94,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM)Â ,Phase 1/2,1/8/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",,63139.99434,17.1917,15.412,15.49,15.8,0.005048228,0.024863513,-0.047028896,-0.012463994,0,0.00274,120.40073
CLNN,0.35,CNM-Au8 - (VISIONARY-MS),Multiple SclerosisÂ ,Phase 2,1/8/2024,"Phase 2 long term data demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), noted Janaury 8, 2024.",9,45.45912,105.0572,5.8,7.08,9.596,0.19941599,0.503488427,-0.047028896,-0.012463994,0.34407,0.07394,1.23283
ABBV,158.39,lutikizumab (ABT-981),Hidradenitis suppurativa (HS)Â ,Phase 2,1/8/2024,"Phase 2 300 mg weekly or 300 mg dose every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo, noted January 8, 2024.",,285010.7059,17.7657,162.14,161.43,162.4,-0.004388547,0.001602268,-0.047028896,-0.012463994,0.77534,0.01816,968.84345
OKYO,1.89,urcosimod (OK-101),Dry Eye Disease (DED)Â ,Phase 2,1/8/2024,Phase 2 data presented at the Biotech Showcase showed that dose was statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after d,33,62.81614,116.6185,1.864,1.89,1.73,0.013852113,-0.074603308,-0.047028896,-0.012463994,0.14343,0.00061,2.14728
NVO,105.64,Icosema - (COMBINE 3),Type 2 diabetesÂ ,Phase 3,1/8/2024,"Phase 3a trial completed, noted January 8, 2024",,3209643.321,35.0538,105.98,106.4,107.16,0.00395518,0.011072648,-0.047028896,-0.012463994,0,0,306.50116
MNMD,4.39,MM-120 (LSD),Attention Deficit Hyperactivity Disorder (ADHD)Â ,Phase 2a,1/8/2024,"Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.",75,176.01577,75.8599,4.09,4.39,3.96,0.070784257,-0.032300945,-0.047028896,-0.012463994,7.00672,0.24783,5.82284
NRIX,9.96,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL)Â ",Phase 1b,1/8/2024,"The company expects to resolve partial hold to enable the introduction of newly manufactured drug product into the ongoing Phase 1 clinical trial., noted January 8, 2024.",76,483.09753,77.1659,9.87,9.96,9.37,0.009077218,-0.051986757,-0.047028896,-0.012463994,18.20078,0.22696,7.33795
INCY,65.82,INCB123667,"Late-stage cancers, ovarian cancerÂ ",Phase 1,1/8/2024,"Phase 1 early clinical activity was observed with several patients with amplified/overexpression of CCNE1, a cell cycle regulator and potential predictive biomarker, achieving partial response (PR), n",195,14750.87005,26.2469,65.26,65.82,62.74,0.008544452,-0.039380088,-0.047028896,-0.012463994,3.11092,0.25653,138.35943
INCY,65.82,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS)Â ,Phase 2,1/8/2024,"Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.",195,14750.87005,26.2469,65.26,65.82,62.74,0.008544452,-0.039380088,-0.047028896,-0.012463994,3.11092,0.25653,138.35943
NVS,103.22,Scemblix - (ASC4FIRST),1L Chronic myeloid leukemia (CML)Â ,Phase 3,1/8/2024,"Phase 3 trial met its primary endpoint, noted January 8, 2024.",,1411.16675,48.0192,4.44,4.4,4.54,-0.009049836,0.022272636,-0.047028896,-0.012463994,0,0.02267,0.52289
CYBN,0.39,CYB004 (IV) and SPL028 (IM),Generalized anxiety disorder (GAD)Â ,Phase 1,1/8/2024,"Intravenous (IV) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment. Intramuscular (IM) do",23,161.0576,99.6434,15.38999,14.88079,15.38999,-0.033646179,0,-0.047028896,-0.012463994,2.46092,0.0154,1.83134
FATE,4.12,FT825/ONO-8250,Solid TumorsÂ ,Phase 1,1/8/2024,"Phase 1 trial initiated, noted January 8, 2024.",115,406.2401,85.4495,3.77,4.12,4.55,0.088778162,0.188052232,-0.047028896,-0.012463994,10.93577,0.39694,14.51773
BPMC,85.31,BLU-945 with osimertinib - (SYMPHONY),Treatment-resistant EGFR-driven NSCLCÂ ,Phase 1/2,1/8/2024,"Phase 1/2 discontinued investment based on the evolving external landscape, emerging clinical data and partnering considerations, noted January 8, 2024.",64,5185.97033,0,0,0,0,#DIV/0!,#DIV/0!,-0.047028896,-0.012463994,0,0,0
BPMC,85.31,BLU-451 - (CONCERTO),EGFR exon 20 insertion-positive NSCLCÂ ,Phase 1/2,1/8/2024,"Phase 1/2 discontinued investment based on the evolving external landscape, emerging clinical data and partnering considerations, noted January 8, 2024.",64,5185.97033,0,0,0,0,#DIV/0!,#DIV/0!,-0.047028896,-0.012463994,0,0,0
SMMT,2.97,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/8/2024,"Phase 2 data reported that the 1-year overall survival rate was 85.6%, and the 2-year overall survival rate was 64.8% for patients in Cohort 1 with squamous histology NSCLC, noted January 8, 2024.",744,2081.50341,81.4745,2.55,2.97,3.1,0.152468594,0.195308752,-0.047028896,-0.012463994,1.34685,0.00269,6.82331
ORIC,8.24,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC)Â ,Phase 1b,1/8/2024,"Phase 1b data demonstrated potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination developmen",97,449.5074,65.973,8.42,8.24,8.6,-0.021609484,0.021152375,-0.047028896,-0.012463994,15.89094,0.13745,3.16223
BMEA,15.94,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,1/8/2024,"Phase 2 was initiated, noted January 8, 2024.",59,569.15023,104.567,14.71,15.94,15.21,0.080304139,0.033425572,-0.047028896,-0.012463994,30.63348,0.02657,16.21399
NUVB,1.55,NUV-1511,Advanced solid tumorsÂ ,IND-Enabling,1/8/2024,"IND cleared by FDA, noted January 8, 2024.",342,339.36328,63.5128,1.49,1.55,1.58,0.039478811,0.058648727,-0.047028896,-0.012463994,1.00643,0.28384,0.87455
AFMD,6.61,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancerÂ ",Phase 1/2,1/8/2024,"Phase 1/2a follow-up showed that three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scan, noted January 8, 2024.",15,98.74317,0,0,0,0,#DIV/0!,#DIV/0!,-0.047028896,-0.012463994,0,0,0
AVIR,3.1,Bemnifosbuvir (AT-527) - (SUNRISE-3),COVID-19Â ,Phase 3,1/8/2024,"Phase 3 8-week study showed a 98% SVR4, which exceeds our efficacy criterion of >90% for continuing the study, noted January 8, 2024",79,258.65009,38.8628,3.09,3.1,3.56,0.003231021,0.141589454,-0.047028896,-0.012463994,4.21518,0.03812,2.29262
ELTX,5.45,ELI-002 (AMPLIFY-201),Solid TumorsÂ ,Phase 1/2,1/9/2024,"Phase 1/2 data presented in a paper on Nature Medicine showed that ELI-002 administered as a monotherapy induced robust, polyfunctional, and durable KRAS specific CD4+ and CD8+ T cell responses. Tumor",16,52.3508,115.2223,7.82,5.45,5.28,-0.361068946,-0.392758457,0.009572539,0.047795155,0.07055,0.02185,16.85986
ALPMY,12.04,Zolbetuximab,HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positiveÂ ,CRL,1/9/2024,"CRL issued by the FDA on January 9, 2024.",,3116898.468,0,0,0,0,#DIV/0!,#DIV/0!,0.009572539,0.047795155,0,0,0
VCEL,37.31,NexoBrid (CIDS),Severe burns - pediatricÂ ,BLA Filing,1/9/2024,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",50,1780.6027,48.4414,34.79,37.31,39.2,0.069931398,0.119346758,0.009572539,0.047795155,12.32144,0.16761,41.97603
MDWD,12.49,NexoBrid (CIDS),Severe burns - pediatricÂ ,BLA Filing,1/9/2024,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",11,115.14857,54.0844,11.82,12.49,12.87,0.055135312,0.08510601,0.009572539,0.047795155,0.36552,0.09114,1.29993
CRBP,7.22,CRB-601,Solid tumorsÂ ,IND-Enabling,1/9/2024,"IND cleared by the FDA, noted January 9, 2024",12,31.93899,98.165,7.16,7.22,6.09,0.008344972,-0.161861899,0.009572539,0.047795155,1.07707,0.0247,0.24508
ALC,76.44,TRYPTYR (acoltremon ophthalmic solution) 0.003%,Dry eye disease (DED)Â ,Phase 3,1/9/2024,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494,93.97313,75.3808,0.0685,0.07,0.065,0.021661497,-0.052446475,0.009572539,0.047795155,0,0.00094,0.15775
ALC,76.44,AR-15512 (AVX-012) - (COMET-2),Dry eye diseaseÂ ,Phase 3,1/9/2024,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494,93.97313,75.3808,0.0685,0.07,0.065,0.021661497,-0.052446475,0.009572539,0.047795155,0,0.00094,0.15775
MRSN,3.25,Emiltatug Ledadotin (XMT-1660) - (Emi-Le),Metastatic triple-negative breast cancer (TNBC)Â ,Phase 1,1/10/2024,"Phase 1 data reported that treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported, noted January 10, 2025.",4,391.89183,203.0704,80.75,81.25,72.25,0.006172859,-0.111225635,0.034012079,0.057837377,6.9619,0.01324,22.86529
FDMT,19.14,4D-150 - (SPECTRA),Wet Age-Related Macular Degeneration (wet AMD)Â ,Phase 2,1/10/2024,"Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi",46,818.30404,55.3857,19.49,19.14,17.75,-0.018121127,-0.093515998,0.034012079,0.057837377,7.53187,0.1473,4.44385
CMND,2.93,CMND-100,Alcohol use disorder (AUD)Â ,IND-Enabling,1/10/2024,"IND submitted March 16, 2023. Phase 1/2a trial sites selected noted May 22, 2023. Type A meeting completed, noted January 10, 2024.",5,4.96092,168.1399,2.07,2.93,1.12,0.347453816,-0.614219922,0.034012079,0.057837377,0.85309,0.00013,140.14555
ACRS,1.01,ATI-1777-AD-202,Atopic dermatitisÂ ,Phase 2b,1/10/2024,"Phase 2b topline data on ATI-1777 2% QD showed a trend toward significance, ATI-1777 2% BID achieved a statistically significant result in the primary efficacy endpoint at week 4, noted January 10, 2",108,71.19038,289.9477,1.28,1.005,1.18,-0.241872536,-0.081345639,0.034012079,0.057837377,8.16841,0.07865,8.51035
VYNE,2.24,Repibresib Gel (VYN201),VitiligoÂ ,Phase 1b,1/10/2024,"Phase 1b biomarker data reported a median reduction in MMP-9 of 40.8% in lesional skin compared to baseline for subjects in the 2.0% cohort, noted January 10, 2024.",25,31.26441,98.3706,2.27,2.24,1.99,-0.013303966,-0.131645193,0.034012079,0.057837377,0.63039,0.06882,0.63224
EYPT,20.23,EYP-1901 - (VERONA),Diabetic macular edema (DME)Â ,Phase 2,1/10/2024,"Phase 2 dosing initiated, noted January 10, 2024.",68,952.30981,171.9504,21.47,20.23,21.87,-0.059489961,0.018459223,0.034012079,0.057837377,11.32262,0.0603,12.44754
BPTH,11.2,BP1002,Refractory/relapsed lymphoma and chronic lymphocytic leukemiaÂ ,Phase 1,1/10/2024,"Phase 1 first cohort completed, noted January 10, 2024.",8,6.91749,167.7256,10.602,11.2,8.694,0.054871116,-0.19840953,0.034012079,0.057837377,3.03726,0.01488,0.1395
SANA,7.18,SC291 - (ARDENT),"Solid tumors, B-cell lymphomas and leukemiasÂ ",Phase 1,1/10/2024,Phase 1 early data discussed at the JPMorgan Healthcare Conference showed in a presentation that three patients saw at least a reduction in their disease while two patients had no detectable disease a,237,1415.40439,91.0515,5.155,7.18,6.12,0.331332266,0.171594979,0.034012079,0.057837377,11.18588,0.19181,454.9816
MRK,117.88,KEYTRUDA with external beam radiotherapy (EBRT) plus concurrent chemotherapy - (KEYNOTE-A18),Cervical cancerÂ ,Approved,1/12/2024,"FDA Approved on January 12, 2024.",,300611.1585,17.4969,118.43,118.63,118.89,0.001687337,0.003876627,0.000552822,0.038535638,0.70507,0.01668,809.44808
ARQT,3.47,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitisÂ ,Phase 3,1/15/2024,"Additional Phase 3 data reported that at Week 4, a statistically significant greater percentage of patients achieved a 50% reduction in EASI scores (EASI-50), with 69.2% of patients treated with roflu",119,343.55075,95.5498,3.64,3.64,3.54,0,-0.027856955,0.015155182,0.015716759,21.3847,0.18356,0
ANIP,55.41,Indomethacin Oral Suspension - (Indocin generic),"Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute gouty arthritis, bursitis, and tendinitisÂ ",Approved,1/16/2024,"Approved January 16, 2024.",21,1057.37147,37.8793,56.74,55.41,56.62,-0.023719347,-0.00211715,0.023272476,0.013248176,1.3833,0.13493,4.76532
CLRB,3.7,CLR 121225 (225Ac-CLR 121225),PLE cancerÂ ,Preclinical,1/16/2024,"Preclinical data reported tumor volume reduction in a dose dependent manner with the highest dose providing near complete eradication of the tumor, noted January 16, 2024.",3,45.46676,85.3388,105.30011,111.00011,110.70011,0.052716729,0.05001037,0.023272476,0.013248176,4.40363,0.09403,9.54823
ALLK,1.19,Lirentelimab (AK002) - (MAVERICK),Chronic Spontaneous UrticariaÂ ,Phase 2b,1/16/2024,"Phase 2b trial did not meet its primary endpoint, noted January 16, 2024.",90,104.09684,0,0,0,0,#DIV/0!,#DIV/0!,0.023272476,0.013248176,0,0,0
ALLK,1.19,Lirentelimab (AK002) - (ATLAS),Atopic DermatitisÂ ,Phase 2,1/16/2024,"Phase 2 trial did not meet its primary endpoint, noted January 16, 2024.",90,104.09684,0,0,0,0,#DIV/0!,#DIV/0!,0.023272476,0.013248176,0,0,0
HALO,36.36,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Â ,Approved,1/16/2024,"Approved January 16, 2024.",116,4803.08728,39.0462,34.43,36.36,34.75,0.054540992,0.009251295,0.023272476,0.013248176,5.56369,0.1562,96.22947
TAK,15.01,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Â ,Approved,1/16/2024,"Approved January 16, 2024.",,6904763.012,18.8962,15.04,15.01,14.73,-0.001996673,-0.020827088,0.023272476,0.013248176,0,0,48.77124
CRSP,63.43,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemiaÂ ,Approved,1/16/2024,"FDA Approved on January 16, 2024.",90,5038.40005,63.7025,64.25,63.43,66.19,-0.012844788,0.02974767,0.023272476,0.013248176,20.4581,0.35855,111.08039
VRTX,437.49,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemiaÂ ,Approved,1/16/2024,"FDA Approved on January 16, 2024.",256,112733.8162,26.2754,433.4,437.49,439.7,0.009392759,0.014431587,0.023272476,0.013248176,1.26358,0.15752,781.85982
SRPT,115.39,SRP-9003-301 - (EMERGENE),Limb-girdle muscular dystrophy type 2E (LGMD2E)Â ,Phase 3,1/16/2024,"Phase 3 screening initiated, noted January 16, 2024.",97,10794.35152,79.6483,116.8,115.39,121.13,-0.012145375,0.036401279,0.023272476,0.013248176,5.01534,0.00434,111.95392
BGNE,173.25,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancerÂ ,Phase 2,1/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",106,18118.12811,0,0,0,0,#DIV/0!,#DIV/0!,0.023272476,0.013248176,0,0,0
ONC,â€”,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancerÂ ,Phase 2,1/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",110,18118.12811,50.2043,175.21,173.25,162.27,-0.011249616,-0.07672364,0.023272476,0.013248176,1.75222,0.2117,51.24319
LPTX,3.47,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancerÂ ,Phase 2,1/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",41,88.71199,109.0559,3.51,3.47,2.85,-0.011461444,-0.208297043,0.023272476,0.013248176,2.21894,0.13506,0.96607
RCUS,16.9,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic CancerÂ ,Phase 1b,1/16/2024,"Phase 1 data showed a median overall survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chem",106,1265.05905,62.104,17.51,16.9,15.44,-0.035458524,-0.125810602,0.023272476,0.013248176,9.70927,0.10653,9.51293
ADAG,3.78,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumorsÂ ,Phase 1/2,1/16/2024,"Phase 1/2 data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more freq",47,165.69506,98.6314,3.17,3.78,3.245,0.175992422,0.023383762,0.023272476,0.013248176,0.05744,0.0423,2.20217
ACXP,4.52,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,1/17/2024,"Phase 2b data showed that that ibezapolstat outperformed vancomycin, a standard of care to treat patients with CDI, with eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 patients (9",1,62.23118,132.0725,95,90.4,80.4,-0.049632624,-0.166862715,0.022712764,0.015160376,2.16989,0.00897,13.53894
EVGN,0.79,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,1/17/2024,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",6,32.51785,44.2229,2.35,2.34,2.3,-0.004264399,-0.021506205,0.022712764,0.015160376,0,0.0988,0.02129
BMY,49.4,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,1/17/2024,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",,101697.192,21.6711,50,49.98,50.24,-0.00040008,0.004788517,0.022712764,0.015160376,1.09669,0.10386,820.94294
KANT,â€”,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumorsÂ ,Phase 1/2,1/17/2024,"Phase 1/2 update reported that KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level, noted January 17, 2024.",13,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.022712764,0.015160376,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
REGN,929.13,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/17/2024,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme",105,98810.17324,18.8661,937.32,929.13,948.24,-0.008776075,0.011582895,0.022712764,0.015160376,0.99899,0.14736,489.40808
MAIA,1.48,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/17/2024,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme",32,25.07676,117.8391,1.23,1.48,1.41,0.185027918,0.136575535,0.022712764,0.015160376,0.55698,0.00002,5.5153
LSTA,2.94,LSTA1,Glioblastoma multiforme (GBM)Â ,Phase 2a,1/17/2024,"Phase 2a trial initiated, noted January 17, 2024.",8,23.92998,67.9985,3.02,2.94,2.75,-0.02684725,-0.09365592,0.022712764,0.015160376,0.73303,0.06336,0.04005
CATX,0.44,212Pb-VMT01,MC1R-positive metastatic melanomaÂ ,Phase 1/2,1/17/2024,"Phase 1/2 second dose escalation cohorts recruitment commenced, noted January 17, 2024.",74,122.35702,140.7214,4.521,4.361,4.886,-0.036031819,0.077640765,0.022712764,0.015160376,0.68891,0.00198,0.37533
CNSP,35.33,Berubicin,Glioblastoma (GBM) (adult)Â ,Phase 2,1/17/2024,"Enrollment completed, noted January 17, 2024.",,3.68793,142.0622,21612.02161,21195.0212,16869.01687,-0.019483411,-0.247771098,0.022712764,0.015160376,4.13206,0.01076,0.12717
PFE,27.32,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 1b,1/17/2024,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",,158946.5342,25.801,28.32,28.15,28.33,-0.006020914,0.000353045,0.022712764,0.015160376,1.01004,0.08557,937.74921
CRDF,1.47,CRDF-004,Metastatic colorectal cancer (mCRC)Â ,Phase 1b,1/17/2024,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",66,65.67544,91.7946,1.63,1.47,1.515,-0.103317614,-0.073164576,0.022712764,0.015160376,2.9479,0.07918,0.36656
IXHL,4.47,IHL-42X - (RePOSA),Obstructive sleep apnea (OSA)Â ,Phase 2/3,1/17/2024,"Phase 2/3 IRB approved protocol to asses drug in patients, noted January 17, 2024.",347,70.95282,157.8562,4.45,4.47,4.03,0.004484312,-0.09913772,0.022712764,0.015160376,0.58984,0.06711,0.09744
PBLA,6.65,CPP-1X (eflornithine),NeuroblastomaÂ ,Phase 1,1/18/2024,"Phase 1 data reported that 2 partial responses (PR), 4 minor responses (MR), 10 Stable disease (SD), 7 progressive disease (PD) and 1 unevaluable patient, noted January 18, 2024.",4,3.19469,186.1696,8.676,6.65,3.25,-0.265943738,-0.981905597,0.01471034,-0.001809546,14.07482,0.00251,0.89986
MTVA,â€”,DA-1241,Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Preclinical,1/18/2024,"Pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone (180 mg/kg/day), DA-1241 alone (100 mg/kg/day), or sitagliptin in combination with DA-1241 (up to 18",24,16.64087,82.9529,3.38,3.43,3.1199,0.014684552,-0.080074759,0.01471034,-0.001809546,0.14051,0.03597,0.30424
CLDX,39.66,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU)Â ",Phase 2,1/18/2024,"Phase 2 data reported that the trial met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups, noted January 18",66,2168.97355,49.6952,39.71,39.66,37.34,-0.001259922,-0.061537907,0.01471034,-0.001809546,12.04683,0.16446,16.69563
CHRS,2.4,Casdozokitug (casdozo),Non-small cell lung cancer (NSCLC)Â ,Phase 2,1/18/2024,"Phase 2 data presented at ASCO GI demonstrated early activity with 38% objective response rate including three complete responses, noted January 18, 2024.",116,267.27397,115.9607,2.46,2.4,2.37,-0.024692613,-0.037271395,0.01471034,-0.001809546,21.75374,0.08676,7.42351
DCPH,13.89,QINLOCK (ripretinib) - (INTRIGUE),Gastrointestinal Stromal Tumors (GIST) - second-lineÂ ,Phase 3,1/18/2024,"Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.",86,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.01471034,-0.001809546,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
ZLAB,23.56,QINLOCK (ripretinib) - (INTRIGUE),Gastrointestinal Stromal Tumors (GIST) - second-lineÂ ,Phase 3,1/18/2024,"Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.",109,2325.82977,58.0974,23.42,23.56,23.03,0.005960001,-0.016792644,0.01471034,-0.001809546,4.25406,0.24629,16.56475
NVS,104.33,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Â ,Phase 3,1/19/2024,Phase 3 data reported that treatment reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3,,1371.44091,47.2033,4.5,4.42,4.75,-0.017937701,0.054067221,-0.022151187,-0.013462839,0,0.00472,0.26782
AZN,65.53,IMFINZI (Durvalumab) + TACE - (EMERALD-1),Locoregional Hepatocellular carcinoma (HCC)Â ,Phase 3,1/19/2024,"Phase 3 data presented at ASCO GI reported that treatment reduced the risk of disease progression or death by 23% compared to TACE alone, noted January 19, 2024.",,162891.0887,21.9162,104.32,105.08,105.46,0.007258867,0.010868636,-0.022151187,-0.013462839,0,0.11419,269.92971
TEVA,11.18,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",,12532.45804,36.9243,10.99,11.18,11.91,0.017140699,0.080392615,-0.022151187,-0.013462839,1.45841,0.05885,112.00724
ALVO,14.14,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",301,3754.59027,41.0179,12.265,14.14,14.65,0.142257983,0.177690658,-0.022151187,-0.013462839,0.0371,0.00996,33.93642
TEVA,11.18,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",,12532.45804,36.9243,10.99,11.18,11.91,0.017140699,0.080392615,-0.022151187,-0.013462839,1.45841,0.05885,112.00724
ALVO,14.14,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,BsUFA,1/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",301,3754.59027,41.0179,12.265,14.14,14.65,0.142257983,0.177690658,-0.022151187,-0.013462839,0.0371,0.00996,33.93642
RCUS,15.34,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic CancerÂ ,Phase 1b,1/19/2024,"Phase 1b results presented at the ASCO Gastrointestinal Cancers Symposium reported that a 37% reduction in risk of death and a 5.9-month improvement in mOS, noted January 19, 2024.",106,1148.28437,61.9759,16.37,15.34,15.13,-0.064986595,-0.078770864,-0.022151187,-0.013462839,9.70927,0.0988,28.67026
BMY,49.53,Opdivo (nivolumab) plus Yervoy - (CheckMate -8HW),Microsatellite Instabilityâ€“High or Mismatch Repair Deficient Metastatic Colorectal CancerÂ ,Phase 3,1/20/2024,"Presentation of data reported that it demonstrated significant efficacy benefit compared to chemotherapy as first-line treatment in MSI-H/dMMR mCRC, noted January 20, 2023.",,101961.7105,21.6679,50.11,50.11,49.7,0,-0.008215656,-0.022266057,-0.013577709,1.09669,0.11558,0
AZN,66.12,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,1/22/2024,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",,164162.2221,21.8561,105.08,105.9,105.68,0.007773288,0.005693695,-0.02473464,-0.042176619,0,0.11419,479.68009
AIM,0.42,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,1/22/2024,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",2,62.64421,61.7909,0.3,0.3,0.28,0,-0.068992871,-0.02473464,-0.042176619,0,0.00817,0.01581
CLRB,3.64,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstromâ€™s macroglobulinemiaÂ ,Phase 2b,1/22/2024,"Phase 2b complete CNS clearance reported in one patient, noted January 22, 2024.",3,44.72946,85.2281,104.4001,109.20011,126.30013,0.044951437,0.190430425,-0.02473464,-0.042176619,4.40363,0.08706,11.26323
TVRD,â€”,KORSUVA (CR845/difelikefalin) oral - (KICK),Stage 3-4 Chronic Kidney Disease-Associated PruritusÂ ,Phase 3,1/22/2024,"Phase 3 trial was discontinued to focus resources on the notalgia paresthetica (NP) program, noted on January 22, 2024.",9,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.02473464,-0.042176619,0,0,0
SGMT,18.42,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 2b,1/22/2024,"Phase 2b topline data reported NASH resolution without worsening of fibrosis with â‰¥2-point reduction in NAS (NAFLD Activity Score) in 36% of denifanstat-treated patients vs 13% with placebo (p=0.002),",32,421.74233,190.8988,6.82,18.42,10.6,0.993577559,0.440994529,-0.02473464,-0.042176619,2.71571,0.19401,666.24046
AGEN,11.77,Neoadjuvant botensilimab plus balstilimab - (NEST-1),Colorectal cancerÂ ,Phase 2,1/22/2024,"Phase 2 trial data presented at ASCO-GI showed a major tumor regression in 67.5% of patients. The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d",31,224.51008,82.6161,11.56,11.77,13.89,0.018003058,0.183618294,-0.02473464,-0.042176619,10.39595,0.07856,8.68774
IONS,51.01,DAWNZERA (Donidalorsen),Hereditary Angioedema (HAE)Â ,Phase 3,1/22/2024,"Phase 3 topline data met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks, noted January 2",159,7318.51279,36.1749,50.98,51.01,52.01,0.000588293,0.020002609,-0.02473464,-0.042176619,5.74523,0.27791,73.53872
SEEL,10.24,SLS-002,Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder (ASIB in MDD)Â ,Phase 2,1/22/2024,"EoP2 minutes with FDA agreed that the primary endpoint in a Phase 3 trial could be the change from baseline in the Montgomery-Ã…sberg Depression Rating Scale (MADRS) total score at Day 16, rather than",,12.53704,0,0,0,0,#DIV/0!,#DIV/0!,-0.02473464,-0.042176619,0,0,0
SPRB,2.44,Tildacerfont - (CAHmelia-204),Congenital Adrenal Hyperplasia (good disease control)Â ,Phase 2b,1/22/2024,"Phase 2b enrollment completed exceeding target enrollment (100/90), noted January 22, 2024.",,99.3343,76.943,179.25045,183.00046,266.25067,0.020704677,0.395654244,-0.02473464,-0.042176619,0.18902,0.05994,0.43152
SXTP,0.75,ARAKODA (tafenoquine),BabesiosisÂ ,Phase 2,1/22/2024,"Type C meeting with FDA on January 17, 2024, concluded that the company now plans to conduct a pivotal clinical study in support of a future indication, noted January 22, 2024.",4,4.35541,129.6486,37.56002,45.06002,31.03201,0.182055192,-0.190920934,-0.02473464,-0.042176619,6.26427,0.0399,0.34512
GILD,77.62,Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel - (EVOKE-01),Non-small cell lung cancer (NSCLC)Â ,Phase 3,1/22/2024,"Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.",,97727.06583,25.6097,87.29,78.43,79.07,-0.107029402,-0.098902373,-0.02473464,-0.042176619,1.36744,0.14949,1598.28976
CRBP,7.3,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,1/23/2024,"Phase 1 dose escalation data from 2024 ASCO GU reported an anti tumor responses across multiple doses were observed, with the first confirmed stable disease at 0.6mg/kg and the first confirmed partial",12,32.29289,101.5123,7.6,7.3,25.16,-0.040273899,1.197107185,0.014598799,0.002699968,0.90025,0.02547,0.63361
ARTL,1.38,ART26.12,Chemotherapy-Induced PainÂ ,Preclinical,1/23/2024,"Preclinical data reported that ART26.12 (10 and 25 mg/kg BID for 15 days) with oxaliplatin prevented thermal hyperalgesia, mitigated mechanical allodynia, and attenuated OXA-induced weight loss, noted",1,4.40076,77.3003,8.34,8.28,8.28,-0.007220248,-0.007220248,0.014598799,0.002699968,0.45607,0.01361,0.01197
LLY,627.56,AK-OTOF,Hearing lossÂ ,Phase 1/2,1/23/2024,"Phase 1/2 clinical trial showed that hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, noted January 23, 2024.",946,566275.781,32.1303,630.88,629.68,644.98,-0.001903916,0.022103638,0.014598799,0.002699968,0.56637,0.0074,1589.9313
VNDA,3.71,VCA-894A,"Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2Â ",IND-Enabling,1/23/2024,"Orphan drug designation, noted June 2, 2023. IND clearance by the FDA on January 23, 2024.",59,213.44372,58.2792,3.79,3.71,3.65,-0.021334142,-0.037638851,0.014598799,0.002699968,3.01072,0.01812,4.21039
HRTX,2.2,ZYNRELEF (bupivacaine and meloxicam) extended-release,Soft tissue and orthopedic surgical proceduresÂ ,Approved,1/23/2024,"FDA Approved on January 23, 2024.",153,330.15981,117.6731,2.34,2.2,2.49,-0.061693569,0.062131781,0.014598799,0.002699968,13.46927,0.05273,8.9777
URGN,15.04,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC)Â ,NDA Filing,1/24/2024,"NDA was submitted to FDA on January 24, 2024",46,464.22945,115.3267,15.11,15.04,15.7,-0.004643458,0.038303936,0.008214754,0.020378833,10.98551,0.0257,3.1923
ANVS,9.09,Buntanetap,Parkinson's Disease (PD)Â ,Phase 3,1/24/2024,"Phase 3 data release postponed due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results, noted January 24, 2024.",19,93.28406,110.1817,11.64,9.09,11.05,-0.247272534,-0.052017014,0.008214754,0.020378833,9.55138,0.02488,11.25504
ENSC,1.5,PF614-MPAR-102 - (MPAR),Overdose ProtectionÂ ,Phase 1,1/25/2024,"Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.",2,4.7191,111.4355,19.94999,22.49999,22.19999,0.120286223,0.106863196,-0.005910451,-0.014149311,7.82831,0.0115,4.17841
PBLA,3.25,SBP-101 in combination with Gemcitabine and Nab-Paclitaxel - (ASPIRE),Pancreatic Ductal Adenocarcinoma (PDA)Â ,Phase 2/3,1/25/2024,"Phase 2/3 enrollment exceeded 50% moving faster than expected, full enrollment anticipated 1Q 2025, noted January 25, 2024.",4,1.56131,197.3261,3.65,3.25,1.26,-0.116072171,-1.063615447,-0.005910451,-0.014149311,9.6494,0.00104,1.08064
VERA,25.31,Atacicept - (ORIGIN 3),IgA NephropathyÂ ,Phase 2b,1/25/2024,"Phase 2b OLE data reported a 59% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 41%, and a 47% reduction in UPCR in the PP analysis, noted January 25, 2024.",63,1124.59784,88.7161,17.02,25.31,38,0.396810451,0.803197037,-0.005910451,-0.014149311,13.61666,0.06404,291.27745
CYTK,82.91,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM)Â ,Phase 2,1/25/2024,"Phase 2 sub-study data reported statistically significant improvements in measures of cardiac structure and function including left ventricular mass index (-11.4 g/m2 Â±19.4, p=0.03), maximum left vent",119,8129.62787,107.8795,81.77,82.91,81.25,0.013845254,-0.006379607,-0.005910451,-0.014149311,14.02121,0.02117,144.08456
EXEL,22.09,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate CancerÂ ,Phase 3,1/25/2024,"Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no",269,6869.41816,28.8653,22.11,22.09,21.75,-0.000904977,-0.016416237,-0.005910451,-0.014149311,2.75382,0.12204,66.65898
IPSEY,27.99,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate CancerÂ ,Phase 3,1/25/2024,"Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no",328,8848.70847,0,0,0,0,#DIV/0!,#DIV/0!,-0.005910451,-0.014149311,0,0,0
SRRK,14.91,SRK-439 with apitegromab - (EMBRAZE),ObesityÂ ,Preclinical,1/25/2024,"Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss, noted January 25, 2024.",96,1075.65598,83.5031,14.74,14.91,14.94,0.011467242,0.013477293,-0.005910451,-0.014149311,16.01552,0.01525,7.92558
PCSA,5.1,NGC-Capecitabine (PCS6422),Gastrointestinal CancerÂ ,Phase 1b,1/25/2024,"Phase 1b preliminary efficacy data reported that of the 11 cancer patients receiving one of the two highest doses of NGC-Cap, five have completed an efficacy evaluation at this time, and four of these",50,6.28155,232.81,2.05,5.1,2.34,0.911400747,0.132311136,-0.005910451,-0.014149311,0.72189,0.02387,377.50898
EPIX,6.8,EPI-7386 and XTANDI (enzalutamide),Castration-resistant prostate cancerÂ ,Phase 1/2,1/25/2024,"Phase 1/2 data due presented at ASCO GU reported that 88% of patients (14 of 16) achieved PSA50, 81% of patients (13 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 da",47,300.1662,0,0,0,0,#DIV/0!,#DIV/0!,-0.005910451,-0.014149311,0,0,0
REGN,948.87,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year oldsÂ ,Approved,1/25/2024,"Approved January 25, 2024.",105,100909.4627,18.7144,948.24,948.87,957.78,0.000664168,0.010010472,-0.005910451,-0.014149311,1.00364,0.14522,374.03127
SNY,47.88,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year oldsÂ ,Approved,1/25/2024,"Approved January 25, 2024.",,114957.327,34.4925,49.89,49.88,48.41,-0.000200461,-0.030114178,-0.005910451,-0.014149311,0,0,143.86749
BMY,49.04,BMS-986365 (CC-94676) - (rechARge),Metastatic CRPCÂ ,Phase 1,1/25/2024,"Phase 1 data reported that treatment induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical act",,100944.3316,21.2537,50.24,49.61,48.67,-0.012619096,-0.031748698,-0.005910451,-0.014149311,1.43437,0.11558,875.10259
CRBP,29.49,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,1/26/2024,"Phase 1 dose escalation data from 2024 ASCO GU reported an ORR of 43% in the mixed tumor population, with no dose discontinuations or reductions in the study to date, noted January 26, 2024.",12,130.45441,202.9898,8.44,29.49,26.72,1.251068914,1.15243004,-0.025656734,0.006006705,0.634,0.01837,981.74354
MRK,119.33,KEYTRUDA (pembrolizumab) - (AMBASSADOR (A031501) KEYNOTE-123),Localized muscle-invasive urothelial carcinoma (MIUC)Â ,Phase 3,1/26/2024,"Phase 3 data reported that treatment doubled median DFS as adjuvant therapy versus observation â€“ 29 months versus 14 months, noted January 26, 2024.",,306160.669,16.7063,120.13,120.82,126.41,0.005727345,0.050956103,-0.025656734,0.006006705,0.82139,0.01027,1002.84273
BMY,49.13,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC)Â ",Phase 3,1/27/2024,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",,101127.4598,21.2552,49.7,49.7,48.71,0,-0.020120585,-0.028598911,0.003064528,1.43437,0.12831,0
HALO,34.21,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC)Â ",Phase 3,1/27/2024,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",116,4519.07634,38.9055,34.21,34.21,33.68,0,-0.01561381,-0.028598911,0.003064528,5.42454,0.16901,0
MRK,119.79,KEYTRUDA (KEYNOTE-564),Renal cell carcinoma (RCC)Â ,Phase 3,1/29/2024,"Additional Phase 3 data reported that treatment reduced the risk of disease recurrence or death by 32%, noted January 29, 2024.",,307326.3196,16.5213,120.82,121.28,126.18,0.003800087,0.043407624,-0.00598838,-0.00192471,0.82139,0.01027,1108.3054
NNVC,1.17,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Phase 1b,1/29/2024,"Phase 1a/1b healthy subjects section of trial completed with no adverse events reported, noted January 29, 2024.",17,13.74229,65.6805,1.07,1.17,1.12,0.0893451,0.045670037,-0.00598838,-0.00192471,2.6085,0.01672,0.49076
AZN,66.17,GC012F,Early-line treatment of multiple myeloma (ELMM).Â ,IND-Enabling,1/29/2024,"IND was cleared by the FDA on January 29, 2024.",,163821.1863,21.4466,105.46,105.68,103.6,0.002083926,-0.017794404,-0.00598838,-0.00192471,0,0.14005,189.76324
ACXP,3.68,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,1/29/2024,"Phase 2b trial showed that 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection, noted",1,50.66609,133.4118,77.4,73.6,62.8,-0.050341755,-0.209031707,-0.00598838,-0.00192471,1.7692,0.00866,0.98344
SRPT,120.5,SRP-5051 - (MOMENTUM),Duchenne muscular dystrophyÂ ,Phase 2,1/29/2024,"Phase 2 data at target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20), noted January 29, 2024.",97,11272.37506,79.8127,118.73,120.5,125.55,0.014797745,0.055852078,-0.00598838,-0.00192471,6.06663,0.00742,139.49092
PALI,14.4,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,1/29/2024,"Preclinical data demonstrated PALI-2108 to be safe and well tolerated, noted January 29, 2024.",9,8.90477,220.9784,7.8,14.39999,7.65,0.613103778,-0.019418086,-0.00598838,-0.00192471,1.39091,0.10296,130.57946
TAK,14.77,GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% solution],Adults with chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Approved,1/29/2024,"FDA Approved on January 29, 2024.",,6843576.482,18.6116,14.6,14.77,13.92,0.011576568,-0.047694874,-0.00598838,-0.00192471,0,0,23.55418
LIXT,2.15,LB-100 with doxorubicin,Ovarian clear cell carcinoma (OCCC)Â ,Phase 1/2,1/29/2024,"Phase 1b/2 dosing was initiated, noted January 29, 2024.",4,4.83597,98.6014,1.99,2.15,2.02,0.077333203,0.014962873,-0.00598838,-0.00192471,0.21087,0.05041,0.08262
IKT,3.21,Risvodetinib - (IkT-148009) - (201 trial),Parkinsonâ€™s diseaseÂ ,Phase 1,1/29/2024,Phase 1 study published at Journal of Parkinson's Disease showed that data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volu,74,19.81944,133.7881,2.96,3.21,2.55,0.081081669,-0.149095909,-0.00598838,-0.00192471,0.1422,0.04909,0.92391
KRBP,1.77,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung CancerÂ ,Phase 1,1/29/2024,"Phase 1 efficacy results from first patient reported a stabilization of the disease, indicating a preliminary progression-free survival of one and one-half months, noted January 29, 2024.",1,2.22747,0,0,0,0,#DIV/0!,#DIV/0!,-0.00598838,-0.00192471,0,0,0
ALVO,15.25,"AVT03-GL-P01 (denosumab) - (PROLIA Biosimilar, Xgeva Biosimilar)",Osteoporosis in postmenopausal women and for bone loss in adult men and womenÂ ,Phase 1,1/29/2024,"Pk trial met its primary endpoints, noted January 29, 2024.",301,4049.32826,41.2867,14.65,15.25,15.49,0.040139168,0.055754319,-0.00598838,-0.00192471,0.04286,0.00989,7.90885
RCUS,15.72,Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10),Non Small Cell Lung Cancer (NSCLC)Â ,Phase 3,1/30/2024,"Phase 3 trial discontinued January 30, 2024.",106,1416.27234,62.2273,15.3,15.72,15.32,0.027080959,0.001306336,0.037820812,0.011519844,7.9399,0.08764,33.25142
KURA,20.85,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML)Â ,Phase 1,1/30/2024,"Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with",86,1577.28007,77.6561,18.6,20.85,20.97,0.114192368,0.119931264,0.037820812,0.011519844,12.38782,0.08526,233.79362
KYKOF,â€”,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML)Â ,Phase 1,1/30/2024,"Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with",540,1238921.869,0,0,0,0,#DIV/0!,#DIV/0!,0.037820812,0.011519844,0,0,0
SCYX,1.96,SCY-247,Pulmonary mucormycosisÂ ,Preclinical,1/30/2024,"Preclinical data reported that SCY-247 resulted in 40% and 50% survival at 21 days post infection for the intermediate (32 mg/kg) and high doses (48 mg/kg), respectively, compared to 0% survival in th",41,72.74125,89.5288,1.95,1.955,1.995,0.002560821,0.022814678,0.037820812,0.011519844,3.78207,0.16682,0.19114
ITRM,1.58,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI)Â ,Phase 3,1/30/2024,"Phase 3 data met the primary endpoint of non-inferiority to augmentin; and demonstrated statistical superiority, noted January 30, 2024.",44,21.22791,121.0978,1.79,1.58,1.58,-0.124790773,-0.124790773,0.037820812,0.011519844,0.35615,0.11428,38.76491
VRTX,446.08,Suzetrigine (VX-548),Acute Pain following bunionectomy or abdominoplasty surgeryÂ ,Phase 3,1/30/2024,"Phase 3 trial data reported a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo, n",256,114947.3147,26.5742,435.82,446.08,416.13,0.023268994,-0.046231603,0.037820812,0.011519844,1.30151,0.15104,1485.48075
NVS,99.74,Sabatolimab (MBG453) - (STIMULUS),Myelodysplastic syndromes (MDS)Â ,Phase 3,1/31/2024,"Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.",,1473.83355,46.5677,4.8,4.75,4.94,-0.0104713,0.028749413,-0.002250479,0.007916802,0,0.00875,0.13899
OTLK,7.72,ONS-5010 / LYTENAVA (bevacizumab-vikg) - (NORSE EIGHT),Wet age-related macular degeneration (wet AMD)Â ,Phase 3,1/31/2024,"Special Protocol Assessment (SPA) dosing initiated, noted January 31, 2024.",44,100.4594,277.1926,8.3,7.72,8.416,-0.072441151,0.013879141,-0.002250479,0.007916802,4.65973,0.01979,0.69519
NVO,113.92,Semaglutide - (STEP HFpEF),"Heart failure with preserved ejection fraction (HFpEF) and obesity, Type 2 diabetesÂ ",Phase 3,1/31/2024,"Phase 3 reported that KCCQ-CSS estimated treatment difference between semaglutide 2.4 mg and placebo of 7.8, noted January 31, 2024.",,3452603.284,34.9479,109.02,114.74,118.66,0.051137348,0.084730909,-0.002250479,0.007916802,0,0,1459.04795
RHHBY,32.97,Vabysmo - (BALATON),Macular edema due to branch and central retinal vein occlusion (BRVO and CRVO)Â ,Phase 3,2/1/2024,"Phase 3 data reported that patients who recieved Vabysmo as a first-line treatment gained 18.1 letters on the eye chart, while people switched from aflibercept to Vabysmo gained 18.8 letters, noted Fe",,187596.3227,0,0,0,0,#DIV/0!,#DIV/0!,-0.006157374,-0.020266757,0,0,0
EDAP,6.34,Transrectal High-intensity focused ultrasound (TR-HIFU),Rectal Deep Infiltrating EndometriosisÂ ,Phase 3,2/1/2024,"Phase 3 enrolment completed, noted February 1, 2024.",37,234.11949,74.3167,6.65,6.34,6.4,-0.047738086,-0.038318864,-0.006157374,-0.020266757,0.18503,0.02299,0.48112
AZN,64.65,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Phase 3,2/2/2024,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",,160599.6154,21.328,104.3,103.6,97.61,-0.006734032,-0.066291415,0.006314149,-0.022999736,0,0.13986,304.91842
BBIO,33.91,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM)Â ,Phase 3,2/2/2024,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",191,5899.22273,52.0258,33.31,33.91,34.47,0.017852304,0.034231728,0.006314149,-0.022999736,9.26687,0.02659,56.43187
LQDA,13.58,L606 (liposomal treprostinil),Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)Â ,Phase 2,2/2/2024,"Open-label trial data presented at the Pulmonary Vascular Research Institute (PVRI) reported that treatment demonstrate sustained plasma levels up to 12 hours, supporting twice daily administration, n",86,1029.52841,62.3854,13.6,13.58,14.81,-0.001471671,0.085232836,0.006314149,-0.022999736,7.27268,0.031,7.84219
FDMT,17.49,4D-150 - (PRISM),Wet age-related macular degeneration (AMD)Â ,Phase 2,2/3/2024,"Phase 2 data reported that the high dose 4D-150 resulted in an 89% reduction in the annualized anti-VEGF injection rate; 84% of patients received 0 or 1 injection, and 63% were injection-free through",46,747.76059,59.3496,17.49,17.49,28.63,0,0.49282583,-0.004989238,-0.034303123,6.73732,0.13273,0
LCTX,0.98,RG6501 - (OpRegen),Geographic atrophy (GA)Â ,Phase 1/2,2/3/2024,"Additional Phase 1/2a data presented at the Angiogenesis, Exudation, and Degeneration Meeting reported that all patients with extensive delivery to GA showed improvement in outer retinal structure on",228,171.48694,65.4291,0.98,0.98,1.08,0,0.097163748,-0.004989238,-0.034303123,4.50364,0.02338,0
KOD,4.03,KSI-501 (KSI-501ABC) - (DAYBREAK),Retinal diseases w/ inflammatory componentÂ ,Phase 1,2/3/2024,"Phase 1 trial initial data presented at the Angiogenesis, Exudation, and Degeneration reported that monthly dosing of KSI-501 was safe and well-tolerated, noted February 3, 2024.",52,210.71268,109.8718,4.03,4.03,5.38,0,0.288921998,-0.004989238,-0.034303123,2.60877,0.18385,0
BRTX,3.45,BRTX-100,Chronic lumbar disc diseaseÂ ,Phase 2,2/4/2024,"Phase 2 initial data presented at ORS reported that Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at weeks 26 and 52 pos",7,13.17937,91.6412,2.8,2.8,1.35,0,-0.729514825,-0.004989238,-0.034303123,0.19429,0.04439,0
EYPT,27.79,DURAVYU (EYP-1901) - (LUGANO),Wet age-related macular degeneration (AMD)Â ,Phase 2,2/5/2024,"Phase 2 subgroup analysis reported numerical superiority in change in BCVA along with strong anatomic control compared to the aflibercept control group, noted February 5, 2024.",68,1308.1903,171.8556,28.7,27.79,29.71,-0.032220879,0.034586567,-0.020143595,-0.056678337,11.05685,0.04709,47.87358
KYKOF,15.85,OTL-203 - (HURCULES),Mucopolysaccharidosis type I (MPS-I)Â ,Phase 3,2/5/2024,"Global Phase 3 registrational trial enrolment initiated across the US and Europe, noted February 5, 2024.",540,1243222.748,0,0,0,0,#DIV/0!,#DIV/0!,-0.020143595,-0.056678337,0,0,0
PLRX,15.8,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC)Â ,Phase 2a,2/5/2024,"Phase 2a data reported that 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period, noted February 5, 2024.",61,946.35614,58.9844,17.4,15.8,17.27,-0.096460266,-0.007499314,-0.020143595,-0.056678337,10.62835,0.0995,33.26628
RANI,3.69,"RT-111 (RaniPill Containing Ustekinumab Biosimilar, CT-P43)","Plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitisÂ ",Phase 1,2/5/2024,Phase 1 data showed that it well-tolerated and delivered ustekinumab with high bioavailability. Data provided clinical validation of our ability to successfully transform an injectable large molecule,71,95.49744,84.5308,3.49,3.69,3.57,0.055724722,0.02266386,-0.020143595,-0.056678337,5.86019,0,0.66708
THAR,6.15,TH104 (AV104),Primary biliary cholangitis (PBC)Â ,Phase 1,2/5/2024,"Phase 1 dosing of first patient completed, noted February 5, 2024.",4,1.03595,234.4007,6.6,6.153,5.775,-0.070129881,-0.133531393,-0.020143595,-0.056678337,1.68519,0.00266,0.22004
ARCT,35.07,Kostaive (ARCT-154),COVID-19 variant vaccineÂ ,Phase 3,2/5/2024,"Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.",27,937.18725,73.8582,34.72,35.07,41.62,0.010030174,0.181264931,-0.020143595,-0.056678337,15.52033,0.28856,9.8856
CSLLY,96.43,Kostaive (ARCT-154),COVID-19 variant vaccineÂ ,Phase 3,2/5/2024,"Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.",968,145043.9195,0,0,0,0,#DIV/0!,#DIV/0!,-0.020143595,-0.056678337,0,0,0
AIMD,1.08,VELDONA,Mild COVID-19Â ,Phase 2,2/5/2024,"Company submitted the clinical hold complete response to the FDA for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, noted February 5, 2024.",4,5.05203,135.7597,5.15,5.4,4.7405,0.047402239,-0.082854099,-0.020143595,-0.056678337,0.78231,0.00382,0.03284
VRTX,428.89,VX-121/tezacaftor/VX-561 - (SKYLINE-102),Cystic FibrosisÂ ,Phase 3,2/5/2024,"Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.",256,110517.7408,26.1837,424.68,428.89,418.53,0.009864532,-0.014587372,-0.020143595,-0.056678337,1.30151,0.18016,823.4821
GSK,41.01,Blenrep,Multiple myelomaÂ ,Phase 3,2/6/2024,"Additional Phase 3 data reported a 59% reduction in risk of disease progression or death, noted February 6, 2024.",,67076.70063,17.7752,16.626,16.53,16.418,-0.005790823,-0.012589441,0.003853133,-0.003500258,0,0.00204,83.34578
SGMO,0.52,Civaparvovec (ST-920) - (STAAR),Fabry diseaseÂ ,Phase 1/2,2/6/2024,Phase 1/2 clinical data reported a statistically significant improvements in disease severity were reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adju,301,92.34457,111.845,0.56,0.5207,0.6701,-0.072762724,0.179490171,0.003853133,-0.003500258,5.16767,0.13793,1.32188
LLY,702.66,Tirzepatide - (SYNERGY-NASH),"Nonalcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatohepatitis (MASH)Â ",Phase 2,2/6/2024,"Phase 2 trial met its primary endpoint, noted February 6, 2024.",946,634038.5813,33.0806,706.2,705.03,742.97,-0.001658128,0.050757184,0.003853133,-0.003500258,0.54335,0.01369,5781.17691
GANX,4.47,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,2/6/2024,"Preclinical data presented at the WORLDSymposium reported that GT-02287 restored motor function in a mouse model, even following a delayed administration of the drug candidate after the initial toxic",35,72.41118,74.6424,4.39,4.47,4.51,0.018059182,0.026967926,0.003853133,-0.003500258,0.63891,0.00009,1.03206
LLY,702.66,VERZENIO (Abemaciclib) - (CYCLONE-2),Prostate CancerÂ ,Phase 3,2/6/2024,"Phase 3 trial was not successful, noted February 6, 2024.",946,634038.5813,33.0806,706.2,705.03,742.97,-0.001658128,0.050757184,0.003853133,-0.003500258,0.54335,0.01369,5781.17691
ABEO,4.3,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA)Â ,Phase 1/2,2/6/2024,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",51,106.52526,62.5767,4.29,4.3,6.31,0.00232829,0.385848944,0.003853133,-0.003500258,2.67242,0.00726,0.54458
RARE,45.89,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA)Â ,Phase 1/2,2/6/2024,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",96,3767.84003,52.9302,44.76,45.89,43.98,0.024932345,-0.017579898,0.003853133,-0.003500258,5.01329,0.20905,33.65444
INKT,0.94,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19Â ,Phase 1/2,2/6/2024,"Phase 1/2 data showed that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile, noted February 6, 2024",4,32.44837,80.2507,8.526,9.4,9.277,0.097589371,0.0844179,0.003853133,-0.003500258,0.50656,0.09106,0.08395
REGN,â€”,Libtayo (cemiplimab-rwlc),High-risk cutaneous squamous cell carcinoma (CSCC) after surgeryÂ ,Phase 3,2/6/2024,"Phase 3 data from ASCO reported a 68% reduction in the risk of disease recurrence or death, noted June 2, 2025.",105,100778.8407,17.7404,936.33,937.81,940.48,0.001579391,0.004422405,0.003853133,-0.003500258,0.99323,0.1296,431.79117
HCM,13.7,Fruquintinib and Paclitaxel - (FRUTIGA),Gastric CancerÂ ,Phase 3,2/7/2024,"Phase 3 data presented at ASCO plenary series noted that the median PFS for patients who received fruquintinib plus paclitaxel was 5.6 months, compared to 2.7 months for those who received paclitaxel",174,1860.4344,52.9492,2.15,2.18,2.185,0.013857035,0.016147986,0.006034212,-0.015257344,0,0.13842,0.21694
RGNX,14.57,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,2/7/2024,"Phase 1/2 dose 2 levels completed; additionally, the company reported interim safety and efficacy data where the third patient at dose level 1 demonstrates the largest increase in microdystrophin expr",50,640.96315,57.2356,13.05,14.57,16.79,0.110176486,0.251995337,0.006034212,-0.015257344,10.03045,0.23949,26.84477
VRPX,3.81,Probudur,Post-operative painÂ ,Phase 2,2/7/2024,"Phase 2 initial data reported that two doses of Probudur showed reduction in incision-induced pain behaviors, noted February 7, 2023.",1,4.46079,122.2015,103.6,95.2,96.5,-0.084557388,-0.070994321,0.006034212,-0.015257344,0.43943,0.0098,0.17993
BCTX,3.94,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,2/7/2024,"Additional Phase 2 data reported a disease control rate of 50%, noted February 7, 2024.",1,84.38281,74.0242,620.99969,590.2497,497.99975,-0.050784915,-0.220731008,0.006034212,-0.015257344,0,0,0.61209
ALEC,6.4,Latozinemab (AL001) - (INFRONT-3),Frontotemporal DementiaÂ ,Phase 3,2/7/2024,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",101,608.03806,82.6857,6.04,6.4,6.27,0.057893978,0.037372343,0.006034212,-0.015257344,5.68428,0.01202,9.33201
GSK,41.27,Latozinemab (AL001) - (INFRONT-3),Frontotemporal DementiaÂ ,Phase 3,2/7/2024,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",,67872.04445,17.7625,16.53,16.726,16.68,0.011787483,0.009033485,0.006034212,-0.015257344,0,0.00204,127.44694
SAVA,25.4,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimerâ€™s diseaseÂ ,Phase 3,2/7/2024,"Phase 3 24-month data reported that treated patients scores declined by an average of 1.04 points on ADAS-Cog11, noted February 7, 2024.",48,1072.81774,84.2715,23.66,25.4,24.1,0.070963315,0.018425982,0.006034212,-0.015257344,31.56632,0.03158,30.61305
RGNX,14.57,clemidsogene lanparvovec (RGX-121) - (CAMPSIITE),MPS II (Hunter Syndrome)Â ,Phase 3,2/7/2024,"Phase 3 topline data reported that trial met primary endpoint, noted February 7, 2024.",50,640.96315,57.2356,13.05,14.57,16.79,0.110176486,0.251995337,0.006034212,-0.015257344,10.03045,0.23949,26.84477
DNLI,16.95,DNL126,MPS IIIA (Sanfilippo syndrome Type A)Â ,Preclinical,2/7/2024,"Preclinical mouse-model data shared at the WORLDSymposium reported that ETV:SGSH lowered substrate accumulation in the CNS and improved cognitive deficits, noted February 7, 2024.",146,2342.43657,59.892,16.63,16.95,17.89,0.019059541,0.073033604,0.006034212,-0.015257344,7.15183,0.29766,14.66151
DNLI,16.95,Tividenofusp alfa (DNL310) - (COMPASS),Hunter syndrome MPS IIÂ ,Phase 1/2,2/7/2024,"Phase 1/2 data at WORLDSymposium showed additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm stu",146,2342.43657,59.892,16.63,16.95,17.89,0.019059541,0.073033604,0.006034212,-0.015257344,7.15183,0.29766,14.66151
ALEC,6.25,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,2/8/2024,"Phase 2 dosing initiated, noted February 8, 2024.",101,593.78717,82.7363,6.4,6.25,6.49,-0.023716527,0.01396454,-0.033167018,-0.05736656,5.68428,0.01202,3.75396
GSK,41.08,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD)Â ,Phase 2,2/8/2024,"Phase 2 dosing initiated, noted February 8, 2024.",,66995.5431,17.8447,16.726,16.51,16.63,-0.012998137,-0.005756102,-0.033167018,-0.05736656,0,0.00204,124.32012
ADVM,19.7,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD)Â ,Phase 2,2/8/2024,"Phase 2 data presented at the Macula Society Annual Meeting on the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes, noted February 8, 2024.",20,199.02353,114.0871,28.1,19.7,20,-0.355150941,-0.340037303,-0.033167018,-0.05736656,1.63607,0.01339,29.91266
AIM,0.38,Ampligen (AMP-518),Post-COVID conditionsÂ ,Phase 2,2/8/2024,ase 2 efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions. Safety results showed Ampligen is generally well tolerated in the treatment o,2,57.42386,57.2609,0.275,0.275,0.285,0,0.035718083,-0.033167018,-0.05736656,0,0.00592,0
BDRX,1.3,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM)Â ,Phase 1,2/8/2024,"Phase 1 PFS data reported that one patient had a survival rate of 12 months from the start of treatment, while 3 patients remain in the study, noted February 8, 2024.",,3.40535,164.0147,337.5,325,397.5,-0.037740328,0.163629424,-0.033167018,-0.05736656,1.73144,0.00063,1.84633
AMLX,15.46,AMX0035 - (HELIOS),Wolfram SyndromeÂ ,Phase 2,2/8/2024,"Phase 2 enrollment completed, noted February 8, 2024.",89,1043.82446,69.2839,15.12,15.46,15.38,0.022237672,0.017049593,-0.033167018,-0.05736656,8.48478,0.08282,8.50014
ATHA,3.17,ATH-1105,Amyotrophic Lateral Sclerosis (ALS)Â ,Preclinical,2/8/2024,"Preclinical data reported that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS, noted February 8, 2024.",3,120.63302,74.9017,31,31.7,36.6,0.022329476,0.166061036,-0.033167018,-0.05736656,1.3503,0.07189,0.55282
TAK,13.95,Oveporexton (TAK-861-2001),Narcolepsy type 1 (NT1)Â ,Phase 2b,2/9/2024,"Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.",,6682008.776,19.4101,14,14.24,14.62,0.016997576,0.043333125,-0.042568955,-0.043105867,0,0,17.17975
CNTA,9.26,SerpinPC - (PRESent-3),Hemophilia BÂ ,Phase 2a,2/9/2024,"Phase 2a data presented at EAHAD reinforce confidence in SerpinPC's novel mechanism of action as we continue to advance the registrational studies, noted February 9, 2024.",134,904.04774,78.2521,7.46,9.26,11.75,0.216148634,0.454297826,-0.042568955,-0.043105867,1.13865,0.16504,28.10975
OKYO,1.71,Urcosimod (OK-101),Neuropathic corneal pain (NCP)Â ,IND-Enabling,2/9/2024,"IND cleared by the FDA, noted February 9, 2024.",33,56.83365,106.8312,1.43,1.71,1.41,0.178818926,-0.01408474,-0.042568955,-0.043105867,0.15403,0.00086,9.83294
NRXP,5.12,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,2/9/2024,"hase 2b/3 enrollment completed, noted February 9, 2024.",19,42.62548,89.7755,4.64,5.12,4.708,0.098440073,0.014548823,-0.042568955,-0.043105867,3.45232,0.02952,1.14597
IRON,68.29,MWTX-003 - (DISC-3405),Polycythemia vera (PV)Â ,Phase 1,2/9/2024,"Orphan drug designation granted by the FDA on February 9, 2024",34,1648.54983,48.1994,66.73,68.29,65.92,0.023108716,-0.012212741,-0.042568955,-0.043105867,5.46485,0.0461,7.88586
ANTX,5.1,EBO-301,Treatment-Refractory MAC Lung DiseaseÂ ,Phase 2/3,2/12/2024,"Phase 2/3 enrollment voluntary pause enables time to evaluate study data further and for the independent DSMB to conduct an unblinded assessment and recommend next steps, which could include changes t",27,151.68137,207.3869,20,5.1,3.64,-1.366491734,-1.703748592,0.025813627,-0.022912127,0.94252,0.02616,29.07324
CSLLY,94.17,CSL112 -(AEGIS-II),Acute myocardial infarction (AMI)Â ,Phase 3,2/12/2024,"Phase 3 study did not meet its primary endpoint, noted February 12, 2024.",968,140212.9869,0,0,0,0,#DIV/0!,#DIV/0!,0.025813627,-0.022912127,0,0,0
LRMR,7.83,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,2/12/2024,"Phase 2 study showed that treatment was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events, noted February 12, 2",85,343.78322,83.6802,7.76,7.83,12.78,0.008980176,0.498899115,0.025813627,-0.022912127,0.7737,0.05605,16.92701
BTAI,1.95,BXCL701 and KEYTRUDA (pembrolizumab),Neuroendocrine Prostate Cancer (NEPC)Â ,Phase 2a,2/12/2024,"Fast Track designation granted by the FDA on February 12, 2024.",14,59.24471,149.9362,33.76,31.2,56.16,-0.078858575,0.50892809,0.025813627,-0.022912127,8.08295,0.04641,19.98635
PYPD,6.84,D-PLEX100 - (SHIELD II),Surgical Site InfectionÂ ,Phase 3,2/12/2024,"Phase 3 trial 100th patient enrollment, noted February 12, 2024.",10,32.8132,111.0529,6.92,6.84,6.4,-0.011628038,-0.078117779,0.025813627,-0.022912127,0.10798,0.00008,0.03391
NUVL,83.55,Neladalkib (NVL-655) - (ALKove-1),ALK non-small cell lung cancer (NSCLC)Â ,Phase 1/2,2/12/2024,"Phase 1/2 trial initiated, noted February 12, 2024.",72,5232.74444,59.8129,82.45,83.55,86.21,0.013253206,0.044594131,0.025813627,-0.022912127,10.05736,0.12256,47.13607
TAK,14.02,EOHILIA (budesonide oral suspension),People 11 years and older with eosinophilic esophagitis (EoE)Â ,Approved,2/12/2024,"FDA approved on February 12, 2024.",,6682008.776,19.4686,14.24,14.31,14.62,0.004903688,0.026335548,0.025813627,-0.022912127,0,0,16.30825
JAGX,5.36,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio choleraeÂ ,Phase 1,2/12/2024,"Orphan Drug Designation (ODD) submited to the FDA, noted February 12, 2024.",2,4.53753,126.8627,125.54975,134.09973,117.14977,0.065881682,-0.069248893,0.025813627,-0.022912127,8.1002,0.00026,2.06956
SGMO,0.81,Civaparvovec (ST-920) - (STAAR),Fabry diseaseÂ ,Phase 1/2,2/12/2024,"Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2",301,142.76432,123.1802,0.5744,0.805,1.38,0.33751626,0.87651276,0.025813627,-0.022912127,5.62785,0.13686,6.84376
TNXP,11.84,TNX-102 SL - (OASIS),"Acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD)Â ",Phase 2,2/12/2024,"FDA Cleared IND on February 12, 2024.",8,21.68733,108.3839,1056,1184,1220.8,0.114410351,0.145018196,0.025813627,-0.022912127,1.08885,0.13187,1.19229
ANIX,4.46,Chimeric endocrine receptor T-cell (CER-T),Ovarian CancerÂ ,Phase 1,2/12/2024,"Phase 1 2nd cohort dosing initiated, noted February 12, 2024.",32,141.43442,62.5941,4.51,4.46,4.05,-0.011148387,-0.107580272,0.025813627,-0.022912127,2.14893,0.08749,0.61229
KTRA,0.12,REM-001,Cutaneous Metastatic Breast Cancer (CMBC)Â ,Phase 3,2/12/2024,"Phase 3 was initiated, noted February 12, 2024.",55,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.025813627,-0.022912127,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
FDMT,27.85,4D-310 - (INGLAXA),Fabry DiseaseÂ ,Phase 1/2,2/12/2024,"Phase 1/2 interim data presented at the WORLDSymposium 2024 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiop",46,1374.10847,107.0605,28.63,27.85,27.26,-0.027622153,-0.049034693,0.025813627,-0.022912127,7.77293,0.09494,53.76899
PHRRF,0.13,KETARX (ketamine),Surgical pain managementÂ ,ANDA Filing,2/12/2024,"ANDA continues to be under review by the FDA and has provided preliminary thoughts on possible deficiencies identified by Quality, noted February 12, 2024.",91,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.025813627,-0.022912127,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
BMRN,88.18,Valoctocogene roxaparvovec (BMN 270-303) - (GENEr8-3),Hemophilia AÂ ,Phase 3,2/12/2024,"Phase 3 trial data presented at EAHAD after liver biopsy analysis suggests efficient hepatocyte transduction occurred, noted February 9, 2024.",192,16610.30532,29.6906,88.46,88.18,88.77,-0.003170293,0.003498283,0.025813627,-0.022912127,1.68528,0.20091,112.83954
KRYS,108.73,KB707 - (KYANITE-1),Solid TumorsÂ ,IND-Enabling,2/13/2024,"The FDA cleared IND and granted fast-track designation on February 13, 2024.",28,3066.87426,48.201,115.88,108.73,111.64,-0.063687428,-0.037275764,0.021277398,0.007763679,7.19433,0.05328,36.54861
KALV,14.85,EKTERLY (sebetralstat),Hereditary Angioedema (HAE)Â ,Phase 3,2/13/2024,"Phase 3 clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile, noted February 13, 2024.",50,513.19683,59.3196,16.04,14.85,13.8,-0.077085737,-0.15041701,0.021277398,0.007763679,7.15732,0.16326,66.19045
CADL,1.8,CAN-3110,GliomaÂ ,Phase 1,2/13/2024,"Fast track designation granted by the FDA on February 13, 2024.",54,52.05566,110.743,1.39,1.8,1.72,0.258482918,0.213020544,0.021277398,0.007763679,0.57462,0.00027,3.47868
LCTX,1.02,AST-OPC1 SCiSTAR - (DOSED),Cervical spinal cord injuryÂ ,IND-Enabling,2/13/2024,"INDa cleared by the FDA on February 13, 2024.",228,192.24778,67.6221,1.08,1.02,1.09,-0.057158414,0.009216655,0.021277398,0.007763679,4.48602,0.02434,0.96536
RCKT,28.97,KRESLADI (marnetegragene autotemcel),Leukocyte Adhesion Deficiency-I (LAD-I)Â ,PDUFA,2/13/2024,"PDUFA date extended by 3 months to June 30, 2024.",107,2611.90319,68.7179,29.99,28.97,28.64,-0.034603181,-0.046059651,0.021277398,0.007763679,9.36909,0.11126,51.99901
CALC,5.23,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF)Â ,IND-Enabling,2/13/2024,"IND cleared by the FDA, noted February 13, 2024.",13,56.1708,116.7181,5.6977,5.23,4.36,-0.085651307,-0.267590527,0.021277398,0.007763679,0.20184,0.03414,0.11315
ROIV,10.8,RVT-2001,Transfusion-Dependent Anemia in Patients with Lower-Risk MDSÂ ,Phase 1/2,2/13/2024,Phase 1/2 development discontinued after interim data analysis.,682,8703.13687,57.2451,10.87,10.8,11.54,-0.006460567,0.05981256,0.021277398,0.007763679,3.1901,0.09307,66.98586
PTIX,0.97,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD)Â ,Phase 1/2,2/13/2024,"Phase 1/2 demonstrated safety at a low dose of 125 micrograms in the initial cohort of patients, with zero reported adverse reactions among subjects, noted February 13, 2024.",,0,0,0,0,0,#DIV/0!,#DIV/0!,0.021277398,0.007763679,0,0,0
PBYI,6.21,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC)Â ,Phase 2,2/13/2024,"Phase 2 was initiated, noted on February 13, 2024.",50,295.41797,67.3613,6.36,6.21,6.79,-0.023867481,0.065422564,0.021277398,0.007763679,6.74136,0.17585,5.63545
OCUL,5.62,AXPAXLI (OTX-TKI) - (SOL-1),Wet Age-related Macular Degeneration (AMD)Â ,Phase 3,2/13/2024,"Phase 3 first three subjects have been screened and dosed with first aflibercept injection, noted February 13, 2024.",174,619.42868,88.9074,5.88,5.62,7.52,-0.045225098,0.246009376,0.021277398,0.007763679,3.59266,0.04326,7.49006
MACK,7.51,Onivyde (NALIRIFOX),Pancreatic cancerÂ ,Approved,2/13/2024,"FDA Approved on February 13, 2024.",14,214.8143,0,0,0,0,#DIV/0!,#DIV/0!,0.021277398,0.007763679,0,0,0
IPSEY,27.94,Onivyde (NALIRIFOX),Pancreatic cancerÂ ,Approved,2/13/2024,"FDA Approved on February 13, 2024.",328,8509.64581,0,0,0,0,#DIV/0!,#DIV/0!,0.021277398,0.007763679,0,0,0
TAK,14.05,Eohilia (formerly TAK-721),Eosinophilic esophagitisÂ ,Approved,2/13/2024,"Approved February 13, 2024.",,6824780.037,19.4638,14.31,14.34,14.82,0.002094242,0.035019026,0.021277398,0.007763679,0,0,30.03886
OPT,2.92,Sozinibercept (OPT-302) with Aflibercept - (COAST),Age-related macular degeneration (AMD)Â ,Phase 3,2/14/2024,"Phase 3 patient enrollment completed, noted February 14, 2024.",171,377.80092,89.5415,0.57,0.57,0.59,0,0.034486176,-0.05001317,-0.041398925,0,0.00614,0.11814
KRBP,2.56,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung CancerÂ ,Phase 1,2/14/2024,"Phase 1 initiated, noted February 14, 2024.",1,3.2667,0,0,0,0,#DIV/0!,#DIV/0!,-0.05001317,-0.041398925,0,0,0
DTIL,11.99,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV)Â ,Preclinical,2/14/2024,"Pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments, noted February 14, 2024.",11,48.72683,78.502,11.17201,11.99,12.36,0.070661426,0.101053909,-0.05001317,-0.041398925,1.35445,0.24252,1.64606
GLSI,10.2,GP2 (GLSI-100) - (FLAMINGO-01),HER2 positive breast cancerÂ ,Phase 3,2/14/2024,"DSMB recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date, noted February 14 2024.",13,131.05128,59.4113,8.31,10.2,13.16,0.204928111,0.459722317,-0.05001317,-0.041398925,1.2026,0.12427,3.37672
ARVN,49.37,Vepdegestrant (ARV-471) - (TACTIVE-U),Solid TumorsÂ ,Phase 1b,2/14/2024,"Phase 1b umbrella trial combination to be initiated in other arms, noted February 14, 2024.",73,3357.11098,78.1336,47.77,49.37,47.7,0.032945125,-0.00146643,-0.05001317,-0.041398925,9.55326,0.16656,33.33137
AZN,60.73,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,2/14/2024,"Phase 1b/2 dosing commenced on February 14, 2024.",,150740.4112,23.3819,96,97.24,101.02,0.012833958,0.050970326,-0.05001317,-0.041398925,0,0.19671,610.15465
AIM,0.41,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,2/14/2024,"Phase 1b/2 dosing commenced on February 14, 2024.",2,59.512,58.1812,0.29,0.285,0.275,-0.017391743,-0.053109825,-0.05001317,-0.041398925,0,0.00779,0.00133
ATRA,19.26,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus NephritisÂ ",Preclinical,2/14/2024,"IND submitted to the FDA, noted February 14, 2024.",7,78.50052,266.2559,19.2525,19.255,19.915,0.000129845,0.033832294,-0.05001317,-0.041398925,7.38733,0.03367,1.13953
ANVS,10.37,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,2/14/2024,"Phase 2/3 last patient completed, noted February 14, 2024.",19,109.71391,114.2025,10.05,10.37,10.18,0.031344388,0.012852377,-0.05001317,-0.041398925,12.39142,0.01275,1.65627
SILO,1.69,SP-26,Fibromyalgia / Chornic painÂ ,Preclinical,2/14/2024,"The preclinical study demonstrated successful drug delivery, noted February 14, 2024.",9,4.87734,65.9588,1.6,1.69,1.56,0.0547249,-0.025317808,-0.05001317,-0.041398925,3.60416,0.16072,0.54503
INKT,1,"Botensilimab plus balstilimab, agenT-797",Gastric cancerÂ ,Phase 2,2/14/2024,"Phase 2 trial initiated, noted February 14, 2024.",4,34.50573,82.0801,9.277,9.996,9.2001,0.074646794,-0.008323865,-0.05001317,-0.041398925,0.54872,0.09373,0.04808
AMPE,1.82,OA-201,OsteoarthritisÂ ,Preclinical,2/14/2024,Preclinical efficacy results from recently completed pre-IND enabling studies with OA-201 reported that the efficacy results of these studies do not support an Investigational New Drug (IND) submissio,1,1.51428,204.7306,1.72,1.82,1.94,0.05651221,0.120363682,-0.05001317,-0.041398925,6.83997,0.00877,0.02701
MESO,1.93,Revascor (Rexlemestrocel-L) - (DREAM-HF),Heart failureÂ ,Phase 3,2/14/2024,"Orphan drug designation was granted on February 14, 2024.",128,279.06982,65.7659,1.85,1.93,2.03,0.042334364,0.092850154,-0.05001317,-0.041398925,0,0,0.50692
RPTX,6.95,RP-1664 - (LIONS),Adult and adolescent with TRIM37-high tumor cells to treat Solid TumorsÂ ,Phase 1,2/15/2024,"Phase 1 dosing initiated, noted February 15, 2024.",42,292.80107,97.6163,6.81,6.95,6.26,0.020349539,-0.084211935,-0.021814311,-0.032492469,4.08919,0.05897,0.64235
APLT,3.75,govorestat (AT-007) - (INSPIRE),Sorbitol Dehydrogenase Deficiency (SORD Deficiency)Â ,Phase 3,2/15/2024,"Phase 3 study met the interim primary endpoint, noted February 15, 2024.",144,289.60953,143.5374,2.68,3.75,5.6,0.335939045,0.736949803,-0.021814311,-0.032492469,4.80658,0.01459,35.20084
IONS,45.28,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS)Â ,Phase 3,2/15/2024,"Orphan Drug Designation granted by the FDA, noted February 15, 2024.",159,6496.41755,37.3671,49.07,45.28,43.98,-0.080382416,-0.109512865,-0.021814311,-0.032492469,5.89077,0.27415,131.94692
CRDL,1.48,CardiolRx - (MAvERIC-Pilot),Recurrent PericarditisÂ ,Phase 2,2/15/2024,"FDA has granted Orphan Drug Designation (ODD), noted February 15, 2024.",83,8.97699,38.3426,0.045,0.045,0.0435,0,-0.033901552,-0.021814311,-0.032492469,0,0.00857,0.0021
ONCY,1.16,Pelareorep and mFOLFIRINOX with and without atezolizumab - (GOBLET),Colorectal and advanced anal cancersÂ ,Phase 1,2/15/2024,"Phase 1 Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion, additionally an enrollment e",100,86.33179,75.2796,1.15,1.16,1.035,0.008658063,-0.105360516,-0.021814311,-0.032492469,0.89484,0.0395,0.28364
MNKD,3.71,Afrezza (Technosphere Insulin) - (INHALE-1),Pediatric type 1/2 diabetesÂ ,Phase 3,2/15/2024,"Phase 3 enrollment goal reached, noted February 15, 2024.",306,1000.12197,54.6426,3.6,3.71,3.59,0.030098031,-0.002781643,-0.021814311,-0.032492469,12.97873,0.05216,10.62758
AUPH,6.02,Aritinercept (AUR200),BAFF/APRIL (B-Cell Activating Factor)Â ,Phase 1,2/15/2024,"Phase 1 was discontinued due to resource allocation, noted February 15, 2024.",135,870.59893,63.2772,7.97,6.02,6,-0.280597233,-0.283925024,-0.021814311,-0.032492469,12.81281,0.22408,118.14681
AUPH,6.02,AUR300,M2 MacrophageÂ ,IND-Enabling,2/15/2024,"The trial was discontinued due to resource allocation, noted on February 15, 2024.",135,870.59893,63.2772,7.97,6.02,6,-0.280597233,-0.283925024,-0.021814311,-0.032492469,12.81281,0.22408,118.14681
ENSC,0.89,PF614-102,Severe painÂ ,Phase 3,2/15/2024,"Phase 3 additional results from the two-part PF614â€‘102 study are very significant as we believe they demonstrate a clear dose relationship between PF614 and oxycodone, which is the foundation for the",2,6.00555,123.8585,13.49999,13.34999,13.42498,-0.011173309,-0.005571794,-0.021814311,-0.032492469,10.05459,0.00446,0.26267
FBIO,1.86,Triplex - (COLT),Cytomegalovirus (CMV)Â ,Phase 1,2/16/2024,Phase 1 data results demonstrated the potential benefit of vaccinating donors with dose to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transpla,29,34.18076,151.7972,1.88,1.86,1.74,-0.010695289,-0.077386664,0.001287416,-0.015743331,8.12348,0.11164,0.65685
CASI,5.8,FOLOTYN (Pralatrexate Injection) - (PROPEL),Peripheral T-cell lymphomaÂ ,Phase 1,2/16/2024,"Phase 1 dosing initiated in China, noted February 16, 2024.",15,77.26474,105.4952,5.97,5.8,5.55,-0.02888901,-0.072949,0.001287416,-0.015743331,0.39574,0.00237,0.08467
RHHBY,31.01,XOLAIR (omalizumab) - (OUtMATCH),Food allergyÂ ,Approved,2/16/2024,"FDA Approved on February 16, 2024.",,183360.2713,0,0,0,0,#DIV/0!,#DIV/0!,0.001287416,-0.015743331,0,0,0
IOVA,9.15,AMTAGVI (Lifileucel (LN-144)) - (TILVANCE-301),Refractory metastatic melanomaÂ ,Approved,2/16/2024,"FDA Approved on February 16, 2024.",361,2341.6538,94.3039,9.87,9.15,15.77,-0.075745974,0.468609548,0.001287416,-0.015743331,16.3984,0.19051,161.66011
AZN,63.3,TAGRISSO (Osimertinib) - (FLAURA2),Non-small cell lung cancer (NSCLC)Â ,Approved,2/17/2024,"Approved February 17, 2024.",,156476.1118,23.5748,100.94,100.94,102.2,0,0.012405397,0,-0.017030747,0,0.20399,0
AZN,64.06,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)Â ",Phase 3,2/19/2024,"Phase 3 data reported that the trial showed statistically significant and highly clinically meaningful improvement in progression-free survival (PFS), noted February 19, 2024.",,161498.7252,24.008,100.94,104.18,102.54,0.031593891,0.015726685,0.008300592,-0.043998907,0,0.20399,195.99508
RAPT,6.87,Zelnecirnon (RPT193),AsthmaÂ ,Phase 2a,2/20/2024,"Phase 2a trial initiated March 29, 2023. Phase 2a trial placed on clinical hold February 20, 2024.",16,236.30195,199.2314,207.76,54.96,71.92,-1.329777919,-1.060829177,0.007326829,-0.099449359,11.47225,0.22387,96.01507
RAPT,6.87,Zelnecirnon (RPT193),Atopic dermatitisÂ ,Phase 2a,2/20/2024,"Phase 2b trial initiated May 23, 2022. Phase 2b trial placed on hold February 20, 2024.",16,236.30195,199.2314,207.76,54.96,71.92,-1.329777919,-1.060829177,0.007326829,-0.099449359,11.47225,0.22387,96.01507
IMRX,6.76,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanomaÂ ",Phase 1,2/20/2024,"Fast Track Designation granted by the FDA on February 20, 2024.",36,197.85926,97.4551,6.6,6.76,6.43,0.023953241,-0.026095111,0.007326829,-0.099449359,9.13148,0.02696,0.59628
IRON,66.42,DISC-0974,Patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemiaÂ ,Phase 1/2,2/20/2024,"Phase 1b/2 ongoing. FDA granted Fast Track designation, noted February 20, 2024.",34,1603.40723,47.9417,65.92,66.42,66.25,0.00755633,0.004993579,0.007326829,-0.099449359,5.46485,0.047,9.20462
SNY,44.97,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,2/20/2024,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",,109252.5946,34.6206,46.18,46.85,48.21,0.014404205,0.043019664,0.007326829,-0.099449359,0,0,108.72283
TEVA,13.07,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD)Â ,Phase 2b,2/20/2024,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",,14651.37063,35.3922,13.02,13.07,13.3,0.003832891,0.021277398,0.007326829,-0.099449359,1.63397,0.04443,154.43069
ARVN,50.6,ARV-102,Parkinson's Disease in Healthy VolunteersÂ ,Phase 1,2/20/2024,"Phase 1 dosing commenced, noted February 20, 2024.",73,3440.74975,78.5178,52.31,50.6,48.01,-0.033235981,-0.085778235,0.007326829,-0.099449359,9.55326,0.1657,39.89061
SPRY,7.52,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxisÂ ,Phase 3,2/20/2024,Phase 3 topline data showed that Repeated doses of neffy under nasal allergen challenge demonstrated a pharmacokinetic profile greater than or similar to injection and a pharmacodynamic profile greate,98,721.89934,131.4907,7.17,7.52,8.82,0.047660483,0.207116215,0.007326829,-0.099449359,5.06437,0.13708,9.60815
JNJ,156.58,TECVAYLI (teclistamab),Relapsed or refractory (R/R) multiple myeloma.Â ,Approved,2/20/2024,"Supplemental approval granted by the FDA, noted February 20, 2024.",,380247.9946,13.4128,156.55,157.86,160.98,0.008333117,0.027904686,0.007326829,-0.099449359,0.51073,0.12424,1499.94499
GSK,41.19,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIVÂ ,Phase 3,2/21/2024,"Phase 3 interim data reported that demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges, noted",,67401.33076,18.0092,16.778,16.61,16.698,-0.010063581,-0.004779553,-0.01897875,-0.094443816,0,0.00379,83.18552
KZIA,0.32,Paxalisib (GDC-0084) with radiotherapy,Brain MetastasesÂ ,Phase 1,2/21/2024,"Phase 1 trial met its primary endpoint, noted February 21, 2024.",1,8.30651,110.1532,19.845,15.755,13,-0.230794311,-0.423002729,-0.01897875,-0.094443816,0.68934,0.0012,6.503
ENLV,3.22,Allocetra,SepsisÂ ,Phase 2,2/21/2024,"Phase 2 enrollment completed, noted February 21, 2024.",23,59.88735,103.9678,3.27,3.22,2.92,-0.015408625,-0.113206369,-0.01897875,-0.094443816,0.86318,0.02177,0.16829
NRSN,1.25,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,2/21/2024,"Additional Phase 2b 6 month data reported a reduction of the risk of ALS disease complications or death by up to 53%, noted February 21, 2024.",23,17.08255,126.4737,1.37,1.25,1.8,-0.091667189,0.272975925,-0.01897875,-0.094443816,0.96673,0.05768,2.831
MNPR,1.12,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Preclinical,2/22/2024,"Preclinical data to date demonstrated compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes, noted February 22, 2024.",6,16.65037,170.072,2.85,5.6,4.15,0.675447603,0.37578934,-0.024357576,-0.062359768,0.14477,0.0098,171.73254
ELEV,2.7,EO-3021 (SYSA1801) with ramucirumab + dostarlimab,Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2Â ,Phase 1,2/22/2024,"Phase 1 first patient dosed in Japan, noted February 22, 2024.",59,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.024357576,-0.062359768,0,0,0
TARS,31.54,TP-05 - (Carpo),Lyme diseaseÂ ,Phase 2a,2/22/2024,"Phase 2a data demonstrated a statistically significant benefit in killing ticks compared to placebo, noted February 22, 2024.",42,1044.11946,59.2184,30.13,31.54,38.22,0.045735228,0.237837586,-0.024357576,-0.062359768,16.40378,0.05627,26.20567
ATXI,10.67,BAER-101,Absence epilepsyÂ ,Preclinical,2/22/2024,"Preclinical data reported full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg, noted February 22, 2024.",3,5.30482,169.2609,11.20503,10.66503,11.37753,-0.04939262,0.015277573,-0.024357576,-0.062359768,1.81549,0.00239,0.29389
PHVS,27.78,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic useÂ ,Phase 2,2/22/2024,Phase 2 data reported that deucrictibant significantly reduced the monthly attack rate by 84.5% (p=0.0008) in participants dosed at 40 mg/day and 79.3% (p=0.0009) in participants dosed at 20 mg/day co,54,1447.57899,75.6085,27.81,27.78,22.94,-0.001079331,-0.192513557,-0.024357576,-0.062359768,0.40739,0.14889,2.28979
ATNM,6.74,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,2/22/2024,"Phase 3 data shared at ASTCT reported that a median overall survival of 5.49 months versus 1.66 months, noted February 22, 2023.",31,187.13093,73.9831,6.66,6.74,8.53,0.01194044,0.247469877,-0.024357576,-0.062359768,6.66452,0.08592,0.94735
GMDA,0.36,NAM-NK (GDA-201),Follicular and diffuse large B cell lymphomasÂ ,Phase 1/2,2/22/2024,"Phase 1/2 results presented at the Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings reported that EAP data for omidubicel are consistent with Phase 3 trial results, noted February 2",154,47.55091,0,0,0,0,#DIV/0!,#DIV/0!,-0.024357576,-0.062359768,0,0,0
VTYX,5.77,Tamuzimod (VTX002),Ulcerative Colitis (UC)Â ,Phase 2,2/22/2024,"Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.",71,340.58539,256.6821,5.04,5.77,7.08,0.135265998,0.339867826,-0.024357576,-0.062359768,8.23299,0.0149,81.75496
REGN,981.2,Dupixent (dupilumab) - (NOTUS),Chronic obstructive pulmonary disease (COPD)Â ,PDUFA priority review,2/23/2024,"PDUFA Priority Review date June 27, 2024.",105,105441.6124,16.847,964.89,981.2,982.82,0.016762207,0.018411885,-0.033320749,-0.075465066,1.16344,0.13895,431.35613
BDRX,1.49,Tolimidone,Type 2 diabetesÂ ,Preclinical,2/23/2024,"Preclinical data reported inconclusive data, noted February 23, 2024.",,3.90306,167.2829,385,372.5,340,-0.033006296,-0.124297717,-0.033320749,-0.075465066,1.78874,0,6.15743
COGT,7.44,Bezuclastinib - (SUMMIT),Non-Advanced Systemic MastocytosisÂ ,Phase 1b,2/23/2024,"Additional Part 1b data from AAAAI reported that 51% week 12 mean change in Total Symptom Score (TSS), including 70% of patients achieving â‰¥50% reduction in TSS at week 12, noted February 23, 2024.",139,772.58631,147.5297,8.95,7.44,7.23,-0.184782683,-0.213414496,-0.033320749,-0.075465066,4.85228,0.01532,38.35931
CMND,1.88,CMND-100,Alcohol use disorder (AUD)Â ,Phase 1/2,2/23/2024,"Phase 1/2a approval to commence dosing, noted February 23, 2024.",5,5.95879,195.5379,1.86,1.88,1.59,0.010695289,-0.156842471,-0.033320749,-0.075465066,4.61801,0.00047,6.65083
BDRX,1.49,MTX110 - (PNOC015),Diffuse Midline Glioma (DMG)Â ,Phase 1,2/23/2024,"Phase 1 results reported that the median overall survival (OS) of patients in the study was 16.5 months, noted February 23, 2024.",,3.90306,167.2829,385,372.5,340,-0.033006296,-0.124297717,-0.033320749,-0.075465066,1.78874,0,6.15743
TEVA,12.89,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,Approved,2/23/2024,"Approved February 23, 2024.",,14449.592,35.2847,13.05,12.89,13.5,-0.012336317,0.033901552,-0.033320749,-0.075465066,1.63397,0.03926,161.91235
ALVO,16.03,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseasesÂ ,Approved,2/23/2024,"Approved February 23, 2024.",301,4256.44144,39.7087,15.57,16.03,15.76,0.029115981,0.012129099,-0.033320749,-0.075465066,0.04062,0.02185,11.48311
CLDX,37.75,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU)Â ,Phase 2,2/24/2024,"Phase 2 data presented at AAAAI reported that treatment demonstrated strong improvement in UAS7 independent of omalizumab status at Week 12, noted February 24, 2024.",66,2064.51719,49.0959,37.75,37.75,51.88,0,0.317947884,-0.02696816,-0.069112477,12.27044,0.13569,0
KALV,13.69,EKTERLY (sebetralstat),Hereditary Angioedema (HAE)Â ,Phase 3,2/25/2024,"Phase 3 additional data presented at AAAAI reported that 94% of attacks required only one dose to achieve primary endpoint, noted February 25, 2024.",50,523.01376,61.1822,12.58,12.58,14.14,0,0.116899409,-0.02696816,-0.069112477,5.94943,0.12173,0
GSK,41.99,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI)Â ,Phase 3,2/26/2024,"EAGLE-1 trial met its primary endpoint, noted February 26, 2024.",,67953.20198,18.0534,16.724,16.746,16.678,0.00131461,-0.002754328,-0.082418612,-0.061201826,0,0.00094,118.72581
ALLK,1.46,AK006,Prurigo nodularisÂ ,Preclinical,2/26/2024,"Preclinical data presented at AAAAI showed evidence of MRGPRX2 mast cell activation and activated macrophages on skin lesions, noted February 26, 2024.",90,127.71545,0,0,0,0,#DIV/0!,#DIV/0!,-0.082418612,-0.061201826,0,0,0
KRYS,157,KB407 - (CORAL-1),Cystic FibrosisÂ ,Phase 1,2/26/2024,"Phase 1 data reported that no severe or serious adverse events were observed in patients treated in Cohort 1, noted February 26, 2024.",28,4441.94071,68.4981,111.33,157,159.95,0.343747042,0.362362503,-0.082418612,-0.061201826,7.17239,0.05104,351.24511
TNYA,5.69,TN-301,Heart Failure with Preserved Ejection FractionÂ ,Preclinical,2/26/2024,"Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.",162,438.12948,100.1762,5.22,5.69,6.61,0.086212846,0.236086252,-0.082418612,-0.061201826,3.47825,0.09021,2.83382
BGNE,160.26,BRUKINSA (zanubrutinib) + Obinutuzumab - (ROSEWOOD),Follicular Non-Hodgkin LymphomaÂ ,Approved,2/26/2024,"Approval noted February 26, 2024.",106,16759.66066,0,0,0,0,#DIV/0!,#DIV/0!,-0.082418612,-0.061201826,0,0,0
ONC,â€”,BRUKINSA (zanubrutinib) + Obinutuzumab - (ROSEWOOD),Follicular Non-Hodgkin LymphomaÂ ,Approved,2/26/2024,"Approval noted February 26, 2024.",110,16759.66066,47.0104,155.1,160.26,167.86,0.032727426,0.079060228,-0.082418612,-0.061201826,1.98601,0.16306,92.80593
TCRX,6.79,"TSC-100, TSC-101 - (ALLOHA)",Hematologic malignanciesÂ ,Phase 1,2/26/2024,"Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February",56,324.72958,102.1748,6.76,6.79,7.12,0.004428052,0.051884835,-0.082418612,-0.061201826,0.50935,0.00016,0.84007
MTNB,0.27,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitisÂ ,Phase 3,2/26/2024,"Phase 3 update from ongoing Compassionate/Expanded use access of the 19 patients enrolled in the program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2",5,58.44415,267.5445,11.97,13.45,13.455,0.116575586,0.116947265,-0.082418612,-0.061201826,0.65451,0.01933,0.64075
JANX,15.1,PSMA-TRACTr (JANX007) - (ENGAGER-PSMA-01),Metastatic castration-resistant prostate cancer (mCPRC)Â ,Phase 1,2/26/2024,"Phase 1 updated clinical data at KOL illustrated a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC, noted Februar",60,696.88655,87.6014,15.69,15.1,42.61,-0.038328823,0.999065401,-0.082418612,-0.061201826,5.30102,0.17205,11.50175
JANX,15.1,EGFR-TRACTr (JANX008),"Metastatic colorectal cancer (mCRC), squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC)Â ",Phase 1,2/26/2024,"Phase 1 data at KOL display differentiated safety and encouraging signs of efficacy in heavily pretreated subjects with different solid tumor types, noted February 26, 2024.",60,696.88655,87.6014,15.69,15.1,42.61,-0.038328823,0.999065401,-0.082418612,-0.061201826,5.30102,0.17205,11.50175
GILD,71.36,Biktarvy,HIVÂ ,Approved,2/26/2024,"Approved for expanded indication to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, noted February 26, 2024.",,90879.25824,25.3457,73.55,72.95,72.25,-0.008191172,-0.01783312,-0.082418612,-0.061201826,1.25723,0.08187,377.7305
NERV,2.8,Roluperidone (MIN-101),SchizophreniaÂ ,CRL,2/27/2024,"CRL issued by the FDA, noted February 27, 2024.",6,19.58154,164.8147,6.8,2.8,2.6,-0.887303195,-0.961411167,-0.042144317,-0.021545549,0.33862,0.03994,5.44997
VKTX,85.05,VK2735 - (VENTURE),ObesityÂ ,Phase 2,2/27/2024,"Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.",113,8667.8403,133.7011,38.48,85.05,87.9,0.793100693,0.826061179,-0.042144317,-0.021545549,11.79401,0.13229,5020.81346
TARS,39.22,TP-04 - (Galatea),RosaceaÂ ,Phase 2a,2/27/2024,Phase 2a topline data reported statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment (IGA) score compared to vehicle at Week 12 TP-04 was genera,42,1342.06471,63.9681,33.16,39.22,35.77,0.167842491,0.075765223,-0.042144317,-0.021545549,16.54856,0.05322,98.80091
ACXP,3.13,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,2/27/2024,"Phase 2b FDA confirmed that trial adequate information was submitted for EoP2 meeting, noted February 27, 2024.",1,43.09372,132.286,65,62.6,59.8,-0.037621992,-0.083381609,-0.042144317,-0.021545549,2.18951,0.01744,0.56528
CGON,46.35,cretostimogene - (PIVOT-006) (EAP),Non-Muscle Invasive Bladder Cancer (NMIBC)Â ,Phase 3,2/27/2024,"Phase 3 dosing initiated, noted February 27, 2024.",76,3081.46439,0,46.01,46.35,41.49,0.007362528,-0.10340633,-0.042144317,-0.021545549,1.46491,0.37122,10.56289
PPBT,0.67,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ,Phase 1,2/27/2024,"Phase 2 was well tolerated with anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR), noted February 27, 2024.",2,70.63308,74.5033,0.273,0.273,0.293,0,0.070700814,-0.042144317,-0.021545549,0,0.06711,0
GANX,4.63,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Phase 1,2/27/2024,"Phase 1 dosing initiated, noted February 27, 2024.",35,75.00307,75.2511,4.5,4.63,4.66,0.028479471,0.034938051,-0.042144317,-0.021545549,0.84936,0.00189,0.48479
PTN,2.45,PL9643 - (MELODY-1),Dry eye disease (DED)Â ,Phase 3,2/28/2024,"Phase 3 final results reported met the first co-primary endpoint in the Intent-to-Treat Analysis, however did not meet the co-primary endpoint showing superiority over vehicle, noted February 28, 2024.Â read less",46,70.68903,69.7187,0.059,0.06,0.066,0.016807118,0.112117298,0.044416421,0.02729099,0,0.00236,0.04342
IXHL,6.27,PSX-001 (Psilocybin treatment) - (PsiGAD2),Generalized anxiety disorder (GAD)Â ,Phase 2,2/28/2024,"Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.",347,99.52442,183.2967,4.22,6.27,4.23,0.395941227,0.002366865,0.044416421,0.02729099,0.61248,0.01455,89.15146
CMPX,1.74,CTX-8371,Solid TumorsÂ ,Preclinical,2/28/2024,"Preclinical data reported that CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings, noted February 28, 2024.Â read less",138,221.77227,73.6305,1.76,1.74,1.96,-0.011428696,0.107630664,0.044416421,0.02729099,1.54758,0.04594,0.28337
SILO,1.62,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Preclinical,2/28/2024,"Preclinical data reported rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal, noted February 28, 2024.",9,4.67532,66.2861,1.55,1.62,1.5299,0.044171218,-0.013052557,0.044416421,0.02729099,2.23434,0.13751,3.01777
HCM,15.21,Amdizalisib (HMPL-689),Follicular Lymphoma and Marginal Zone LymphomaÂ ,Phase 2,2/28/2024,"Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.",174,2082.32107,51.6748,2.485,2.44,2.37,-0.01827462,-0.047382704,0.044416421,0.02729099,0,0.11973,0.13211
SNSE,0.84,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1,2/28/2024,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024.Â read less",1,20.99706,92.5836,15.4,16.8,18.642,0.087011377,0.19104959,0.044416421,0.02729099,0.57242,0.15126,0.15641
REGN,987.61,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1,2/28/2024,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024.Â read less",105,106130.4431,16.8107,993.35,987.61,972.1,-0.005795186,-0.021624389,0.044416421,0.02729099,1.27527,0.13895,479.97155
VANI,3.74,NPM-115 (exenatide implant) - (LIBERATE-1),Subdermal implants in development for chronic weight managementÂ ,Preclinical,2/28/2024,"Preclinical data showed that implant generated significant weight loss comparable to injectable semaglutide (Ozempic/Wegovy) from a single administration with expected twice-yearly dosing, noted February 28, 2024.Â read less",59,190.83372,192.7424,1.01,3.74,2.21,1.309135281,0.783042185,0.044416421,0.02729099,0.3625,0.00057,556.55458
AVIR,4.37,Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD),Hepatitis C Virus (HCV)Â ,Phase 2,2/28/2024,"Phase 2 final data from the 60-patient lead-in cohort reported that the SVR4 rate exceeded the protocol-defined efficacy criterion of â‰¥90% SVR4 for continuing the study, noted February 28, 2024.",79,367.79906,47.7314,4.56,4.37,4.03,-0.042559614,-0.123556248,0.044416421,0.02729099,1.92715,0.03677,3.66716
BLRX,1.32,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 2,2/28/2024,"Phase 2 trial initiated, noted February 28, 2024.",3,342.27559,78.981,0.299,0.315,0.318,0.052129065,0.061607809,0.044416421,0.02729099,0,0.00678,0.48022
KANT,â€”,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumorsÂ ,Phase 1/2,2/29/2024,"Phase 1/2 initial data reported a partial Response in 1 patient with a PD-L1 negative mucoepidermoid carcinoma and a 54% reduction in target lesions and a complete response in non-target lesions, noted March 12, 2024. Phase 1/2 new enrollment terminated, noted February 29, 2024.Â read less",13,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0,0.027357936,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
IMUX,1.47,IMU-838 - (CALLIPER),Progressive Multiple SclerosisÂ ,Phase 2,2/29/2024,"Phase 2 interim data presented at ACTRIMS reported that serum NfL was decreased in the treatment group by 22.4%, noted February 29, 2024.",98,131.74601,78.4561,1.4,1.465,1.46,0.045383006,0.041964199,0,0.027357936,2.80674,0.13566,0.96432
IMUX,1.47,IMU-838 - (CALVID-1),COVID-19Â ,Phase 2,2/29/2024,"Additional Phase 2 data reported that 80% of patients who received placebo reported fatigue, compared to 50% who received 45 mg vidofludimus calcium, noted February 29, 2024.",98,131.74601,78.4561,1.4,1.465,1.46,0.045383006,0.041964199,0,0.027357936,2.80674,0.13566,0.96432
IRWD,9.43,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF)Â ,Phase 3,2/29/2024,"Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024.Â read less",162,1476.06515,78.162,15.12,9.43,8.93,-0.472122274,-0.526601976,0,0.027357936,9.96442,0.04938,297.32597
CLNN,8.05,CNM-Au8 - (VISIONARY-MS),Multiple SclerosisÂ ,Phase 2,2/29/2024,"Phase 2 full clinical results presented at ACTRIMS Forum reported that treatment demonstrated significant improvement of vision as measured by low contrast letter acuity (LCLA) through 35 months from randomization, noted February 29, 2024.Â read less",9,51.67444,111.9083,8.68,8.048,8.13,-0.075597915,-0.065460605,0,0.027357936,0.17811,0.03295,0.70426
IMNN,1.14,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5Â ,Preclinical,2/29/2024,"Challenge study data reported that a single dose produced IgG neutralizing antibody and T-cell responses, noted February 29, 2024.",2,10.71518,85.7357,12.7826,14.86956,12.7826,0.151231299,0,0,0.027357936,5.53814,0.02506,1.07745
CUE,2.08,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancerÂ ,Phase 1,2/29/2024,"Phase 1 data reported from the Multi-disciplinary Head and Neck Cancers Symposium that overall response rate (ORR) of 47% in first line (1L) patients treated with CUE-101 and pembrolizumab, compared to the historical ORR of 19% reported in the KEYNOTE-48 trial, noted February 29, 2024.Â read less",76,93.63081,77.9897,2.12,2.075,1.97,-0.021454935,-0.073382546,0,0.027357936,8.44038,0.19909,0.33103
CRDF,1.77,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal CancerÂ ,Phase 2,2/29/2024,"Phase 2 data reported a 50% ORR rate in Bev Naive patients and 0% ORR in Bev Exposed patients, noted February 29, 2024.",66,78.8552,78.2095,1.82,1.765,3.51,-0.030685811,0.656779536,0,0.027357936,2.65794,0.06812,3.4809
TGTX,17.22,BRIUMVI (ublituximab-xiiy) - (ENHANCE),Relapsing forms of Multiple Sclerosis (RMS)Â ,Phase 3,2/29/2024,"Phase 3b data presented at ACTRIMS reported that 18 (86%) of participants completed the infusion without interruption or slowing, with a median infusion duration of 60 min, noted February 29, 2024.",158,2493.14094,85.1538,17.63,17.22,18,-0.023530497,0.020769761,0,0.027357936,24.71081,0.15503,106.8718
RYTM,43.42,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevanceÂ ,Phase 2,2/29/2024,"Phase 2 data showed that nearly 97% of followed patients were relapse-free at 90 days post Zeposia discontinuation; patients that did relapse showed no evidence of rebound effect, noted February 29, 2024.Â read less",66,2611.30029,63.2772,44.38,43.42,41.67,-0.021868753,-0.063007472,0,0.027357936,14.56852,0.14954,22.77058
ATRA,19.45,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus NephritisÂ ",IND-Enabling,2/29/2024,"IND cleared by the FDA, noted February 29, 2024",7,79.29551,267.3769,19.0125,19.45,17.4075,0.022750412,-0.08819551,0,0.027357936,10.66789,0.03106,4.2351
CGEM,18.51,CLN-619 - (MICB),Relapsed or Refractory Multiple MyelomaÂ ,IND-Enabling,3/1/2024,"IND Clearaed by the FDA, noted March 1, 2024.",59,791.86972,60.4564,18.47,18.51,16.79,0.002163332,-0.095364323,-0.023199635,-0.005370637,1.83242,0.07541,8.38808
BIVI,1.89,NE3107,Parkinson's diseaseÂ ,Phase 2a,3/1/2024,"Additional Phase 2a data reported significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson's Disease, whereas placebo patients experienced a worsening of +1.0 points, noted March 1, 2024Â read less",7,75.41421,181.5353,124,189,71.8,0.421465449,-0.54639709,-0.023199635,-0.005370637,2.57721,0.00233,175.17597
BIVI,1.89,NE3107,Alzheimerâ€™s diseaseÂ ,Phase 3,3/1/2024,"Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS, +1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL, noted March 1, 2024.Â read less",7,75.41421,181.5353,124,189,71.8,0.421465449,-0.54639709,-0.023199635,-0.005370637,2.57721,0.00233,175.17597
KRBP,2.36,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung CancerÂ ,Phase 1,3/1/2024,"Phase 1 third patient enrolled completed treatment, noted March 1, 2024",1,3.04024,0,0,0,0,#DIV/0!,#DIV/0!,-0.023199635,-0.005370637,0,0,0
LEXX,2.92,HYPER-H23-1 (DehydraTECH-CBD),HypertensionÂ ,IND-Enabling,3/1/2024,"IND Cleared by the FDA, noted March 1, 2024",19,35.03684,103.6784,3.45,2.92,5.5,-0.166790615,0.466373861,-0.023199635,-0.005370637,5.71471,0.00887,4.70875
SLS,1,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 1,3/1/2024,"Phase 1 dose-escalation topline data for the heavily pretreated AML patients showed evidence of anti-tumor activity increasing with higher dose levels and no significant safety issues. Treatment with SLS009 resulted in a complete remission (CR) with no minimal residual disease (MRD) after three cycles as a monotherapy in an AML patient who had failed prior venetoclax plus azacytidine (aza/ven) therapy. The CR lasted eight months with the patient achieving one year survival at the latest assessment. This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy. Notably, the median survival for patients relapsed after aza/ven therapy is approximately 2.5 months. All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024.Â read less",105,42.26289,115.3931,1.01,1,1.26,-0.009950331,0.22116139,-0.023199635,-0.005370637,9.19793,0.1291,1.08164
JNJ,160.8,RYBREVANT (amivantamab) - (PAPILLON),Non-small cell lung cancerÂ ,Approved,3/1/2024,"FDA approved on March 1, 2024.",,390509.343,13.2816,161.38,162.12,159.52,0.004574969,-0.011592526,-0.023199635,-0.005370637,0.45519,0.1225,919.24229
WHWK,â€”,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour)Â ,Phase 2,3/1/2024,"Phase 2 long-term efficacy and safety results demonstrated 40 months median duration of response and median survival >53 months, noted March 1, 2024.",47,47.08965,133.2758,1.97,1.92,2.14,-0.025708357,0.082772286,-0.023199635,-0.005370637,4.03782,0.01134,5.26143
RNA,18.86,Delpacibart etedesiran (del-desiran) - (MARINA-OLE),Myotonic dystrophy type 1 (DM1)Â ,Phase 2,3/4/2024,"Phase 2 preliminary data anticipated at the MDA conference showed reversal of disease progression in multiple functional measures, noted March 4, 2024.",128,1505.78227,84.5925,20.11,18.86,21.02,-0.064173927,0.044257162,0.020598768,0.047397458,9.68352,0.09712,74.10601
NVO,â€”,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,3/4/2024,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated â‰¥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024.Â read less",,3914623.24,27.8692,124.23,127.95,131.24,0.029504876,0.054893022,0.020598768,0.047397458,0,0,872.22863
AKRO,31.07,Efruxifermin - (HARMONY),Nonalcoholic SteatohepatitisÂ ,Phase 2b,3/4/2024,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated â‰¥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024.Â read less",79,1749.1642,158.4807,27.81,31.07,29.31,0.110847055,0.052533086,0.020598768,0.047397458,15.7995,0.10523,265.0884
CLRB,4.24,CLR 131 (iopofosine) in combination with external beam radiation (EBRT),Head & neck cancerÂ ,Phase 1,3/4/2024,"Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.",3,129.11665,88.4062,126.00013,127.20013,113.10011,0.009478734,-0.108009583,0.020598768,0.047397458,7.76741,0.05668,12.59765
NVS,98.29,Zolgensma (onasemnogene abeparvovec) - (SMART),Spinal muscular atrophy (SMA)Â ,Phase 3,3/4/2024,"Phase 3b data reported that nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy, noted March 4, 2024.Â read less",,1303.17914,53.8789,4.05,4.2,4.1,0.036367644,0.012270093,0.020598768,0.047397458,0,0.00181,0.14593
INDP,2.36,Decoy-20 - (INDP-D101),Advanced/metastatic solid tumorsÂ ,Phase 1,3/4/2024,"Phase 1 data following completion of second cohort trial of Decoy 20 leads the independent Safety Review Committee to recommend initiating a multi-dosing cohort, noted March 4, 2024. Single dose cohort data expected to be published at a scientific conference in 2024Â read less",1,19.82644,76.7485,58.51998,66.07997,56.55998,0.121497441,-0.034066566,0.020598768,0.047397458,0.20422,0.05483,7.97632
BCDA,6.83,CardiAMP (BCDA-01),Ischemic Heart FailureÂ ,Phase 3,3/4/2024,"Phase 3 data reported that patients had 37% relative risk reduction in heart death equivalent and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at mean 20-month follow-up compared to control patients on guideline-directed heart medications alone, noted March 4, 2024.Â read less",5,11.79323,179.4466,8.697,6.8265,6.3225,-0.242166041,-0.318863439,0.020598768,0.047397458,1.14827,0.01903,1.63556
VTVT,14.01,Cadisegliatin (TTP399),Type 1 DiabetesÂ ,Phase 3,3/4/2024,"Phase 3 announced the submission of the study protocol to the FDA to initiate the trial, noted March 4, 2024.",3,35.04555,147.5029,16.55,14.01,15.02,-0.166614741,-0.097003455,0.020598768,0.047397458,1.72791,0.00051,1.0205
LNTH,65.36,DEFINITY (Perflutren Lipid Microsphere),Ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiogramsÂ ,Approved,3/4/2024,"FDA approved on March 4, 2024.",67,4478.83034,68.0206,64.64,65.36,62.72,0.011077036,-0.030153038,0.020598768,0.047397458,7.33668,0.00631,59.11198
MTEM,3.85,MT-6402,Solid tumorsÂ ,Phase 1,3/4/2024,"Phase 1 dose-escalation data showed that treatment appears generally well-tolerated at the 63 and 83 mcg/kg doses with no Grade 4 or Grade 5 adverse events and no instances of CLS seen at any dose, noted March 4, 2024.Â read less",6,20.69093,0,0,0,0,#DIV/0!,#DIV/0!,0.020598768,0.047397458,0,0,0
NRXP,5.2,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,3/4/2024,"Phase 2/3 last patient dosed, noted March 4, 2024.",19,47.32464,107.6566,4.381,5.2,6.69,0.171381617,0.423336865,0.020598768,0.047397458,4.2504,0.03217,2.42754
PCVX,71.55,VAX-24,Pneumococcal Disease in infantsÂ ,Phase 2,3/4/2024,"Phase 2 enrollment completed, noted March 4, 2024.",129,7756.57308,39.7577,71.71,71.55,70.25,-0.002233702,-0.0205699,0.020598768,0.047397458,9.82674,0.0238,44.71102
BCDA,6.83,Allogeneic CardiALLO,Heart failureÂ ,Phase 1/2,3/4/2024,"Data presented at the Technology and Heart Failure Therapeutics Conference (THT) reported that first patient has been enrolled and treated in the low dose group and is doing well clinically, noted March 4, 2024.Â read less",5,11.79323,179.4466,8.697,6.8265,6.3225,-0.242166041,-0.318863439,0.020598768,0.047397458,1.14827,0.01903,1.63556
GSK,42.09,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four monthsÂ ,Phase 1,3/4/2024,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",,67682.93047,17.8337,16.618,16.678,16.75,0.00360404,0.007911813,0.020598768,0.047397458,0,0.00103,85.0566
PFE,25.51,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four monthsÂ ,Phase 1,3/4/2024,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",,146195.0934,26.4556,26.59,25.89,28.37,-0.026678411,0.064797044,0.020598768,0.047397458,1.07461,0.07343,2246.67527
APGE,59.3,APG777 - (APEX),"Healthy volunteers, Atopic dermatitis (AD)Â ",Phase 1,3/5/2024,"Phase 1 interim data reported a half-life of approximately 75 days across doses tested and Pharmacodynamic (PD) data showed deep and sustained inhibition of key AD biomarkers pSTAT6 and TARC for ~3 months, noted March 5, 2024.Â read less",59,2877.19603,83.7909,41.74,59.3,69.34,0.351149404,0.507562039,0.006074203,0.046014312,6.79805,0.17131,377.03397
GSK,42.25,Cabotegravir ultra long-acting (CAB-ULA) - (4 month dosing),HIVÂ ,Phase 1,3/5/2024,"Phase 1 data reported that intramuscular dosing of CAB-ULA has a safety and pharmacokinetic (PK) profile that supports a longer dose interval, noted March 5, 2024.",,68316.0122,17.8574,16.678,16.834,16.852,0.009310165,0.010378858,0.006074203,0.046014312,0,0.00103,85.54386
NVO,123.76,Semaglutide - (FLOW),Renal impairment in people with type 2 diabetes and chronic kidney disease (CKD)Â ,Phase 3,3/5/2024,"Phase 3 trial stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo, noted March 5, 2024.Â read less",,3815552.748,28.0478,127.95,124.65,135.11,-0.026129753,0.054449699,0.006074203,0.046014312,0,0,599.29277
CASI,5.66,BI-1206 with rituximab - (China trial),Non-Hodgkin's Lymphoma (NHL)Â ,Phase 1,3/5/2024,"Phase 1 initial data showed promising responses including a long-lasting complete response for patients with difficult-to-treat disease, noted March 5, 2024.",15,75.39973,106.5545,5.085,5.66,4.1,0.107128863,-0.215308056,0.006074203,0.046014312,0.39885,0.00097,55.37822
MNPR,1.06,MNPR-101-Zr (uPAR),Solid tumorsÂ ,Preclinical,3/5/2024,"Addtional preclinical data demonstrated highly preferential uptake in the tumor. The new imaging data released today support the tumor-targeting ability of MNPR-101, noted March 5, 2024.",6,15.75838,177.6299,4.9505,5.3,4.13,0.068218239,-0.181211175,0.006074203,0.046014312,0.42268,0.00335,1.74942
ALNY,149.68,Zilebesiran - (KARDIA-2),HypertensionÂ ,Phase 2,3/5/2024,"Phase 2 trial met the primary endpoint, noted March 5, 2024.",131,18851.5663,39.3577,150.04,149.68,146.65,-0.002402243,-0.02285313,0.006074203,0.046014312,3.16632,0.31728,105.3123
RGNX,24.61,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD)Â ,Phase 1/2,3/5/2024,"Phase 1/2 new three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression. Patient aged 12 years at dosing had expression level at 75.7% of control, noted March 5, 2024.Â read less",50,1093.36213,75.2986,21.36,24.61,21.98,0.14163285,0.028612935,0.006074203,0.046014312,9.39539,0.11372,69.04503
CRVO,13,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB)Â ,Phase 2a,3/5/2024,"Phase 2a data presented at AD/PD reported that there was a mean 3.7 pg/mL increase GFAP levels in placebo vs. mean 12.3 pg/mL reduction with neflamapimod, noted March 5, 2024.",9,80.21623,102.5337,12.7,13,17.57,0.023347364,0.324590909,0.006074203,0.046014312,0.65847,0.00027,0.31624
GANX,4.66,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Preclinical,3/5/2024,"Preclinical data presented at AD/PD reported that GT-02287, through its interaction with glucocerebrosidase (GCase) in the endoplasmic reticulum (ER), aids correct GCase folding, preventing ER retention, ER stress, and ER-associated degradation of mutated GCase enzyme, noted March 5, 2024.Â read less",35,75.48906,75.2859,4.72,4.66,4.56,-0.012793351,-0.034486176,0.006074203,0.046014312,0.84936,0.00309,3.24716
IMMP,2.61,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC)Â ,Phase 2/3,3/5/2024,"Phase 2/3 90mg data reported a 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate overall, noted March 5, 2024.",145,451.75713,51.7776,2.35,2.61,2.55,0.104934893,0.081678031,0.006074203,0.046014312,0,0,1.37827
LLY,776.31,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA)Â ,Phase 2b,3/5/2024,https://www.biopharmcatalyst.com/company/NKTR/news/189917,946,699958.8762,28.7736,792.28,777.59,754.95,-0.018715472,-0.048263343,0.006074203,0.046014312,0.57244,0.0081,2463.94088
NKTR,0.88,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA)Â ,Phase 2b,3/5/2024,https://www.biopharmcatalyst.com/company/NKTR/news/189917,19,162.3365,88.7003,13.49999,13.26149,13.34999,-0.017824598,-0.011173309,0.006074203,0.046014312,1.33641,0.02909,5.08314
ONCY,1.03,mFOLFIRINOX +/- atezolizumab and pelareorep - (PanCAN),Pancreatic Ductal Adenocarcinoma (PDAC)Â ,Phase 1/2,3/5/2024,"Company submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort, noted March 5, 2024.",100,77.6589,81.563,0.92,1.03,1.06,0.112940411,0.141650517,0.006074203,0.046014312,1.22473,0.02796,0.44063
LIPO,0.81,LP-410,Graft-Versus-Host Disease (GVHD)Â ,IND-Enabling,3/5/2024,"IND cleared by the FDA noted, March 5, 2024.",4,5.04878,129.9728,8.24,6.4624,5.636,-0.242999578,-0.37982575,0.006074203,0.046014312,0.4103,0.01172,0.95773
IBRX,4.82,Anktiva (N-803),HIVÂ ,Phase 1,3/5/2024,"Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated, noted March 5, 2024.",945,3230.99585,134.3936,5.07,4.82,5.05,-0.05056689,-0.003952574,0.006074203,0.046014312,7.03236,0.01625,17.65885
OPK,0.93,SAR441236,human immunodeficiency virus (HIV)Â ,Phase 1,3/5/2024,"Phase 1 study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans, noted March 5, 2024.",793,651.61752,86.7239,1,0.9349,0.9279,-0.067315707,-0.074831311,0.006074203,0.046014312,14.05216,0.07567,14.55008
GILD,71.4,Bictegravir and Lenacapavir - (ARTISTRY-1),HIVÂ ,Phase 2/3,3/5/2024,"Phase 2/3 data reported that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study, noted March 5, 2024.",,90929.08922,25.069,72.25,72.99,75.08,0.010190118,0.038421885,0.006074203,0.046014312,1.59581,0.07912,458.40859
NVS,98.42,Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) interchangeable,multiple myeloma and in patients with bone metastases from solid tumorsÂ ,Approved,3/5/2024,"FDA biosimilar of Xgeva (denosumab) and Prolia (denosumab) approved on March 5, 2024.",,1303.17914,53.8789,4.2,4.2,4.03,0,-0.041318149,0.006074203,0.046014312,0,0.00181,0.00995
BTAI,2.96,BXCL501 - (SERENITY III),Agitation associated with bipolar I or II disorder or schizophreniaÂ ,Phase 3,3/6/2024,"A Type C meeting with FDA feedback resulted in an amended Phase 3 trial planned for the at-home setting, noted March 6, 2024.",14,89.93044,140.0889,48.32,47.36,45.92,-0.020067563,-0.050944802,0.006759168,0.024014178,24.55265,0.02276,1.40351
VNDA,3.91,HETLIOZ (tasimelteon),InsomniaÂ ,CRL,3/6/2024,"CRL issued by FDA on March 6, 2024.",59,224.97162,60.8849,4.14,3.91,3.84,-0.057158414,-0.075223421,0.006759168,0.024014178,5.14407,0.00941,6.03893
BMEA,15.8,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetesÂ ",Phase 1/2,3/6/2024,"Phase 1/2 data presented at ATTD reported that across 100mg QD, 200mg QD, and 100mg BID cohorts, 38% of patients had â‰¥0.5% HbA1c reduction, and 23% of patients had â‰¥1.0% HbA1c reduction at Week 26, noted March 6, 2024.Â read less",59,564.15142,108.0851,17.52,15.8,17.4,-0.103333145,-0.006872879,0.006759168,0.024014178,32.999,0.03954,49.82017
XOMA,25,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemiaÂ ",Preclinical,3/6/2024,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less",12,287.1952,61.4019,24.59,25,25.61,0.016535969,0.040643044,0.006759168,0.024014178,2.55024,0.00058,0.40653
RZLT,1.8,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemiaÂ ",Preclinical,3/6/2024,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024.Â read less",90,71.12736,89.0371,1.78,1.795,1.92,0.008391658,0.075711822,0.006759168,0.024014178,2.55211,0.00367,0.2199
KURA,22.7,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,3/6/2024,"Phase 1 dosing initiated, noted March 6, 2024.",86,1728.30906,77.5201,21.04,22.7,22.83,0.075939537,0.081650073,0.006759168,0.024014178,13.80528,0.07022,35.81819
BMY,51.98,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC)Â ,Phase 1,3/6/2024,"Phase 1 dosing initiated, noted March 6, 2024.",,107944.6843,21.5146,51.82,53.38,52.65,0.029659969,0.015890063,0.006759168,0.024014178,1.55743,0.12183,1157.93626
ASLN,5.35,eblasakimab versus dupilumab,human tissue model of chronic obstructive pulmonary disease (COPD)Â ,Preclinical,3/6/2024,"Preclinical new translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations, noted March 6, 2024.Â read less",2,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.006759168,0.024014178,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
COYA,9.67,COYA 302,Frontotemporal dementia (FTD)Â ,Preclinical,3/6/2024,"Preclinical biomarker data shared at the AD/PD 2024 Conference clearly depicts a compromised peripheral immune environment present in patients with FTD that, we believe, contributes to the pathophysiology of the disease process, noted March 5, 2024. IND filing intended later in 2024 and Phase 2 initiation, noted March 6, 2024.Â read less",16,139.29949,81.6073,9.54,9.67,9.79,0.013534824,0.025867971,0.006759168,0.024014178,0.1546,0.00236,0.78757
BHC,9.23,RELISTOR (methylnaltrexone bromide: MNTX),Resectable head and neck squamous cell carcinomaÂ ,Phase 2,3/6/2024,"Phase 2 initiated sponsored by Salix Pharmaceuticals, noted March 6, 2024.",369,3372.75233,42.3824,9.56,9.23,9.28,-0.035128679,-0.02972618,0.006759168,0.024014178,5.89081,0.16951,24.56074
REGN,972.1,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,3/6/2024,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",105,104463.7091,17.2866,965.21,972.1,965.47,0.007112986,0.000269335,0.006759168,0.024014178,1.27527,0.13251,356.59933
MAIA,1.47,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC)Â ,Phase 2,3/6/2024,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",32,24.96979,123.0616,1.48,1.47,1.3401,-0.006779687,-0.09929785,0.006759168,0.024014178,2.5578,0.00184,3.23699
GILD,71.04,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,3/6/2024,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024.Â read less",,90480.61036,25.0199,72.99,72.63,75.94,-0.004944386,0.039621109,0.006759168,0.024014178,1.59581,0.07912,448.15092
MRK,122.23,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV)Â ,Phase 2,3/6/2024,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024.Â read less",,313414.6792,16.1292,122.83,123.75,122.16,0.007462116,-0.005469625,0.006759168,0.024014178,0.66406,0.0006,1021.10605
GSK,42.27,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIVÂ ,Phase 3,3/6/2024,"Phase 3 data reported that 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC, noted March 6, 2024.",,67902.07414,17.8764,16.834,16.732,16.952,-0.006077597,0.00698517,0.006759168,0.024014178,0,0.00103,101.39759
ZLAB,19.8,ZEJULA (niraparib) - (NORA),Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)Â ,Phase 3,3/6/2024,"Phase 3 data reported that treatment demonstrated a favorable OS trend versus placebo in this disease setting, regardless of BRCA-gene mutation status. No new safety signals were identified during the long-term follow up period subsequent to the primary analysis, noted March 6, 2024.Â read less",109,1954.60696,57.1708,18.91,19.8,20.16,0.045991055,0.064009561,0.006759168,0.024014178,4.74981,0.18805,8.35944
GILD,71.04,Biktarvy - (ALLIANCE),HIV/HBV CoinfectionÂ ,Phase 3,3/6/2024,"Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024.Â read less",,90480.61036,25.0199,72.99,72.63,75.94,-0.004944386,0.039621109,0.006759168,0.024014178,1.59581,0.07912,448.15092
DYN,26.78,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,3/6/2024,"Phase 1/2 initial data show levels of exon skipping, dystrophin, and PDPF increased at 6 months vs. baseline, noted March 6, 2024.",142,2194.83706,95.7142,25.87,26.78,27.77,0.034571344,0.070872305,0.006759168,0.024014178,8.84366,0.06854,30.81853
BMY,51.88,Opdivo (nivolumab) plus Yervoy (ipilimumab),Urothelial carcinomaÂ ,Approved,3/7/2024,"Approved March 7, 2024.",,107742.4649,21.4987,53.38,53.28,52.49,-0.001875118,-0.016813469,0.011754795,0.058298873,1.55743,0.12183,918.17754
MNMD,9,MM-120 (LSD),Generalized Anxiety Disorder (GAD)Â ,Phase 2b,3/7/2024,"Phase 2b data 12-week data reported that the trial met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate, noted March 7, 2024.Â read less",75,372.00876,94.8051,5.94,9,8.14,0.415515444,0.315081047,0.011754795,0.058298873,8.29487,0.22287,342.94969
FBIO,2.07,MB-101 - (City of Hope),High-Grade GliomaÂ ,Phase 1,3/7/2024,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",29,38.03987,151.881,2.215,2.07,1.68,-0.067703796,-0.27645861,0.011754795,0.058298873,8.92794,0.09839,0.60512
MBIO,1.39,MB-101 - (City of Hope),High-Grade GliomaÂ ,Phase 1,3/7/2024,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",7,70.30113,59.9078,66,69.5,49.735,0.051672011,-0.282945831,0.011754795,0.058298873,0.08438,0.11009,5.54137
GSK,43.22,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple MyelomaÂ ,Phase 3,3/7/2024,"Phase 3 trial met its primary endpoint, noted March 7, 2024",,69444.19632,18.0914,16.732,17.112,16.878,0.022456918,0.008687945,0.011754795,0.058298873,0,0.00103,174.20889
IMRN,4.55,Travelan - (CHIM),Enterotoxigenic Escherichia coli (ETEC)Â ,Phase 2,3/7/2024,"Phase 2 interim data reported that the intended attack rate for this study was approximately 70%. The attack rate for the Placebo group of this study was only 37%, noted March 7, 2024.",6,28.47479,157.8071,1.6501,4.55,2.82,1.014291341,0.535900993,0.011754795,0.058298873,0,0,244.68916
TELO,8.7,Telomir-1,Age-related conditionsÂ ,Preclinical,3/7/2024,"Preclinical data reported that Telomir-1 was observed to cause cell cytotoxicity at a concentration of 500 M in both MRC-5 and HUVEC cells, noted March 7, 2024.",32,257.60538,0,8.76,8.7,6.51,-0.006872879,-0.296856449,0.011754795,0.058298873,0.01001,0.86973,0.30182
APVO,6.6,ALG.APV-527,Solid tumorsÂ ,Phase 1,3/7/2024,"Phase 1 data reported 2 stable disease responses, noted March 7, 2024.",3,3.51648,91.0689,4736.00474,4884.00488,3729.60373,0.030771657,-0.238891909,0.011754795,0.058298873,0.08378,0.07383,23.99023
ATHA,3.58,Fosgonimeton (ATH-1017) - (SHAPE),Parkinsonâ€™s disease dementiaÂ ,Phase 2,3/8/2024,"Phase 2 data presented at AD/PD reported that changes in ADAS-Cog13 observed in the fosgonimeton 40 mg dose arm were suggestive of a pro-cognitive effect, noted March 8, 2024.",3,137.20941,79.4269,41.5,35.8,26.2,-0.147745534,-0.459934016,0.020039521,0.042176794,1.69681,0.03147,6.6453
AMLX,3.36,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML)Â ,Phase 3,3/8/2024,"Phase 3 topline results did not meet the primary endpoint, noted March 8, 2024.",89,227.74799,256.5398,18.97,3.36,3.24,-1.73091781,-1.767285454,0.020039521,0.042176794,7.34621,0.0378,206.52855
KYTX,28.67,KYV-101,Non-relapsing and progressive forms of multiple sclerosisÂ ,Phase 1,3/8/2024,"Phase 1 trial with Stanford University commenced, noted March 8, 2024.",43,1221.79275,0,28.78,28.67,29.71,-0.003829422,0.031802988,0.020039521,0.042176794,1.36724,0.45613,7.64617
NVO,132.12,Wegovy (Semaglutide),Cardiovascular risk reduction in adults with obesityÂ ,Approved,3/8/2024,"Approved March 8, 2024.",,4038684.488,30.5049,135.92,133.07,132.37,-0.021191172,-0.026465446,0.020039521,0.042176794,0,0,1698.64414
ABOS,4.37,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimerâ€™s disease (AD)Â ,Phase 1,3/8/2024,"Phase 1 biomarker results presented at PD/AD support sabirnetug's downstream pharmacological effects in the brain in early AD, noted March 8, 2024.",60,253.06872,86.2306,4.37,4.37,4.18,0,-0.044451763,0.020039521,0.042176794,1.17377,0.05985,1.48282
MNKD,5.27,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 DiabetesÂ ,Phase 3,3/8/2024,"Phase 4 data presented at ATTD reported that post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps, noted March 8, 2024.Â read less",306,1425.10399,57.2436,5.15,5.27,4.47,0.023033648,-0.141608306,0.020039521,0.042176794,12.81512,0.02152,27.05728
TLSA,0.49,Foralumab (Intranasal),Alzheimerâ€™s DiseaseÂ ,Phase 1,3/8/2024,"IND clearance by FDA, noted August 15, 2023. Phase 1 data presented at the AD/PD Conference on March 8, 2024.",111,48.84991,57.4364,0.5187,0.487,0.4997,-0.063061558,-0.037317763,0.020039521,0.042176794,0.30576,0.01965,0.03935
ARQT,11.15,Roflumilast Cream (ARQ-151) - (DERMIS-1),Plaque psoriasisÂ ,Phase 3,3/9/2024,"Additional data shared at AAD reported a clinically meaningful response in >70% of patients, noted March 9, 2024.",119,1281.92953,109.4401,11.15,11.15,10.66,0,-0.044941079,0.021657808,0.043795081,14.73609,0.09407,0
MLTX,47.05,Nanobody sonelokimab - (IZAR),Active psoriatic arthritis (PsA)Â ,Phase 2b,3/10/2024,"Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.",64,2867.71219,82.3884,45.61,45.61,47.25,0,0.035325663,0.021657808,0.043795081,10.51676,0.03112,0
ARQT,10.04,ZORYVE (roflumilast) Cream 0.05%,Atopic Dermatitis - ages of 2-5 years oldÂ ,Phase 3,3/10/2024,"Phase 3 data to be shared at late-breaking presentation at AAD reported significant improvements in atopic dermatitis across multiple efficacy endpoints and all timepoints, noted March 10, 2024.",119,1281.92953,109.4401,11.15,11.15,10.66,0,-0.044941079,0.021657808,0.043795081,14.73609,0.09407,0
LXRX,2.81,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD)Â ,NDA Filing,3/11/2024,"After public Notice of Opportunity for Hearing (NOOH) proceeding in late 2023, the FDA issued feedback for sotagliflozin resbmisssion, noted March 11, 2024.",363,685.70939,107.5032,2.17,2.81,2.52,0.258457316,0.149531734,0.028185314,0.062552958,8.63253,0.0361,82.8835
AMGN,273.41,Otezla - (SPROUT),Plaque psoriasis in pediatric patientsÂ ,Phase 3,3/11/2024,"Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.",538,147570.6286,22.751,273.75,275.36,270.9,0.005864051,-0.010465532,0.028185314,0.062552958,2.05594,0.01736,509.72551
INCY,60.79,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS)Â ,Phase 2,3/11/2024,"Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024.Â read less",195,13648.94332,27.945,60.02,60.79,57.34,0.012747462,-0.04567938,0.028185314,0.062552958,3.46247,0.16218,133.32159
INCY,60.79,Povorcitinib (INCB54707),Prurigo NodularisÂ ,Phase 2,3/11/2024,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.",195,13648.94332,27.945,60.02,60.79,57.34,0.012747462,-0.04567938,0.028185314,0.062552958,3.46247,0.16218,133.32159
ASLN,13.04,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD)Â ,Phase 2b,3/11/2024,"Phase 2b preliminary review of blinded data from 22 patients treated to date, 45% (10/22) of patients saw at least a 90% reduction in their EASI score (EASI-90) and 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, noted March 11, 2024.Â read less",2,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.028185314,0.062552958,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
NRIX,14.13,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL)Â ",Phase 1b,3/11/2024,"Phase 1a/1b clinical hold lifted by the FDA, noted March 11, 2024.",76,690.87341,85.7088,14.85,14.13,12.84,-0.049699669,-0.145434567,0.028185314,0.062552958,14.00249,0.1782,12.81804
SONN,2.07,SON-080 - (SB211),Chemotherapy Induced Peripheral Neuropathy (CIPN)Â ,Phase 1/2,3/11/2024,"Phase 1b/2a cleared after review by the independent DSMB, noted March 11, 2024.",6,6.35389,97.7855,14.8,16.56,18.08,0.112362968,0.200179174,0.028185314,0.062552958,8.27734,0.04156,6.5386
APRE,6.77,APR-1051 - (ACESOT-1051),Solid tumorsÂ ,IND-Enabling,3/11/2024,"IND cleared by the FDA, noted March 11, 2024.",5,25.29728,96.6218,7.13,6.77,6.55,-0.051810148,-0.084846185,0.028185314,0.062552958,1.87742,0.04508,7.80276
LLY,733.16,Lebrikizumab,Moderate-to-severe atopic dermatitisÂ ,Phase 3,3/11/2024,"Phase 3 data reported that 68% of people experienced significant improvement of at least 75% in disease extent and severity (EASI-75), noted March 11, 2024.",946,661053.7686,29.172,762.14,734.37,762.66,-0.037117277,0.000682057,0.028185314,0.062552958,0.60249,0.00423,2914.60731
VTYX,8.04,VTX3232,Parkinson's diseaseÂ ,Phase 1,3/11/2024,"Phase 1 clinical update presented at virtual investor event showed that treatment was well-tolerated with no dose-limiting toxicities identified. All treatment-emergent adverse events were graded mild or moderate, noted March 11, 2024.Â read less",71,476.28247,265.9507,9.92,8.04,7.98,-0.210123838,-0.21761451,0.028185314,0.062552958,15.51744,0.01312,62.19627
VTYX,8.04,VTX2735,"Healthy volunteers, cryopyrin-associated periodic syndrome (CAPS)Â ",Phase 2,3/11/2024,"Phase 2 trial ongoing, with clinical update presented at virtual investor event showed that treatment demonstrated clinically meaningful improvements in disease activity, including an 85% mean reduction in the Key Symptom Score during Treatment Period 1, noted March 11, 2024.Â read less",71,476.28247,265.9507,9.92,8.04,7.98,-0.210123838,-0.21761451,0.028185314,0.062552958,15.51744,0.01312,62.19627
VTYX,8.04,Tamuzimod (VTX002),Ulcerative Colitis (UC)Â ,Phase 2,3/11/2024,"Phase 2 OLE clinical update presented at the virtual investor event data continues to support the potentially differentiated profile of VTX002 in ulcerative colitis, with robust rates of clinical remission and endoscopic remission observed among participants completing 52 weeks of treatment with VTX002, noted March 11, 2024.Â read less",71,476.28247,265.9507,9.92,8.04,7.98,-0.210123838,-0.21761451,0.028185314,0.062552958,15.51744,0.01312,62.19627
NVCR,15.99,Tumor Treating Fields (TTFields) - (INNOVATE-3),Ovarian cancerÂ ,Phase 3,3/11/2024,"Phase 3 exploratory subgroup analysis finds that pegylated liposomal doxorubicin (PLD) -naÃ¯ve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naÃ¯ve patients treated with paclitaxel alone, noted March 11, 2024.Â read less",111,1712.42398,68.1107,16.54,15.99,13.82,-0.033818163,-0.179664871,0.028185314,0.062552958,5.2674,0.05056,18.10626
TVTX,7.99,FILSPARI (sparsentan),IgA nephropathy (IgAN)Â ,sNDA Filing,3/11/2024,"sNDA submitted to the FDA, noted March 11, 2024.",89,608.0269,105.6802,8.66,7.99,7.18,-0.080523963,-0.18741534,0.028185314,0.062552958,13.4837,0.14398,8.94008
LGND,72.25,FILSPARI (sparsentan),IgA nephropathy (IgAN)Â ,sNDA Filing,3/11/2024,"sNDA submitted to the FDA, noted March 11, 2024.",19,1279.20699,42.4473,73.77,72.25,72.14,-0.020819818,-0.022343469,0.028185314,0.062552958,4.30741,0.38777,8.406
JNJ,159.92,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024Â read less",,388365.5402,13.0223,159.52,161.23,156.76,0.010662611,-0.017453333,0.028185314,0.062552958,0.6165,0.11902,745.01578
PTGX,30.12,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024Â read less",62,1755.24294,52.3404,30.32,30.12,28.46,-0.006618158,-0.063307968,0.028185314,0.062552958,5.03761,0.09328,17.56864
JNJ,159.92,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024.Â read less",,388365.5402,13.0223,159.52,161.23,156.76,0.010662611,-0.017453333,0.028185314,0.062552958,0.6165,0.11902,745.01578
PTGX,30.12,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasisÂ ,Phase 2b,3/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024.Â read less",62,1755.24294,52.3404,30.32,30.12,28.46,-0.006618158,-0.063307968,0.028185314,0.062552958,5.03761,0.09328,17.56864
ALMS,â€”,Izokibep,Hidradenitis Suppurativa (HS)Â ,Phase 2b,3/11/2024,"Phase 2b long-term data reported that data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time, noted March 11, 2024.Â read less",104,0,0,0,0,0,#DIV/0!,#DIV/0!,0.028185314,0.062552958,0,0,0
ALMS,â€”,Izokibep,Psoriatic arthritis (PsA)Â ,Phase 2,3/11/2024,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.",104,0,0,0,0,0,#DIV/0!,#DIV/0!,0.028185314,0.062552958,0,0,0
VTRS,11.84,Glatiramer (GA Depot),Primary Progressive Multiple Sclerosis (PPMS)Â ,CRL,3/11/2024,"CRL announced March 11, 2024.",,14215.20271,29.1862,12.26,11.97,11.76,-0.023938411,-0.041637988,0.028185314,0.062552958,3.58073,0.05048,99.14716
ACAD,24.13,NUPLAZID (pimavanserin) - (Advance-2),Adjunctive treatment in patients with negative symptoms of schizophreniaÂ ,Phase 3,3/11/2024,"Phase 3 study did not meet its primary endpoint, noted March 11, 2024.",168,3975.9368,63.9444,23.44,24.13,18.72,0.029011915,-0.224851494,0.028185314,0.062552958,6.55787,0.10196,50.128
TERN,7.43,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML)Â ,Phase 1,3/11/2024,"Orphan drug designation grated by the FDA, noted March 11, 2024",87,459.1333,83.3845,8.11,7.43,6.085,-0.087572009,-0.287271142,0.028185314,0.062552958,7.09125,0.00013,6.01965
LRMR,8.63,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,3/11/2024,"Phase 2 OLE dosing initiated, noted March 11, 2024.",85,549.23689,99.5185,10.2,8.63,8.35,-0.167143215,-0.200126181,0.028185314,0.062552958,0.79634,0.01034,15.25411
PSTV,1.61,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM)Â ,Phase 1,3/11/2024,"Phase 1 Cohort 5 dosing completed, noted March 11, 2024.",99,6.88449,103.2547,1.69,1.61,1.72,-0.04849435,0.017595762,0.028185314,0.062552958,0.95391,0.1034,0.0804
NVS,â€”,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD)Â ,Phase 1b,3/12/2024,"Phase 1b MAD data from the second cohort, reported that a mechanistic dose response was observed at a 2mg/kg dose level based on urinary biomarker analyses, noted March 12, 2024.",,1250.43141,54.0149,4.1,4.03,4.02,-0.017220598,-0.019705071,-0.002784512,0.031259101,0,0.00203,0.14675
PFE,27.23,ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHELON-3),Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Â ,Phase 3,3/12/2024,"Phase 3 data reported a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo, noted March 12, 2024.",,158166.2637,27.7079,28.37,28.01,27.63,-0.01277066,-0.02643011,-0.002784512,0.031259101,1.17093,0.04515,1365.71791
KANT,â€”,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumorsÂ ,Phase 1/2,3/12/2024,"Phase 1/2 initial data reported a partial Response in 1 patient with a PD-L1 negative mucoepidermoid carcinoma and a 54% reduction in target lesions and a complete response in non-target lesions, note",13,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.002784512,0.031259101,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
CRNX,40.75,Paltusotine,Carcinoid syndrome associated with neuroendocrine tumors (NETs)Â ,Phase 2,3/12/2024,"Phase data from treatment demonstrated rapid and sustained reductions in the frequency and severity of flushing episodes and bowel movements. Results confirm initial positive data previously reported,",94,3175.62859,52.9207,41.57,40.75,45.18,-0.019922914,0.083275758,-0.002784512,0.031259101,6.08553,0.00502,21.44118
CYBN,0.42,CYB003 - (EXTEND and EMBRACE),Major Depressive Disorder (MDD) and Alcohol use disorder (AUD)Â ,Phase 2,3/13/2024,"Additional Phase 2 durability data reported with significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses, noted March 13, 2024.",23,172.73831,100.3928,16.71999,15.95999,15.95999,-0.046520044,-0.046520044,0.018358764,0.010869672,2.27217,0.04751,19.11532
SLN,25.61,Zerlasiran (formerly SLN360) - (ALPACAR-360),Cardiovascular diseases and Polycythemia veraÂ ,Phase 2,3/13/2024,"Phase 2 study met its primary endpoint, noted March 13, 2024.",46,1190.92319,71.3521,25.9,25.61,22.91,-0.011260068,-0.122669472,0.018358764,0.010869672,0.09934,0.00339,14.08222
PRTC,25.81,LYT-200,Relapsed/refractory AML and MDSÂ ,Phase 1b,3/13/2024,"Phase 1b orphan drug designation granted by FDA, noted March 13, 2024.",24,528.529,53.1547,2.015,1.956,2.19,-0.029717624,0.083282348,0.018358764,0.010869672,0,0.08986,0.80379
SGMO,0.79,STAC-BBB,Neurological diseasesÂ ,Preclinical,3/13/2024,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.Â read less",301,140.45938,142.0796,0.8611,0.7851,0.8161,-0.092399543,-0.053673745,0.018358764,0.010869672,5.62389,0.00833,2.25051
LLY,â€”,STAC-BBB,Neurological diseasesÂ ,Preclinical,3/13/2024,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024.Â read less",946,682180.6283,29.3934,754.95,757.84,772.86,0.00382076,0.023446398,0.018358764,0.010869672,0.60249,0.00423,1786.59719
XOMA,25.61,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune ThrombocytopeniaÂ ,Phase 2,3/13/2024,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",12,297.7374,62.036,25.65,25.61,24.62,-0.001560671,-0.040984451,0.018358764,0.010869672,2.50798,0.00055,0.22096
TAK,14.13,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune ThrombocytopeniaÂ ,Phase 2,3/13/2024,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",,6705542.501,19.8275,14.37,14.42,14.55,0.003473432,0.012448294,0.018358764,0.010869672,0,0,21.46886
PHIO,9.18,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,3/13/2024,"Phase 1b new trial sites opened, noted March 13, 2024.",5,2.49232,161.6794,8.82,9.18,9.63,0.040005335,0.087861356,0.018358764,0.010869672,1.88099,0.00726,0.49926
SPRB,5.19,Tildacerfont - (CAHmelia-203),Congenital Adrenal Hyperplasia (poor disease control)Â ,Phase 2b,3/13/2024,"Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.",,212.94519,86.4598,372.00093,389.25097,55.86014,0.045327948,-1.896045287,0.018358764,0.010869672,0.08209,0.02952,18.8958
SPRB,5.19,Tildacerfont - (CAHptain-205),Pediatric Classic Congenital Adrenal HyperplasiaÂ ,Phase 2,3/13/2024,"Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024.Â read less",,212.94519,86.4598,372.00093,389.25097,55.86014,0.045327948,-1.896045287,0.018358764,0.010869672,0.08209,0.02952,18.8958
MIRM,27.77,LIVMARLI (maralixibat),Progressive Familial Intrahepatic Cholestasis (PFIC)Â ,Approved,3/13/2024,"Approval announced March 13, 2024.",50,1294.47839,49.5023,27.48,27.77,26.99,0.010497834,-0.01799204,0.018358764,0.010869672,16.43598,0.03376,16.21376
CALC,4.34,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF)Â ,Preclinical,3/13/2024,"Preclinical data consistent with clinical observations made with Auxora, supporting the KOURAGE trial, noted March 13, 2024.",13,46.6121,116.6849,4.5,4.34,3.46,-0.036203049,-0.262808808,0.018358764,0.010869672,0.19387,0.03769,0.1494
IMNN,0.87,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5Â ,IND-Enabling,3/13/2024,"IND filed to FDA, noted March 13, 2024.",2,8.18677,89.8988,12.13043,11.36086,10.17391,-0.065543057,-0.175890571,0.018358764,0.010869672,5.22566,0.00783,0.03267
IONS,43.16,ION224,"metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH)Â ",Phase 2,3/13/2024,"Phase 2 achieved statistically significant liver histologic improvement as measured by at least a 2-point reduction in NAFLD Activity Score (NAS), noted March 13, 2024.",159,6290.64756,37.5726,43.17,43.16,42.78,-0.000231669,-0.009075106,0.018358764,0.010869672,6.24815,0.16264,47.9335
PCRX,30.29,PCRX-201 (enekinragene inzadenovec) - (ASCEND),Osteoarthritis of the kneeÂ ,Phase 1,3/13/2024,"Additional 104-week data presented at ACR reported MRI B-score change from baseline ranged from 2.3 to 5.4 in the not pretreated cohort and from 2.6 to 5.9 in the steroid pretreated cohort, noted November 17, 2024. RMAT designation granted March 13, 2024.Â read less",44,1408.50857,38.2209,30.56,30.29,30.02,-0.008874339,-0.017828138,0.018358764,0.010869672,8.97619,0.05502,11.20621
OCGN,1.04,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,3/13/2024,"Phase 1/2 dosing initiated March 13, 2024.",292,266.76253,88.5833,0.984,1.04,1.24,0.055350095,0.231240762,0.018358764,0.010869672,14.28804,0.00067,5.77878
IMRX,2.9,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanomaÂ ",Phase 1,3/14/2024,"Phase 1 topline data reported that 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, with 53% of patients had â‰¥ 1 target lesion(s) regress when treated with IMM-1-104 at either 320mg or 240mg, noted March 14, 2024.Â read less",36,84.92149,139.0675,5.88,2.9,2.73,-0.706846025,-0.767255153,0.024921784,0.019761433,9.16767,0.15118,18.20639
NVCT,9.15,NXP800,Ovarian Clear Cell CarcinomaÂ ,Phase 1b,3/14/2024,"Phase 1b preliminary data reported that a 33% response rate and 100% disease control rate, defined as partial response (""PR"") plus stable disease (""SD""), in patients evaluated for efficacy, noted March 14, 2024.Â read less",25,162.58474,78.0102,9.64,9.15,9.05,-0.052167229,-0.063156351,0.024921784,0.019761433,4.07243,0.03497,3.99054
GERN,1.75,RYTELO (imetelstat) - (IMerge),Myelodysplastic syndromes with transfusion-dependent (TD) anemiaÂ ,NDA Filing,3/14/2024,"Advisory committee voted 12 to 2 in favor, noted March 14, 2024.",638,955.60379,71.9228,1.75,1.75,3.33,0,0.643356516,0.024921784,0.019761433,8.22365,0.01183,0
MDGL,243.57,Rezdiffra (resmetirom),Non-alcoholic steatohepatitis (NASH) with liver fibrosis (also known as MASH)Â ,Approved,3/14/2024,"Approved on March 14, 2024.",22,4846.41581,68.6183,272.98,243.57,255.27,-0.113994157,-0.067076724,0.024921784,0.019761433,17.41337,0.11609,422.1336
BGNE,168.9,TEVIMBRA,Esophageal Squamous Cell Carcinoma (ESCC)Â ,Approved,3/14/2024,"Approved March 14, 2024.",106,17637.8436,0,0,0,0,#DIV/0!,#DIV/0!,0.024921784,0.019761433,0,0,0
ONC,â€”,TEVIMBRA,Esophageal Squamous Cell Carcinoma (ESCC)Â ,Approved,3/14/2024,"Approved March 14, 2024.",110,17637.8436,50.4984,176.47,168.9,163.7,-0.043844066,-0.075115406,0.024921784,0.019761433,1.84568,0.11454,66.74911
BMY,51.11,Breyanzi (lisocabtagene maraleucel),Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Â ,Approved,3/14/2024,"Approved March 14, 2024.",,106144.9321,21.9067,52.65,52.49,51.59,-0.003043563,-0.020338383,0.024921784,0.019761433,1.61446,0.05966,757.43952
BGNE,168.9,Tislelizumab-jsgr (Tevimbra),Esophageal squamous cell carcinoma (ESCC)Â ,Approved,3/14/2024,"Approved March 14, 2024.",106,17637.8436,0,0,0,0,#DIV/0!,#DIV/0!,0.024921784,0.019761433,0,0,0
ONC,â€”,Tislelizumab-jsgr (Tevimbra),Esophageal squamous cell carcinoma (ESCC)Â ,Approved,3/14/2024,"Approved March 14, 2024.",110,17637.8436,50.4984,176.47,168.9,163.7,-0.043844066,-0.075115406,0.024921784,0.019761433,1.84568,0.11454,66.74911
AQST,6.09,Anaphylm (AQ-109)- (103),AnaphylaxisÂ ,Phase 3,3/15/2024,"Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.",99,446.40431,89.0039,5.25,6.09,4.38,0.148420005,-0.181179352,0.01600888,0.009467652,2.47183,0.02076,38.4921
JSPR,25.08,Briquilimab (JSP191),Fanconi Anemia (FA)Â ,Phase 1/2,3/15/2024,"Additional Phase 1/2 data reported that all six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated, noted March 15, 2024.Â read less",16,377.80251,99.5691,24.35,25.08,29.23,0.029538866,0.18266373,0.01600888,0.009467652,1.91756,0.0244,8.74658
JNJ,156.89,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,BLA Filing,3/15/2024,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",,381179.4835,13.1235,159.21,158.18,155.23,-0.00649046,-0.025316197,0.01600888,0.009467652,0.61624,0.12001,2082.51879
LEGN,64.02,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,BLA Filing,3/15/2024,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",183,11638.12704,38.4628,66.11,64.02,58.14,-0.032124487,-0.128466126,0.01600888,0.009467652,5.64169,0.05095,162.69127
OPTN,1.88,XHANCE,Chronic sinusitisÂ ,Approved,3/15/2024,"Approved March 15, 2024.",10,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.01600888,0.009467652,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
TSVT,4.01,Abecma (idecabtagene vicleucel; ide-cel),Multiple MyelomaÂ ,BLA Filing,3/15/2024,"AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.",53,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.01600888,0.009467652,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
BMY,50.97,Abecma (idecabtagene vicleucel; ide-cel),Multiple MyelomaÂ ,BLA Filing,3/15/2024,"AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.",,105841.6031,21.8861,52.49,52.34,51.93,-0.002861778,-0.010726017,0.01600888,0.009467652,1.61446,0.05961,6468.45371
PHVS,23.35,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic useÂ ,Phase 2,3/15/2024,"Phase 2 full results presented at ITACA reported that treatment significantly reduced the monthly attack rate, noted March 15, 2024.",54,1256.00792,75.3128,23.68,23.35,24.35,-0.014033826,0.02790104,0.01600888,0.009467652,0.1888,0.04074,2.79005
WHWK,â€”,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour)Â ,Phase 2,3/18/2024,"Phase 2 data presented at SGO reported that the overall response rate to nab-sirolimus for the subgroup was 37.5% (6/16), noted March 18, 2024.",47,52.05492,139.2003,2.17,2.12,2.17,-0.023311079,0,0.009121828,0.021774796,3.86631,0.00002,0.3894
AZN,65.85,Imfinzi (durvalumab) in combination with carboplatin and paclitaxel,Endometrial cancer (EC)Â ,Phase 3,3/18/2024,"Additional Phase 3 data reported that treatment demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone, noted March 18, 2024.Â read less",,159516.1478,23.6523,102.94,102.9,103.94,-0.000388651,0.009667515,0.009121828,0.021774796,0,0.22998,399.77093
ALGS,0.92,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2a,3/18/2024,"Phase 2a study initiated, noted March 18, 2024.",6,69.61502,91.9322,23.0375,23,23.4675,-0.001629107,0.018493162,0.009121828,0.021774796,0.48775,0.04782,0.23324
IVA,4.36,Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND),"Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D)Â ",Phase 2a,3/18/2024,"Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2",95,197.63683,50.3545,3.71,3.8,3.425,0.02396919,-0.079930405,0.009121828,0.021774796,0,0.04019,0.57454
PMVP,1.67,Rezatapopt (PC14586) - (PYNNACLE),Solid tumorsÂ ,Phase 1/2,3/18/2024,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",52,85.91063,143.3366,1.76,1.67,1.7,-0.052490183,-0.034685558,0.009121828,0.021774796,3.85544,0.12093,0.64165
MRK,120.71,Rezatapopt (PC14586) - (PYNNACLE),Solid tumorsÂ ,Phase 1/2,3/18/2024,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",,307564.2718,16.0549,121.52,121.44,125.31,-0.000658545,0.030711809,0.009121828,0.021774796,0.65563,0.00037,1009.39653
PBM,1.25,Psilocybin,Adjustment Disorder due to a recent cancer diagnosisÂ ,Preclinical,3/18/2024,"Recent study published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog, noted March 18, 2024.",1,16.73779,273.9197,771.09952,747.18946,675.45927,-0.031498664,-0.132424585,0.009121828,0.021774796,0.60219,0.00949,1.11182
JNJ,154.94,EDURANT (rilpivirine),HIV in pediatric patients (2-12 years)Â ,Approved,3/19/2024,"Approved March 19, 2024.",,376432.2109,13.1567,156.76,156.21,155.77,-0.003514717,-0.006335413,-0.023497971,0.002801122,0.61624,0.12001,1224.78388
CRNX,45.18,PALSONIFY (paltusotine),AcromegalyÂ ,Phase 3,3/19/2024,"Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.",94,3520.85644,57.8602,37.93,45.18,43.37,0.174912155,0.134025602,-0.023497971,0.002801122,6.08553,0.00618,139.60882
DTIL,12,PBGENE-PMM,Primary mitochondrial myopathiesÂ ,Preclinical,3/19/2024,"Preclinical data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS' ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing, noted March 19, 2024.Â read less",11,78.76747,97.4203,11.73,12,12.75,0.022756987,0.083381609,-0.023497971,0.002801122,0.74085,0.19921,0.64477
AXSM,76.87,Sunosi (Solriamfetol) - (PARADIGM),Major depressive disorder (MDD)Â ,Phase 3,3/19/2024,"Phase 3 initiated, noted March 19, 2024.",49,3641.66821,50.6771,72.54,76.87,76.72,0.05797755,0.056024297,-0.023497971,0.002801122,15.76873,0.035,94.66341
CERS,2.04,INTERCEPT (ReCePI),Patients undergoing complex cardiac surgery proceduresÂ ,Phase 3,3/19/2024,"Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.",191,369.81676,83.9142,1.86,2.04,1.74,0.09237332,-0.066691374,-0.023497971,0.002801122,2.47988,0.3618,40.34613
KRBP,2.83,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung CancerÂ ,Phase 1,3/19/2024,"Phase 1 results reported that stable disease status was confirmed, and the new onset metastatic disease, which completely resolved on repeat MRI imaging performed six weeks from the beginning of treat",1,3.64571,0,0,0,0,#DIV/0!,#DIV/0!,-0.023497971,0.002801122,0,0,0
SEEL,5.2,SLS-005 (IV trehalose) - (HEALEY ALS Platform Trial),Amyotrophic lateral sclerosis (ALS)Â ,Phase 2/3,3/19/2024,"Phase 2/3 trial did not meet the primary and secondary endpoint in the Full Analysis Set (FAS), noted March 19, 2024.",,8.89233,0,0,0,0,#DIV/0!,#DIV/0!,-0.023497971,0.002801122,0,0,0
HOTH,1.35,HT-ALZ,Alzheimer's DiseaseÂ ,Preclinical,3/19/2024,"Preclinical data research presented compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheim",13,5.86769,68.9724,1.15,1.35,1.49,0.16034265,0.259014178,-0.023497971,0.002801122,1.75675,0.03068,26.41213
JSPR,26.24,Subcutaneous briquilimab - (SPOTLIGHT),Chronic inducible urticaria (CIndU)Â ,Phase 1/2,3/19/2024,"Phase 1b/2a patient enrollment commenced, noted March 19, 2024",16,395.27663,99.5738,24.86,26.24,27.89,0.054024878,0.115008116,-0.023497971,0.002801122,1.91756,0.0244,2.58805
ALIM,4.05,ILUVIEN - (New Day),Visual Acuity Loss due to Radiation RetinopathyÂ ,Phase 1,3/19/2024,"Phase 1 first patient dosed, noted March 19, 2024.",54,212.03552,0,0,0,0,#DIV/0!,#DIV/0!,-0.023497971,0.002801122,0,0,0
LGND,72.21,V116 - (STRIDE-6),Pneumococcal Conjugate VaccineÂ ,Phase 3,3/19/2024,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",19,1278.49877,42.4473,72.14,72.21,68.64,0.000969865,-0.04973322,-0.023497971,0.002801122,4.30741,0.38747,7.35502
MRK,121.47,V116 - (STRIDE-6),Pneumococcal Conjugate VaccineÂ ,Phase 3,3/19/2024,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",,309489.0812,16.0549,121.44,122.2,125.52,0.006238733,0.033044795,-0.023497971,0.002801122,0.65563,0.00037,1429.35189
CVM,2.03,CEL-4000,Rheumatoid arthritis (RA)Â ,Preclinical,3/19/2024,"Preclinical data published at the scientific journal Frontiers in Immunology showed that treatment may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weak",6,109.57779,114.4745,61.50615,60.90609,56.40564,-0.009804,-0.086568016,-0.023497971,0.002801122,12.92444,0.15418,0.44145
TAK,14.12,ICLUSIG (ponatinib) - (PhALLCON),Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)Â ,Approved,3/19/2024,"FDA approved on March 19, 2024.",,6868709.655,19.7231,14.56,14.41,14.39,-0.010355633,-0.011744522,-0.023497971,0.002801122,0,0,25.63821
TSHA,2.25,TSHA-102 - (REVEAL),Rett syndromeÂ ,Phase 1/2,3/19/2024,Phase 1/2 clinical data from cohort one (low dose) showed that dosing was well-tolerated with no treatment-emergent SAEs as of 35-week assessment. Data from second adult patient showed TSHA-102 (low d,272,420.79112,108.7634,2.13,2.25,3.06,0.054808236,0.362292936,-0.023497971,0.002801122,7.42392,0.00023,9.0731
AEON,14.4,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis)Â ,Phase 2,3/19/2024,"FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine, noted March 19, 2024.",11,535.09762,95.1466,1172.87991,1036.79992,821.51993,-0.123323216,-0.356061267,-0.023497971,0.002801122,0.21534,0.02224,5.11453
BMY,50.52,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9DW),Hepatocellular carcinoma (HCC)Â ,Phase 3,3/20/2024,"Phase 3 trial met primary endpoint, noted March 20, 2024.",,105148.2421,21.9573,51.8,51.88,53.25,0.00154321,0.027607655,-0.014282179,-0.011231311,1.61083,0.05961,541.43644
ALMS,â€”,Subcutaneous lonigutamab - (LONGITUDE),Thyroid eye disease (TED)Â ,Phase 1/2,3/20/2024,"Phase 1/2 proof of concept data exhibited rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile, noted March 20, 2024.",104,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.014282179,-0.011231311,0,0,0
ENTX,1.52,N-Tab (GLP-2 agonist),Short Bowel SyndromeÂ ,Preclinical,3/20/2024,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",45,53.93164,105.0588,1.4102,1.52,1.54,0.074978797,0.088050878,-0.014282179,-0.011231311,0.00372,0.01383,2.1907
OPK,0.89,N-Tab (GLP-2 agonist),Short Bowel SyndromeÂ ,Preclinical,3/20/2024,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",793,620.32259,86.8377,0.8703,0.89,1.07,0.022383483,0.206575948,-0.014282179,-0.011231311,14.21294,0.11588,15.35336
TFFP,7.95,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,3/20/2024,"Phase 2 data reported that eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC, with favorable safety results with no mortality or discontinuations due to advers",4,923.568,86.4614,42.65,42.65,42.55,0,-0.002347419,-0.014282179,-0.011231311,0,0,0
BNOX,1,BNC210 - (ATTUNE),Post-Traumatic Stress Disorder (PTSD)Â ,Phase 2b,3/21/2024,Phase 2b results reported that BNC210 led to statistically significant improvement (p<0.05) in the following secondary endpoints: depressive symptoms as measured by the Montgomery-Ã…sberg Depression Ra,2,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.016956744,0.002841359,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
MRK,122.88,KEYTRUDA + LYNPARZA - (KEYLYNK-006),Metastatic nonsquamous non-small cell lung cancer (NSCLC)Â ,Phase 3,3/21/2024,"Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.",,313085.4355,16.126,123.85,123.62,131.95,-0.001858812,0.063351907,0.016956744,0.002841359,0.65563,0.00037,1008.28242
PHIO,7.56,INTASYL,Hematological malignanciesÂ ,Preclinical,3/21/2024,"Preclinical data presented at Immunotherapy of Cancer Conference (ITOC10) reported a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation, noted March 21, 2024.",5,2.0525,164.791,9.63,7.56,6.12,-0.242012036,-0.453321129,0.016956744,0.002841359,1.88099,0.00572,0.89428
VRTX,415.71,VX-407,"Autosomal Dominant Polycystic Kidney Disease (ADPKD), healthy volunteersÂ ",IND-Enabling,3/21/2024,"IND cleared by the FDA, noted March 21, 2024.",256,107381.1422,27.2335,412.11,415.71,418.01,0.008697598,0.014215052,0.016956744,0.002841359,1.56972,0.16665,372.18433
ALPN,41.6,ALPN-303 - (DENALI),Systemic lupus erythematosus (SLE)Â ,Preclinical,3/21/2024,"Preclinical data presented at SLEuro demonstrated greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion, noted March 21, 2024.",68,67.06623,56.5052,7.65,7.7,7.7,0.006514681,0.006514681,0.016956744,0.002841359,0,0.02988,0.00508
NKTX,12.98,NKX101,Acute myeloid leukemia / myelodysplastic syndromesÂ ,Phase 1,3/21/2024,"Phase 1 trial update reported that enrollment has been closed, with the aggregate CR/CRi rate (5 of 20 patients) was lower than what had been observed in the first 6 patients in the cohort, noted Marc",71,641.42209,174.7807,12.79,12.98,10.81,0.014746096,-0.168191984,0.016956744,0.002841359,8.58393,0.0116,8.76864
ABBV,175.15,Mirvetuximab - (MIRASOL),Cancer - ovarian cancer and relapsed endometrial cancerÂ ,Approved,3/22/2024,"Approved March 22, 2024.",,315971.9541,16.3268,177.5,178.45,182.1,0.005337841,0.025585378,0.026935146,0.003261616,0.80574,0.04423,728.85261
OKYO,1.54,urcosimod (OK-101),Dry Eye Disease (DED)Â ,Phase 2,3/22/2024,"Phase 2 additional efficacy data showed a statistically significant and durable reduction in ocular pain statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study,",33,51.01734,88.3224,1.76,1.535,1.49,-0.136783428,-0.166537689,0.026935146,0.003261616,0.19447,0.0243,3.27982
SMMT,3.37,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC)Â ,Phase 2,3/22/2024,Phase 2 combination data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that patients experienced a median PFS of 11.1 months (95% CI: 9.5 â€“ 16.3 months). The frequency of treatme,744,2364.74033,99.5833,3.55,3.37,4.14,-0.052034859,0.153748184,0.026935146,0.003261616,2.27319,0.00001,9.48939
SMMT,3.37,ivonescimab (AK112-202),Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesÂ ,Phase 2,3/22/2024,Phase 2 monotherapy data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that treatment led to intracranial responses among 34% of patients with brain metastases at baseline â€“ 23%,744,2364.74033,99.5833,3.55,3.37,4.14,-0.052034859,0.153748184,0.026935146,0.003261616,2.27319,0.00001,9.48939
ABBV,175.15,ELAHERE (mirvetuximab soravtansine-gynx),Platinum-Resistant Ovarian CancerÂ ,Approved,3/22/2024,"Full approval announced March 22, 2024.",,315971.9541,16.3268,177.5,178.45,182.1,0.005337841,0.025585378,0.026935146,0.003261616,0.80574,0.04423,728.85261
IVVD,4.36,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Approved,3/22/2024,"EUA approval announced March 22, 2024.",120,518.16999,138.3544,3.09,4.36,4.44,0.344300966,0.362483286,0.026935146,0.003261616,1.60536,0.00136,16.09801
IVVD,4.36,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 PreventionÂ ,Phase 3,3/22/2024,"Additional Phase 3 data reported that only one patient (0.03%) was symptomatic after 90 days, noted March 22, 2024.",120,518.16999,138.3544,3.09,4.36,4.44,0.344300966,0.362483286,0.026935146,0.003261616,1.60536,0.00136,16.09801
ESPR,2.29,NEXLETOL (bempedoic acid) - (CLEAR Outcomes),Cardiovascular DiseasesÂ ,Approved,3/22/2024,"Approved March 22, 2024.",201,423.77069,102.1068,2.11,2.29,2.68,0.08186387,0.239128847,0.026935146,0.003261616,9.16014,0.22077,22.16828
TELO,6.49,Telomir-1,Age-related conditionsÂ ,Preclinical,3/22/2024,"Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells, noted March 22, 202",32,192.16769,0,6.79,6.49,5.15,-0.045188411,-0.276454227,0.026935146,0.003261616,0.01533,0.02488,0.18384
SLRX,4.96,Seclidemstat,Ewing's and other FET-rearranged sarcomasÂ ,Phase 1/2,3/22/2024,"Phase 1/2 trial enrollment resumed, noted March 22, 2024.",,2.6749,68.8412,70.21208,74.39996,63.43197,0.057935028,-0.101552383,0.026935146,0.003261616,0.41744,0.00973,0.87018
ZLAB,16.18,ZL-1310 (DLL3 ADC),"Solid tumors, relapsed and refractory second-line+ SCLCÂ ",Preclinical,3/22/2024,"Preclinical data presented at ELCC reported strong and specific binding to DLL3 on the cell surface, leading to internalization, cell cycle arrest and the induction of apoptosis in tumor cells, noted",109,1597.24952,58.7946,17.25,16.18,16.02,-0.064036232,-0.073974202,0.026935146,0.003261616,4.11671,0.10484,12.65582
AXSM,77.35,Reboxetine (AXS-12) - (SYMPHONY),NarcolepsyÂ ,Phase 3,3/25/2024,"Phase 3 trial met its primary endpoint, noted March 25, 2024.",49,3664.40791,50.87,80.66,77.35,76.99,-0.041902212,-0.046567246,0.00934235,-0.003094821,15.76873,0.04264,108.2002
AZN,65.46,ULTOMIRIS (ravulizumab-cwvz),Neuromyelitis Optica Spectrum Disorder (NMOSD)Â ,Approved,3/25/2024,"Approved March 25, 2024.",,161128.3615,23.3597,104.82,103.94,106.78,-0.008430784,0.01852605,0.00934235,-0.003094821,0,0.22717,161.92335
AZN,65.46,ULTOMIRIS (ravulizumab-cwvz) - (CHAMPION-NMOSD),Neuromyelitis optica spectrum disorder (NMOSD)Â ,Approved,3/25/2024,"FDA Approved on March 25, 2024.",,161128.3615,23.3597,104.82,103.94,106.78,-0.008430784,0.01852605,0.00934235,-0.003094821,0,0.22717,161.92335
ATXS,14.75,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteersÂ ",Phase 1/2,3/25/2024,"Phase 1b/2 proof of concept data reported favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, noted March 25, 2024.",56,809.82015,78.6996,15.13,14.75,13.51,-0.025436445,-0.113249376,0.00934235,-0.003094821,3.09051,0.05098,66.50343
APGE,65,APG808,"Healthy volunteer, asthma, COPDÂ ",Phase 1,3/25/2024,"Phase 1 dosing commenced and preclinical data demonstrated the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks",59,3594.07874,83.549,68.43,65,65.05,-0.051424055,-0.05065512,0.00934235,-0.003094821,5.66855,0.03232,46.3192
MBRX,5.25,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 1/2,3/25/2024,"Phase 1/2 topline data reported a complete response composite (CRc) rate of 39% in all currently evaluable, intent to treat subjects (n= 18), noted March 25, 2024.",30,11.69446,105.8889,5.7047,5.25,5.67,-0.08306232,-0.006101279,0.00934235,-0.003094821,0.40235,0.013,4.80754
REGN,961.09,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,CRL,3/25/2024,CRL issued by FDA on March 25 2024.,105,103280.5536,16.9925,967.24,961.09,969.31,-0.006378598,0.002137823,0.00934235,-0.003094821,1.26284,0.09936,309.74777
ZLAB,16.25,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL)Â ,CRL,3/25/2024,CRL issued by FDA on March 25 2024.,109,1604.15975,58.7551,16.18,16.25,16.72,0.004316997,0.032829696,0.00934235,-0.003094821,4.11671,0.10484,10.30801
ARWR,27.89,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),HypertriglyceridemiaÂ ,Phase 2,3/25/2024,"Phase 2 expanded Access Program (EAP) initiated, noted March 25, 2024.",138,3455.48493,78.1288,27.21,27.89,28.24,0.024683649,0.03715486,0.00934235,-0.003094821,7.13408,0.11894,14.4307
RYTM,39.65,RM-718,Hypothalamic ObesityÂ ,Phase 1,3/25/2024,"Phase 1 trial dosing initiated, noted March 25, 2024.",66,2384.57063,61.6344,40.55,39.65,42.68,-0.022444832,0.051194646,0.00934235,-0.003094821,14.97223,0.16686,17.18197
MRK,124.56,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)Â ,Phase 2,3/25/2024,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",,317365.6036,16.1577,123.85,125.31,130.99,0.011719511,0.056049828,0.00934235,-0.003094821,0.65563,0.00099,953.07716
BYSI,3.47,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)Â ,Phase 2,3/25/2024,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",40,135.3837,124.8625,3.12,3.47,3.6,0.106321592,0.143100844,0.00934235,-0.003094821,4.83015,0.00034,0.96628
SYRS,6.4,Tamibarotene (SY-1425) and VIDAZA (azaciditine) - (SELECT-MDS-1),Myelodysplastic SyndromeÂ ,Phase 3,3/25/2024,"Phase 3 enrollment completed, noted March 25, 2024",26,166.44264,108.2511,6.27,6.4,5.04,0.020521636,-0.218370273,0.00934235,-0.003094821,5.08413,0.00744,0.99864
MTNB,0.29,Docetaxel,Metastatic and unresectable tumorsÂ ,Preclinical,3/25/2024,"Preclinical in vivo data reported that an oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak wei",5,63.05016,267.4354,13.9,14.51,18.49,0.042949227,0.285341205,0.00934235,-0.003094821,0.67657,0.01333,0.88929
STOK,6.5,Zorevunersen (STK-001) - (EMPEROR),Dravet syndromeÂ ,Phase 1/2,3/25/2024,"Phase 1/2a end of study data of 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines, noted March 25, 2024.",54,300.97433,88.5564,6.3,6.5,13.49,0.031252544,0.761399037,0.00934235,-0.003094821,8.13107,0.0998,16.68324
NKGN,2.16,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1,3/25/2024,Phase 1 additional data suggested clinical activity regarding cognitive function in patients with advanced Alzheimer's disease in addition to previously disclosed positive effects on amyloid protein a,124,47.28019,185.5783,2.32,2.16,1.95,-0.071458964,-0.173737813,0.00934235,-0.003094821,1.53495,0.01307,3.2785
AMRX,5.91,ciprofloxacin and dexamethasone otic suspension,"Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa.Â ",Approved,3/25/2024,"ANDA Approval from the FDA, noted March 25, 2024.",314,1823.55549,56.4704,6.07,5.91,6.05,-0.026712774,-0.003300333,0.00934235,-0.003094821,0.59166,0.02434,5.25562
REGN,961.09,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL)Â ,CRL,3/25/2024,"CRL issued March 25, 2024.",105,103280.5536,16.9925,967.24,961.09,969.31,-0.006378598,0.002137823,0.00934235,-0.003094821,1.26284,0.09936,309.74777
ZLAB,16.25,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL)Â ,CRL,3/25/2024,"CRL issued March 25, 2024.",109,1604.15975,58.7551,16.18,16.25,16.72,0.004316997,0.032829696,0.00934235,-0.003094821,4.11671,0.10484,10.30801
PRAX,62.18,PRAX-628,Photo-Paroxysmal Response (PPR)Â ,Phase 2,3/26/2024,"Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024",21,823.16054,107.3277,50.5,62.18,55.57,0.208060068,0.095670151,-0.023884279,0.02170797,3.09213,0.00745,51.3562
SLS,1.06,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 1/2,3/26/2024,"Phase 1b/2 topline data reported a 10% response rate in the 45 mg QW safety cohort , 20% response rate in the 60 mg QW cohort, and 50% response rate in the 60 mg, 2 x 30 mg BIW cohort, noted March 26,",105,58.45491,125.4697,1.04,1.06,1.18,0.019048195,0.126293725,-0.023884279,0.02170797,9.39311,0.08916,4.43732
TECX,â€”,TX45,Group 2 Pulmonary HypertensionÂ ,Phase 1a,3/26/2024,"Phase 1a clinical program advancing on track based on promising initial data, noted March 26, 2024.",18,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.023884279,0.02170797,0,0,0
VKTX,80.83,VK2735,Metabolic and endocrine disorders (GLP-1)Â ,Phase 1,3/26/2024,Phase 1 data was shown to be safe and well-tolerated in the 28-day study with low rates of GI-related adverse events. Up to 3.3% placebo-adjusted mean weight loss (5.3% from baseline) observed after 2,113,8839.26908,144.5414,69.19,80.83,77.35,0.15549184,0.111484234,-0.023884279,0.02170797,10.1886,0.08294,1581.46862
CERS,1.74,INTERCEPT,PlateletsÂ ,Approved,3/26/2024,"FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.",191,315.43194,84.7095,1.75,1.74,1.76,-0.005730675,0.005698021,-0.023884279,0.02170797,2.79544,0.35107,2.89939
LITS,â€”,Voruciclib plus Venclexta (venetoclax),B-Cell Malignancies or Acute Myeloid Leukemia (AML)Â ,Phase 1,3/26/2024,"Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff",35,25.71863,59.6074,3.872,3.86,4,-0.003103986,0.032523192,-0.023884279,0.02170797,0.13652,0.03506,0.09834
MEIP,3.86,Voruciclib plus Venclexta (venetoclax),B-Cell Malignancies or Acute Myeloid Leukemia (AML)Â ,Phase 1,3/26/2024,"Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff",6,25.71863,0,0,0,0,#DIV/0!,#DIV/0!,-0.023884279,0.02170797,0,0,0
STOK,10.29,Zorevunersen (STK-001),Dravet SyndromeÂ ,Phase 1/2,3/26/2024,Phase 1/2 data demonstrated durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior were maintained over 12 months with continued dosing at,54,476.46552,109.4844,6.5,10.29,13.08,0.459370373,0.699282169,-0.023884279,0.02170797,7.67461,0.0998,200.33613
ATNM,8.12,Iomab-ACT,Targeted conditioning prior to CD19 CAR T-cell therapyÂ ,Phase 1,3/26/2024,"Phase 1 trial has commenced enrollment, noted March 26, 2024.",31,225.44557,85.8685,8.67,8.12,8.6,-0.065538637,-0.008106588,-0.023884279,0.02170797,6.56736,0.02218,4.59985
ZVRA,5.72,Serdexmethylphenidate (SDX) - (KP1077),Idiopathic hypersomnia (IH)Â ,Phase 2,3/26/2024,"Phase 2 topline data demonstrated clinically meaningful impact and encouraging outcomes on both clinical safety and efficacy, noted March 26, 2024.",56,237.29656,54.9098,5.64,5.72,5.115,0.01408474,-0.097706666,-0.023884279,0.02170797,5.14019,0.04863,1.07783
MRK,124.77,WINREVAIR (sotatercept-csrk),Pulmonary arterial hypertension (PAH)Â ,Approved,3/26/2024,"Approved March 26, 2024.",,317897.4588,16.1371,125.31,125.52,130.35,0.001674441,0.039432473,-0.023884279,0.02170797,0.9143,0.00099,1112.65974
ARGX,398.59,Efgartigimod - (RHO),Primary Sjogren's syndromeÂ ,Phase 2,3/27/2024,"Phase 2 trial data reported safety and tolerability profile that was consistent with other clinical trials, and a treatment effect across multiple clinical endpoints, noted March 27, 2024.",60,21866.12476,57.8697,366,368.2,366.9,0.005992935,0.002455998,-0.023457734,0.017961622,0,0.00092,18.54439
MRNA,110.59,mRNA-1283 - (NEXTCove),COVID-19Â ,Phase 3,3/27/2024,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389,42342.65629,55.2924,107.41,110.59,101.21,0.029176381,-0.059455721,-0.023457734,0.017961622,5.80525,0.17776,505.96794
MRNA,110.59,mRNA-1283 - (NEXTCove),COVID-19Â ,Phase 3,3/27/2024,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389,42342.65629,55.2924,107.41,110.59,101.21,0.029176381,-0.059455721,-0.023457734,0.017961622,5.80525,0.17776,505.96794
NVCR,14.64,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung CancerÂ ,Phase 3,3/27/2024,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie",111,1567.84784,70.7797,13.07,14.64,14.42,0.113437981,0.098296604,-0.023457734,0.017961622,5.17429,0.05545,174.78974
ZLAB,16.19,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung CancerÂ ,Phase 3,3/27/2024,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie",109,1598.2367,58.7915,15.95,16.19,15.9,0.014934938,-0.00313972,-0.023457734,0.017961622,3.71131,0.10484,16.79591
ATAI,1.79,BPL-003,Resistant DepressionÂ ,Phase 2a,3/27/2024,"Phase 2a initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD, noted March 27,",214,297.15875,93.0453,1.73,1.79,2.39,0.034094211,0.323171957,-0.023457734,0.017961622,3.13558,0.17239,2.4025
ALT,8.89,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese VolunteersÂ ",Phase 2,3/27/2024,"Phase 2 body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass, noted March 27, 2024.",88,630.25909,123.4174,8.65,8.89,9.29,0.027367729,0.071379232,-0.023457734,0.017961622,17.64779,0.03559,99.07734
ALT,8.89,HepTCell,Hepatitis BÂ ,Phase 2,3/27/2024,"Phase 2 clinical trial evaluating the efficacy has been completed. The overall response in the trial was deemed to be insufficient to warrant further advancement. As a result, any further development",88,630.25909,123.4174,8.65,8.89,9.29,0.027367729,0.071379232,-0.023457734,0.017961622,17.64779,0.03559,99.07734
AVTX,4.75,AVTX-009 (anti-IL-1Î² mAb) - (LOTUS),Hidradenitis suppurativa (HS)Â ,Phase 2,3/27/2024,"Avalo acquires Phase 2-ready anti-IL-1Î² mAb, AVTX-009, through acquisition of AlmataBio, Inc, noted March 27 , 2024. Phase 2 topline results from trial planned expected in 2026.",13,3.8076,154.6038,4.6242,4.75,16.31,0.026841235,1.260475034,-0.023457734,0.017961622,8.38087,0.00025,14.95633
TFFP,6.59,Voriconazole Inhalation Powder - (VORI),Invasive Pulmonary Aspergillosis (IPA)Â ,Phase 2,3/27/2024,"Phase 2 data continue to demonstrate antifungal activity and a favorable safety and tolerability profile, noted March 27, 2024.",4,936.576,75.7081,42.55,42.55,43.2,0,0.01516064,-0.023457734,0.017961622,0,0,0
TFFP,6.59,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,3/27/2024,"Phase 2 8/8 patients successfully transitioned from oral tacrolimus to TFF TAC with no sign of acute rejection at reduced systemic exposures, noted March 27, 2024.",4,936.576,75.7081,42.55,42.55,43.2,0,0.01516064,-0.023457734,0.017961622,0,0,0
GMDA,0.06,NAM-NK (GDA-201),Follicular and diffuse large B cell lymphomasÂ ,Phase 1,3/27/2024,"Gamida Cell does not plan to conduct further development of GDA-201 at this time, as noted on March 27, 2024.",154,9.11982,0,0,0,0,#DIV/0!,#DIV/0!,-0.023457734,0.017961622,0,0,0
REGN,966.3,Pexa-Vec in combination with cemiplimab - (REN026),Metastatic or unresectable renal cell carcinoma (RCC).Â ,Phase 1/2,3/27/2024,"Phase 1b/2a study demonstrated an acceptable safety profile and encouraging efficacy of the combination therapy of Pexa-Vec, an engineered oncolytic vaccinia virus, and Libtayo (cemiplimab), anti-PD-1",105,103840.4301,16.9862,963.55,966.3,950.95,0.002849964,-0.013162896,-0.023457734,0.017961622,1.29575,0.09936,304.14776
RARE,46.82,Setrusumab (BPS-804) - (ORBIT),Osteogenesis ImperfectaÂ ,Phase 2/3,3/27/2024,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,96,3854.95687,52.9429,45.46,46.82,47.08,0.029477644,0.035015464,-0.023457734,0.017961622,4.59209,0.12166,25.8143
MREO,3,Setrusumab (BPS-804) - (ORBIT),Osteogenesis ImperfectaÂ ,Phase 2/3,3/27/2024,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,155,420.02985,72.3245,2.95,3,3.41,0.016807118,0.144907121,-0.023457734,0.017961622,1.56701,0.00363,1.35525
AKBA,2.24,Vafseo (vadadustat),Anemia due to Chronic Kidney Disease in Adult Patients on DialysisÂ ,Approved,3/27/2024,"Approved March 28, 2024.",265,468.9939,79.9819,2,2.24,1.49,0.113328685,-0.294371061,-0.023457734,0.017961622,4.83656,0.01774,23.70108
CSLLY,93.88,Vafseo (vadadustat),Anemia due to Chronic Kidney Disease in Adult Patients on DialysisÂ ,Approved,3/27/2024,"Approved March 28, 2024.",968,138379.419,0,0,0,0,#DIV/0!,#DIV/0!,-0.023457734,0.017961622,0,0,0
RVPH,3.9,Brilaroxazine - (RECOVER),SchizophreniaÂ ,Phase 3,3/27/2024,"Phase 3 safety and efficacy shared at ASCPT reported that the 50 mg dose provided a significant decrease in primary (Total PANSS) with a discontinuation rate lower than 6%, noted March 27, 2024.",68,108.88238,111.4055,3.83,3.9,3.66,0.01811175,-0.045401656,-0.023457734,0.017961622,2.33054,0.02134,2.56773
PTIX,1.82,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD)Â ,Phase 1,3/27/2024,Phase 1 single-dose results demonstrated safety at a medium dose of 500 micrograms administered subcutaneously in the third of five planned cohorts of subjects in the single dose portion of the Phase,,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.023457734,0.017961622,0,0,0
MIST,1.79,CARDAMYST (etripamil) - (RAPID),Paroxysmal supraventricular tachycardia (PSVT)Â ,NDA Filing,3/28/2024,"NDA resubmitted to FDA, noted March 28, 2024.",84,106.91139,102.1289,1.8,1.79,1.75,-0.005571045,-0.028170877,0.000210748,0.058802187,0.80387,0.02918,0.81365
IRWD,8.71,Apraglutide - (STARGAZE),Acute Graft-Versus-Host DiseaseÂ ,Phase 2,3/28/2024,"Phase 2 initial data reported that treatment was well-tolerated with an acceptable safety profile, noted March 28, 2024.",162,1363.36452,78.6411,8.62,8.71,8.15,0.010386706,-0.056067157,0.000210748,0.058802187,11.99453,0.00536,23.51162
LPCN,5.2,LPCN 1148,"Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopeniaÂ ",Phase 2,3/28/2024,"Phase 2 data reported that that participants who received LPCN 1148 during Stage 1 had a significant increase in L3-SMI of 4.1 cm2/m2 (8.8%) at Week 24, noted March 28, 2024.",5,27.64232,72.2802,5.1288,5.2,4.61,0.013786912,-0.106643857,0.000210748,0.058802187,2.32541,0.07874,0.25498
GILD,72.39,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,3/28/2024,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",,91201.90629,25.0263,73.01,73.25,69.55,0.00328183,-0.0485505,0.000210748,0.058802187,1.54592,0.06238,613.08075
XLO,1.08,Efarindodekin Alfa (XTX301),Solid tumorsÂ ,Phase 1,3/28/2024,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",51,37.21725,127.9774,0.639,1.08,1.21,0.524811866,0.638471184,0.000210748,0.058802187,0.16723,0.00526,37.30241
SNDX,23.8,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,3/28/2024,"Phase 2 enrollment completed, noted March 28, 2024.",86,2022.17857,54.32,23.07,23.8,22.62,0.031152508,-0.019698601,0.000210748,0.058802187,9.80319,0.23862,25.1893
OCEA,3.79,VRON-0200,Hepatitis BÂ ,Phase 1b,3/28/2024,"Phase 1b preliminary data reported that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, noted March 28, 2024.",232,129.02006,225.2459,4.06,3.785,2.69,-0.070137087,-0.41164178,0.000210748,0.058802187,2.56212,0.00004,2.58502
PPBT,0.67,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ,Phase 1/2,3/28/2024,"Phase 1/2 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence, noted March 28, 2024.",2,65.33385,83.862,0.243,0.246,0.251,0.012270093,0.032391496,0.000210748,0.058802187,0,0.05014,0.05256
GRTX,0.14,Rucosopasem (GC4711) - (GRECO-1),Non-Small Cell Lung Cancer (NSCLC)Â ,Phase 1/2,3/28/2024,"Trial discontinued, noted March 28, 2024.",75,7.6149,170.51,0.1535,0.14,0.162,-0.092058144,0.053895768,0.000210748,0.058802187,5.15214,0.00261,0.60394
GRTX,0.14,Rucosopasem (GC4711) - (GRECO-2),Pancreatic CancerÂ ,Phase 2b,3/28/2024,"Trial discontinued, noted March 28, 2024.",75,7.6149,170.51,0.1535,0.14,0.162,-0.092058144,0.053895768,0.000210748,0.058802187,5.15214,0.00261,0.60394
APLT,6.8,Govorestat (AT-007) - (ACTION-Galactosemia kids),GalactosemiaÂ ,PDUFA priority review,3/28/2024,"PDUFA PR date of August 28, 2024. The FDA has set a new PDUFA target action date of November 28, 2024.",144,720.03045,137.4531,6.85,6.8,5.92,-0.00732604,-0.145912203,0.000210748,0.058802187,3.58148,0.02576,10.61324
NBIX,137.92,NBI-1065890,CNS IndicationsÂ ,Phase 1,3/28/2024,"Phase 1 initiated, noted March 28, 2024.",99,13724.07302,25.9576,137.83,137.92,137.61,0.000652765,-0.001597444,0.000210748,0.058802187,2.49601,0.10011,171.80198
CADL,1.58,CAN-3110,GliomaÂ ,Phase 1b,3/28/2024,"Phase 1b showed that serial procedures were well tolerated without observed dose-limiting toxicity in first cohort, noted March 28, 2024.",54,46.369,109.5176,1.54,1.58,6.4,0.025642431,1.424515574,0.000210748,0.058802187,0.50183,0.00256,0.04838
BMY,52.81,KRAZATI (adagrasib) and Taxotere (Docetaxel) - (KRYSTAL-12),Non-small cell lung cancer (NSCLC)Â ,Phase 3,3/28/2024,"Phase 3 trial met its primary endpoints, noted March 28, 2024.",,109911.1251,22.1533,53.25,54.23,51.4,0.018236456,-0.035359632,0.000210748,0.058802187,1.83812,0.05421,778.10267
CNTX,1.38,CTIM-76,Various cancersÂ ,IND-Enabling,3/28/2024,"IND submitted on March 28, 2024.",89,22.03315,91.5653,1.382,1.38,1.28,-0.001448226,-0.076671647,0.000210748,0.058802187,0.10649,0.03993,0.07734
EQ,2.11,Itolizumab (EQ001) - (EQUALISE),Systemic lupus erythematosus (SLE) and lupus nephritis (LN)Â ,Phase 1b,4/1/2024,"Phase 1b topline data continues to show clinically meaningful response in highly proteinuric subjects. More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted",59,74.38753,126.3377,2.31,2.11,1.92,-0.090559577,-0.184922338,0.0453815,0.048474059,1.15985,0,0.85247
GRTS,2.35,GRANITE-CRC-1L,1L Microsatellite-Stable Colorectal Cancer (MSS-CRC)Â ,Phase 2/3,4/1/2024,"Phase 2/3 preliminary data reported that the PFS trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population and 0.52 in a high-risk group, noted April 1, 2024.",118,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.0453815,0.048474059,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
NVCR,15.49,Tumor Treating Fields (TTFields) with pembrolizumab and temozolomide - (TIGER),Glioblastoma (GBM)Â ,Phase 2,4/1/2024,"Phase 2 long-term data presented at ASCO reported that the median OS and PFS were 19.6 months (95% CI, 17.9â€“22.4) and 10.2 months, noted April 1, 2024.",111,1658.87726,71.3457,15.63,15.49,14.18,-0.00899749,-0.097359623,0.0453815,0.048474059,5.17429,0.04326,25.92805
LQDA,14.92,YUTREPIA,Interstitial lung disease (PH-ILD)Â ,PDUFA,4/1/2024,"A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap",86,1134.33442,64.3697,14.75,14.92,15.13,0.011459512,0.025436445,0.0453815,0.048474059,9.54316,0.0076,19.1627
AZN,66.84,VOYDEYA (danicopan) add-on to SoC with ULTOMIRIS (ravulizumab-cwvz) or SOLIRIS (eculizumab)- (ALPHA),Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)Â ,Approved,4/1/2024,"FDA Approved on April 1, 2024.",,165530.9452,23.6886,106.78,106.78,106.1,0,-0.006388597,0.0453815,0.048474059,0,0.21885,0
AXSM,76.99,Sunosi (Solriamfetol) - (ENGAGE),Binge eating disorderÂ ,Phase 3,4/1/2024,"Phase 3 initiated, noted April 1, 2024.",49,3647.35313,50.6075,79.8,76.99,72.11,-0.035847961,-0.101330774,0.0453815,0.048474059,15.40452,0.0485,45.12476
VRTX,420.48,inaxaplin (VX-147) - (AMPLITUDE),Proteinuric kidney disease with two mutations in the APOL1 gene (AMKD)Â ,Phase 2/3,4/1/2024,Phase 2/3 trial part 3 dosing initiated with expanded access to include adolescents with AMKD ages 10 to 17 years. An Independent Data Monitoring Committee (IDMC) reviewed Phase 2 safety and efficacy,256,108613.2705,27.1608,418.01,420.48,404.22,0.00589156,-0.033546071,0.0453815,0.048474059,1.597,0.17971,322.82436
IRON,34.21,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP)Â ,Phase 2,4/1/2024,"Phase 2 study met its primary endpoint. Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi",34,844.33797,99.9469,62.26,34.21,31.78,-0.598801166,-0.672482004,0.0453815,0.048474059,5.12306,0.03585,212.75938
VTGN,5.4,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD)Â ,Phase 3,4/1/2024,"PALISADE-3 initiated, noted April 1, 2024.",30,145.93613,84.1482,5.28,5.4,5.17,0.022472856,-0.021053409,0.0453815,0.048474059,4.9388,0.00107,5.08424
SRZN,10.1,SZN-043,Severe alcohol associated hepatitisÂ ,Phase 1a,4/1/2024,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8,20.5872,109.3215,15.71,10.1,11.2299,-0.441762028,-0.335717588,0.0453815,0.048474059,0.16415,0.0098,2.24533
ATNM,8.56,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,4/1/2024,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20",31,251.63328,86.55,7.83,8.56,9.13,0.08913768,0.153603185,0.0453815,0.048474059,6.20272,0.02186,5.37038
CORT,25.74,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,4/1/2024,"Phase 3 enrollment completed, noted April 1, 2024.",105,2664.53757,62.3111,25.19,25.74,24.23,0.021599112,-0.038855556,0.0453815,0.048474059,19.52845,0.01082,21.57125
BMEA,12.8,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,4/2/2024,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com",59,459.38381,112.5755,15.3,12.8,12.8,-0.178407657,-0.178407657,0.030398793,0.023829905,31.22022,0.00012,36.00533
LLY,761.64,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 1b,4/2/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,946,688149.2698,28.6376,760.55,763.96,757.24,0.004473576,-0.004361612,0.030398793,0.023829905,0.61466,0.00391,1983.84292
VERV,8.32,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 1b,4/2/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,89,23780.60371,0,0,0,0,#DIV/0!,#DIV/0!,0.030398793,0.023829905,0,0,0
VTGN,$5.40 ,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD)Â ,Phase 3,4/1/2024,"PALISADE-3 initiated, noted April 1, 2024.",30,145.93613,84.1482,5.28,5.4,5.17,0.022472856,-0.021053409,0.0453815,0.048474059,4.9388,0.00107,5.08424
SRZN,$10.10 ,SZN-043,Severe alcohol associated hepatitisÂ ,Phase 1a,4/1/2024,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8,20.5872,109.3215,15.71,10.1,11.2299,-0.441762028,-0.335717588,0.0453815,0.048474059,0.16415,0.0098,2.24533
ATNM,$8.56 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,4/1/2024,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20",31,251.63328,86.55,7.83,8.56,9.13,0.08913768,0.153603185,0.0453815,0.048474059,6.20272,0.02186,5.37038
CORT,$25.74 ,Relacorilant - (GRADIENT),Cushingâ€™s syndromeÂ ,Phase 3,4/1/2024,"Phase 3 enrollment completed, noted April 1, 2024.",105,2664.53757,62.3111,25.19,25.74,24.23,0.021599112,-0.038855556,0.0453815,0.048474059,19.52845,0.01082,21.57125
BMEA,$12.80 ,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D)Â ,Phase 2,4/2/2024,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com",59,459.38381,112.5755,15.3,12.8,12.8,-0.178407657,-0.178407657,0.030398793,0.023829905,31.22022,0.00012,36.00533
LLY,$761.64 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 1b,4/2/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,946,688149.2698,28.6376,760.55,763.96,757.24,0.004473576,-0.004361612,0.030398793,0.023829905,0.61466,0.00391,1983.84292
VERV,$8.32 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 1b,4/2/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,89,23780.60371,0,0,0,0,#DIV/0!,#DIV/0!,0.030398793,0.023829905,0,0,0
ZLDPF,$94.49 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH)Â ,Phase 1b,4/2/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,70,40883.45675,0,0,0,0,#DIV/0!,#DIV/0!,0.030398793,0.023829905,0,0,0
ROIV,$10.92 ,Brepocitinib - (NEPTUNE),Non-infectious uveitis (NIU)Â ,Phase 2,4/2/2024,"Phase 2 topline data showed the strongest efficacy data in NIU observed to date. The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm, n",682,8799.83839,43.3311,10.43,10.92,11.41,0.045909701,0.089803895,0.030398793,0.023829905,3.91776,0.07353,222.14696
GNPX,$2.84 ,Oncoprex,Anti-PD1 resistant non-small cell lung cancer (NSCLC)Â ,Preclinical,4/2/2024,"Preclinical data from mouse model reported that NPRL2 treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. The antitumor effect was greater in humanized than non-hum",,5.42554,125.076,148.5,142,153.5,-0.044757901,0.033115609,0.030398793,0.023829905,4.20195,0.16994,0.16032
KNSA,$18.73 ,Abiprubart (KPL-404),Rheumatoid arthritisÂ ,Phase 2,4/2/2024,"Phase 2 cohort 4 data reported a a statistically significant reduction of approximately 40% in Rheumatoid Factor in the abiprubart group, noted April 2, 2024.",74,1322.61936,45.0308,19.7,18.73,17.73,-0.050492119,-0.105360516,0.030398793,0.023829905,4.06071,0.03907,7.97321
KRBP,$3.00 ,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung CancerÂ ,Phase 1,4/2/2024,"Phase 1 data from third patient after reviewing safety and efficacy findings from the first cohort, the Safety Monitoring Committee (SMC) recommended not to escalate the cell dose level and instead t",1,3.67147,0,0,0,0,#DIV/0!,#DIV/0!,0.030398793,0.023829905,0,0,0
CRBP,$37.46 ,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinomaÂ ",Phase 1,4/2/2024,"Phase 1 US dosing initiated, noted April 2, 2024.",12,393.6011,225.823,37.99,37.46,37.47,-0.01404927,-0.013782354,0.030398793,0.023829905,3.84296,0.0012,10.14754
SGHT,$5.44 ,TearCare - (SAHARA RCT),Dry Eye DiseaseÂ ,Phase 1,4/2/2024,"Phase 1 clinical results demonstrate long-term efficacy of the OMNI Surgical System for primary open-angle glaucoma and support use of TearCare technology as a primary treatment for dry eye disease, n",52,269.57034,183.0342,5.31,5.44,6.07,0.024187226,0.13376677,0.030398793,0.023829905,3.28276,0.13531,4.36926
VNDA,$3.91 ,FANAPT (iloperidone),Bipolar DisorderÂ ,Approved,4/2/2024,"Approved April 2, 2024.",59,224.97162,60.1671,4.12,3.91,4.36,-0.052315789,0.056618894,0.030398793,0.023829905,5.2157,0.00824,8.30067
FGEN,$1.47 ,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 1,4/3/2024,"Phase 1 topline data reported a PSA50 response in 36% of patients, a confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months, noted April 3, 2024.",4,145.1937,171.7006,54,36.75,35.75,-0.384845821,-0.412433777,0.013209938,0.008082865,5.59708,0.03677,15.2019
LENZ,$21.22 ,VIZZ (aceclidine ophthalmic solution),PresbyopiaÂ ,Phase 3,4/3/2024,Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours. Rapid onset and long duration shown with 71% of participants achiev,28,541.82157,0,21.01,21.22,21.03,0.009945618,0.000951475,0.013209938,0.008082865,0.49117,0,8.29278
MRK,$129.12 ,"Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01)",Ovarian cancerÂ ,Phase 2/3,4/3/2024,"Phase 2/3 trial portion 2 initiated, noted April 3, 2024.",,328990.439,17.2012,130.35,129.9,126.75,-0.003458217,-0.028006498,0.013209938,0.008082865,0.9143,0.00011,1005.61241
DSNKY,$31.22 ,"Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01)",Ovarian cancerÂ ,Phase 2/3,4/3/2024,"Phase 2/3 trial portion 2 initiated, noted April 3, 2024.",,8966006.44,0,0,0,0,#DIV/0!,#DIV/0!,0.013209938,0.008082865,0,0,0
PRFX,$1.77 ,PRF-110,BunionectomyÂ ,Phase 3,4/3/2024,"Phase 3 enrollment target reached 50%, noted April 2, 2024.",1,3.05915,86.9105,41.51999,42.47999,35.03999,0.022858144,-0.169685017,0.013209938,0.008082865,0.80285,0.09197,0.01342
NBTX,$6.13 ,NBTXR3 - (MD Anderson Study 2020-0123),Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/3/2024,"Phase 1 dose escalation study completed, noted April 2, 2024.",47,274.18724,80.3013,6.1,6.13,6.4,0.004905979,0.048009219,0.013209938,0.008082865,0,0,1.38696
SPRY,$9.40 ,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxisÂ ,CRL,4/3/2024,The Company submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffyÂ® (epinephrine nasal spray) for the treatment of Type I allergic reactions,98,907.11461,55.1106,9.28,9.4,9.27,0.012848142,-0.001078167,0.013209938,0.008082865,4.40902,0.14079,5.18818
MRNA,$101.21 ,mRNA-3927 (Paramount),Propionic AcidemiaÂ ,Phase 1/2,4/3/2024,"Phase 1/2 has been well tolerated in participants at the doses administered, with no dose-limiting toxicities observed. Fifteen participants reported treatment-emergent adverse events (TEAEs), while n",389,38751.24553,55.566,103.61,101.21,107.14,-0.023436284,0.03350254,0.013209938,0.008082865,5.80525,0.17896,523.03456
MGNX,$13.67 ,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 2,4/3/2024,"Phase 2 preliminary safety data suggested that reducing the dose and frequency of cobra duo improves its safety and tolerability in men with mCRPC, noted April 3, 2024.",63,853.44562,68.8997,13.31,13.67,18.25,0.026688018,0.315649448,0.013209938,0.008082865,8.97386,0.04891,23.93714
ACHL,$0.90 ,ATL001 - (CHIRON),Non-Small Cell Lung Cancer (NSCLC)Â ,Phase 1/2,4/4/2024,"Phase 1/2 data reported that 25% of higher dose (>100M cNeT) patients demonstrated stable disease with some reduction in tumor volume, noted April 4, 2024.",41,54.83395,0,0,0,0,#DIV/0!,#DIV/0!,0.009491297,-0.002632735,0,0,0
ACHL,$0.90 ,ATL001 - (THETIS),MelanomaÂ ,Phase 1/2,4/4/2024,"Phase 1/2a data reported that 3 of 12 patients demonstrated stable disease with some reduction in tumor volume, noted April 4, 2024.",41,54.83395,0,0,0,0,#DIV/0!,#DIV/0!,0.009491297,-0.002632735,0,0,0
CVAC,$2.96 ,Flu-SV-mRNA,Multivalent seasonal flu vaccineÂ ,Phase 2,4/4/2024,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4",224,662.81418,66.4663,2.91,2.96,2.96,0.017036187,0.017036187,0.009491297,-0.002632735,2.16817,0.0015,12.33373
GSK,$40.15 ,Flu-SV-mRNA,Multivalent seasonal flu vaccineÂ ,Phase 2,4/4/2024,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4",,66909.27752,17.9443,16.54,16.375,16.29,-0.010025908,-0.015230267,0.009491297,-0.002632735,0,0.00021,192.74587
ADCT,$4.71 ,ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7),B-cell non-Hodgkin lymphomaÂ ,Phase 1b,4/4/2024,"Phase 1b dose escalation trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients a",112,388.71418,139.4517,4.43,4.71,4.68,0.061288324,0.054898526,0.009491297,-0.002632735,1.13868,0.03439,5.7379
AMLX,$2.61 ,RELYVRIO (sodium phenylbutyrate and taurursodiol),Amyotrophic lateral sclerosis (ALS)Â ,Phase 3,4/4/2024,Company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate and taurursodiol [also known as ursodo,89,176.91138,258.4008,2.63,2.61,2.29,-0.007633625,-0.138432029,0.009491297,-0.002632735,7.51218,0.02751,7.38386
AMLX,$2.61 ,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML)Â ,Phase 3,4/4/2024,"Based on Phase 3 previous results, the company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate",89,176.91138,258.4008,2.63,2.61,2.29,-0.007633625,-0.138432029,0.009491297,-0.002632735,7.51218,0.02751,7.38386
CADL,$6.40 ,CAN-2409 plus valacyclovir (prodrug),"Non-Metastatic Pancreatic Cancer, Pancreatic ductal adenocarcinoma (PDAC)Â ",Phase 2,4/4/2024,"Phase 2 interim data reported that at 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation, noted April 4, 2024.",54,187.8238,217.62,1.68,6.4,7.28,1.337504197,1.466337069,0.009491297,-0.002632735,0.50183,0.00059,921.15513
EFTR,$2.96 ,Tomivosertib (MNK1/2) - (KICKSTART),Non-small cell lung cancer (NSCLC)Â ,Phase 2b,4/4/2024,"Phase 2b study did not meet the pre-specified threshold of pâ‰¤0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respect",4,10.91444,265.1333,16.47,2.96,2.235,-1.716351276,-1.997299316,0.009491297,-0.002632735,8.62597,0.0076,25.87623
GOVX,$2.01 ,GEO-CM04S1- (COH04S1),COVID-19 in immunocompromised patientsÂ ,Preclinical,4/4/2024,"Preclinical data presented at the Annual World Vaccine showed that vaccine-induced immunity protects against infections, serious disease symptoms, and death against the original Wuhan variant as well",25,4.36627,69.9417,1.94,2.01,1.83,0.035446749,-0.058372006,0.009491297,-0.002632735,0.76238,0.01345,0.17064
DTIL,$14.34 ,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) DeficiencyÂ ,IND-Enabling,4/4/2024,"IND Cleared by the FDA, noted April 4, 2024.",11,99.17887,100.1952,15.44,14.34,14.45,-0.073908709,-0.06626713,0.009491297,-0.002632735,2.57417,0.20879,2.00952
CRBU,$4.54 ,CB-010 - (GALLOP),"Lupus nephritis (LN), extrarenal lupus (ERL)Â ",IND-Enabling,4/4/2024,"IND Clearance by FDA, noted April 4, 2024. Phase 1 trial planned by year end 2024.",93,410.02784,92.1156,4.68,4.54,4.33,-0.030371098,-0.077730568,0.009491297,-0.002632735,11.15339,0.0415,8.62016
HCM,$16.36 ,HMPL-295,Solid tumorsÂ ,Preclinical,4/5/2024,Preclinical data from AACR reported that HMPL-295 significantly improved the anti-tumor activity of standard-of-care chemotherapy as well as targeted agents in KRAS- or BRAF-mutant tumor models both,174,2227.40082,59.6042,2.67,2.61,2.9,-0.022728251,0.082632265,-0.01011738,0.015086978,0,0.08476,0.05729
HCM,$16.36 ,HMPL-506,LeukemiaÂ ,Preclinical,4/5/2024,Preclinical data from AACR reported that in In vivo studies demonstrated the dose- and exposure- dependent target regulation of MEIS1 and anti-tumor efficacy following HMPL-506 treatment in multiple t,174,2227.40082,59.6042,2.67,2.61,2.9,-0.022728251,0.082632265,-0.01011738,0.015086978,0,0.08476,0.05729
HCM,$16.36 ,HMPL-A067 (HMA800067),B-cell malignanciesÂ ,Preclinical,4/5/2024,"Preclinical data reported that an intravenous injection of HMA800067 at 10 mg/kg single dose induced complete tumor regression in all the animals within 10 days of administration, noted April 5, 2024.",174,2227.40082,59.6042,2.67,2.61,2.9,-0.022728251,0.082632265,-0.01011738,0.015086978,0,0.08476,0.05729
AZN,$67.04 ,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited diseaseÂ ,Phase 3,4/5/2024,"Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.",,164633.5008,23.8531,107.36,106.2,110.64,-0.010863564,0.030094014,-0.01011738,0.015086978,0,0.22766,277.1461
CYTK,$72.71 ,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM)Â ,Phase 3,4/5/2024,Phase 3 first cohort efficacy and safety datacompleting 1-year follow-up data from ACC.24 reported that treatment with aficamten for 48 weeks resulted in substantial and sustained reductions in averag,119,7489.47246,109.8718,69.18,72.71,71.56,0.049767123,0.033824455,-0.01011738,0.015086978,14.36557,0.00454,73.23969
OCGN,$1.83 ,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,4/5/2024,"Phase 1/2 Data and Safety Monitoring Board (DSMB) convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study, noted April 5, 2024.",292,469.39945,103.0871,1.51,1.83,1.71,0.192206316,0.12438372,-0.01011738,0.015086978,13.79975,0.00937,38.06601
IGXT,$0.19 ,Buprenorphine Buccal Film - (Belbuca Biosimilar),PainÂ ,CRL,4/5/2024,"In an Amendment Acknowledgement received from the FDA by the company, the FDA granted priority review with a Generic Drug User Fee Act (GDUFA) date for review of the Amendment of March 8, 2024, unless",174,29.51722,0,0,0,0,#DIV/0!,#DIV/0!,-0.01011738,0.015086978,0,0,0
TARA,$3.63 ,TARA-002 - (ADVANCED-1),Non-muscle invasive bladder cancer (NMIBC)Â ,Phase 1b,4/5/2024,"Phase 1b data reported a complete response rate of 43% at three months, noted April 5, 2024.",38,41.50483,92.9852,4.02,3.63,3,-0.102049254,-0.292669614,-0.01011738,0.015086978,0.53737,0.09455,31.16703
TSVT,$4.92 ,Abecma (idecabtagene vicleucel; ide-cel),Multiple MyelomaÂ ,Approved,4/5/2024,"Approved April 5, 2024.",53,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.01011738,0.015086978,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
BMY,$50.56 ,Abecma (idecabtagene vicleucel; ide-cel),Multiple MyelomaÂ ,Approved,4/5/2024,"Approved April 5, 2024.",,104013.2573,22.4379,51.4,51.32,48.28,-0.001557633,-0.062620776,-0.01011738,0.015086978,1.83812,0.05109,466.78342
CDTX,$23.20 ,CCR5-001,Colorectal cancerÂ ,Preclinical,4/5/2024,"Preclinical data shared at the AACR conference demonstrated potent efficacy in colorectal cancer mouse model, noted April 5 2024.",25,105.11809,58.148,21.6,23.2,16.2,0.071458964,-0.287682072,-0.01011738,0.015086978,0.19804,0.002,2.65867
CDTX,$23.20 ,CBO421,Tumor immune evasion preventionÂ ,Preclinical,4/5/2024,"Preclinical data shared at AACR data demonstrated improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines, noted April 5, 2024.",25,105.11809,58.148,21.6,23.2,16.2,0.071458964,-0.287682072,-0.01011738,0.015086978,0.19804,0.002,2.65867
HOWL,$5.92 ,WTX-518,Solid tumorsÂ ,Preclinical,4/5/2024,"Preclinical data presented at AACR reported complete tumor regression in the MC38 mouse tumor model, noted April 5, 2024.",45,253.00417,119.2685,6,5.92,4.69,-0.01342302,-0.246326887,-0.01011738,0.015086978,1.01075,0.01455,0.54923
HOWL,$5.92 ,WTX-712,Solid tumorsÂ ,Preclinical,4/5/2024,"Preclinical data presented at AACR reported that treatment demonstrated inducibility and antitumor activity with regressions in the MC38 mouse tumor model, noted April 5, 2024.",45,253.00417,119.2685,6,5.92,4.69,-0.01342302,-0.246326887,-0.01011738,0.015086978,1.01075,0.01455,0.54923
JNJ,$152.39 ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,Approved,4/5/2024,"FDA Approval on April 5, 2024.",,367226.8396,13.4207,152.5,152.39,147.52,-0.000721572,-0.033200836,-0.01011738,0.015086978,0.65728,0.1388,1033.66442
LEGN,$54.93 ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple MyelomaÂ ,Approved,4/5/2024,"FDA Approval on April 5, 2024.",183,9992.3731,38.4153,55.14,54.93,52.92,-0.003815758,-0.041094066,-0.01011738,0.015086978,5.77745,0.03369,35.47055
AZN,$67.04 ,Trastuzumab deruxtecan - (DESTINY-CRC02),HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC)Â ,Phase 2,4/5/2024,"Phase 2 data showed a confirmed ORR of 51.4% and a median DoR range of 19.4 months, noted April 5, 2024.",,164633.5008,23.8531,107.36,106.2,110.64,-0.010863564,0.030094014,-0.01011738,0.015086978,0,0.22766,277.1461
AMRN,$1.05 ,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular diseaseÂ ,Phase 1,4/6/2024,Phase 1 data presented at the American College of Cardiology's Annual Scientific Session & Expo show that findings presented on VASCEPA/VAZKEPA utility in REDUCE-IT patient subgroups by baseline High/,20,431.20539,88.2212,21,21,19.14,0,-0.092742052,-0.002436594,0.022767764,4.42949,0.08408,0
XLO,$1.47 ,XTX501,Solid TumorsÂ ,Preclinical,4/7/2024,"Preclinical data shared at AACR reported superior PK profile compared to non-masked PD1/IL2 in mice, akin to PD1 antibodies, projected to achieve >95% PD-1 RO with once every 3 weeks (Q3W) dosing, no",51,41.36144,138.8019,1.2,1.2,1.18,0,-0.016807118,-0.002436594,0.022767764,0.16719,0.00871,0
REPL,$7.12 ,RP1 (vusolimogene oderparepvec) - (ARTACUS),Liver and kidney transplant recipients with recurrent Cutaneous squamous cell carcinomaÂ ,Phase 1/2,4/7/2024,"Phase 1/2 open-label data presented at AACR reported an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most respo",78,451.81411,109.2251,7.36,7.36,7.14,0,-0.030347156,-0.002436594,0.022767764,11.27959,0.02094,0
ALNY,$156.04 ,Zilebesiran - (KARDIA-2),HypertensionÂ ,Phase 2,4/7/2024,"Phase 2 full data shared at the American College of Cardiology Scientific Sessions reported that zilebesiran demonstrated clinically significant and sustained placebo-adjusted, time-adjusted reduction",131,19417.98432,35.2499,153.56,153.56,148.5,0,-0.033506412,-0.002436594,0.022767764,2.12491,0.22756,0
ARWR,$25.70 ,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),HypertriglyceridemiaÂ ,Phase 2,4/7/2024,"Phase 2 clinical data presented at ACC.24 reported a dose-dependent placebo-adjusted reductions in triglycerides, with Significant and durable triglyceride and APOC3 reductions to week 48, noted April",138,3194.06244,77.5738,25.78,25.78,24.7,0,-0.042795754,-0.002436594,0.022767764,7.42775,0.12943,0
BNTX,$89.31 ,Cevumeran (BNT122),Resected pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 1,4/7/2024,"Phase 1 data presented at AACR reported that in 8 of 16 patients, autogene cevumeran elicited high-magnitude T cells specific to the encoded neoantigens. 98% of the T cells targeting individual neoant",239,21518.93353,34.132,90.52,90.52,86.48,0,-0.045657647,-0.002436594,0.022767764,1.29653,0.10852,0
IONS,$42.24 ,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS)Â ,Phase 3,4/7/2024,"Phase 3 trial met her primary endpoint, noted April 7, 2024.",159,6299.39267,34.54,43.22,43.22,41.74,0,-0.034843449,-0.002436594,0.022767764,6.6316,0.15992,0
ITOS,$12.22 ,EOS-984 - (APT-008),Adenosine on T and B cellsÂ ,Preclinical,4/7/2024,"Preclinical data presented at AACR reported a blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of memory T cells and TILs despite high adenosine concentrations, result",44,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.002436594,0.022767764,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
INO,$11.34 ,GT-30,Cancer Vaccine in advanced hepatocellular carcinomaÂ ,Phase 1/2,4/7/2024,"Phase 1/2 trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate, noted April 7, 2024.",53,275.65346,107.4811,11.795,11.795,11.03,0,-0.06705688,-0.002436594,0.022767764,8.8072,0.02043,0
EWTX,$16.88 ,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM)Â ,Preclinical,4/7/2024,Preclinical data presented at ACC blunted the HCM-mediated progressive slowing of LV diastolic relaxation; additionally the candidate preserved myocardial distensibility and maintained cardiac reserve,105,1579.15617,93.1117,16.96,16.96,16.37,0,-0.035407239,-0.002436594,0.022767764,4.81641,0.02114,0
SNDX,$22.81 ,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemiasÂ ,Phase 2,4/8/2024,"Phase 2 data reported a complete remission (CR) or CR with partial hematological recovery (CRh) rate was 23%, and the overall response rate was 46%, noted April 8, 2024.",86,1938.38664,51.0945,22.89,22.81,21.62,-0.003501098,-0.057081322,-0.016060185,0.043398868,9.80155,0.2702,9.73326
ZYME,$9.62 ,ZW191,"Non-small cell lung cancer, endometrial cancer, and triple-negative breast cancerÂ ",Preclinical,4/8/2024,"Preclinical data reported superior internalization, payload delivery, and spheroid penetration to other FRÎ±-targeted multi-specific antibodies, noted April 8, 2024.",75,678.8663,46.4301,9.65,9.62,9.09,-0.003113651,-0.059783007,-0.016060185,0.043398868,5.60663,0.03155,2.92621
BMRN,â€”,BMN 401 (INZ-701) - (adults trial),ENPP1 deficiencyÂ ,Phase 1/2,4/8/2024,"Phase 2 topline data showed avorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing",192,16467.60829,29.1894,86.95,87.28,91.51,0.003788101,0.051115015,-0.016060185,0.043398868,1.5711,0.05879,117.38881
MIST,$1.82 ,Etripamil - (NODE-303),Paroxysmal supraventricular tachycardia (PSVT)Â ,Phase 3,4/8/2024,Phase 3 data shared at ACC24 demonstrated that symptom-prompted treatment with etripamil was effective at restoring sinus rhythm as compared to placebo with a median time-to-conversion of 17.0 minutes,84,108.7032,102.344,1.8,1.82,1.755,0.011049836,-0.025317808,-0.016060185,0.043398868,0.80387,0.01554,0.45022
PSTX,$2.97 ,P-BCMA-ALLO1,Multiple myelomaÂ ,Phase 1,4/8/2024,Phase 1 clinical early update presented at AACR suggests patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-AL,97,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.016060185,0.043398868,0,0,0
KANT,â€”,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumorsÂ ,Phase 1/2,4/8/2024,"Phase 1/2 data presented at AACR showed a partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts, noted April 8, 2024.",13,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.016060185,0.043398868,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
VINC,$4.78 ,VIP236,Solid tumorsÂ ,Phase 1,4/8/2024,"Phase 1 initial data presented at AACR demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid",5,102.35596,152.4755,111,95.6,17.4,-0.149357381,-1.853059995,-0.016060185,0.043398868,4.03344,0.00269,10.60969
CRDF,$5.88 ,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal CancerÂ ,Phase 1/2,4/8/2024,Phase 1/2 data presented at AACR showed enhanced clinical efficacy signal in bev naÃ¯ve patients is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-li,66,262.70175,115.9133,5.84,5.88,5.28,0.006825965,-0.100804699,-0.016060185,0.043398868,6.29721,0.01782,4.97709
NUVL,$68.44 ,Zidesamtinib - (NVL-330) - (HEROEX-1),HER2-mutant tumorsÂ ,Preclinical,4/8/2024,"Preclinical data presented at AACR continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile , Zidesa",72,4384.78915,41.5223,70.2,68.44,65.28,-0.025390862,-0.0726626,-0.016060185,0.043398868,11.0059,0.11771,86.92955
MRUS,$44.01 ,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancerÂ ,Preclinical,4/8/2024,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2",75,2581.19878,52.9413,44.7,44.01,41.27,-0.015556621,-0.079837658,-0.016060185,0.043398868,6.98709,0.25394,20.02195
GMAB,â€”,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancerÂ ,Preclinical,4/8/2024,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2",661,133454.9172,36.9417,2057,2051,2058,-0.002921132,0.000486027,-0.016060185,0.043398868,0,0.094,132.87609
INKT,$1.32 ,FAP-CAR-IL-15 iNKT (MiNK-215),Non-small cell lung cancer (NSCLC)Â ,Preclinical,4/8/2024,Preclinical data shared at AACR exhibits potent anti-tumor activity through multiple mechanisms including immune activation and eliminated MSS colorectal cancer liver metastases in human organoid mode,4,45.80275,84.4882,15.6,13.2,9.085,-0.167054085,-0.540646212,-0.016060185,0.043398868,0.13389,0.01656,0.60655
CADL,$6.43 ,Alpha 201-macro-1 (enLIGHTEN Discovery Platform),"Solid tumors, breast cancerÂ ",Preclinical,4/8/2024,"Preclinical data shared at AACR reported that treatment was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in",54,188.70422,217.8762,6.64,6.43,5.82,-0.032137425,-0.131811702,-0.016060185,0.043398868,0.50183,0.01595,99.97077
COGT,$6.52 ,CGT4255 - (ErbB2),Solid tumorsÂ ,Preclinical,4/8/2024,Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet,139,623.39934,149.775,6.71,6.52,6.5,-0.028724575,-0.031796774,-0.016060185,0.043398868,10.07551,0.00215,3.29282
AGEN,$9.31 ,BMS-986442 (AGEN1777),Solid tumorsÂ ,Preclinical,4/8/2024,"Preclinical data presented at AACR reported that treatment demonstrated superior immune activation as monotherapy and in combination with PD-(L)1 blockade compared to conventional anti-TIGIT mAb, note",31,195.00729,106.8075,10.074,9.31,6.5,-0.078868756,-0.43815567,-0.016060185,0.043398868,10.9199,0.04262,12.29673
ADCT,$5.09 ,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC)Â ",Phase 1b,4/8/2024,"Phase 1b additional data presented at AACR reported that due to the incidence of TEAE judged related to Mipa and the preliminary activity observed, 15mg was selected as the highest dose to be tested i",112,420.0754,139.9339,5,5.09,4.37,0.017839918,-0.134674903,-0.016060185,0.043398868,1.13868,0.03134,3.20478
ALXO,$12.14 ,ALX148 and Vidaza (azacitidine) - (ASPEN-02),Myelodysplastic syndromes (MDS)Â ,Phase 1,4/8/2024,"Phase 1 data presented at AACR reported that the combination results in high CR rates in patients with relapsed refractory iNHL, noted April 8, 2024.",53,608.84628,92.7385,12.23,12.14,12.89,-0.007386164,0.052559867,-0.016060185,0.043398868,5.8098,0.10737,10.85633
PYXS,$5.58 ,PYX-106,Solid TumorsÂ ,Preclinical,4/8/2024,Additional preclinical data shared at AACR reported that Siglec-15 and PD-L1 mRNA expression are not broadly mutually exclusive across cancer indications and instead expression of each gene varies bro,62,324.38423,108.6148,5.46,5.58,4.74,0.021739987,-0.141411654,-0.016060185,0.043398868,2.81013,0.02367,3.16234
ELTX,$8.66 ,ELI-002 (AMPLIFY-201),Solid TumorsÂ ,Phase 1,4/8/2024,Phase 1 trial data presented at AACR reported that a majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline. Durab,16,88.51398,134.9312,8.85,8.66,9.23,-0.021702736,0.042041589,-0.016060185,0.043398868,0.27791,0.01395,1.19713
RIGL,$12.60 ,REZLIDHIA (olutasidenib) - (CONNECT),High-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutationÂ ,Phase 2,4/8/2024,"Phase 2 showed induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens, noted April 8, 2024.",17,220.97604,74.6803,12.9,12.6,11.5,-0.023530497,-0.114880276,-0.016060185,0.043398868,2.81941,0.11488,8.01427
PTN,$2.02 ,PL9643 - (MELODY-1),Dry eye disease (DED)Â ,Phase 3,4/8/2024,Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p,46,83.64869,73.3743,0.074,0.071,0.077,-0.041385216,0.039740329,-0.016060185,0.043398868,0,0.00178,0.01211
SUPN,$31.43 ,ONAPGO (apomorphine hydrochloride) injection (SPN-830),Motor fluctuations in Parkinsonâ€™s disease (PD)Â ,CRL,4/8/2024,"CRL announced April 8, 2024.",56,1720.31967,40.5167,33.55,31.43,29.99,-0.065274013,-0.112172871,-0.016060185,0.043398868,8.99609,0.09086,24.8198
ORIC,$10.75 ,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC)Â ,Preclinical,4/8/2024,"Preclinical data demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition, noted April 8, 2024.",97,724.29036,70.7196,10.97,10.75,9.54,-0.02025852,-0.139670789,-0.016060185,0.043398868,10.2825,0.12339,5.40708
PFE,$25.84 ,DOVATO (Dolutegravir and lamivudine) - (DANCE),HIV-1 infection in adolescents 12 years + and weighing at least 25 kg with no antiretroviral (ARV) treatment historyÂ ,Approved,4/8/2024,"FDA Approved on April 8, 2024.",,150510.3475,26.873,26.66,26.58,25.91,-0.003005261,-0.02853532,-0.016060185,0.043398868,1.2654,0.03367,649.38534
ENTX,$1.95 ,EB613,OsteoporosisÂ ,Phase 2,4/8/2024,"Phase 2 publication in the Journal of Bone Mineral Research showed that despite the superior benefits of bone building (anabolic) agents and guidelines supporting their use, these medications are used",45,69.18862,108.2337,1.985,1.95,2.52,-0.017789542,0.238639987,-0.016060185,0.043398868,0.02281,0.00662,0.70408
CHRS,$2.51 ,CHS-1000,Solid TumorsÂ ,Preclinical,4/8/2024,"Preclinical studies showed a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion, noted April 8, 20",116,282.91337,117.632,2.43,2.51,2.2,0.032391496,-0.099433897,-0.016060185,0.043398868,22.98948,0.05653,5.2981
NVCT,$7.81 ,NXP900,Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/8/2024,"Phase 1 data presented at AACR demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone, noted April 8, 2024.",25,138.77452,85.5507,7.78,7.81,6.41,0.003848626,-0.193697067,-0.016060185,0.043398868,4.31145,0.00793,0.18998
CCCC,$7.66 ,CFT1946,Solid tumorsÂ ,Preclinical,4/8/2024,"Preclinical data reported that a CFT1946 as a single agent and in combination with cetuximab demonstrates superior activity to the standard of care combination, BRAFi with cetuximab, in all CRC models",71,525.48113,189.3951,7.52,7.66,6.86,0.018445846,-0.091858696,-0.016060185,0.043398868,7.70697,0.05637,7.94621
CORT,$24.23 ,Relacorilant plus ABRAXANE (nab-paclitaxel) - (ROSELLA),Ovarian cancerÂ ,Phase 3,4/8/2024,"Phase 3 enrollment completed, noted April 8, 2024.",105,2508.22631,62.5862,25.2,24.23,23.15,-0.03925246,-0.084849214,-0.016060185,0.043398868,19.52845,0.01165,23.08751
INMB,$10.36 ,INB03,MUC4 expressing cancerÂ ,Phase 1,4/8/2024,Trial data reported that the increase in T cell infiltrate did not occur unless both anti-HER2 and INB03 immunotherapy were used in combination. Decreases in T cell and macrophage immune checkpoint p,26,185.97004,72.2976,10.34,10.36,9.58,0.001932368,-0.076342277,-0.016060185,0.043398868,8.04625,0.0216,2.31955
BMRN,â€”,BMN 401 (INZ-701),ABCC6 deficiencyÂ ,Phase 1/2,4/8/2024,"Phase 1/2 topline data reported a reduction or stabilization of cIMT was observed across all dose cohorts, and increased choroidal thickness was observed across all dose cohorts, noted April 8, 2024.",192,16467.60829,29.1894,86.95,87.28,91.51,0.003788101,0.051115015,-0.016060185,0.043398868,1.5711,0.05879,117.38881
MRKR,$4.71 ,Neldaleucel (MT-601) - (APOLLO),Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatmentÂ ,Phase 1,4/8/2024,"Phase 1 data reported that the initial dose level was well tolerated and demonstrated durable objective responses after MT-601 treatment, noted April 8, 2024.",12,41.93265,101.6656,4.67,4.71,4.44,0.008528836,-0.050504695,-0.016060185,0.043398868,1.68151,0.00777,0.09578
NVS,$95.48 ,Leqvio - (V-INITIATE),Low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD)Â ,Phase 3,4/8/2024,"Phase 3b data reported significant reductions in LDL-C compared to those receiving usual care (60% vs. 7%), noted April 8, 2024.",,1306.28195,51.1609,4.21,4.21,4.3,0,0.021152375,-0.016060185,0.043398868,0,0.00056,0
NXTC,$2.05 ,LNCB74,B7-H4 expressing cancersÂ ,Preclinical,4/8/2024,"Preclinical data reported durable tumor regression in multiple CDX and PDX tumor models, suggesting activity comparable or superior to competitor B7-H4 targeting ADCs, noted April 8, 2024.",2,57.2012,81.669,26.16001,24.60001,20.04001,-0.061485059,-0.266501134,-0.016060185,0.043398868,3.0093,0.06988,0.33645
OCS,$10.76 ,OCS-01 - (OPTIMIZE-2),Inflammation and pain following ocular surgeryÂ ,Phase 3,4/8/2024,"Phase 3 trial data reported that 57.2% of patients treated with OCS-01 were inflammation free (i.e. absence of anterior chamber cells) at Day 15, and 75.5% had absence of ocular pain at Day 4, noted A",43,394.35083,43.2457,11.16,10.76,12.03,-0.036500402,0.075067573,-0.016060185,0.043398868,0.12882,0.00951,0.08709
CVKD,$6.13 ,tecarfarin - (ARIES-HM3),Thromboembolism and thrombosisÂ ,Phase 2,4/9/2024,"FDA granted orphan drug designation, noted April 9, 2024.",2,6.54266,123.1122,7.65,6.1305,5.8485,-0.221429335,-0.26852043,0.004990307,0.054442169,0.26246,0.02223,2.49104
ATOS,$1.84 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,4/9/2024,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all",129,230.55948,72.9284,1.75,1.84,1.54,0.050149784,-0.127833372,0.004990307,0.054442169,8.43033,0.03839,7.10928
LLY,$754.94 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerÂ ,Phase 2,4/9/2024,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all",946,682096.1216,28.2202,777.29,757.24,746.74,-0.026133267,-0.040096445,0.004990307,0.054442169,0.60178,0.00582,1866.47317
IMRX,$2.19 ,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanomaÂ ",Preclinical,4/9/2024,Preclinical data presented at AACR demonstrated that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibiti,36,64.13037,159.4041,2.12,2.19,1.84,0.032485455,-0.141650517,0.004990307,0.054442169,9.82096,0.16422,0.86856
CMPX,$1.67 ,CTX-009 in combination with paclitaxel,Biliary Tract Cancer (cholangiocarcinoma)Â ,Preclinical,4/9/2024,Preclinical data presented at AACR suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expressio,138,229.77392,82.9639,1.7,1.67,1.57,-0.017804625,-0.079552632,0.004990307,0.054442169,1.18007,0.0208,0.40601
MTEM,$1.85 ,MT-6402,Solid tumorsÂ ,Phase 1,4/9/2024,"Phase 1 interim data presented at AACR showed that drug has been well tolerated with no drug-related Grade 4 or Grade 5 adverse events observed, noted April 9, 2024.",6,9.9424,0,0,0,0,#DIV/0!,#DIV/0!,0.004990307,0.054442169,0,0,0
NRIX,$17.48 ,NX-5948,B-cell malignancies / graft-versus-host diseaseÂ ,Phase 1a,4/9/2024,Additional data with higher dose levels and longer treatment duration were reported at AACR; The company presented new case studies demonstrating clinical responses in two patients with B cell maligna,76,859.15588,91.0673,13.8,17.48,14.65,0.236388778,0.059771743,0.004990307,0.054442169,14.17901,0.21503,33.38701
IOBT,$1.61 ,IO102-IO103 - (IOB-032),Squamous cell carcinoma of the head and neck (SCCHN)Â ,Phase 1/2,4/9/2024,"Phase 1/2 early data presented at AACR demonstrated the mechanism. Based on these results the company hopes to confirm its ongoing Phase 3 pivotal study, noted April 9, 2024.",65,106.06827,68.8127,1.54,1.61,1.51,0.044451763,-0.019672766,0.004990307,0.054442169,0.10352,0.06338,0.10657
RAPT,$8.44 ,tivumecirnon (FLX475) in combination with pembrolizumab,Advanced CancerÂ ,Phase 2,4/9/2024,"Phase 2 data shared at AACR confirmed an objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status, noted April 9, 2024.",16,293.70943,209.3697,66.56,67.52,65.04,0.014320054,-0.023101331,0.004990307,0.054442169,8.55399,0.07872,13.09483
FHTX,$7.48 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Preclinical,4/9/2024,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",56,318.39296,124.8815,7.17,7.48,6.03,0.042327137,-0.173158644,0.004990307,0.054442169,2.80103,0.04787,0.38751
LLY,$754.94 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC)Â ,Preclinical,4/9/2024,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",946,682096.1216,28.2202,777.29,757.24,746.74,-0.026133267,-0.040096445,0.004990307,0.054442169,0.60178,0.00582,1866.47317
INAB,$1.09 ,INB-300,Solid TumorsÂ ,Preclinical,4/9/2024,"Preclinical data presented at AACR supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue, noted April 9, 2024.",4,47.18317,132.2812,32.70003,32.70003,29.40903,0,-0.106074225,0.004990307,0.054442169,0.11924,0.00307,2.50044
TPST,$3.87 ,TPST-1120,renal cell carcinoma (RCC)Â ,Preclinical,4/9/2024,"Preclinical data shared at AACR showed that TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the tumor microenvironment, consistent with modulation of the tumor microenvironment to a more im",4,85.88312,560.2734,51.86998,50.30998,43.54999,-0.030536736,-0.174830729,0.004990307,0.054442169,4.3696,0.0001,2.94595
AZN,$67.99 ,FPI-2265 - (AlphaBreak),Prostate cancerÂ ,Phase 2,4/9/2024,"Phase 2 preliminary data presented at AACR demonstrate that FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those",,165997.6955,23.8594,106.1,107.08,108.78,0.009194173,0.024945448,0.004990307,0.054442169,0,0.22766,183.79008
PRLD,$4.99 ,PRT7732,lymphoid malignanciesÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses, noted April 9, 2024.",56,377.87075,98.1302,4.7,4.99,4.91,0.059873401,0.043711433,0.004990307,0.054442169,0.8212,0.10664,0.32043
PRLD,$4.99 ,PRT2527,Solid tumors and hematological malignanciesÂ ,Preclinical,4/9/2024,"Additional preclinical data shared at the AACR provides improved depth and duration of response in combination with BTK/BCL2 inhibition, noted April 9, 2024.",56,377.87075,98.1302,4.7,4.99,4.91,0.059873401,0.043711433,0.004990307,0.054442169,0.8212,0.10664,0.32043
PRLD,$4.99 ,PRT3645,CancerÂ ,Preclinical,4/9/2024,"Preclinical data at AACR showed that drug is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC, noted April 9, 2024.",56,377.87075,98.1302,4.7,4.99,4.91,0.059873401,0.043711433,0.004990307,0.054442169,0.8212,0.10664,0.32043
CRVS,$1.63 ,Soquelitinib - (CPI-818),Peripheral T-cell lymphoma (PTCL)Â ,Phase 3,4/9/2024,"Phase 3 dosing initiated, noted April 9, 2024.",74,79.93289,78.8561,1.71,1.63,1.47,-0.047913356,-0.15123097,0.004990307,0.054442169,2.85005,0.00986,0.31969
MCRB,$0.71 ,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)Â ",Phase 1b,4/9/2024,"Phase 1b cohort 2 patient enrollment completed, noted April 9, 2024.",8,107.12611,135.3566,14.648,14.188,12.722,-0.03190727,-0.140971029,0.004990307,0.054442169,12.45171,0.00305,4.95895
QLGN,$0.40 ,QN-302,"Pancreatic cancer, Prostate cancer and other solid tumorsÂ ",Phase 1,4/9/2024,"Phase 1 results demonstrated that for the first five patients (three of whom were PDAC patients), QN-302 is overall well-tolerated (no SAE) and they have reported a ""good"" quality of life during the d",1,2.516,64.7714,19.075,19.945,14.99,0.044599908,-0.240995265,0.004990307,0.054442169,1.26728,0.00734,0.03345
BCTX,$2.85 ,SV-BR-1-GM,Metastatic breast cancerÂ ,Phase 2,4/9/2024,"Phase 2 efficacy and safety data shared at AACR shows that Bria-IMT provides prolonged progression-free survival and clinical benefits in heavily pre-treated, ADC resistant breast cancer patients comp",1,62.00858,87.3342,439.49978,427.51479,341.99983,-0.027648332,-0.250826977,0.004990307,0.054442169,0,0,0.09448
BCTX,$2.85 ,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,4/9/2024,Phase 2 data shared at AACR showed that Bria-IMT's tumor reductions observed in all breast cancer subtypes in patients with intracranial disease underlines its potential clinical effectiveness in mana,1,62.00858,87.3342,439.49978,427.51479,341.99983,-0.027648332,-0.250826977,0.004990307,0.054442169,0,0,0.09448
IPHA,$2.60 ,IPH45,Nectin-4 expressing tumorsÂ ,Preclinical,4/9/2024,"Preclinical data presented at AACR reported that treatment effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models, note",92,185.93657,79.6483,2.6,2.6,2.59,0,-0.003853569,0.004990307,0.054442169,0,0,0.04602
ALXO,$12.34 ,ALX148 (evorpacept) + rituximab and lenalidomide,Non-Hodgkin lymphoma (NHL)Â ,Phase 1,4/9/2024,"Phase 1 trial data presented at AACR reported that the best ORR of 94% and a CRR of 83%, noted April 9, 2024.",53,618.87669,92.3812,12.14,12.34,14.49,0.016340233,0.176952971,0.004990307,0.054442169,6.22301,0.10737,5.4246
GNPX,$3.07 ,REQORSA (GPX-001) with KEYTRUDA (pembrolizumab) - (Acclaim-2),Non-Small Cell Lung Cancer (NSCLC)Â ,Preclinical,4/9/2024,"Preclinical data presented at AACR reported that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect, noted April 9, 2024.",,5.86493,125.5804,148,153.5,115,0.036488293,-0.252280145,0.004990307,0.054442169,3.66133,0.16201,0.38958
CGEN,$2.36 ,COM503,Solid tumorsÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted",93,211.29126,161.6351,2.33,2.36,2.03,0.012793351,-0.137832475,0.004990307,0.054442169,2.3365,0.02795,0.35894
GILD,$69.12 ,COM503,Solid tumorsÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted",,87080.7007,25.0705,69.42,69.94,67.31,0.007462721,-0.030866196,0.004990307,0.054442169,1.81296,0.05626,414.61859
NTBL,$1.41 ,Volasertib,Relapsed/refractory acute myeloid leukemiaÂ ,Preclinical,4/9/2024,"Preclinical data presented at AACR suggest a strong correlation between volasertib resistant fractions treated with 31.6 and 100 nM of volasertib and AUCs, which could represent a suitable metric to s",9,0,11.5755,10.66325,10.66555,10.9553,0.000215671,0.027020107,0.004990307,0.054442169,0,0,0
PFE,$26.03 ,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD)Â ,Phase 3,4/9/2024,"Phase 3 trial met its primary endpoint, noted April 9, 2024.",,151642.8558,26.7971,26.58,26.78,25.69,0.007496287,-0.034057242,0.004990307,0.054442169,1.14785,0.03367,1210.28579
BGNE,$154.02 ,Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204),Small cell lung cancer (SCLC)Â ,Phase 2,4/9/2024,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s",106,16093.59878,0,0,0,0,#DIV/0!,#DIV/0!,0.004990307,0.054442169,0,0,0
ONC,â€”,Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204),Small cell lung cancer (SCLC)Â ,Phase 2,4/9/2024,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s",110,16093.59878,49.4643,149.75,154.02,134.05,0.028115227,-0.110754372,0.004990307,0.054442169,1.65346,0.10578,17.74326
BGNE,$154.02 ,BGB-10188,Solid tumorsÂ ,Phase 1a,4/9/2024,Phase 1a data presented at AACR reported that BGBâ€‘10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of,106,16093.59878,0,0,0,0,#DIV/0!,#DIV/0!,0.004990307,0.054442169,0,0,0
ONC,â€”,BGB-10188,Solid tumorsÂ ,Phase 1a,4/9/2024,Phase 1a data presented at AACR reported that BGBâ€‘10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of,110,16093.59878,49.4643,149.75,154.02,134.05,0.028115227,-0.110754372,0.004990307,0.054442169,1.65346,0.10578,17.74326
CCCC,$7.97 ,CFT8634,Synovial sarcomaÂ ,Phase 1,4/9/2024,"Phase 1 data presented at AACR reported that selective targeting of EP300 with targeted protein degradation is a safe and effective treatment strategy for advanced tumors, noted April 9, 2024.",71,546.74733,188.6694,7.66,7.97,6.83,0.039672509,-0.11468731,0.004990307,0.054442169,13.33713,0.05637,9.24566
BCYC,$23.07 ,BT7455,EphA2-expressing cancersÂ ,Preclinical,4/9/2024,"Preclinical data shared at AACR reported that treatment engages EphA2 and CD137 with high affinity, resulting in potent EphA2-dependent activity in vitro and robust anti-tumor activity in vivo with in",69,982.46329,65.9098,22.96,23.07,21.93,0.004779501,-0.045898009,0.004990307,0.054442169,5.97035,0.13263,7.37649
APRE,$6.04 ,ATRN-119,Advanced solid tumorsÂ ,Phase 1/2,4/9/2024,Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg,5,32.79524,101.1676,6.2,6.0394,5.85,-0.026244623,-0.058107631,0.004990307,0.054442169,1.94887,0.06963,0.04363
YS,$0.90 ,PIKA Rabies Vaccine,RabiesÂ ,Phase 3,4/10/2024,"Phase 3 trial met its primary endpoints, noted April 10, 2024.",93,169.49516,0,0,0,0,#DIV/0!,#DIV/0!,0.003936152,0.079342749,0,0,0
WHWK,â€”,Nab-sirolimus in combination with fulvestrant,Breast CancerÂ ,Preclinical,4/10/2024,"Preclinical data presented at AACR reported that nab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cells, noted April 1",47,49.10841,137.48,2.1,2,1.82,-0.048790164,-0.143100844,0.003936152,0.079342749,3.84075,0,0.76471
BTAI,$2.63 ,Dexmedetomidine (BXCL501) - (TRANQUILITY III),Agitation associated with Alzheimerâ€™s DiseaseÂ ,Phase 3,4/10/2024,"Phase 3 expanded to In-Care study, trial planned to initiate soon following FDA meeting, noted April 10, 2024.",14,80.41661,134.8601,41.12,42.08,41.44,0.023077947,0.007751977,0.003936152,0.079342749,8.14721,0.00881,1.02688
VSTM,$11.30 ,GFH375/VS-7375,Cancer KRAS G12DÂ ,Preclinical,4/10/2024,"Preclinical data shared at AACR shown potent efficacy and safety of orally administered GFH375 in animal models, noted April 8, 2024.",61,285.83909,65.5951,11.74,11.3,10.84,-0.038199089,-0.079758818,0.003936152,0.079342749,2.50825,0.01894,1.04005
GALT,$3.82 ,GR-MD-02 (belapectin) - (NAVIGATE),Non-alcoholic steatohepatitis (NASH) with cirrhosisÂ ,Phase 2/3,4/10/2024,"5th DSMB recommends the continuation, without modifications, noted April 10, 2024.",64,236.47203,65.1492,3.94,3.82,3.38,-0.030930301,-0.153305014,0.003936152,0.079342749,3.62737,0.00641,2.47281
ALKS,$26.14 ,ALKS 2680 - (Vibrance-1),NarcolepsyÂ ,Phase 1,4/10/2024,Phase 1 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopath,165,4422.47454,42.7603,26.73,26.14,24.01,-0.022319822,-0.10731612,0.003936152,0.079342749,8.47354,0.0131,53.07385
ACRV,$10.39 ,ACR-2316,"Dual WEE1 and PKMYT1 inhibitor, Solid tumorsÂ ",Preclinical,4/10/2024,"Preclinical data presented at AACR reported that treatment was highly potent across multiple human tumor cell lines and patient-derived ex vivo tumor models, noted April 10, 2024.",31,235.19792,123.5201,9.62,10.39,10.34,0.07699954,0.072175604,0.003936152,0.079342749,2.35439,0.02049,10.91246
AIM,$0.56 ,"Ampligen, cisplatin and KEYTRUDA (pembrolizumab)",Ovarian cancerÂ ,Phase 2,4/10/2024,"Phase 2 protocol planned interim results by leading the investigator to concluded that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease, noted",2,76.21713,63.3467,0.37,0.365,0.355,-0.013605652,-0.041385216,0.003936152,0.079342749,0,0.0195,0.04281
BCTX,$2.73 ,Bria-Pros+,Prostate cancerÂ ,Preclinical,4/10/2024,"Preclinical data reported that treatment engaged with multiple facets of the adaptive immune response, which may result in lasting anti-cancer effects in patients, noted April 10, 2024.",1,59.13189,87.4939,427.51479,409.4998,323.99984,-0.043052469,-0.277245862,0.003936152,0.079342749,0,0,0.23505
AMLX,$2.46 ,AMX0035 - (HELIOS),Wolfram SyndromeÂ ,Phase 2,4/10/2024,"Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with dise",89,166.74406,258.4846,2.67,2.46,2,-0.081917122,-0.288931292,0.003936152,0.079342749,8.86243,0.02915,7.79873
REGN,$936.20 ,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/10/2024,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs",105,100605.827,16.8881,943.89,936.2,901.19,-0.008180505,-0.046293522,0.003936152,0.079342749,1.32271,0.11602,364.89799
BNTX,$88.65 ,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC)Â ,Phase 1,4/10/2024,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs",239,21363.80774,34.0293,90.05,88.65,86.4,-0.015669039,-0.041377396,0.003936152,0.079342749,1.27674,0.10852,38.06959
APVO,$2.40 ,ALG.APV-527,Solid tumorsÂ ,Phase 1,4/10/2024,"Phase 1 Cohort 5 dosing imminent, trial more than 50% enrolled, noted April 10, 2024.",3,1.27872,118.6123,2412.40241,1776.00178,527.25053,-0.306258455,-1.520702556,0.003936152,0.079342749,6.42942,0.03701,1.75114
APVO,$2.40 ,mipletamig (APVO711),Solid tumorsÂ ,Preclinical,4/10/2024,"Preclinical studies ongoing, in vivo studies have confirmed that APVO711 reduces the size of PD-L1-expressing tumors, noted April 10, 2024.",3,1.27872,118.6123,2412.40241,1776.00178,527.25053,-0.306258455,-1.520702556,0.003936152,0.079342749,6.42942,0.03701,1.75114
CRBU,$4.35 ,CB-012,Acute Myeloid Leukemia (AML)Â ,Preclinical,4/10/2024,"Preclinical data presented at AACR reported that in robust tumor control, leading to significant prolongation of survival in AML xenograft models, noted April 10, 2024.",93,392.86808,92.1171,4.46,4.35,3.91,-0.024972921,-0.131611392,0.003936152,0.079342749,11.29577,0.04959,9.28858
VRTX,$397.58 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 2,4/10/2024,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",256,102758.2656,27.1086,404.48,397.58,393.1,-0.01720612,-0.028538259,0.003936152,0.079342749,1.53816,0.19209,408.18743
ALPN,$47.04 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathyÂ ",Phase 2,4/10/2024,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",68,67.50173,23.0024,7.7,7.75,7.5,0.006472515,-0.026317308,0.003936152,0.079342749,0,0.02553,0.03972
KRYS,$175.70 ,KB707 - (KYANITE-1),Solid TumorsÂ ,Preclinical,4/10/2024,"Preclinical data shared at AACR reported that KB703/KB704 treatment enhanced the frequency of IFNÎ³-expressing T cells both in the tumor and tumor-draining lymph node, leading to higher levels of circu",28,5010.00591,70.3148,179.77,175.7,169.64,-0.022900261,-0.057999711,0.003936152,0.079342749,7.62476,0.01445,43.04632
LPCN,$6.41 ,LPCN 2401,"Obesity, Chronic Weight ManagementÂ ",Phase 2,4/11/2024,Phase 2 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%. Reduced android fat (AF) by 4.1% and i,5,34.07447,75.8804,6.51,6.41,5.44,-0.015480185,-0.179560395,0.020214052,0.074646878,2.04839,0.06649,14.13277
PRTC,$27.93 ,LYT-200,"Solid tumors, urothelial and head and neck cancers, acute myeloid leukemia (AML)Â ",Phase 1/2,4/11/2024,"Fast track designation granted by the FDA, noted April 11, 2024.",24,586.35375,50.3245,2.175,2.17,2.075,-0.002301497,-0.047067511,0.020214052,0.074646878,0,0.09069,1.33893
CLYM,â€”,Budoprutug (TNT119),Systemic lupus erythematosusÂ ,Phase 2,4/11/2024,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67,128.43817,89.6996,2.67,4.58,4.18,0.539620526,0.448232774,0.020214052,0.074646878,0.04713,0.00002,179.10551
CLYM,â€”,Budoprutug (TNT119),Immune thrombocytopeniaÂ ,Phase 2,4/11/2024,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67,128.43817,89.6996,2.67,4.58,4.18,0.539620526,0.448232774,0.020214052,0.074646878,0.04713,0.00002,179.10551
CLYM,â€”,Budoprutug (TNT119),Membranous nephropathyÂ ,Phase 1,4/11/2024,"Phase 1 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67,128.43817,89.6996,2.67,4.58,4.18,0.539620526,0.448232774,0.020214052,0.074646878,0.04713,0.00002,179.10551
BOLD,$11.63 ,BBI-355/BBI-825 - (POTENTIATE),Resistance gene amplificationsÂ ,Phase 1/2,4/11/2024,"Phase 1/2 dosing commenced, noted April 11, 2024.",22,258.60976,0,11.87,11.63,11.3,-0.020426242,-0.049211483,0.020214052,0.074646878,0,0,1.81944
AZN,$69.02 ,FASENRA (benralizumab) - (TATE),Eosinophilic asthma aged 6 to 11 with an eosinophilic phenotypeÂ ,Approved,4/11/2024,"FDA approved on April 11, 2024.",,169936.3314,23.9938,107.32,109.62,109.14,0.021204814,0.016816436,0.020214052,0.074646878,0,0.22766,295.81242
RARE,$42.87 ,GTX-102 - (Aspire),Angelman SyndromeÂ ,Phase 1/2,4/15/2024,"Phase 1/2 data from expansion cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170, noted April",96,3529.7309,51.6463,47,42.87,43.69,-0.091975321,-0.073028359,0.02923781,0.051203738,4.75909,0.10488,74.04914
LGND,$79.77 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,4/15/2024,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,19,1412.35074,41.7769,81.36,79.77,68.53,-0.019736258,-0.171612146,0.02923781,0.051203738,3.79595,0.26731,14.0108
MRNS,$1.30 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE)Â ,Phase 3,4/15/2024,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,55,3971.16328,41.6345,53.5,53,52.51,-0.00938974,-0.018678026,0.02923781,0.051203738,0,0.00299,1.8815
TFFP,$3.52 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,4/15/2024,Phase 2 updates data to be presented at the upcoming ISHLT 2024 meeting provided strong biomarker evidence that treatment with TFF TAC results in normalization of rejection-related genes; the treatmen,4,979.936,70.4002,43.2,43.2,45,0,0.040821995,0.02923781,0.051203738,0,0,0
VIRX,$0.78 ,Nanatinostat - (NAVAL-1),Epstein Barr Virus-associated cancersÂ ,Phase 2,4/15/2024,Phase 2 Stage 1 data from patients in the Nana-val treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the int,39,51.44689,0,0,0,0,#DIV/0!,#DIV/0!,0.02923781,0.051203738,0,0,0
RNAZ,$0.54 ,TTX-MC138,Metastatic solid tumorsÂ ,Phase 1/2,4/15/2024,"IND clearance by the FDA, noted April 15, 2024.",,3.11448,172.2113,574.08156,495.54151,424.11627,-0.147120353,-0.302763837,0.02923781,0.051203738,0.68803,0.00522,1.91874
ONVO,$1.35 ,FXR314,MASH & Primary Biliary CholangitisÂ ,Phase 2,4/15/2024,"Phase 2 16-week details study results demonstrated a statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo, noted April 15, 2024.",1,13.55404,0,0,0,0,#DIV/0!,#DIV/0!,0.02923781,0.051203738,0,0,0
CORT,$23.15 ,Dazucorilant (DAZALS),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2,4/15/2024,"Phase 2 enrollment completed, noted April 15, 2024.",105,2403.83039,63.5507,23.51,23.15,22.3,-0.015431082,-0.052839184,0.02923781,0.051203738,20.54224,0.01707,16.77039
EWTX,$16.48 ,sevasemten (EDG-5506) - (ARCH),Becker muscular dystrophy (BMD)Â ,Phase 1b,4/15/2024,"Phase 1b 24-months topline data showed that significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with sk",105,1539.40464,92.4571,16.37,16.48,15.08,0.006697133,-0.082081029,0.02923781,0.051203738,6.12809,0.02428,6.65024
ORIC,$9.54 ,ORIC-114,"Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLCÂ ",Phase 1b,4/15/2024,"Phase 1b expansion cohorts initiated, noted April 15, 2024.",97,642.76558,69.8516,9.8,9.54,8.72,-0.0268889,-0.116763148,0.02923781,0.051203738,12.07832,0.13655,3.16931
TELO,$8.84 ,Telomir-1,Age-related conditionsÂ ,Preclinical,4/15/2024,"Preclinical data confirmed our hypothesis that TELOMIR-1 affects telomere length, promoting its extension in primary cell strains including MRC-5, HUVEC, and MSCs (~40% increase), noted April 15, 2024",32,261.75076,0,9,8.84,5.605,-0.017937701,-0.473565521,0.02923781,0.051203738,0.05305,0.09532,0.5129
LBPH,$18.25 ,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs)Â ,Phase 1/2,4/15/2024,"Phase 1b/2a data presented at the AAN Annual Meeting reported that treatment with bexicaserin reduced seizures in all participant subgroups, including LGS and DEE Other, noted April 15, 2024.",39,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.02923781,0.051203738,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
NVS,$94.41 ,Fabhalta (iptacopan),IgA nephropathy (IgAN)Â ,Phase 3,4/15/2024,"Phase 3 data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo, noted April 15, 2024.",,1334.20722,51.7048,4.3,4.3,4.88,0,0.126530197,0.02923781,0.051203738,0,0.00104,0.20961
HALO,$38.38 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Phase 3,4/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",116,4876.34864,38.5893,38.72,38.38,38.97,-0.008819772,0.006435857,0.019883696,0.019411274,6.20677,0.21406,24.65124
ARGX,$370.68 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Phase 3,4/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",60,20749.65778,57.74,358,349.4,349.2,-0.024315589,-0.024888162,0.019883696,0.019411274,0,0.0014,23.5562
ZLAB,$14.42 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP)Â ,Phase 3,4/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",109,1423.50668,57.9772,14.2,14.42,15.12,0.015374167,0.062776406,0.019883696,0.019411274,3.91761,0.10967,5.78216
JNJ,â€”,CAPLYTA (lumateperone) - (Study 501),Major depressive disorder (MDD)Â ,Phase 3,4/16/2024,"Phase 3 topline results for the 42 mg Cohort achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, noted April 16, 2024.",,348093.1622,13.8239,147.59,144.45,149.56,-0.021504732,0.013259491,0.019883696,0.019411274,0.6616,0.15359,1845.32838
PRTC,$25.48 ,Deupirfenidone (LYT-100) - (ELEVATE IPF),Idiopathic pulmonary fibrosis (IPF)Â ,Phase 2,4/16/2024,"Phase 2 enrollment completed, noted April 16, 2024.",24,568.79016,49.496,2.135,2.105,2.13,-0.01415118,-0.002344667,0.019883696,0.019411274,0,0.09548,0.75435
CGEM,$17.32 ,CLN-978,Relapsed/refractory B-cell non-Hodgkin lymphomaÂ ,Phase 1,4/16/2024,"The company has discontinued enrollment in its B-NHL study to focus ongoing development on autoimmune indications, noted April 16, 2024.",59,745.89697,59.6374,16.55,17.32,16.67,0.045475801,0.007224595,0.019883696,0.019411274,3.33446,0.09648,58.0983
PALI,$5.93 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,4/16/2024,"Preclinical data completion of exvivo analysis, noted April 16, 2024.",9,5.04881,138.6343,4.16,5.93,5.92,0.354509139,0.352821375,0.019883696,0.019411274,3.22069,0.05738,171.82315
CMPX,$1.57 ,CTX-8371,Solid TumorsÂ ,Phase 1,4/16/2024,"Phase 1 dosing initiated, noted April 16, 2024.",138,216.015,81.9536,1.58,1.57,1.52,-0.006349228,-0.038714512,0.019883696,0.019411274,1.18007,0.02318,1.12837
ABOS,$3.50 ,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimerâ€™s disease (AD)Â ,Phase 1,4/16/2024,"Phase 1 additional data presented at AAN demonstrated a favorable safety and tolerability profile in participants with early AD with a relatively low incidence of ARIA-E, noted April 16, 2024.",60,210.27922,88.1311,3.53,3.5,3.16,-0.008534902,-0.110725843,0.019883696,0.019411274,2.06279,0.07411,0.7796
LEXX,$2.31 ,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight lossÂ ",Preclinical,4/16/2024,"Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.",19,29.76591,138.7244,1.99,2.31,2.24,0.149112886,0.118341227,0.019883696,0.019411274,3.80611,0.00332,0.70809
CLNN,$6.20 ,CNM-Au8 - (VISIONARY-MS),Multiple SclerosisÂ ,Phase 2,4/16/2024,"Phase 2 LTE emonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints, noted April 16, 2024.",9,39.81445,113.0767,6.628,6.2,6.702,-0.066753808,0.01110289,0.019883696,0.019411274,0.12683,0.06053,2.89327
PXMD,$0.66 ,PAX-HAT-301,Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (Stage 1 TBR HAT)Â ,NDA Filing,4/16/2024,"NDA Company received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies",10,4.92732,213.8016,0.74,0.66,0.716,-0.114410351,-0.032970019,0.019883696,0.019411274,1.79114,0.05293,2.56833
TEVA,$13.09 ,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,Approved,4/16/2024,"FDA approved on April 16, 2024.",,14826.26542,30.9571,13.23,13.09,13.01,-0.010638398,-0.016768686,0.019883696,0.019411274,1.0202,0.03118,105.87137
ALVO,$12.73 ,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.Â ,Approved,4/16/2024,"FDA approved on April 16, 2024.",301,3558.8862,47.4421,12.5,12.73,13.4,0.018232768,0.069526063,0.019883696,0.019411274,0.06832,0.02187,4.80792
SAGE,$12.57 ,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI)Â ,Phase 2,4/17/2024,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",62,401663.162,9.871,50,50,50,0,0,0.025195017,0.019699841,0,0.0162,0.335
SUPN,â€”,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI)Â ,Phase 2,4/17/2024,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",56,1587.31372,40.0297,29.43,29,30.26,-0.014718732,0.027812146,0.025195017,0.019699841,8.8111,0.11292,11.42107
LLY,$748.49 ,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA)Â ,Phase 3,4/17/2024,"Phase 3 trial data showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints, noted April 17, 2024.",946,676268.1649,27.4928,746.74,750.77,732.2,0.005382281,-0.019663365,0.025195017,0.019699841,0.60178,0.01132,2304.38866
GSK,$38.91 ,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI)Â ,Phase 3,4/17/2024,"Phase 3 EAGLE-1 data from ESCMID reported that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxon",,64968.39771,18.1341,16.105,15.9,16.36,-0.012810674,0.015709548,0.025195017,0.019699841,0,0.00195,117.46287
RHHBY,$30.08 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MSÂ ,Phase 3,4/17/2024,Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be,,177318.7064,0,0,0,0,#DIV/0!,#DIV/0!,0.025195017,0.019699841,0,0,0
HALO,$38.02 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MSÂ ,Phase 3,4/17/2024,Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be,116,4830.60905,38.5577,38.38,38.02,39.12,-0.009424154,0.019097355,0.025195017,0.019699841,6.20677,0.21406,27.90124
NVS,$93.08 ,Kesimpta (ofatumumab) - (ALITHIOS),Relapsing Multiple SclerosisÂ ,Phase 3,4/17/2024,"Additional Phase 3 data reported that significant reductions in ARR (71.3%) and in MRI lesion activity (Gd+ T1: 98.5% reduction; neT2: 93% reduction), and rapid increase in rates of NEDA-3, noted Apri",,1334.20722,51.4945,4.3,4.3,4.35,0,0.011560822,0.025195017,0.019699841,0,0.00104,0.1763
MTVA,â€”,DA-1726,NASH and obesityÂ ,Phase 1a,4/17/2024,"Phase 1a dosing initiated, noted April 17, 2024.",24,16.97487,113.5985,3.4,3.46,3.1,0.017493157,-0.09237332,0.025195017,0.019699841,1.26157,0.00645,0.03974
VIGL,$2.92 ,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)Â ,Phase 2,4/17/2024,"Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.",46,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.025195017,0.019699841,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
SNY,â€”,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)Â ,Phase 2,4/17/2024,"Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.",,107608.2844,34.9606,45.8,46.11,46.61,0.006745755,0.017531019,0.025195017,0.019699841,0,0,171.29293
VIGL,$2.92 ,VGL101 - (ILLUMINATE),Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)Â ,Phase 2,4/17/2024,"Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.",46,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.025195017,0.019699841,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
SNY,â€”,VGL101 - (ILLUMINATE),Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)Â ,Phase 2,4/17/2024,"Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.",,107608.2844,34.9606,45.8,46.11,46.61,0.006745755,0.017531019,0.025195017,0.019699841,0,0,171.29293
DMAC,$2.60 ,Rinvecalinase Alfa (DM199) - (ReMEDy2),Acute ischaemic stroke (AIS)Â ,Phase 2/3,4/17/2024,"Phase 2/3 resumed with dosing of first patient, noted April 17, 2024.",51,98.6908,60.0722,2.37,2.6,2.45,0.09262149,0.033198069,0.025195017,0.019699841,0.53261,0.06571,0.1061
GLPG,$29.22 ,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL)Â ,Phase 1/2,4/17/2024,"Phase 1/2 preliminary data reported that six patients responded to treatment (ORR 86%), including four CRs (CRR 57%), noted April 17, 2024.",65,1804.2618,27.1339,27.7,27.38,27.12,-0.011619593,-0.02116095,0.025195017,0.019699841,0,0.03344,2.86274
ATHA,$2.11 ,ATH-1020,"Healthy volunteers, Neuropsychiatric conditionsÂ ",Preclinical,4/17/2024,"Preclinical data presented at AAN reported that significantly enhanced neurite outgrowth, increased synaptic count, and promoted survival in primary neuron cultures, noted April 17, 2024.",3,80.86923,93.05,21.1,21.1,20.1,0,-0.048553225,0.025195017,0.019699841,2.63379,0.03941,0.23531
GLPG,$29.22 ,GLPG5201 - (EUPLAGIA-1),"B-cell malignancies, Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)Â ",Phase 1/2,4/17/2024,"Phase 1/2 data reported an ORR of 93% , noted April 17, 2024.",65,1804.2618,27.1339,27.7,27.38,27.12,-0.011619593,-0.02116095,0.025195017,0.019699841,0,0.03344,2.86274
ABBV,$163.15 ,Tavapadon - (TEMPO-3),Late Parkinsonâ€™s diseaseÂ ,Phase 3,4/18/2024,"Phase 3 trial met its primary endpoint, noted April 18, 2024.",,291554.7322,18.6511,164.25,164.66,167.29,0.002493085,0.018339176,0.021734794,0.029126527,0.74102,0.07372,737.71368
OCUL,$5.86 ,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR)Â ,Phase 1,4/18/2024,"Phase 1 interim data showed that demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm. No patient",174,870.95679,102.3882,7.58,5.86,4.2,-0.257363596,-0.590428674,0.021734794,0.029126527,7.94491,0.04768,35.59393
BPTH,$4.20 ,BP1002,Acute Myeloid Leukemia (AML)Â ,Phase 1b,4/18/2024,"Phase 1/1b second dose cohort completed, noted April 18, 2024.",8,3.16594,116.8904,3.24,4.2,2.635,0.259511195,-0.206690148,0.021734794,0.029126527,8.94222,0.00265,350.85696
BNTC,$6.82 ,BB-301,Oculopharyngeal muscular dystrophy (OPMD)Â ,Phase 1/2,4/18/2024,"Phase 1b/2a interim safety and efficacy data reported that facilitated improvements across multiple measures of swallowing function in the first subject, as compared to pretreatment assessments conduc",26,17.6804,98.1887,4.8,6.82,6.94,0.351243554,0.368685857,0.021734794,0.029126527,0.42285,0.03629,23.99093
PBLA,$0.49 ,Lvospemin (SBP-101),Ovarian cancerÂ ,Phase 1,4/18/2024,"Phase 1 data presented at AACR results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum-",4,2.37645,269.4529,0.516,0.4895,0.44,-0.052722304,-0.159332039,0.021734794,0.029126527,0.28641,0.00031,0.03245
ATNM,$6.67 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML)Â ,Phase 3,4/18/2024,Phase 3 data presented at the Annual European Bone Marrow Transplant Society Meeting (EBMT) demonstrated that Iomab-B led bone marrow transplant produced high rates of complete remission and durable c,31,196.07406,89.0766,7.25,6.67,6.56,-0.083381609,-0.100010866,0.021734794,0.029126527,7.43877,0.0117,2.80721
IMNN,$1.13 ,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5Â ,IND-Enabling,4/18/2024,"IND Cleared by the FDA, noted April 18, 2024.",2,10.57475,119.2511,14.86956,14.67391,18.7826,-0.013245083,0.233614739,0.021734794,0.029126527,4.7157,0.00729,0.23045
ABBV,$163.15 ,Upadacitinib (RINVOQ) - (SELECT-GCA),Giant cell arteritis (GCA)Â ,Phase 3,4/18/2024,"Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not",,291554.7322,18.6511,164.25,164.66,167.29,0.002493085,0.018339176,0.021734794,0.029126527,0.74102,0.07372,737.71368
NRSN,$1.52 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,4/18/2024,Phase 2b data presented at AAN reported that PrimeC met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0,23,26.34774,138.3702,1.6,1.52,1.26,-0.051293294,-0.238891908,0.021734794,0.029126527,0.36758,0.10794,0.40763
PHRRF,$0.17 ,KETARX (ketamine),Surgical pain managementÂ ,CRL,4/18/2024,"CRL issued by FDA, noted April 18, 2024.",91,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.021734794,0.029126527,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
RHHBY,$30.05 ,Alecensa(alectinib),Non-small cell lung cancer (NSCLC)Â ,Approved,4/18/2024,"FDA approved on April 18, 2024.",,177185.6367,0,0,0,0,#DIV/0!,#DIV/0!,0.021734794,0.029126527,0,0,0
MGTX,$5.01 ,AAV2-hAQP1 - (AQUAx2),XerostomiaÂ ,Phase 1,4/18/2024,"Phase 1 data presented at AAOM resulted in no treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study, noted April 18, 2024.",80,321.728,78.6553,5.25,5.01,4.71,-0.046792162,-0.108540169,0.021734794,0.029126527,1.78449,0.15064,1.17857
BRNS,$2.71 ,VTP-200 - (APOLLO),Human papillomavirus (HPV)Â ,Phase 1/2,4/18/2024,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",40,105.47649,103.5361,2.6,2.71,2.4289,0.04143719,-0.068072965,0.021734794,0.029126527,0.02603,0.00011,0.02527
CLYD,â€”,VTP-200 - (APOLLO),Human papillomavirus (HPV)Â ,Phase 1/2,4/18/2024,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",,1.02,370.1367,0.03,0.03,0.03,0,0,0.021734794,0.029126527,0,NM,0
TAK,$13.16 ,ENTYVIO (vedolizumab),Crohn's DiseaseÂ ,Approved,4/18/2024,"FDA Approved by the FDA, noted April 18, 2024.",,6415330.036,19.1128,13.15,13.16,13.07,0.000760167,-0.006102231,0.021734794,0.029126527,0,0,16.94672
TVGN,$1.85 ,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19Â ,Phase 1,4/19/2024,"Phase 1 study proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities, noted April 11, 2024.",196,304.53667,185.8154,2.12,1.85,1,-0.13623045,-0.751416089,-0.003229088,-0.000119782,0.00695,0.00204,0.38824
OCGN,$1.32 ,OCU410 - (ArMaDa),Geographic Atrophy (GA)Â ,Phase 1/2,4/19/2024,"Phase 1/2 Cohort 2 dosing completed, noted April 19, 2024.",292,339.66935,105.9363,1.32,1.32,1.28,0,-0.030771659,-0.003229088,-0.000119782,16.89809,0.02626,8.77352
CNTA,$10.00 ,ORX750 - (CRYSTAL-1),Narcolepsy and other sleep-wake disordersÂ ,IND-Enabling,4/22/2024,"IND cleared by the FDA, noted April 22, 2024",134,1003.0585,80.2238,10.57,10,9.29,-0.055434707,-0.129081247,-0.022207216,-0.031959952,1.73293,0.18078,2.1081
KRYS,$157.25 ,KB707 - (KYANITE-1),Solid TumorsÂ ,Phase 1,4/22/2024,"Phase 1 dosing initiated, noted April 22, 2024.",28,4483.91252,70.5204,158.53,157.25,157.99,-0.008106954,-0.00341211,-0.022207216,-0.031959952,7.62476,0.02848,53.75009
ENLV,$1.27 ,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA)Â ,Phase 2,4/22/2024,"Phase 2 trial initiated, noted April 22, 2024.",23,23.89096,159.9022,1.32,1.27,1.66,-0.038614836,0.229185866,-0.022207216,-0.031959952,1.25656,0.02864,0.06544
CORT,$22.30 ,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome)Â ,Phase 3,4/22/2024,"Phase 3 additional results exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints, noted April 22,",105,2315.5688,63.6788,22.95,22.3,23.37,-0.028731258,0.018135212,-0.022207216,-0.031959952,20.54224,0.02016,86.92498
ASLN,$3.64 ,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD)Â ,Phase 2b,4/22/2024,Phase 2b data reported that 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg,2,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.022207216,-0.031959952,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
PHIO,$7.47 ,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Preclinical,4/22/2024,Preclinical studies demonstrated PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME) Intratumoral injection of murine,5,3.81065,131.7579,5.7591,7.4691,6.075,0.259993297,0.053400777,-0.022207216,-0.031959952,0.46584,0.00048,6.0937
ABEO,$7.36 ,ZEVASKYN (prademagene zamikeracel),Recessive dystrophic epidermolysis bullosa (RDEB)Â ,CRL,4/22/2024,"CRL issued by the FDA, noted April 22, 2024.",51,201.33307,76.2204,7.57,7.36,3.44,-0.028133135,-0.788721596,-0.022207216,-0.031959952,7.29028,0.00265,7.56636
AZTR,$5.85 ,ATR12-351,Netherton SyndromeÂ ,Preclinical,4/22/2024,"Preclinical data suggests ATR-12 can significantly reduce IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome, noted April 22, 2024.",3,5.6169,228.6311,38.96104,38.96104,43.95604,0,0.120627871,-0.022207216,-0.031959952,0.69588,0.00839,0.25979
TOVX,$10.28 ,VCN-01 (VIRAGE),Metastatic PDACÂ ,Preclinical,4/22/2024,"Preclinical data demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft, noted April 22, 2024.",9,7.04784,93.5829,10.38,10.275,10.5,-0.010167117,0.011494379,-0.022207216,-0.031959952,2.39682,0.05056,0.47476
ACET,$2.00 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",Preclinical,4/22/2024,"Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models, noted April 22, 2024",83,181.22987,105.0366,1.95,2,1.59,0.025317808,-0.204095356,-0.022207216,-0.031959952,8.48325,0.02528,0.6507
IBRX,$4.94 ,ANKTIVA,BCG-Unresponsive Non-Muscle Invasive Bladder CancerÂ ,Approved,4/22/2024,"Approved April 22, 2024.",945,3344.39685,132.5152,5.27,4.94,8.99,-0.064665031,0.534082486,-0.022207216,-0.031959952,8.08936,0.00683,27.01443
TOVX,$9.42 ,VCN-01 (zabilugene almadenorepvec),RetinoblastomaÂ ,Phase 1,4/23/2024,"Phase 1 topline data in collaboration with Sant Joan de DÃ©u-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee, safety and clinical outcomes su",9,6.46309,94.3608,10.275,9.4225,10.0625,-0.086613314,-0.020898118,-0.002266087,-0.010334475,2.39682,0.05056,0.44982
TLSA,$0.78 ,Foralumab (Intranasal),Secondary Progressive Multiple Sclerosis (SPMS)Â ,Phase 2a,4/23/2024,"Phase 2a FDA allowed its intranasal foralumab na-SPMS Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients, noted April 23, 2024.",111,77.73856,66.4584,0.7536,0.775,0.65675,0.028001306,-0.137558295,-0.002266087,-0.010334475,0.32117,0.02904,1.94762
UBX,$1.49 ,UBX1325 - (ASPIRE),Diabetic macular edema (DME)Â ,Phase 2,4/23/2024,"Phase 2 study of UBX1325 has been extended from 24 to 36 weeks to assess potentially greater durability compared to aflibercept. In addition, the study is being upsized from 40 to 50 patients to incre",17,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.002266087,-0.010334475,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
SILO,$1.78 ,SPC-15,Post-traumatic stress disorder (PTSD)Â ,Preclinical,4/23/2024,"Preclinical study of intranasal delivery showed rapid and effective drug exposure for PTSD Therapy, noted April 23, 2024.",9,5.06167,67.532,1.99,1.78,1.8377,-0.111521274,-0.079619849,-0.002266087,-0.010334475,2.15896,0.10808,9.36999
NBIX,$140.09 ,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorderÂ ,Phase 2,4/23/2024,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã…sb",99,14090.32183,25.9813,133.66,140.09,137.54,0.046985811,0.028615522,-0.002266087,-0.010334475,2.41211,0.11564,225.23922
TAK,$13.38 ,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorderÂ ,Phase 2,4/23/2024,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Ã…sb",,6467145.334,19.1697,13.36,13.38,13.08,0.001495887,-0.021180822,-0.002266087,-0.010334475,0,0,22.77858
ANRO,$13.88 ,ALTO-101,SchizophreniaÂ ,Phase 1,4/23/2024,Phase 1 study in healthy volunteers demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administrat,27,372.85723,0,13.64,13.88,15.51,0.017442303,0.128478325,-0.002266087,-0.010334475,8.9213,0.00026,1.18509
HOWL,$6.44 ,IL-10 Indukine (PREDATOR Platform),Ulcerative Colitis (UC)Â ,Preclinical,4/23/2024,"Preclinical data in animal models supported unique conditionally active cytokine immunotherapy approach for the potential treatment, noted April 23, 2024.",45,279.15702,116.7671,6.09,6.44,6.24,0.055880458,0.024332101,-0.002266087,-0.010334475,1.0889,0.00604,2.53729
INMB,$10.14 ,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimerâ€™s diseaseÂ ,Phase 2,4/23/2024,"Phase 3 preparation ongoing after 24-month validation data completed, noted April 23, 2024.",26,190.37835,80.8152,10.625,10.14,11.84,-0.046721717,0.108273915,-0.002266087,-0.010334475,8.1276,0.04747,1.81114
NVS,$97.28 ,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)Â ,Approved,4/23/2024,"FDA approved on April 23, 2024.",,1427.29144,54.9715,4.88,4.6,4.36,-0.059088916,-0.112673163,-0.002266087,-0.010334475,0,0.00057,0.09887
DAWN,$16.64 ,OJEMDA (tovorafenib),Low-grade GliomaÂ ,Approved,4/23/2024,"FDA Approved on April 23, 2024.",102,1453.95599,60.4801,15.38,16.64,17.1,0.078741471,0.106010499,-0.002266087,-0.010334475,10.28268,0.17464,111.5693
RHHBY,$30.54 ,HB-700,KRAS-mutated cancersÂ ,IND-Enabling,4/24/2024,"IND cleared by the FDA, noted April 24, 2024.",,178960.9072,0,0,0,0,#DIV/0!,#DIV/0!,0.029598949,-0.030696515,0,0,0
HOOK,$8.50 ,HB-700,KRAS-mutated cancersÂ ,IND-Enabling,4/24/2024,"IND cleared by the FDA, noted April 24, 2024.",12,106.57989,100.3754,7.65,8.5,8.99,0.105360516,0.161407201,0.029598949,-0.030696515,0.25259,0.02106,8.87726
ALVO,$13.54 ,AVT05 (biosimilar to golimumab),Rheumatoid ArthritisÂ ,Phase 3,4/24/2024,"Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi. Additionally, no clinically meaningful differences in safety were observed through",301,3785.33537,47.1227,13.4,13.54,14.48,0.010393561,0.07751368,0.029598949,-0.030696515,0.05711,0.00774,2.58735
IMMP,$2.59 ,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2b,4/24/2024,"Phase 2b enrollment completed, noted November 9, 2023. Phase 2b data from efti in combination in patients who do not express PD-L1 (TACTI-003, Cohort B) showed a preliminary 26.9% response rate, the p",145,534.97555,55.9075,2.51,2.59,2.6,0.031375123,0.035228692,0.029598949,-0.030696515,0,0,3.6384
ALKS,$24.65 ,ALKS 2680 - (Vibrance-1),NarcolepsyÂ ,Phase 2,4/24/2024,"Phase 2 initiated, noted April 24, 2024.",165,4170.39011,40.3317,24.26,24.65,24.01,0.015947997,-0.010358493,0.029598949,-0.030696515,7.98986,0.02329,42.81752
ATAI,$1.87 ,BPL-003,Resistant DepressionÂ ,Phase 2a,4/24/2024,"Phase 2a OLE study initiated, noted April 24, 2024.",214,313.06167,98.924,1.97,1.87,2.05,-0.052095112,0.03980625,0.029598949,-0.030696515,3.52501,0.11802,1.57589
RDHL,$10.50 ,RHB-107 (upamostat) - (ACESO PROTECT),Early COVID-19 outpatient treatmentÂ ,Phase 2,4/24/2024,"Phase 2 dosing commenced, noted April 24, 2024.",3,13.38094,243.0954,10.69465,10.4975,11.275,-0.018606483,0.052844269,0.029598949,-0.030696515,2.32669,0.00003,0.08109
AMRX,$6.05 ,Naloxone hydrochloride nasal spray - (generic Narcan),Opioid overdoseÂ ,Approved,4/24/2024,"FDA Approved, noted April 24, 2024.",314,1866.75308,48.2579,5.4,6.05,6.12,0.113659318,0.125163143,0.029598949,-0.030696515,0.90884,0.05161,18.55227
CALC,$5.49 ,Auxora - (CARPO),Acute PancreatitisÂ ,Phase 2b,4/24/2024,"Phase 2b enrolment completed, noted April 24, 2024.",13,58.96323,114.4365,4.59,5.49,5.96,0.179048231,0.261190457,0.029598949,-0.030696515,0.31291,0.11831,0.42117
NVS,$98.35 ,Coartem (artemether-lumefantrine) - (CALINA),Malaria in babies <5 kgÂ ,Phase 2/3,4/24/2024,"Phase 2/3 data reported that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review, noted April 24, 2024.",,1349.72125,55.5675,4.6,4.35,4.36,-0.055880458,-0.053584246,0.029598949,-0.030696515,0,0.00057,0.03342
GANX,$3.19 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's DiseaseÂ ,Phase 1,4/24/2024,"Phase 1 data reported that treatment was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events, noted April 24, 2024.",35,51.74087,77.1706,3.39,3.19,2.97,-0.060809005,-0.132267969,0.029598949,-0.030696515,0.92231,0.00054,0.46833
ACRV,$9.50 ,ACR-368,"Platinum-resistant ovarian,(PROC) endometrial, and urothelial cancersÂ ",Phase 2b,4/24/2024,"Phase 2b initial data demonstrated a 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers, noted April 24, 2024.",31,293.30407,125.8634,9.82,9.5,8.23,-0.033129324,-0.176635108,0.029598949,-0.030696515,3.32162,0.00541,3.04218
IBRX,$5.11 ,Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055),"NSCLC, Various tumorsÂ ",Phase 2,4/25/2024,"Phase 2 results reported significant prolongation of overall survival, noted April 25, 2024.",945,3459.48743,129.1174,4.82,5.11,8.97,0.058425476,0.621111748,0.005375394,-0.051090748,8.10017,0.00683,43.72129
VTGN,$4.70 ,PH15,Psychomotor impairment caused by mental fatigueÂ ,Phase 2a,4/25/2024,"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants, noted April 25, 2024.",30,127.01848,74.976,4.72,4.7,4.41,-0.004246291,-0.06793411,0.005375394,-0.051090748,4.78306,0.00209,0.91558
BLCO,$14.76 ,LCD supplement capsule,Dry eyesÂ ,Phase 1,4/25/2024,"Trial met both primary endpoints, noted April 25, 2024.",353,5180.70344,37.9347,14.9,14.76,13.86,-0.009440394,-0.072354219,0.005375394,-0.051090748,0.46399,0.087,3.70883
TLSA,$0.84 ,Foralumab,"Non-active, secondary-progressive multiple sclerosis (na-SPMS)Â ",Phase 2,4/25/2024,"Phase 2 data quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab, noted April 25, 2024.",111,84.36891,66.8253,0.7901,0.8411,0.7051,0.062551039,-0.113819883,0.005375394,-0.051090748,0.25699,0.02904,0.74832
BIVI,$4.89 ,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's diseaseÂ ,Phase 2,4/25/2024,"Phase 2 data shared at the Annual Alzheimer's & Parkinson's Drug Development Summit shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and infla",7,26.84144,196.7348,50.54,48.89,49.99,-0.033192225,-0.010942117,0.005375394,-0.051090748,2.02737,0.0114,0.38388
ROIV,$10.88 ,Namilumab - (RESOLVE-Lung),SarcoidosisÂ ,Phase 2,4/25/2024,"Phase 2 enrollment completed, noted April 25, 2024.",682,8767.60455,38.4991,10.9,10.88,11.24,-0.001836548,0.030716055,0.005375394,-0.051090748,5.60026,0.11755,40.47067
ALGS,$20.45 ,ALG-097558,COVID-19Â ,Phase 1,4/25/2024,"Phase 1 data presented at ECCMID showed that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy v",6,61.89683,89.3154,20.725,20.45,21.15,-0.013357819,0.020299204,0.005375394,-0.051090748,0.86853,0.1542,0.10918
NKGN,$1.98 ,Troculeucel (SNK01),Alzheimer's DiseaseÂ ,Phase 1,4/25/2024,Preclinical data to be presented at the Alzheimer's & Parkinson's Drug Development Summit shows a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting imm,124,45.15517,182.8366,1.71,1.98,1.32,0.146603474,-0.258861634,0.005375394,-0.051090748,1.85819,0.00513,4.09522
PFE,$24.69 ,BEQVEZ (fidanacogene elaparvovec-dzkt),Hemophilia BÂ ,Approved,4/26/2024,"Approval announced April 26, 2024.",,143828.5488,26.1615,25.26,25.4,27.81,0.005527057,0.096173551,-0.039351685,-0.090188842,1.20198,0.02483,1181.77201
GILD,$64.06 ,Biktarvy,HIVÂ ,Approved,4/26/2024,"Approved for updated label on (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads, noted April 2",,81452.95167,25.1053,65.27,65.42,64.78,0.002295509,-0.007535599,-0.039351685,-0.090188842,1.70127,0.07102,810.05824
CDTX,$12.63 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal InfluenzaÂ ,Phase 2a,4/26/2024,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,25,57.61492,83.9854,13,12.63,12.51,-0.028874421,-0.038421033,-0.039351685,-0.090188842,0.17906,0.02553,2.52736
JNJ,$143.86 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal InfluenzaÂ ,Phase 2a,4/26/2024,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,,352165.6955,13.5345,146.82,146.14,149.27,-0.00464228,0.0165494,-0.039351685,-0.090188842,0.68735,0.12025,903.58099
ENTA,$12.37 ,EDP-235 - (SPRINT),COVID-19Â ,Phase 2,4/27/2024,"Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.",21,261.69951,64.58,12.37,12.37,15.17,0,0.204045607,-0.024023403,-0.074860559,12.97295,0.05986,0
AZN,$75.02 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancerÂ ",Phase 3,4/29/2024,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024",,186399.7855,22.4032,119.88,120.24,120.5,0.002998503,0.00515851,-0.013443781,-0.081506574,0,0.19694,445.38615
DSNKY,$32.70 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancerÂ ",Phase 3,4/29/2024,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024",,9606688.477,0,0,0,0,#DIV/0!,#DIV/0!,-0.013443781,-0.081506574,0,0,0
AQST,$3.74 ,Libervant (diazepam) - (pediatric),Acute treatment seizure activityÂ ,Approved,4/29/2024,"FDA Approved on April 29, 2024.",99,340.02892,93.2461,4.07,3.735,3.5,-0.085895181,-0.150880031,-0.013443781,-0.081506574,4.40314,0.00101,28.56347
XFOR,$1.09 ,XOLREMDI (mavorixafor),WHIM syndromeÂ ,Approved,4/29/2024,"Approved April 29, 2024.",11,183.05216,108.8899,34.95003,32.70003,36.00004,-0.066543332,0.029600723,-0.013443781,-0.081506574,7.30319,0.15033,23.86821
PRME,$4.86 ,PM359,Chronic Granulomatous Disease (CGD)Â ,IND-Enabling,4/29/2024,"IND cleared by the FDA, noted April 29, 2024.",134,560.32309,88.6465,4.425,4.86,5.4,0.093768159,0.199128675,-0.013443781,-0.081506574,8.85887,0.22345,6.16477
ADXN,$7.54 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),EpilepsyÂ ,Phase 2,4/29/2024,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",1,8.0802,146.5067,0.1155,0.063,0.075,-0.606135804,-0.431782416,-0.013443781,-0.081506574,0,0.00142,0.73788
JNJ,$144.53 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),EpilepsyÂ ,Phase 2,4/29/2024,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",,353804.348,13.1314,146.14,146.82,148.58,0.00464228,0.016558467,-0.013443781,-0.081506574,0.68735,0.12025,948.69035
ATHE,$2.20 ,ATH434,Parkinson's DiseaseÂ ,Preclinical,4/29/2024,"Preclinical data presented at the World Orphan Drug Congress USA 2024 Indicated that ATH434 can function as an iron chaperone to redistribute iron, noted April 29, 2024.",15,31.47069,180.6609,2.51,2.195,2.01,-0.134100707,-0.222148031,-0.013443781,-0.081506574,0,0,0.3751
ITRM,$1.54 ,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI)Â ,NDA Filing,4/29/2024,"NDA resubmitted to the FDA, noted April 29, 2024.",44,25.49452,128.5134,1.67,1.54,1.59,-0.08104121,-0.04908961,-0.013443781,-0.081506574,7.23115,0.07299,0.78766
SLS,$1.21 ,Galinpepimut-S - (REGAL),Acute Myeloid Leukemia (AML)Â ,Phase 3,4/29/2024,"IDMC recommended the continuation of the trial, noted April 29, 2024.",105,69.88346,118.6534,1.46,1.21,1.29,-0.187816076,-0.123794217,-0.013443781,-0.081506574,9.8107,0.01803,4.03264
AZN,$75.02 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,4/29/2024,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",,186399.7855,22.4032,119.88,120.24,120.5,0.002998503,0.00515851,-0.013443781,-0.081506574,0,0.19694,445.38615
AIM,$0.41 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic CancerÂ ,Phase 1/2,4/29/2024,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",2,73.08492,60.5892,0.34,0.35,0.345,0.028987537,0.014598799,-0.013443781,-0.081506574,0,0.02082,0.00044
LGND,$70.46 ,V116 - (STRIDE-10),Pneumococcal vaccineÂ ,Phase 3,4/29/2024,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",19,1265.34562,43.1683,70.57,70.46,72.83,-0.001559952,0.031522833,-0.013443781,-0.081506574,4.60292,0.30034,13.92712
MRK,$128.50 ,V116 - (STRIDE-10),Pneumococcal vaccineÂ ,Phase 3,4/29/2024,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",,329597.628,16.6636,131.2,130.12,127.57,-0.008265775,-0.028057643,-0.013443781,-0.081506574,0.80654,0.01085,888.63802
ANVS,$7.28 ,Buntanetap (ANVS401),Alzheimerâ€™s disease (AD)Â ,Phase 2/3,4/29/2024,"Phase 2/3 AD study data reported a significantly higher improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD (n=90), after unblinding the data to scre",19,80.16226,182.5694,18.01,7.28,5.39,-0.905796297,-1.206381774,-0.013443781,-0.081506574,13.19292,0.04736,69.85489
TERN,$5.10 ,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML)Â ,Phase 1,4/29/2024,"Phase 1 interim data showed no clinically significant difference in exposure between fed and fasted dosing, noted April 29, 2024.",87,329.84138,90.3146,4.91,5.1,5.79,0.037966598,0.16485835,-0.013443781,-0.081506574,6.79779,0.00001,2.51141
TFFP,$2.71 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,4/29/2024,"Phase 2 demonstrated that treatment with TFF TAC prevents Lung Transplant Rejection at only one-sixth of the dose of oral Tacrolimus and at Two-thirds of the oral Tacrolimus Systemic Trough Exposures,",4,923.568,69.8436,45,45,45,0,0,-0.013443781,-0.081506574,0,0,0
PFE,$24.92 ,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapyÂ ,Approved,4/29/2024,"Approved April 29, 2024.",,145187.5587,25.7947,25.4,25.64,28.16,0.009404458,0.103153357,-0.013443781,-0.081506574,1.20198,0.02483,1068.53174
GMAB,$28.57 ,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapyÂ ,Approved,4/29/2024,"Approved April 29, 2024.",661,127379.8139,32.5572,1954.5,1970,2004,0.007899136,0.025010777,-0.013443781,-0.081506574,0,0.07436,245.88555
MOLN,$3.70 ,MP0533,Acute myeloid leukemia (AML)Â ,Preclinical,4/29/2024,"Preclinical data of tetra-specific T cell engager MP0533 demonstrated preferential T cell mediated killing of AML cells, while sparing healthy cells, noted April 29 2024.",40,104.68745,56.5668,3.36,3.185,3.35,-0.053488685,-0.002980628,-0.013443781,-0.081506574,0,0.05956,0.02266
VERU,$1.35 ,Enobosarm with semaglutide (Wegovy) - (PLATEAU),ObesityÂ ,Phase 2b,4/30/2024,"IND cleared February 6, 2024. Phase 2b first patient dosed April 30, 2024.",14,197.61459,127.22,12.5,13.5,16.3,0.076961041,0.265436464,-0.02094378,-0.055825804,7.5501,0.00012,5.01321
NBIX,$137.54 ,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD)Â ,Phase 2,4/30/2024,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",99,13833.84156,26.0777,138.89,137.54,143.19,-0.009767469,0.030490167,-0.02094378,-0.055825804,2.00974,0.13381,132.93709
TAK,$13.08 ,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD)Â ,Phase 2,4/30/2024,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",,6515782.283,15.6201,13.17,13.08,13.28,-0.00685717,0.008317628,-0.02094378,-0.055825804,0,0,11.89756
AUPH,$5.09 ,LUPKYNIS (Voclosporin) - (updated label),Lupus NephritisÂ ,Approved,4/30/2024,"Updated label approved April 30, 2024.",135,736.10441,62.8945,5.01,5.09,5.12,0.015841915,0.021718524,-0.02094378,-0.055825804,7.87767,0.15708,8.04763
VRPX,$2.65 ,Probudur,Pain ReliefÂ ,Preclinical,4/30/2024,"MTD data reported that all doses were well-tolerated, noted April 30, 2024.",1,3.10375,147.4997,69.25,66.25,54,-0.04428768,-0.248739099,-0.02094378,-0.055825804,1.26696,0.00175,0.0479
SNTI,$3.60 ,SENTI-202,Acute Myeloid Leukemia (AML)Â ,Preclinical,4/30/2024,"Preclinical data reported that the engineered NK cells killed multiple AML subtypes while protecting primary hematopoietic stem cells (HSCs), noted April 30, 2024.",26,16.45206,138.9015,3.097,3.6,4.018,0.150499944,0.260350365,-0.02094378,-0.055825804,0.36157,0.0115,0.86334
NRXP,$2.58 ,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,4/30/2024,"Phase 2/3 top line data reported that NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduc",19,26.88722,145.5802,3.55,2.58,2.81,-0.319158205,-0.23376312,-0.02094378,-0.055825804,4.90173,0.0582,2.41909
VXRT,$0.71 ,Norovirus vaccine - (lactating mothers trial),NorovirusÂ ,Phase 1,4/30/2024,"Phase 1 topline data reported no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity, noted April 30, 2024.",228,126.38613,80.7235,0.7133,0.7147,0.7384,0.001960785,0.034583594,-0.02094378,-0.055825804,10.37269,0.07211,1.41053
INMB,$11.84 ,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimerâ€™s diseaseÂ ,Phase 1b,4/30/2024,"Phase 1b compassionate use data reported that treatment has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients. Furthermore, the patients expr",26,233.97006,81.1599,11.77,11.84,11.18,0.005929708,-0.051427454,-0.02094378,-0.055825804,7.5953,0.07743,5.22798
GRTS,$0.80 ,CORAL-CEPI,COVID-19 vaccineÂ ,Phase 1,4/30/2024,"Additional data reported that all doses of the three samRNA vaccine candidates were well tolerated in both HIV-negative participants and PLWH participants irrespective of age, SARS-CoV-2 serostatus, o",118,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,-0.02094378,-0.055825804,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
SCYX,$1.69 ,SCY-247,Pulmonary mucormycosisÂ ,Preclinical,4/30/2024,"Preclinical data shared at the ECCMID reported that SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species, no",41,63.84786,70.0318,1.82,1.69,1.845,-0.074107972,0.013642776,-0.02094378,-0.055825804,2.75213,0.08018,0.40047
NBIX,$137.54 ,INGREZZA SPRINKLE (valbenazine) Capsules,Tardive dyskinesia (TD)Â ,Approved,4/30/2024,"Approved April 30, 2024.",99,13833.84156,26.0777,138.89,137.54,143.19,-0.009767469,0.030490167,-0.02094378,-0.055825804,2.00974,0.13381,132.93709
ACXP,$2.20 ,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,4/30/2024,"Phase 2b data results shared at ESCMID einforced earlier findings related to the anti-recurrence properties, noted April 30, 2024.",1,34.81082,96.7135,43.8,44,39.4,0.004555817,-0.105868001,-0.02094378,-0.055825804,3.65997,0.02867,0.07951
MRK,$127.20 ,KEYTRUDA (pembrolizumab) in combination with trastuzumab - (KEYNOTE-811),HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinomaÂ ,Phase 3,5/1/2024,"Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.",,326254.0307,16.7253,129.22,128.8,129.55,-0.003255564,0.002550529,-0.043022361,-0.051700916,0.80654,0.01085,759.37994
PALI,$7.08 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,5/1/2024,"Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-Î± production in a whole blood (WB) assay, noted May 1, 2024.",9,6.02792,149.0113,6.03,7.08,7.06,0.160526897,0.157698041,-0.043022361,-0.051700916,4.05402,0.04972,86.8387
SLS,$1.28 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphomaÂ ",Phase 2,5/1/2024,"Phase 2 30 mg cohort showed a 100% overall response rate in patients with ASXL1 mutation, treatment exhibited strong anti-leukemic activity in 62% of patients with a favorable safety profile across al",105,73.92631,115.9323,1.24,1.28,1.28,0.031748698,0.031748698,-0.043022361,-0.051700916,9.8107,0.01803,12.18197
ALRN,$4.16 ,LTI-03 - (Caveolin-1),Idiopathic pulmonary fibrosis (IPF)Â ,Phase 1b,5/1/2024,Phase 1a low dose data showed a reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epit,21,87.95066,0,0,0,0,#DIV/0!,#DIV/0!,-0.043022361,-0.051700916,0,0,0
COCP,$1.53 ,CC-42344,Influenza AÂ ,Phase 2a,5/1/2024,"Phase 2a enrollment completed, noted May 1, 2024.",10,15.5659,59.2579,1.55,1.53,1.605,-0.012987196,0.034868826,-0.043022361,-0.051700916,0.01466,0.00898,0.03566
DNLI,$16.16 ,DNL343 - (HEALEY),Amyotrophic lateral sclerosis (ALS)Â ,Phase 2/3,5/1/2024,"Phase 2/3 trial enrollment completed noted May 1, 2024.",146,2303.43879,82.1006,15.44,16.16,18.9,0.045577508,0.202200377,-0.043022361,-0.051700916,6.71793,0.22361,21.99846
BCDA,$5.64 ,CardiAMP (BCDA-02),Chronic Myocardial IschemiaÂ ,Phase 3,5/1/2024,"Phase 3 data reported that 100% of patients responded for the change in Angina Episodes per week, noted May 1, 2024.",5,10.10756,169.4965,5.8065,5.643,5.91,-0.028562141,0.017667852,-0.043022361,-0.051700916,1.00929,0.02775,0.46309
KZIA,$0.30 ,EVT801,Renal cell carcinoma and soft-tissue sarcomaÂ ,Phase 1,5/1/2024,"Phase 1 trial successful and complete, noted May 1, 2024.",1,7.87418,119.1072,16.74,14.935,14.46,-0.114093613,-0.146414848,-0.043022361,-0.051700916,0.06959,0.00567,0.20678
GLTO,$17.00 ,GB1211 in combination with KEYTRUDA (pembrolizumab),Melanoma and head and neck squamous cell carcinoma (HNSCC)Â ,Phase 2,5/1/2024,"Phase 2 trial initiated, noted May 1, 2024.",1,18.43933,68.9614,16.8875,17.0025,17.625,0.006786689,0.042744645,-0.043022361,-0.051700916,0.06624,0.08647,0.03217
AZN,$75.34 ,"Calquence (acalabrutinib) with chemoimmunotherapy, bendamustine and rituximab - (ECHO)",Mantle cell lymphoma (MCL)Â ,Phase 3,5/2/2024,"Phase 3 data reported a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care, noted May 2, 2024.",,188446.5696,22.4079,121.7,121.56,123.32,-0.001151032,0.013223603,-0.029893377,-0.018717579,0,0.19694,243.90747
CNTX,$1.75 ,CTIM-76,Various cancersÂ ,IND-Enabling,5/2/2024,"IND Cleared by the FDA, noted May 2, 2024.",89,27.94059,86.0993,1.36,1.75,1.83,0.252131088,0.296831267,-0.029893377,-0.018717579,0.25309,0.06172,46.43829
PTN,$2.05 ,Bremelanotide with Tirzepatide (GLP-1),ObesityÂ ,IND-Enabling,5/2/2024,"IND clearance by the FDA, noted May 2, 2024.",46,78.93609,69.1163,0.066,0.067,0.061,0.015037877,-0.078780878,-0.029893377,-0.018717579,0,0.00002,0.10254
ALLR,$36.90 ,Stenoparib,Advanced ovarian cancer (AOC)Â ,Phase 2,5/2/2024,"Phase 2 trial discontinued early due to clear clinical benefit, including tumor shrinkage and long-term disease stability, noted May 2, 2024.",14,0.38,96.5127,41.10004,36.90004,22.62002,-0.10779646,-0.59717374,-0.029893377,-0.018717579,34.00495,0.21126,116.08748
ELAB,$0.71 ,EL-22 (BLS-M22),GLP-1 Weight Loss Drugs and Age-Related SarcopeniaÂ ,Preclinical,5/2/2024,"Preclinical data reported statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth, noted May 2, 2024.",,12.21511,0,3194.80051,3454.50055,3346.21054,0.07815324,0.046303876,-0.029893377,-0.018717579,0.31627,0.00972,1.11235
IMMP,$2.69 ,Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO),Soft tissue sarcomaÂ ,Phase 2,5/2/2024,"Phase 2 trial is well tolerated and has led to encouraging initial efficacy data. Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are r",145,499.31052,55.9186,2.6,2.69,3.01,0.034029749,0.146428634,-0.029893377,-0.018717579,0,0,0.45351
AEON,$1.70 ,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis)Â ,Phase 2,5/3/2024,"Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.",11,65.93051,166.1129,241.91998,122.39999,124.55999,-0.681312722,-0.663819563,-0.025040432,0.002266547,1.11607,0.0421,1.58373
XOMA,$24.78 ,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH)Â ,Phase 2,5/3/2024,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,12,288.31567,57.6104,25.44,24.78,25.44,-0.026285862,0,-0.025040432,0.002266547,2.42188,0.00305,0.20352
GOSS,$0.74 ,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH)Â ,Phase 2,5/3/2024,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,227,167.4018,93.9671,0.7713,0.74,0.7423,-0.041427217,-0.038323929,-0.025040432,0.002266547,4.91226,0.14032,3.20387
CGON,$36.27 ,Cretostimogene - (BOND-003),BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in SituÂ ,Phase 3,5/3/2024,"Phase 3 data presented at AUA showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy. Although the median duration of response (DOR) was not rea",76,2416.89686,0,39.5,36.27,28.5,-0.085309719,-0.326396585,-0.025040432,0.002266547,4.20452,0.1641,88.61363
URGN,$14.30 ,UGN-102 - (ATLAS),Non-Muscle-Invasive Bladder CancerÂ ,Phase 3,5/4/2024,"Data from AUA 2024 reported that DOR at 12 months after achieving CR at 3 months was 87.5% and 69.1% in new and recurrent patients, respectively. Also, patients achieved similar probabilities of DFS r",46,487.94584,61.9111,14.3,14.3,12.74,0,-0.115512887,-0.006646015,0.020660964,12.30565,0.02043,0
MNMD,$10.00 ,MM120 ODT (Lysergide (LSD)) - (Emerge),Major Depressive Disorder (MDD)Â ,Phase 2,5/4/2024,"Phase 2 data at APA reported clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints, noted May 4, 2024.",75,718.72422,102.3772,10,10,9.26,0,-0.076881044,-0.006646015,0.020660964,9.63392,0.10019,0
IRD,â€”,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME)Â ,Phase 2,5/5/2024,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a â‰¥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti",59,50.96093,67.2031,1.99,1.99,1.72,0,-0.145810348,-0.006646015,0.020660964,6.17083,0.04518,0
VTRS,$11.57 ,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME)Â ,Phase 2,5/5/2024,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a â‰¥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti",,13989.56458,27.6857,11.78,11.78,11.16,0,-0.054067221,-0.006646015,0.020660964,3.46463,0.07658,0
NNVC,$1.40 ,NV-387,"Influenza A viruses, Bird Flu H5N1Â ",Preclinical,5/6/2024,"Preclinical data reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-",17,16.4906,67.2,1.13,1.4,1.82,0.214254604,0.476618868,-0.004988647,0.001111976,0.95189,0.0137,1.49503
EYPT,$11.20 ,DURAVYU ( EYP-1901 vorolanib intravitreal) - (PAVIA),Non-proliferative diabetic retinopathy (NPDR)Â ,Phase 2,5/6/2024,"Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.",68,583.34246,182.3796,19.74,11.2,12.22,-0.566733256,-0.47957308,-0.004988647,0.001111976,12.549,0.04381,108.1063
GLYC,$0.32 ,Uproleselan (GMI-1271),Acute myeloid leukemia (AML) newly diagnosed and refractory - cancerÂ ,Phase 3,5/6/2024,"Phase 3 final analysis and topline results did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone, noted May 6, 2024.",13,20.33423,0,0,0,0,#DIV/0!,#DIV/0!,-0.004988647,0.001111976,0,0,0
APLM,$0.42 ,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Â ,Phase 3,5/6/2024,"Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the",1,37.57924,94.3481,39.65,41.99,34.98,0.057340547,-0.125314478,-0.004988647,0.001111976,0.23383,0.09373,0.08339
GLYC,$0.32 ,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Â ,Phase 3,5/6/2024,"Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the",13,20.33423,0,0,0,0,#DIV/0!,#DIV/0!,-0.004988647,0.001111976,0,0,0
ADCT,$4.45 ,ZYNLONTA (loncastuximab tesirine-lpyl),Relapsed/refractory (r/r) marginal zone lymphoma (MZL)Â ,Phase 2,5/6/2024,"Phase 2 data reported that treatment was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations, with both of these patients remain in CR at 10 an",112,368.5223,137.7915,4.9,4.45,4.19,-0.096331109,-0.156534471,-0.004988647,0.001111976,1.07244,0.02701,14.9719
VYNE,$2.71 ,VYN202,Moderate-to-severe plaque psoriasisÂ ,IND-Enabling,5/6/2024,"IND Cleared by the FDA, noted April 6, 2024.",25,38.20799,78.9668,2.62,2.71,2.83,0.033774317,0.077102394,-0.004988647,0.001111976,0.68676,0.12469,0.09688
LYRA,$0.52 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitisÂ ,Phase 3,5/6/2024,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp,1,31.79317,299.795,201.5,26.075,18.13,-2.04481238,-2.408221357,-0.004988647,0.001111976,0.54713,0.00963,56.65847
LIAN,$0.31 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitisÂ ,Phase 3,5/6/2024,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp,108,34.05579,0,0,0,0,#DIV/0!,#DIV/0!,-0.004988647,0.001111976,0,0,0
BCAB,$3.17 ,BA3361 (CAB-Nectin-4),Multiple tumor typesÂ ,IND-Enabling,5/6/2024,"IND cleared by the FDA, noted May 6 2024.",58,152.49703,136.4554,3.25,3.17,2.64,-0.024923408,-0.207876079,-0.004988647,0.001111976,11.25706,0.3139,1.77734
DRTS,$2.46 ,Alpha DaRT,Pancreatic CancerÂ ,Preclinical,5/6/2024,"Preclinical data reported that a statistically significant (FDR adjusted p-value < 0.05) decline in secondary tumor growth rate was found at days 21, 25 and 29 in those mice that received Alpha DaRT",70,171.38971,44.6909,2.49,2.46,2.65,-0.012121361,0.06227693,-0.004988647,0.001111976,0.06251,0.01584,0.10786
CALT,$20.13 ,Setanaxib with pembrolizumab,Squamous Cell Carcinoma of the Head and Neck (SCCHN)Â ,Phase 2,5/6/2024,"Phase 2 final data reported statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statis",26,641.4408,24.8776,5.3,5.34,5.3,0.007518832,0,-0.004988647,0.001111976,0,0.00835,0.04139
BLTE,$43.30 ,Tinlarebant (LBS-008) - (DRAGON),Adolescent Stargardt disease (STGD1)Â ,Phase 2/3,5/6/2024,"Phase 2/3 24-month data shared at ARVO 2024 provided further support for the potential of Tinlarebant to slow and potentially halt lesion growth, May 6, 2024.",32,1262.17093,51.3364,43.2,43.3,41.685,0.00231214,-0.035699143,-0.004988647,0.001111976,0.11666,0.01319,1.54274
NVS,â€”,RGSL8429,ADPKDÂ ,Phase 1b,5/6/2024,"Phase 1b Cohort 4 advanced, noted May 6, 2024.",,1424.18863,54.1777,4.4,4.59,4.5,0.042275483,0.022472856,-0.004988647,0.001111976,0,0.00374,0.08381
LCTX,$1.30 ,RG6501 - (OpRegen),Geographic atrophy (GA)Â ,Phase 1/2,5/6/2024,"Additional Phase 1/2a data suggested that OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 year",228,245.43759,86.9611,1.06,1.3,1.09,0.204095356,0.027908788,-0.004988647,0.001111976,5.60533,0.01288,5.33418
EWTX,$20.34 ,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM)Â ,Phase 2,5/6/2024,"Phase 2 initiated, noted May 6, 2024.",105,1899.96908,90.7827,19.52,20.34,17.48,0.04114981,-0.110382211,-0.004988647,0.001111976,6.16896,0.04917,11.94772
RYTM,$43.88 ,IMCIVREE (setmelanotide),"Obesity due to biallelic POMC, PCSK1, LEPR deficiency, or BBS (ages 2-6 years old)Â ",Phase 3,5/6/2024,"Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20",66,2675.49125,60.5892,43.76,43.88,40.2,0.002738477,-0.084853162,-0.004988647,0.001111976,16.72863,0.16876,43.11052
MRUS,$47.34 ,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,BLA Filing,5/6/2024,"BLA accepted for priority review by the FDA, noted May 6, 2024.",75,2778.26866,49.8375,48.36,47.34,45.85,-0.021317422,-0.053297827,-0.004988647,0.001111976,5.60655,0.35683,24.53916
GMAB,â€”,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancerÂ ,BLA Filing,5/6/2024,"BLA accepted for priority review by the FDA, noted May 6, 2024.",661,129426.9693,33.011,2061,2004,1990,-0.028046119,-0.035056663,-0.004988647,0.001111976,0,0.08219,207.93704
DTIL,$10.57 ,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) DeficiencyÂ ,Phase 1/2,5/7/2024,"Fast track designation granted by the FDA, noted May 7, 2024.",11,73.10465,96.5744,10.66,10.57,11.62,-0.008478619,0.086229333,0.016361877,-0.002205559,5.05574,0.24688,0.35133
ANNX,$4.73 ,ANX007 - (ARCHER-II),Geographic atrophyÂ ,Phase 2,5/7/2024,"Phase 2 data presented at ARVO demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings, noted May 7, 2024.",109,431.0987,97.6733,4.81,4.73,4.82,-0.016771882,0.002076844,0.016361877,-0.002205559,4.5447,0.05272,11.04964
DNLI,$16.85 ,DNL788 (SAR443820) - (HIMALAYA),Amyotrophic lateral sclerosis (ALS)Â ,Phase 2,5/7/2024,"Phase 2 trial did not meet the primary endpoint, noted May 7, 2024.",146,2402.96226,80.393,17.14,16.85,19.75,-0.017064256,0.141738578,0.016361877,-0.002205559,6.71466,0.23383,18.52346
ELDN,$2.26 ,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejectionÂ ,Phase 1b,5/7/2024,"Phase 1b data reported that two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year, noted May 7, 2024.",59,56.07767,76.8291,2.44,2.26,2.34,-0.076633226,-0.04184711,0.016361877,-0.002205559,0.12547,0.01205,5.72421
ASLN,$3.30 ,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD)Â ,Phase 2,5/7/2024,"Additional Phase 2 data reported discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo, noted May 7, 2024.",2,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.016361877,-0.002205559,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
MBRX,$5.09 ,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML)Â ,Phase 1/2,5/7/2024,"Phase 1/2 topline data reported a CRc rate of 45% and an overall remission rate (ORR) of 55% for all subjects, noted May 7, 2024.",30,11.33806,97.5563,5.04,5.09,4.85,0.009871748,-0.038427377,0.016361877,-0.002205559,1.19748,0.02328,0.51504
NRSN,$1.29 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 2b,5/7/2024,"Additional Phase 2b data analysis reported a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02), noted May 7, 2024.",23,22.36091,137.88,1.27,1.29,1.12,0.015625318,-0.125688215,0.016361877,-0.002205559,0.51005,0.09678,0.52436
REGN,$955.76 ,Otoferlin gene therapy (DB-OTO) - (CHORD),Genetic hearing lossÂ ,Phase 1/2,5/8/2024,"Phase 1/2 data presented at ASGCT reported an average 84 dB improvement from baseline and one frequency measure reaching 10 dB in hearing level per PTA. Across all tested frequencies, an average 80 dB",105,103112.6484,17.021,969.97,955.76,978.21,-0.014758308,0.008459228,0.016164445,-0.023821056,1.28576,0.09316,406.12632
VYGR,$8.57 ,TRACER (GBA1),Parkinson's DiseaseÂ ,Preclinical,5/8/2024,"Preclinical data reported that showed further enhanced blood-brain barrier (BBB) penetrance, greater liver detargeting, and transduction of 50-75% of cells across diverse brain regions, with upwards o",55,466.10804,69.7361,8.77,8.57,8.57,-0.023069074,-0.023069074,0.016164445,-0.023821056,6.3664,0.06605,3.33586
ALDX,$4.07 ,Reproxalap (ADX-102) - (TRANQUILITY),Dry eye diseaseÂ ,Phase 3,5/8/2024,"Phase 3 first patient enrollment, noted May 8, 2024.",59,241.81697,79.8807,4.17,4.07,4.17,-0.024273036,0,0.016164445,-0.023821056,3.97412,0.24598,0.83036
CYTK,$65.27 ,CK-4021586 (CK-586) - (AMBER-HFpEF),Heart failure with preserved ejection fraction (HFpEF)Â ,Phase 1,5/8/2024,"Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.",119,6838.5963,107.0368,65.28,65.27,60.5,-0.000153198,-0.076042346,0.016164445,-0.023821056,13.40261,0.00807,76.66693
TEVA,$15.74 ,Olanzapine LAI (44749) - (SOLARIS),SchizophreniaÂ ,Phase 3,5/8/2024,"Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.",,17827.763,34.5178,13.95,15.74,16.78,0.120725735,0.184708193,0.016164445,-0.023821056,1.02911,0.05207,605.95613
CYTK,$65.27 ,Aficamten - (CEDAR-HCM),obstructive HCMÂ ,Phase 3,5/8/2024,"Phase 3 initiated, noted May 8, 2024.",119,6838.5963,107.0368,65.28,65.27,60.5,-0.000153198,-0.076042346,0.016164445,-0.023821056,13.40261,0.00807,76.66693
PRME,$5.36 ,PM359,Chronic Granulomatous Disease (CGD)Â ,Preclinical,5/8/2024,"Preclinical data presented at ASGCT demonstrated the ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-targe",134,617.9695,83.5837,5.57,5.36,6.76,-0.038431079,0.193627836,0.016164445,-0.023821056,8.85887,0.2113,3.45228
LLY,$772.64 ,VERVE-102 - (Heart-2),PCSK9Â ,Phase 1b,5/8/2024,"Phase 1b dosing initiated, noted May 8, 2024.",946,697814.1742,27.3015,777.77,775,787.02,-0.003567821,0.01182281,0.016164445,-0.023821056,0.61482,0.02855,1619.69885
VERV,$6.08 ,VERVE-102 - (Heart-2),PCSK9Â ,Phase 1b,5/8/2024,"Phase 1b dosing initiated, noted May 8, 2024.",89,24058.53626,0,0,0,0,#DIV/0!,#DIV/0!,0.016164445,-0.023821056,0,0,0
CVM,$1.39 ,Multikine - (IT-MATTERS),Head and Neck cancerÂ ,Phase 3,5/8/2024,"Phase 3 Go-Ahead received by the FDA for its study, noted May 8, 2024.",6,75.0311,95.0992,50.10501,41.70417,43.20432,-0.183519879,-0.148180513,0.016164445,-0.023821056,12.62154,0.15651,5.88041
LEXX,$3.54 ,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight lossÂ ",Phase 1,5/8/2024,"Phase 1 dosing initiated, noted May 8, 2024.",19,45.61528,141.251,3.43,3.54,3.08,0.031566466,-0.107630664,0.016164445,-0.023821056,3.38035,0.00124,0.37812
PRQR,$2.00 ,AX-0810,"Healthy volunteers, deficiency of sodium taurocholate cotransporting polypeptide (NTCP), cholestatic diseasesÂ ",Preclinical,5/8/2024,"Preclinical data shared at the American Society of Gene & Cell Therapy (ASGCT) confirmed findings in in vitro models and showed translatability across models, noted May 8, 2024",105,162.70918,82.6366,1.99,2,1.91,0.005012542,-0.041031397,0.016164445,-0.023821056,0.29688,0.06308,0.23441
CTMX,$4.19 ,CX-904,Advanced solid tumorsÂ ,Phase 1,5/8/2024,"Phase 1 data demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall, noted May 8, 2024.",164,326.48216,180.098,4.07,4.19,1.96,0.029057734,-0.730698526,0.016164445,-0.023821056,4.61241,0.02665,169.7928
OCS,$12.37 ,OCS-05 - (ACUITY),Acute optic neuritisÂ ,Phase 2,5/8/2024,"Phase 2 enrollment completed, noted May 8, 2024.",43,516.32745,39.4763,12.64,12.37,12.01,-0.021592202,-0.051126753,0.016164445,-0.023821056,0.06127,0.01789,0.53248
MRK,$128.61 ,KEYTRUDA versus chemotherapy - (KEYNOTE-B21),High-Risk Endometrial CancerÂ ,Phase 3,5/9/2024,"Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.",,329847.3654,16.7348,129.55,130.23,130.88,0.005235211,0.010213966,0.010945102,-0.038309583,0.74044,0.01233,1200.29605
PRTC,$27.46 ,SPT-300 (Glyph allopregnanolone; formerly LYT-300),"Healthy volunteers, neurological and neuropsychological conditionsÂ ",Phase 2a,5/9/2024,"Phase 2a demonstrated nine times greater allopregnanolone exposure in humans dosed orally than published data for oral allopregnanolone, validating Glyph platform's ability to enhance oral bioavailabi",24,603.02042,48.3971,2.215,2.23,2.22,0.006749182,0.002254792,0.010945102,-0.038309583,0,0.10713,0.52339
TCRX,$7.80 ,TSC-203-A0201 - (PRAME),Targeting PRAME Solid tumorsÂ ,Phase 1,5/9/2024,"Phase 1 dosing initiated, noted May 9, 2024.",56,392.94308,91.423,8.01,7.8,8.9,-0.026567027,0.105360516,0.010945102,-0.038309583,0.78998,0.008,1.86279
ANVS,$6.03 ,Buntanetap,Parkinson's Disease (PD)Â ,Phase 3,5/9/2024,"The phase 3 study was completed, noted May 9, 2024.",19,66.39813,188.0369,4.82,6.03,8.03,0.223973083,0.5104106,0.010945102,-0.038309583,14.59964,0.03173,12.79998
PSTX,$2.71 ,P-KLKB1-101,Gene TherapyÂ ,Preclinical,5/9/2024,"Preclinical early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profile, noted May",97,0,0,0,0,0,#DIV/0!,#DIV/0!,0.010945102,-0.038309583,0,0,0
PSTX,$2.71 ,P-FVIII-101,Hemophilia AÂ ,Preclinical,5/9/2024,"Preclinical data highlight sustained Hemophilia A correction following a single dose and support potential for repeat dosing and precise tuning of Factor VIII levels, noted May 9, 2024.",97,0,0,0,0,0,#DIV/0!,#DIV/0!,0.010945102,-0.038309583,0,0,0
IKT,$1.36 ,IkT-001Pro,Pulmonary Arterial Hypertension (PAH)Â ,Preclinical,5/9/2024,Pre-IND meeting with FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension. FDA agreed that the 505(b)(2) pa,74,8.80851,120.8211,1.4,1.36,1.76,-0.028987537,0.228841572,0.010945102,-0.038309583,2.08829,0.03318,0.04714
FATE,$3.90 ,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,5/9/2024,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note",115,443.94468,92.31,3.7,3.9,4.14,0.052643733,0.112362968,0.010945102,-0.038309583,19.44892,0.20862,15.2216
FATE,$3.90 ,FT819,B-cell Leukemias and LymphomasÂ ,Phase 1b,5/9/2024,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note",115,443.94468,92.31,3.7,3.9,4.14,0.052643733,0.112362968,0.010945102,-0.038309583,19.44892,0.20862,15.2216
FATE,$3.90 ,FT522,LupusÂ ,Preclinical,5/9/2024,"Preclinical data to be presented at ASGCT showed dose-dependent trafficking, infiltration, and residency in secondary and tertiary tissues without cytokine support at human dose equivalency levels of",115,443.94468,92.31,3.7,3.9,4.14,0.052643733,0.112362968,0.010945102,-0.038309583,19.44892,0.20862,15.2216
RAPT,$4.66 ,Zelnecirnon (RPT193),AsthmaÂ ,Phase 2a,5/9/2024,"Trial closed due to clinical hold, noted May 9, 2024.",16,162.65018,220.1641,63.84,37.28,33.12,-0.537922963,-0.656242624,0.010945102,-0.038309583,9.22853,0.08535,22.71497
RAPT,$4.66 ,Zelnecirnon (RPT193),Atopic dermatitisÂ ,Phase 2a,5/9/2024,"Trial closed due to clinical hold, noted May 9, 2024.",16,162.65018,220.1641,63.84,37.28,33.12,-0.537922963,-0.656242624,0.010945102,-0.038309583,9.22853,0.08535,22.71497
AZN,$77.13 ,FPI-2265 - (AlphaBreak),Prostate cancerÂ ,Phase 2/3,5/9/2024,"Phase 2/3 trial AlphaBreak initiated, noted May 9, 2024.",,191174.9833,22.2545,122.64,123.32,121.66,0.005529368,-0.008022966,0.010945102,-0.038309583,0,0.19837,164.01042
ANAB,$26.23 ,Imsidolimab (ANB019) - (GEMINI-1),Generalized pustular psoriasisÂ ,Phase 3,5/9/2024,Phase 3 data showed that All 8 patients who responded to IV imsidolimab in GEMINI-1 and received monthly SC maintenance dosing in GEMINI-2 maintained clear/almost clear skin through 24 weeks with no f,28,716.56803,59.0176,25.75,26.23,25.47,0.018469167,-0.010933338,0.010945102,-0.038309583,16.01451,0.04242,5.93685
PDSB,$3.83 ,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19)Â ,Phase 2,5/9/2024,"Phase 2 data presented at a KOL showed a 30-month median overall survival (OS); median OS independent of patient CPS score; ORR 34% (CPSâ‰¥1); 48% (CPSâ‰¥20, noted May 9, 2024.",46,140.48162,83.1742,4.02,3.83,3.53,-0.048417099,-0.129984032,0.010945102,-0.038309583,18.71362,0.11043,4.78176
PHIO,$6.93 ,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Preclinical,5/9/2024,"Preclinical data presented at ASCGT data demonstrates that intratumoral injection of PH-762 significantly inhibits tumor growth in murine cells and may generate memory-specific T cells, noted May 9, 2",5,3.5356,133.728,7.2,6.93,6.5916,-0.038221213,-0.088284915,0.010945102,-0.038309583,4.0222,0.00563,0.0678
FDMT,$25.64 ,4D-175 - (GAZE),Geographic AtrophyÂ ,Preclinical,5/9/2024,Preclinical data presented at ARVO showed that intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina a,46,1325.67548,109.8702,26.33,25.64,25.64,-0.026555341,-0.026555341,0.010945102,-0.038309583,18.61105,0.08633,8.28182
FDMT,$25.64 ,4D-150 - (PRISM),Wet age-related macular degeneration (AMD)Â ,Phase 2,5/9/2024,"Phase 2 interim 24-week landmark data presented at ARVO demonstrated that a high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with",46,1325.67548,109.8702,26.33,25.64,25.64,-0.026555341,-0.026555341,0.010945102,-0.038309583,18.61105,0.08633,8.28182
FRLN,â€”,FLT201 - (GALILEO-1),Gaucher diseaseÂ ,Phase 1/2,5/9/2024,Phase 1/2 results shared at the ASGCT reported an early lyso-Gb1 data and reduction in BMB and fatigue suggest potential for meaningful improvements in clinical outcomes over existing standard of care,4,5728.08693,0,0,0,0,#DIV/0!,#DIV/0!,0.010945102,-0.038309583,0,0,0
CELU,$3.05 ,CYNK-201,Solid TumorsÂ ,Preclinical,5/9/2024,Preclinical data presented on at ASGCT reported that PT-CD16VS can be combined with various monoclonal antibodies to engage in anti-tumor antibody-dependent cellular cytotoxicity against diverse cance,26,66.43773,132.1547,2.99,3.05,3.05,0.019868203,0.019868203,0.010945102,-0.038309583,2.73145,0.09107,0.11389
INSM,$26.38 ,Treprostinil Palmitil Inhalation Powder (TPIP),Pulmonary hypertension associated with interstitial lung disease (PH-ILD)Â ,Phase 2,5/9/2024,"Phase 2 topline results reported that serious adverse events occurred in 20.7% of TPIP-treated patients and 40.0% of placebo-treated patients, noted May 9, 2024.",211,3920.18798,37.6896,26,26.38,25.1,0.014509609,-0.035228692,0.010945102,-0.038309583,5.74059,0.09221,63.85057
EWTX,$20.00 ,EDG-5506 - (DUNE),Becker muscular dystrophy (BMD)Â ,Phase 2,5/9/2024,Phase 2 data reported that sevasemten was well tolerated across all 21 participants and significantly reduced biomarkers of muscle damage associated with exercise with a mean post-exercise reduction o,105,1867.97534,90.0411,20.89,20,18.18,-0.043538302,-0.138948487,0.010945102,-0.038309583,6.98411,0.04917,20.5297
CANF,$2.14 ,Namodenoson (CF102),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,IND-Enabling,5/9/2024,"IND cleared by the FDA, noted May 9, 2024.",10,40.42247,38.5545,0.027,0.027,0.026,0,-0.037740328,0.010945102,-0.038309583,0,0.04767,1.22032
MRNA,$117.31 ,mRESVIA (mRNA-1345) - (ConquerRSV),Respiratory syncytial virus (RSV) vaccineÂ ,PDUFA,5/10/2024,"PDUFA decision due on May 12, 2024. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024, The FDA has",389,44957.85226,53.18,122.69,117.31,132.9,-0.044840845,0.079936117,-0.010063822,-0.024423949,5.49839,0.16404,497.21937
IPSC,$3.13 ,CNTY-101 - (CALiPSO-1),Systemic Lupus ErythematosusÂ ,Preclinical,5/10/2024,"Preclinical data demonstrates the potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK-mediated rejection in allogeneic cell therapies, as noted on",86,259.31228,102.7914,3.04,3.13,3.01,0.029175489,-0.009917437,-0.010063822,-0.024423949,1.87728,0.03834,0.21839
RCKT,$22.72 ,RP-L301,Pyruvate Kinase Deficiency (PKD)Â ,Phase 1,5/10/2024,"Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023. Phase 1",107,2062.57183,46.019,23.33,22.72,22.62,-0.026494492,-0.030905615,-0.010063822,-0.024423949,10.83579,0.09814,9.13203
AZTR,$6.48 ,ATR12-351,Netherton SyndromeÂ ,Preclinical,5/10/2024,Preclinical data presented at ASGCT from In vitro data showed that LEKTI (lympho-epithelial Kazal-type-related inhibitor) protein secreted by ATR-12 has nanomolar inhibition of a key protease that dr,3,6.22179,230.7498,49.65035,43.15684,36.36364,-0.140164518,-0.311436066,-0.010063822,-0.024423949,1.02826,0.01343,0.48685
IMMX,$2.18 ,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosisÂ ,Phase 1/2,5/10/2024,"Phase 1/2 data presented at ASGCT showed a 92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis. Best responder duration of response was 28.0 months with response ongoing, no",28,57.58317,105.4319,2.18,2.18,2.47,0,0.124893274,-0.010063822,-0.024423949,1.46702,0.02293,0.87973
PLX,$1.10 ,PRX-115,Severe GoutÂ ,Phase 1,5/10/2024,"Phase 1 initial data from the seven cohorts, and following the review and acceptance of the safety data from cohort 7 by the safety and monitoring committee for dose escalation for the FIH Study, the",79,80.64769,56.2253,1.25,1.1,1.14,-0.127833372,-0.092115289,-0.010063822,-0.024423949,9.52807,0.06223,2.39603
MGNX,$3.31 ,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 2,5/10/2024,"Phase 2 interim data showed PSA50 responses 43.9%/36.6%, ORR 17.8%/25% confirmed. Unfortunately, 5 deaths were found: 1 unrelated, 2 pneumonitis under investigation., noted May 10, 2024",63,207.31675,225.2949,14.67,3.31,4.365,-1.488856403,-1.212186403,-0.010063822,-0.024423949,15.909,0.00186,116.34107
BMY,$44.27 ,Opdivo (nivolumab) + Yervoy (ipilimumab) versus CCRT - (CheckMate-73L),Stage III non-small cell lung cancer (NSCLC)Â ,Phase 3,5/10/2024,"Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.",,91097.87831,23.3945,44.74,44.94,44.03,0.004460311,-0.015996736,-0.010063822,-0.024423949,1.3825,0.03278,390.9598
ACET,$1.47 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC)Â ",Preclinical,5/10/2024,"Preclinical data featured at ASGCT data reported robust efficacy maintained across multiple relevant tumor models of varying stringency, noted May 10, 2024.",83,133.20396,105.0398,1.63,1.47,1.6,-0.103317614,-0.018576386,-0.010063822,-0.024423949,8.47008,0.02186,1.38139
MRK,$127.68 ,KEYTRUDA (KeyVibe-010),Resected high-risk melanoma (Stage IIB-IV)Â ,Phase 3,5/13/2024,Phase 3 pre-planned analysis data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria. A higher rate of discontinuation of all adjuvant therapy b,,327466.5274,16.651,130.06,129.29,130.99,-0.005937939,0.007125102,-0.029512538,-0.045792602,0.74044,0.01416,919.24052
VALN,$7.61 ,VLA1553-321 - (Adolescents trial),Chikungunya Vaccine for adolecentsÂ ,Phase 3,5/13/2024,"Phase 3 day 180 results confirm the initial positive immunogenicity and safety data Valneva reported previously, noted May 13, 2024.",81,479.09556,53.7255,7.4198,7.61,8.84,0.025311069,0.175134774,-0.029512538,-0.045792602,0,0,0.02173
MRUS,$45.85 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/13/2024,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",75,2690.82421,50.2344,44.52,45.85,43.63,0.029436672,-0.020193539,-0.029512538,-0.045792602,5.7613,0.31259,38.20029
GMAB,â€”,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/13/2024,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",661,128536.3288,30.7879,2003,1990,2041,-0.006511418,0.018793827,-0.029512538,-0.045792602,0,0.08977,231.41113
INAB,$1.02 ,INB-200,GlioblastomaÂ ,Phase 1,5/13/2024,"Phase 1 data presented at ASGCT data provide additional insight into the complex gene-expression changes that occur throughout the manufacturing of our gamma-delta T cell products, which demonstrate a",4,45.0064,131.6757,30.30003,30.60003,30.60003,0.009852287,0.009852287,-0.029512538,-0.045792602,0.40778,0.01113,0.04587
CYTK,$57.89 ,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM)Â ,Phase 3,5/13/2024,"Phase 3 full results due presented at Heart Failure showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, noted May 13, 2024.",119,6069.99331,107.383,62.1,57.89,60.6,-0.070201331,-0.024451096,-0.029512538,-0.045792602,13.03782,0.00609,205.63645
EWTX,$17.48 ,Sevasemten (EDG-5506) - (CANYON),Becker Muscular Dystrophy (BMD)Â ,Phase 2,5/13/2024,"Phase 2 trial met primary endpoint, noted May 13, 2024.",105,1632.61045,90.1391,18.33,17.48,18.77,-0.047481692,0.023720789,-0.029512538,-0.045792602,6.98411,0.04146,11.14219
PLRX,$14.14 ,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP)Â ,Phase 2a,5/14/2024,"Phase 2a 12-week post-hoc analysis reported that bexotegrast-treated patients showed a reduction in SUV in the lung compared to an increase seen in placebo, noted May 14, 2024.",61,853.00726,56.8182,13.67,14.14,14.59,0.03380401,0.065132712,-0.02992168,-0.01862826,12.50717,0.07149,13.77512
HCM,$21.40 ,SULANDA (surufatinib),Metastatic pancreatic ductal adenocarcinoma (PDAC) in ChinaÂ ,Phase 2/3,5/14/2024,"Phase 2/3 study initiated in China, noted May 14, 2024.",174,2936.56334,58.9812,3.5,3.44,3.15,-0.017291497,-0.105360516,-0.02992168,-0.01862826,0,0.07558,0.19084
KOD,$3.84 ,Tarcocimab tedromer (KSI-301) - (GLOW2),Non-proliferative diabetic retinopathyÂ ,Phase 3,5/14/2024,"Phase GLOW2 dosing initiated, noted May 14, 2024.",52,201.1013,118.0289,3.83,3.84,3.21,0.002607563,-0.176593866,-0.02992168,-0.01862826,4.96722,0.18154,1.0907
HCM,$21.40 ,HMPL-306 - (RAPHAEL),Relapsed / refractory acute myeloid leukemia (AML)Â ,Phase 3,5/14/2024,"Phase 3 initiated, noted May 14, 2024.",174,2936.56334,58.9812,3.5,3.44,3.15,-0.017291497,-0.105360516,-0.02992168,-0.01862826,0,0.07558,0.19084
DVAX,$11.00 ,HEPLISAV-B,End Stage Renal Disease on Dialysis undergoing hemodialysisÂ ,CRL,5/14/2024,"CRL announced May 14, 2024.",117,1439.80881,27.2035,11.03,11,11.46,-0.00272356,0.038243878,-0.02992168,-0.01862826,14.99154,0.00753,37.45375
NNVC,$2.26 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Preclinical,5/14/2024,"Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.",17,26.62054,80.6808,1.82,2.26,2.18,0.216528312,0.180488376,-0.02992168,-0.01862826,0.8508,0.0254,1.51749
NMRA,$9.58 ,Navacaprant (NMRA-140),Bipolar DepressionÂ ,Phase 2,5/14/2024,"Phase 2 initiated, noted May 14, 2024.",161,1528.23989,73.2447,8.96,9.58,9.45,0.066907365,0.053244515,-0.02992168,-0.01862826,4.12565,0.03723,5.63684
EQ,$1.54 ,Itolizumab - (EQUATOR),1st line Acute graft-versus-host disease (aGVHD)Â ,Phase 3,5/14/2024,"Phase 3 enrollment target surpassed, noted May 14, 2024.",59,54.29232,130.6274,1.54,1.54,1.51,0,-0.019672766,-0.02992168,-0.01862826,1.07335,0.00213,0.22114
ATYR,$1.82 ,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosisÂ ,Phase 3,5/14/2024,"Second DSMB recommended that the ongoing Phase 3 study could continue without any modifications after a second pre-planned, interim analysis, noted May 14, 2024.",97,125.59991,62.1767,1.7,1.82,1.95,0.06820825,0.137201122,-0.02992168,-0.01862826,0.92191,0.1034,0.75622
GNPX,$2.57 ,REQORSA Immunogene Therapy (quratusugene ozeplasmid) - (Acclaim-3),Extensive-stage small cell lung cancer (ES-SCLC)Â ,Phase 1/2,5/14/2024,"Phase 1/2 trial dosing initiated, noted May 14, 2024.",,5.39353,113.7772,119.5,128.5,117.5,0.072612533,-0.016878038,-0.02992168,-0.01862826,2.38067,0.22629,0.44551
CRIS,$15.69 ,CA-4948 - (TakeAim Lymphoma),Relapsed or Refractory Non-Hodgkin LymphomaÂ ,Phase 2,5/14/2024,"Phase 2 data reported that 3 of 3 patients who were naÃ¯ve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.",12,92.47819,112.6435,15.66,15.69,10.795,0.001913876,-0.372026627,-0.02992168,-0.01862826,1.14199,0.08505,0.44114
KYMR,$35.09 ,KT-333,Cutaneous T-cell lymphoma (CTCL)Â ,Phase 1a,5/14/2024,"Phase 1a data reported two complete responses in two cHL patients at DL4, three partial responses in CTCL patients at DL2, 4 and 5, and stable disease in four solid tumor patients at DL3-4, noted May",71,2153.06141,63.1839,38.36,35.09,35.32,-0.08909906,-0.082565874,-0.02992168,-0.01862826,16.14831,0.28987,36.1434
TFFP,$2.01 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post)Â ,Phase 2,5/15/2024,"Phase 2 additional data showed that patient enrollment has accelerated to now 10 patients, 6/6 who completed 12-week tratemetn chosen to remain on TFF TAC, 1 patient has been treated for over a year a",4,899.72,76.7722,45,41.75,44.1,-0.074963038,-0.020202707,-0.019742147,-0.015195701,0,0,0
VNDA,$5.36 ,Tradipitant - (Motion Serifos),Motion sicknessÂ ,Phase 3,5/15/2024,"Phase 3 trial conducted in real-world conditions on boats in U.S. coastal waters, both the 170 mg and 85 mg doses of tradipitant demonstrated superiority over placebo in preventing vomiting, noted May",59,311.94274,74.7768,5.13,5.36,5.14,0.043858316,0.00194742,-0.019742147,-0.015195701,3.9601,0.00212,4.86883
THRD,$12.92 ,THB335,Mast cell-mediated inflammatory diseasesÂ ,IND-Enabling,5/15/2024,IND was cleared by the FDA during 2Q 2024.,45,0,0,0,0,0,#DIV/0!,#DIV/0!,-0.019742147,-0.015195701,0,0,0
SGMT,$4.62 ,Denifanstat (PK Study),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 1,5/15/2024,"Phase 1 data reported that denifanstat was well-tolerated and no safety signals were reported, noted May 15, 2024.",32,147.44216,200.6955,4.38,4.62,5.08,0.053345981,0.148262537,-0.019742147,-0.015195701,6.89939,0.13131,1.89366
IMMP,$2.82 ,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC)Â ,Phase 2/3,5/15/2024,"Phase 2/3 data reported an 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate, with three patients having stable disease as best over",145,529.03138,57.1376,2.93,2.82,3.12,-0.038265538,0.062830579,-0.019742147,-0.015195701,0,0,0.73628
OLMA,$9.85 ,Palazestrant (OP-1250) and ribociclib - (OPERA-02),Breast CancerÂ ,Phase 1/2,5/15/2024,Phase 1b/2 data to be shared at ESMO Breast Cancer showed that treatment was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of eit,68,550.55073,75.8931,10.17,9.85,9.21,-0.031970755,-0.09915236,-0.019742147,-0.015195701,15.03284,0.05742,16.09688
ACXP,$2.25 ,Ibezapolstat,C. difficile InfectionÂ ,Phase 2b,5/15/2024,"Phase 3 agreement with the FDA after EoP2 meeting, noted May 15, 2024.",1,35.64698,83.481,41.8,45,51,0.07376615,0.198929293,-0.019742147,-0.015195701,3.88466,0.03056,0.38358
BCAB,$3.00 ,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Â ",Phase 2,5/15/2024,"Phase 2 data reported 11 responses at the combined 2Q3W and Q2W dose regimens (5 confirmed, including 1 complete response), noted May 15, 2024.",58,144.34775,136.2625,2.61,3,2.28,0.139262067,-0.135174778,-0.019742147,-0.015195701,11.07718,0.28555,3.9458
BCDA,$6.00 ,BCDA-03,Ischemic heart failureÂ ,Phase 1/2,5/15/2024,"Phase 1/2 data reported that treatment-emergent adverse events, arrhythmias, rejection, or allergic response have been observed, noted May 15, 2024.",5,10.91891,90.8696,5.94,5.9985,4.6395,0.009800305,-0.247102532,-0.019742147,-0.015195701,0.96255,0.02884,0.03647
PHIO,$7.20 ,PH-762 (direct drug therapy),MelanomaÂ ,Phase 1b,5/15/2024,"Phase 1b dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going, noted May 15, 2024",5,3.67335,134.6893,6.6042,7.2,7.02,0.086375216,0.061057408,-0.019742147,-0.015195701,4.0222,0.00258,0.08387
AXGN,$5.95 ,Avance Nerve Graf - (RECON),Severed peripheral nervesÂ ,BLA Filing,5/15/2024,"BLA submitted on May 15, 2024.",46,260.04222,59.5963,5.77,5.95,6.2,0.030719139,0.071877212,-0.019742147,-0.015195701,4.15643,0.08974,0.81598
LLY,$770.05 ,Insulin efsitora alfa (efsitora) - (QWINT-2 and QWINT-4),Type 2 diabetesÂ ,Phase 3,5/16/2024,"Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.",946,694320.6013,26.2437,787.02,771.12,808.45,-0.020409658,0.026865173,0.015561552,0.0361717,0.5674,0.03144,1773.30842
PFE,$28.53 ,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancerÂ ,Phase 1b,5/16/2024,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",,163877.8666,26.3687,28.82,28.92,28.69,0.003463807,-0.004520961,0.015561552,0.0361717,1.10312,0.0212,1159.04946
ARVN,$32.11 ,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancerÂ ,Phase 1b,5/16/2024,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",73,2197.34802,66.8885,32.33,32.11,35.23,-0.006828084,0.085902401,0.015561552,0.0361717,12.65675,0.10887,43.0292
AZN,$76.57 ,Sipavibart (AZD3152) - (SUPERNOVA),COVIDâ€‘19Â ,Phase 3,5/16/2024,"Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.",,188601.5931,21.5588,121.72,121.66,124.04,-0.000493056,0.018880769,0.015561552,0.0361717,0,0.20815,200.648
RHHBY,$32.65 ,CT-388,Obesity and type 2 diabetesÂ ,Phase 1b,5/16/2024,"Phase 1b data reported significant weight loss in healthy adults with obesity compared to placebo, noted May 16, 2024.",,189539.6107,0,0,0,0,#DIV/0!,#DIV/0!,0.015561552,0.0361717,0,0,0
BIIB,$230.04 ,ION582 (BIIB121) - (HALOS),Angelman SyndromeÂ ,Phase 1/2,5/16/2024,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",146,33493.10973,26.2675,235.32,230.04,218.06,-0.022693083,-0.076176036,0.015561552,0.0361717,2.1621,0.18633,215.47341
IONS,$37.62 ,ION582 (BIIB121) - (HALOS),Angelman SyndromeÂ ,Phase 1/2,5/16/2024,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",159,5491.21737,30.8211,39.21,37.62,38,-0.041395992,-0.031345657,0.015561552,0.0361717,5.99709,0.16096,124.67035
TRML,$15.00 ,TOUR006 - (TRANQUILITY),Atherosclerotic cardiovascular disease (ASCVD)Â ,Phase 2,5/16/2024,"Phase 2 dosing initiated, noted May 16, 2024.",25,384.69764,102.2965,15.25,15,13.66,-0.016529302,-0.110107649,0.015561552,0.0361717,12.12055,0.00799,3.20702
BIIB,$230.04 ,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 1/2,5/16/2024,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",146,33493.10973,26.2675,235.32,230.04,218.06,-0.022693083,-0.076176036,0.015561552,0.0361717,2.1621,0.18633,215.47341
IONS,$37.62 ,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS)Â ,Phase 1/2,5/16/2024,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",159,5491.21737,30.8211,39.21,37.62,38,-0.041395992,-0.031345657,0.015561552,0.0361717,5.99709,0.16096,124.67035
ASND,$122.80 ,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphomaÂ ,Approved,5/16/2024,"Approved May 16, 2024.",60,7041.98921,36.801,124.04,122.8,129.44,-0.010047079,0.042613359,0.015561552,0.0361717,6.44529,0.0983,61.86099
BMY,$42.97 ,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphomaÂ ,Approved,5/16/2024,"Approved May 16, 2024.",,89415.38524,23.1178,44.55,44.11,41.54,-0.00992564,-0.069955335,0.015561552,0.0361717,1.3825,0.03278,695.42551
PHIO,$6.59 ,PH-762,Cutaneous Squamous Cell CarcinomaÂ ,Phase 1b,5/16/2024,"Phase 1b data reported that treatment was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth, noted May 16, 2024.",5,3.36296,135.0024,7.2,6.5916,6.9102,-0.088284915,-0.041082445,0.015561552,0.0361717,4.0222,0.00258,0.06625
MLTX,$40.86 ,Nanobody (sonelokimab) - (VELA),Hidradenitis suppurativaÂ ,Phase 3,5/16/2024,"Phase 3 trial VELA initiated, noted May 16, 2024.",64,2569.05767,54.3327,40.69,40.86,39.96,0.004169227,-0.018103408,0.015561552,0.0361717,11.02638,0.05724,9.64807
ATXI,$3.63 ,AJ201,Spinal and bulbar muscular atrophy (SBMA)Â ,Phase 1/2,5/16/2024,"Phase 1b/2 last patient dosed completed, noted May 16, 2024.",3,3.41578,176.0946,3.65,3.63,3.62,-0.005494519,-0.008253142,0.015561552,0.0361717,1.82064,0.01324,0.1657
IVA,$3.65 ,Lanifibranor - (NATiV3),Nonalcoholic steatohepatitis (NASH)Â ,Phase 3,5/16/2024,"Positive recommendation from DMC on May 16, 2024.",95,178.58536,52.8749,3.52,3.41,3.325,-0.031748698,-0.056991316,0.015561552,0.0361717,0,0.09918,0.1428
AMGN,$310.30 ,IMDELLTRA (tarlatamab-dlle),Extensive-stage small cell lung cancer (ES-SCLC)Â ,Approved,5/17/2024,"Approved May 17, 2024.",538,167619.7482,26.7228,314.72,312.47,305.84,-0.00717489,-0.028621265,0.003462083,0.041456714,1.81116,0.02106,616.88515
MRNS,$1.33 ,Ganaxolone - (TrustTSC),Tuberous Sclerosis ComplexÂ ,Phase 3,5/17/2024,"Phase 3 enrollment completed, noted May 17, 2024.",55,4494.90726,40.2005,59.65,59.99,53.57,0.005683733,-0.107504939,0.003462083,0.041456714,0,0.00845,0.53991
AZTR,$5.46 ,ATR04-484,EGFRi-associated rashÂ ,Preclinical,5/17/2024,"Preclinical data reported that treatment reduced IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin,",3,5.24244,230.6059,39.62038,36.36364,38.002,-0.085774258,-0.041704842,0.003462083,0.041456714,1.02826,0.01114,2.1416
LEXX,$3.15 ,DehydraTECH-powered GLP-1 drugs (semaglutide) - (WEIGHT-A24-1),DiabetesÂ ,Preclinical,5/17/2024,"Preclinical trial initiated, noted May 17, 2024.",19,40.58987,140.6186,3.14,3.15,3.12,0.003179653,-0.006389798,0.003462083,0.041456714,1.99575,0.00028,0.88715
ARWR,$24.77 ,Plozasiran (ARO-APOC3) - (CAPITAN),Mixed hyperlipidemiaÂ ,Phase 2b,5/18/2024,"Phase 2b data reported that treatment significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased HDL, across all dose levels at Week 24 in patients with mixed dys",138,3076.4397,79.0301,24.77,24.77,24.88,0,0.004431024,-0.011883487,0.026111144,7.74045,0.18258,0
NNVC,$2.12 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Preclinical,5/20/2024,"Preclinical data reported that NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV in",17,24.98661,90.8918,2.07,2.115,2.23,0.021506205,0.074452978,-0.004268132,0.026111144,0.84828,0.02801,0.39121
DYN,$35.38 ,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1)Â ,Phase 1/2,5/20/2024,"Phase 1/2 data reported that patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splici",142,3081.23178,83.2802,27.68,35.38,31.22,0.245436558,0.120348784,-0.004268132,0.026111144,11.06178,0.125,162.67452
DYN,$35.38 ,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD)Â ,Phase 1/2,5/20/2024,"Phase 1/2 data reported that patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change, noted May 20, 2024.",142,3081.23178,83.2802,27.68,35.38,31.22,0.245436558,0.120348784,-0.004268132,0.026111144,11.06178,0.125,162.67452
BCLI,$8.51 ,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,5/20/2024,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",10,39.73565,169.2925,7.8015,8.505,8.0595,0.086338203,0.032535497,-0.004268132,0.026111144,2.99414,0.10377,0.34736
PLUR,$6.05 ,NurOwn,Amytrophic lateral sclerosis (ALS)Â ,Phase 3,5/20/2024,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",8,32.60219,86.648,6.1,6.05,6.0199,-0.008230499,-0.013218123,-0.004268132,0.026111144,0.7302,0.05488,0.02354
ESPR,$2.48 ,Bempedoic acid - (Japan trial),HypercholesterolemiaÂ ,Phase 3,5/20/2024,"Phase 3 data reported that the percentage change from baseline in LDL-C at Week 12, the primary endpoint, was -25.25%% in the group receiving bempedoic acid placebo group and -3.46% in the placebo gro",201,469.86153,100.8292,2.36,2.48,2.13,0.049596941,-0.102539639,-0.004268132,0.026111144,10.48621,0.23432,14.55998
ARWR,$24.82 ,ARO-RAGE-1001,AsthmaÂ ,Phase 1/2,5/20/2024,"Phase 1/2a trial data presented at ATS reported that after two doses of ARO-RAGE in patients with mild to moderate asthma, serum sRAGE was reduced up to 88% with a mean maximum reduction up to 77%, no",138,3082.64971,78.9099,24.77,24.82,24.88,0.002016536,0.004431024,-0.004268132,0.026111144,7.74045,0.18258,11.02909
AMGN,$312.35 ,TEZSPIRE (tezepelumab-ekko) - (COURSE),Chronic obstructive pulmonary disease (COPD)Â ,Phase 2,5/20/2024,"Phase 2 data presented at ATS reported that a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significan",538,168730.168,26.7323,312.47,314.54,305.84,0.006602789,-0.021446375,-0.004268132,0.026111144,1.81116,0.02106,438.71505
GILD,$66.49 ,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC)Â ,Phase 3,5/20/2024,"Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.",,84593.43289,24.0191,67.72,67.9,65.68,0.002654477,-0.030587092,-0.004268132,0.026111144,1.69843,0.07141,320.47809
SONN,$13.92 ,SON-1010 with Trabectedin - (SB101),Solid tumorsÂ ,Phase 1,5/20/2024,"Additional safety data reported a 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNÎ³ responses, with no evidence of cytokine release syndrome at a",6,5.41558,86.0203,14.72,13.92,13.2,-0.055880458,-0.108990284,-0.004268132,0.026111144,12.8577,0.06649,0.07184
RHHBY,$32.77 ,SON-1010 in combination with atezolizumab - (SB221),Platinum-resistant ovarian cancerÂ ,Phase 1/2,5/20/2024,Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have,,191277.2453,0,0,0,0,#DIV/0!,#DIV/0!,-0.004268132,0.026111144,0,0,0
SONN,$13.92 ,SON-1010 in combination with atezolizumab - (SB221),Platinum-resistant ovarian cancerÂ ,Phase 1/2,5/20/2024,Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have,6,5.41558,86.0203,14.72,13.92,13.2,-0.055880458,-0.108990284,-0.004268132,0.026111144,12.8577,0.06649,0.07184
GRI,$5.59 ,GRI-0621,Idiopathic pulmonary fibrosis (IPF)Â ,Preclinical,5/20/2024,"Preclinical data reported that GRI-0621 was shown to reduce the fibrotic score, inhibit the production of TGFÎ² and VCAM-1 and reduce the immune cell, noted May 20, 2024.",2,1.62302,150.5529,92.82002,95.03002,70.27801,0.023530492,-0.278203402,-0.004268132,0.026111144,0.43047,0.00229,1.09731
KRRO,$54.60 ,KRRO-110 - (REWRITE),Alpha-1 Antitrypsin Deficiency (AATD)Â ,Preclinical,5/20/2024,Preclinical data presented at ATS showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo ge,9,506.30509,95.4233,54.66,54.6,48.85,-0.001098298,-0.112377802,-0.004268132,0.026111144,1.33702,0.00011,2.03587
LRMR,$7.27 ,Nomlabofusp (CTI-1601),Friedreichâ€™s ataxia (FA)Â ,Phase 2,5/20/2024,"Phase 2 clinical hold removed, noted May 20, 2024.",85,463.84066,91.0578,7.38,7.27,7.08,-0.015017347,-0.041499731,-0.004268132,0.026111144,6.12048,0.02682,5.62276
VTVT,$28.21 ,Azeliragon,Refractory to first-line treatment of metastatic pancreatic cancerÂ ,Phase 1/2,5/20/2024,"Phase 1/2 Orphan Drug Designation granted by the FDA on May 20, 2024.",3,180.64116,159.8436,27.9,28.21,27.72,0.011049836,-0.006472515,-0.004268132,0.026111144,0.41543,0.00052,0.26867
ARCT,$30.50 ,Kostaive (ARCT-154),COVID-19 variant vaccineÂ ,Phase 1/2,5/20/2024,"Phase 1/2 additional results demonstrate that two 5 Î¼g doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no",27,821.42069,64.6101,29.78,30.5,30.41,0.023889656,0.020934474,-0.004268132,0.026111144,18.25466,0.29851,9.51335
CSLLY,$92.08 ,Kostaive (ARCT-154),COVID-19 variant vaccineÂ ,Phase 1/2,5/20/2024,"Phase 1/2 additional results demonstrate that two 5 Î¼g doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no",968,134295.9334,0,0,0,0,#DIV/0!,#DIV/0!,-0.004268132,0.026111144,0,0,0
GLUE,$4.30 ,MRT-6160,Autoimmune conditionsÂ ,Preclinical,5/21/2024,"Preclinical data reported that MRT-6160-mediated murine (m)VAV1 degradation prevented disease progression by 85% compared to vehicle (P<0.0001), and also reduced the disease activity index (DAI) score",61,262.59841,109.9002,4.95,4.295,4.18,-0.141936021,-0.16907633,0.001084364,0.034623083,3.13201,0.18288,2.21366
IRWD,$6.78 ,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF)Â ,Phase 3,5/21/2024,"Additional Phase 3 data to be presented at the Digestive Disease Week reported that significantly more apraglutide-patients gained additional days off from PS per week at week 24 versus placebo, noted",162,1077.72929,82.6746,6.42,6.78,5.88,0.054558984,-0.087861356,0.001084364,0.034623083,12.63204,0.00201,15.70096
GILD,$65.89 ,Depemokimab - (SWIFT-1 and SWIFT-2),Severe asthma with type 2 inflammation characterised by blood eosinophil countÂ ,Phase 3,5/21/2024,"Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.",,83833.46243,23.9321,67.9,67.29,63.94,-0.009024397,-0.060090891,0.001084364,0.034623083,1.69843,0.07141,383.63563
CTXR,$0.73 ,Mino-Lok,Catheter related blood stream infection (CRBSI)Â ,Phase 3,5/21/2024,"Phase 3 topline data study met its primary endpoint with a statistically significant improvement in the time to failure event, noted May 21, 2024.",17,131.89155,68.3558,16.495,18.25,15.7975,0.101107775,-0.043205605,0.001084364,0.034623083,7.98581,0.01613,15.84007
PRTC,$29.50 ,VE303 - (RESTORATiVE303),Clostridioides difficile infection (CDI)Â ,Phase 3,5/21/2024,"Phase 3 dosing initiated, noted May 21, 2024.",24,611.92003,46.9567,2.285,2.26,2.26,-0.011001211,-0.011001211,0.001084364,0.034623083,0,0.10067,0.64292
ASLN,$3.84 ,eblasakimab versus dupilumab,human tissue model of chronic obstructive pulmonary disease (COPD)Â ,Preclinical,5/21/2024,"Preclinical data presented at American Thoracic Society results support further investigation of eblasakimab as a potential therapeutic option for COPD, noted May 20, 2024.",2,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),(Invalid Identifier),#VALUE!,#VALUE!,0.001084364,0.034623083,(Invalid Identifier),(Invalid Identifier),(Invalid Identifier)
ONVO,$1.03 ,FXR314 with Tofacitinib,Inflammatory Bowel DiseaseÂ ,Preclinical,5/21/2024,"Preclinical data reported that FXR314 alone improved measures of colon health and colon histopathology similarly to approved IBD therapies tofacitinib and IL-12/23 antagonist, noted May 21, 2024.",1,13.34217,0,0,0,0,#DIV/0!,#DIV/0!,0.001084364,0.034623083,0,0,0
PALI,$5.41 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC)Â ,Preclinical,5/21/2024,"Preclinical data presented at DDW exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human us",9,5.07221,150.3663,5.85,5.41,4.76,-0.078192568,-0.206193993,0.001084364,0.034623083,19.03703,0.04173,0.1657
GRI,$5.39 ,GRI-0124,Systemic Lupus Erythematosus (SLE)Â ,Preclinical,5/21/2024,"Preclinical data reported that it inhibited pro-inflammatory cytokines and signaling pathways in NZBWF1 mice, noted May 21, 2024.",2,1.56451,150.5624,95.03002,91.60452,69.61501,-0.036712226,-0.311212637,0.001084364,0.034623083,0.43047,0.00229,1.32085
GRI,$5.39 ,GRI-0803,Systemic lupus erythematosus (SLE)Â ,Preclinical,5/21/2024,"Preclinical data reported favorable solubility profile, and an excellent bioavailability, noted May 21, 2024.",2,1.56451,150.5624,95.03002,91.60452,69.61501,-0.036712226,-0.311212637,0.001084364,0.034623083,0.43047,0.00229,1.32085
BDRX,$58.25 ,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP)Â ,Phase 2,5/21/2024,"Phase 2 results presented at DDW showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden at 6 months, noted May 21, 2024.",,13.03752,207.6051,317.5,582.5,270,0.606851367,-0.162055859,0.001084364,0.034623083,36.7441,0.05173,292.77557
BHC,â€”,larsucosterol (DUR-928) - (AHFIRM),Alcoholic hepatitis (AH)Â ,Phase 2b,5/21/2024,"Breakthrough Therapy designation (BTD) granted by the FDA, noted May 21, 2024.",369,2402.51852,39.0905,6.5,6.55,6.2,0.007662873,-0.047252885,0.001084364,0.034623083,5.59087,0.12826,18.85395
LLY,$802.05 ,Mirikizumab - (VIVID-1),Crohn's diseaseÂ ,Phase 3,5/21/2024,"Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.",946,723178.5939,26.4651,783.18,803.17,807.86,0.025203843,0.031026222,0.001084364,0.034623083,0.5674,0.03089,3481.33956
XOMA,$25.90 ,RZ402,Diabetic macular edema (DME)Â ,Phase 2,5/21/2024,"Phase 2 study met its primary endpoint, noted May 21, 2024.",12,301.43852,54.1587,25.03,25.9,25.5,0.034167863,0.018603347,0.001084364,0.034623083,2.33185,0.00232,0.22233
RZLT,$3.00 ,RZ402,Diabetic macular edema (DME)Â ,Phase 2,5/21/2024,"Phase 2 study met its primary endpoint, noted May 21, 2024.",90,120.40544,90.4443,2.81,3,3.69,0.065427805,0.272441975,0.001084364,0.034623083,0.7845,0.02002,11.56727
LIPO,$0.73 ,LP-10 (liposomal tacrolimus),Hemorrhagic cystitisÂ ,Phase 2b,5/21/2024,"Phase 2b type C meeting with the FDA resulted in a preliminary agreement to proceed to Phase 2b expected to initiated in 2H 2024, noted May 21, 2024.",4,5.53842,68.7969,6.04,5.8256,4.96679,-0.036142014,-0.195630256,0.001084364,0.034623083,0.42141,0.01103,0.15897
ALGS,$15.96 ,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH)Â ,Phase 2a,5/21/2024,"Phase 2a enrollment completed, noted May 21, 2024",6,49.87317,79.3178,16.7775,15.9625,15.325,-0.049796482,-0.090553221,0.001084364,0.034623083,1.07344,0.14747,0.23945
SANA,$8.30 ,SC379,Secondary progressive multiple sclerosisÂ ,Preclinical,5/21/2024,"Preclinical data published in a paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) â€“ the cells that give rise to the glial support cells of the",237,1838.47414,104.9544,8.63,8.3,7.8,-0.03898899,-0.101120771,0.001084364,0.034623083,11.58027,0.11894,10.65727
IFRX,$1.52 ,Gohibic (vilobelimab) - (PANAMO),COVID-19Â ,Phase 3,5/21/2024,"Phase 3 data shared at ATS 2024 showed that co-administration of vilobelimab with baricitinib or tocilizumab was not associated with safety concerns, noted May 21, 2024.",59,89.50257,78.2632,1.54,1.52,1.46,-0.013072082,-0.053345981,0.001084364,0.034623083,0.22326,0.04854,0.38046
JBIO,â€”,AV-101 - (IMPAHCT),Pulmonary arterial hypertension (PAH)Â ,Phase 2b,5/21/2024,Phase 2b portion of study outcomes shared at the ATS conference showed that baseline characteristics reflect a patient population with significant disease despite treatment with two to three targeted,32,0,0,0,0,0,#DIV/0!,#DIV/0!,0.001084364,0.034623083,0,0,0
RVPH,$1.31 ,Brilaroxazine,Idiopathic pulmonary fibrosis (IPF)Â ,Preclinical,5/21/2024,"Preclinical data shared at ATS reported that interactions with multiple 5-HT targets, particularly 5-HT2B/7 receptors, within the pulmonary tissue, provide an underlying basis for this agent's effecti",68,36.43372,94.2628,1.54,1.305,1.38,-0.165579376,-0.109698917,0.001084364,0.034623083,4.47701,0.01735,1.2585
LYRA,$0.36 ,LYR-220 - (BEACON),Chronic rhinosinusitisÂ ,Phase 2,5/21/2024,"Development paused, noted May 21, 2024.",1,21.66691,301.15,18.65,17.77,16.675,-0.048334504,-0.111935554,0.001084364,0.034623083,0.67874,0.0005,1.71719
AMPH,$43.46 ,Albuterol Sulfate Inhalation Aerosol (AMP-008),BronchospasmÂ ,Approved,5/22/2024,"Approved May 22, 2024.",46,2125.2794,40.7428,41.91,43.46,41.64,0.036316513,-0.006463218,0.02487828,0.045693511,8.1531,0.08162,14.12846
PLRX,$14.18 ,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP)Â ,Phase 2a,5/22/2024,Phase 2a data reported that seven previously identified plasma biomarkers of interstitial lung disease (ILD) progression were significantly modulated in participants with IPF receiving bexotegrast ove,61,855.4203,57.8286,14.59,14.18,12.62,-0.028503841,-0.145053505,0.02487828,0.045693511,12.50717,0.07887,3.83315
RNAC,$25.46 ,Descartes-08 - (AURORA),"Generalized myasthenia gravis (MG), Multiple Myeloma and Autoimmune DiseasesÂ ",Phase 2b,5/22/2024,"Regenerative Medicine Advanced Therapy (RMAT) granted by the FDA, noted May 22, 2024.",26,453.08751,126.2033,24.6,25.46,29,0.03436215,0.164549387,0.02487828,0.045693511,4.40676,0.03004,1.48376
INKT,$1.00 ,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19Â ,Phase 1/2,5/22/2024,"Phase 1/2 data reported that allogeneic iNKT therapy was safely administered with rapid decrease in IL-18 and other inflammatory cytokines, noted May 22, 2024.",4,39.36763,89.9178,9.9,10,9.688,0.010050336,-0.021646751,0.02487828,0.045693511,0.22215,0.04247,0.0879
SRRK,$11.71 ,SRK-439 with apitegromab - (EMBRAZE),ObesityÂ ,Phase 2,5/22/2024,"Phase 2 trial initiated, noted May 22, 2024.",96,933.9201,73.115,12.27,11.71,9.21,-0.046714081,-0.286867408,0.02487828,0.045693511,16.77973,0.01424,11.40688
ABUS,$3.41 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,5/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",191,643.52637,43.1936,3.21,3.41,3.36,0.060441354,0.045670037,0.02487828,0.045693511,3.07634,0.07562,7.42613
BRNS,$2.30 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,5/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",40,89.77626,85.5807,2.1513,2.3,2.09,0.066836812,-0.028908245,0.02487828,0.045693511,0.04873,0.00122,0.02489
CLYD,â€”,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV)Â ,Phase 2a,5/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",,1.02,370.1367,0.03,0.03,0.03,0,0,0.02487828,0.045693511,0,NM,0
INDP,$2.48 ,Decoy 20,Solid tumorsÂ ,Phase 1a,5/22/2024,"Phase 1a first-in-human trial confirms ""Pulse-Prime"" hypothesis targeting stimulation of innate and adaptive immune systems, this data to be presented at ASCO 24, noted May 22, 2024.",1,21.17641,74.3768,65.79997,69.43997,77.27997,0.053843256,0.160815419,0.02487828,0.045693511,0.30224,0.0995,0.24026
BIVI,$4.84 ,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's diseaseÂ ,Phase 2a,5/22/2024,Phase 2a full dataset presented at IAPRD suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worse,7,29.52163,182.7196,48.37,48.42,43.74,0.001033165,-0.100616772,0.02487828,0.045693511,2.0868,0.01306,0.36422
ANL,$12.75 ,Palupiprant (AN0025) + Keytruda - (ARTEMIS),"TNBC, NSCLC, bladder cancer, microsatellite stable CRC and cervical cancerÂ ",Phase 2,5/22/2024,"Phase 2 trial initiated, noted May 22, 2024.",36,470.47842,104.2793,12.75,12.75,8.26,0,-0.434106684,0.02487828,0.045693511,0.03114,0.00053,0.00296
PTIX,$1.80 ,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD)Â ,Phase 1/2,5/22/2024,"Phase 1/2a safety data demonstrated no clinically relevant Adverse Events Reported in the single-dose portion, with the multiple-dose portion to commence, noted May 22, 2024.",,0,0,0,0,0,#DIV/0!,#DIV/0!,0.02487828,0.045693511,0,0,0
KYMR,$35.70 ,KT-621 (STAT6),Type 2 inflammation in allergic diseasesÂ ,Preclinical,5/22/2024,"Preclinical data reported that KT-621 was comparable to a saturating dose of the IL-4RÎ± antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the teste",71,2190.48995,59.8255,35.32,35.7,32.49,0.010701313,-0.083517026,0.02487828,0.045693511,16.14831,0.27002,18.39485
CNTB,$1.68 ,Rademikibart - (Seabreeze STAT Asthma),AsthmaÂ ,Phase 2b,5/22/2024,"Phase 2b data presented at ATS showed that treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24, noted May 22, 2024.",55,92.57044,129.6297,1.77,1.68,1.5999,-0.052185753,-0.101038419,0.02487828,0.045693511,0.05668,0.00037,0.04415
TNGX,$7.09 ,TNG348,"BRCA1/2-Mutant and Other HRD+ Cancers, Solid TumorsÂ ",Phase 1/2,5/23/2024,"Phase 1/2 first patient dosed January 3, 2024. Phase 1/2 discontinued due to toxicity observed in the initial study cohorts. No patient had yet received a combination of TNG348 and olaparib., noted Ma",111,757.54,56.8593,7.39,7.09,6.66,-0.041442394,-0.10400825,0.036910267,0.035447868,10.19008,0.00461,8.68088
CYTO,$1.71 ,Bentrio (AM-301) - (NASAR),Seasonal allergic rhinitis (SAR)Â ,Phase 1,5/23/2024,"Phase 1 data published at in video format showed that the study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score",4,27.41421,121.4821,0.51,0.51,0.46,0,-0.103184236,0.036910267,0.035447868,0,0.00474,0.01193
NNVC,$2.23 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infectionÂ ",Phase 1b,5/23/2024,"Phase 1b trial completed, the company also engaged with Aagami, Inc for partnership developments and licensing opportunities, noted May 23, 2024.",17,26.34522,90.4996,2.27,2.23,2.43,-0.017778246,0.068111426,0.036910267,0.035447868,0.84828,0.02801,0.79282
EVGN,$7.20 ,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of",6,27.86026,52.4132,1.99,2,1.96,0.005012542,-0.015190165,0.036910267,0.035447868,0,0.11493,0.004
BMY,$40.47 ,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinomaÂ ",Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of",,84205.73799,22.6783,42.34,41.54,40.25,-0.019075447,-0.050622262,0.036910267,0.035447868,1.3825,0.03537,516.67282
SUPN,$27.77 ,SPN-817,Treatment-resisted seizuresÂ ,Phase 2,5/23/2024,"Phase 2 interim data reported that 81% of subjects with focal seizures had 30% or more seizure reduction, noted May 23, 2024.",56,1526.63503,36.3314,27.87,27.77,26.57,-0.00359454,-0.047768082,0.036910267,0.035447868,8.76868,0.11794,17.31576
MRUS,$44.07 ,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,",75,2586.36037,49.2683,43.4,44.07,57.3,0.015319838,0.277841183,0.036910267,0.035447868,5.7613,0.29835,71.09584
GMAB,â€”,MCLA-145 with Keytruda (pembrolizumab),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,",661,130727.4937,31.2085,2055,2025,1931,-0.014706147,-0.062237845,0.036910267,0.035447868,0,0.09384,216.03105
BCYC,$23.48 ,BT5528 and OPDIVO (nivolumab),Solid tumorsÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data from ASCO abstract reported that BT5528-related AEs occurred in 91% of patients, of which 22% were Grade â‰¥3, noted May 23, 2024.",69,1004.81188,61.345,21.42,23.48,21.92,0.09182393,0.023074397,0.036910267,0.035447868,6.51743,0.10273,48.69421
BCAB,$2.10 ,Evalstotug (BA3071),Oncology (various)Â ,Phase 2,5/23/2024,"Phase 2 data from abstract reported two treatment related discontinuations with responses in three of eight patients who received evalstotug 350mg(1 CR, 1 PR, 1 unPR), noted May 23, 2024.",58,101.04343,137.7567,2.28,2.1,1.515,-0.082238098,-0.408760004,0.036910267,0.035447868,11.07718,0.29957,1.23228
NKGN,$1.86 ,SNK02,Solid TumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02, noted May 23, 2024.",124,46.29131,194.2951,1.78,1.86,1.57,0.043963123,-0.125537745,0.036910267,0.035447868,2.21258,0.00116,3.53924
FGEN,$1.28 ,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC)Â ,Phase 1/2,5/23/2024,"Phase 1b/2 data from abstract reported a preliminary estimate of median radiographic progression free survival (rPFS) of 10.2 months, noted May 23, 2024.",4,127.32848,163.6463,30.75,32,28.75,0.039845909,-0.067252227,0.036910267,0.035447868,6.95632,0.05229,2.05146
VSTM,$12.18 ,VS-6766 and defactinib - (RAMP 205),Metastatic pancreatic cancerÂ ,Phase 1/2,5/23/2024,"Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r",61,308.46521,64.5026,11.88,12.18,3.99,0.024938948,-1.091065083,0.036910267,0.035447868,3.25902,0.02172,3.76073
IMAB,$1.75 ,Ragistomig (ABL503),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported an overall response rate of 25% at 5 mg/kg, based on 3 partial responses (PR) out of 12 patients with median progression free survival (PFS) of 15.6 weeks, not",81,141.22779,72.1521,1.76,1.75,1.74,-0.005698021,-0.011428696,0.036910267,0.035447868,1.43217,0.15627,0.19121
CGEM,$22.65 ,CLN-619 - (MICA) monotherapy and in combination with pembrolizumab,Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that confirmed partial responses (PR) were observed in 3 patients, noted May 23, 2024.",59,1305.4154,76.0291,23.14,22.65,22.79,-0.02140287,-0.015240879,0.036910267,0.035447868,4.08873,0.12008,13.48887
REGN,$980.57 ,REGN7075 in combination with cemiplimab,Solid TumorsÂ ,Phase 1/2,5/23/2024,"Phase 1/2 updated data to be presented at ASCO on June 3, 2024. Phase 1/2 data from ASCO abstract reported a 6% (n=3) overall response rate (ORR) and 29% (n=15) disease control rate (DCR), noted May 2",105,105789.2877,16.8217,983.8,980.57,969.91,-0.003288589,-0.014219341,0.036910267,0.035447868,1.4588,0.09017,309.59929
MURA,$3.59 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n",17,60.75672,67.8356,3.77,3.59,3.35,-0.048922799,-0.118114656,0.036910267,0.035447868,10.16275,0,0.38631
ALKS,$24.00 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid TumorsÂ ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n",165,4061.31146,37.386,24.21,24,23.21,-0.008711941,-0.042182551,0.036910267,0.035447868,7.61973,0.04095,36.8357
IOVA,$10.26 ,LN-145 - (IOV-COM-202),Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract reported a confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses, noted May 23, 2024.",361,2871.08373,98.7374,10.33,10.26,9,-0.006799443,-0.137827706,0.036910267,0.035447868,17.88762,0.14133,59.13376
HOWL,$5.16 ,WTX-124,Solid TumorsÂ ,Phase 1b,5/23/2024,"Phase 1/1b data from ASCO abstract reported that treatment was well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers, noted May 23, 2024.",45,224.22969,93.9386,4.89,5.16,5.36,0.053744276,0.091771672,0.036910267,0.035447868,0.95383,0.00968,0.67445
CMPX,$1.50 ,CTX-471 (CD137 agonist),Solid tumorsÂ ,Phase 1,5/23/2024,"Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors, noted",138,205.69581,78.8482,1.56,1.495,1.36,-0.042559614,-0.137201122,0.036910267,0.035447868,1.19404,0.03297,0.25523
INAB,$1.04 ,INB-200,GlioblastomaÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO reported no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity, noted May 23, 2024.",4,45.88447,129.8115,31.50003,31.19703,30.90003,-0.0096656,-0.019231343,0.036910267,0.035447868,0.40778,0.00698,0.0253
EVAX,$3.88 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2b,5/23/2024,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",6,20.99487,179.5699,19.05,19.4,17.997,0.018205964,-0.056862024,0.036910267,0.035447868,0.98328,0.01641,0.07265
MRK,$129.46 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic MelanomaÂ ,Phase 2b,5/23/2024,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",,332025.5788,16.7711,131.1,131.09,124.53,-7.63E-05,-0.05141374,0.036910267,0.035447868,0.74044,0.01723,895.47409
AGEN,$12.35 ,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM)Â ,Phase 1b,5/23/2024,"Phase 1b data to be presented at ASCO 2024, ASCO abstract released across different NLM sites, overall response rates (ORR) ranged from 18-33%, and disease control rates (DCR) ranged from 67-82%. Over",31,259.34087,123.6229,11.91,12.35,15.11,0.03627768,0.237978393,0.036910267,0.035447868,15.4211,0.11062,7.41058
MRUS,$44.07 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/23/2024,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",75,2586.36037,49.2683,43.4,44.07,57.3,0.015319838,0.277841183,0.036910267,0.035447868,5.7613,0.29835,71.09584
GMAB,â€”,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 2,5/23/2024,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",661,130727.4937,31.2085,2055,2025,1931,-0.014706147,-0.062237845,0.036910267,0.035447868,0,0.09384,216.03105
AFMD,$4.71 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancerÂ ",Phase 2,5/23/2024,"Phase 2 data due to be presented at ASCO on June 1, 2024. Phase 2 ASCO abstract to be presented showed that of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and",15,71.72135,0,0,0,0,#DIV/0!,#DIV/0!,0.036910267,0.035447868,0,0,0
ZNTL,$11.28 ,Azenosertib and gemcitabine,Relapsed or refractory (R/R) osteosarcomaÂ ,Phase 1,5/23/2024,Phase 1 data from ASCO abstract support further investigation of azenosertib administered in combination with gemcitabine in patients with R/R osteosarcoma in an upcoming investigator-initiated Phase,72,801.02927,70.3117,11.98,11.28,11.97,-0.060207347,-0.000835073,0.036910267,0.035447868,24.64759,0.04105,5.79658
BPMC,$102.39 ,BLU-222 - (VELA),(HR+/HER2-) breast cancer.Â ,Phase 1,5/23/2024,Phase 1 dose escalation data presented at ASCO abstract showed that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting tox,64,6411.3446,0,0,0,0,#DIV/0!,#DIV/0!,0.036910267,0.035447868,0,0,0
SNSE,$1.45 ,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",1,36.36736,84.983,27.2,29,15.1,0.064078857,-0.588522229,0.036910267,0.035447868,0.23975,0.04288,1.26901
REGN,$980.57 ,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancerÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",105,105789.2877,16.8217,983.8,980.57,969.91,-0.003288589,-0.014219341,0.036910267,0.035447868,1.4588,0.09017,309.59929
COGT,$7.49 ,Bezuclastinib and SUTENT (sunitinib) - (PEAK),Gastrointestinal Stromal Tumors (GIST)Â ,Phase 3,5/23/2024,Phase 3 updated data presented at an ASCO abstract showed d that study reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior tre,139,716.14434,148.6761,8.03,7.49,7.29,-0.06961573,-0.096680982,0.036910267,0.035447868,12.59651,0.00118,8.49571
HOOK,$10.40 ,Eseba-vec (formerly HB-200) in combination with KEYTRUDA (pembrolizumab),Head and neck squamous cell carcinoma (HNSCC)Â ,Phase 1/2,5/23/2024,"Phase 2 data due to be presented at ASCO 2024, abstract from updated data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 8",12,130.40363,100.3438,9.8,10.4,7.517,0.05942342,-0.265215263,0.036910267,0.035447868,0.51337,0.16829,1.71901
CADL,$10.69 ,CAN-2409 + valacyclovir,Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/23/2024,"Phase 2 data from ASCO abstract showed that treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic",54,317.97117,225.1874,10.58,10.69,8.62,0.010343299,-0.204880342,0.036910267,0.035447868,3.54595,0.00483,10.79297
ELTX,$8.85 ,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancersÂ ,Phase 2,5/23/2024,"Phase 2 ASCO abstract showed that treatment administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels, noted May",16,90.7641,129.236,8.86,8.85,7.51,-0.001129306,-0.165311299,0.036910267,0.035447868,0.83233,0.00223,0.15996
PBYI,$3.99 ,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC)Â ,Phase 1b,5/23/2024,Phase 1/1b data shared at ASCO abstract showed that intermittent dosing of alisertib 30 mg BID in combination with osimertinib 80 mg daily demonstrated no dose-limiting toxicities and was identified a,50,192.47301,77.9612,4.23,3.99,3.81,-0.058410762,-0.104572804,0.036910267,0.035447868,6.45295,0.07724,1.62452
IPHA,$2.96 ,IPH6501,Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL)Â ,Preclinical,5/23/2024,"Preclinical data from ASCO abstract reported that IPH6501, at well-tolerated doses, significantly boosted peripheral NK cell proliferation, drove their accumulation at tumor locations, and effectively",92,215.84811,71.6335,2.9998,2.96,2.75,-0.013356351,-0.086944708,0.036910267,0.035447868,0,0,0.06977
ALXO,$14.69 ,Evorpacept w/ cetuximab and pembrolizumab,Colorectal cancerÂ ,Phase 2,5/23/2024,"Phase 2 data from the abstract has ORR was 6.3% (1 ongoing partial response, 95% confidence interval [CI] 0.2-30.2%), disease control rate was 12.5% (95% CI 1.6-38.4%), median progression-free surviva",53,765.35057,90.2735,15,14.69,10.65,-0.020883211,-0.342490309,0.036910267,0.035447868,6.07009,0.0751,20.00262
BNTX,$99.00 ,BNT327/PM8002,Non-small cell lung cancer (NSCLC)Â ,Phase 1/2,5/23/2024,"Phase 1b/2 data from ASCO abstract reported a 47% ORR in cohort 6, 19.4% ORR in cohort 7, noted May 23, 2024.",239,23890.54457,33.3241,102.3,99,98.75,-0.032789823,-0.035318269,0.036910267,0.035447868,1.5296,0.08657,153.81729
CUE,$1.74 ,CUE-102,Wilms' Tumor (WT1)-expressing cancersÂ ,Phase 1,5/23/2024,"Phase 1 data from abstract reported that stable disease of â‰¥ 6 weeks (range 6-36 weeks), as determined by RECIST 1.1, has been observed in 10 of 23 patients (DCR 43.5%), noted May 23, 2024.",76,84.63937,95.9008,1.91,1.74,1.59,-0.093218129,-0.183369226,0.036910267,0.035447868,10.19414,0.067,0.279
CUE,$1.74 ,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancerÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that of CUE-101 plus pembrolizumab, an ORR of 47% (1 CR, 8 PRs), a Disease Control Rate (ORR + durable SDs) of 74%, and mPFS of 5.8 months, noted May 23, 2024.",76,84.63937,95.9008,1.91,1.74,1.59,-0.093218129,-0.183369226,0.036910267,0.035447868,10.19414,0.067,0.279
MRK,$129.46 ,Sacituzumab tirumotecan (SKB264/MK-2870) - (OptiTROP-Breast01),Locally recurrent or metastatic triple-negative breast cancer (TNBC)Â ,Phase 3,5/23/2024,"Phase 3 data from ASCO abstract reported an objective response rate assessed by BICR was 43.8% with SKB264 and 12.8% with chemotherapy, noted May 23, 2024.",,332025.5788,16.7711,131.1,131.09,124.53,-7.63E-05,-0.05141374,0.036910267,0.035447868,0.74044,0.01723,895.47409
PFE,$28.30 ,PF-07248144,ER+ HER2âˆ’ breast cancerÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that for the fulvestrant combination (n=43), with median duration of follow-up of 9.2 mos, the ORR was 30.2% (17.2, 46.1), median DOR was 9.2 mos (7.2, NE), CB",,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871
PFE,$28.30 ,Mevrometostat (PF-06821497),Castration-resistant prostate cancer (CRPC)Â ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that the OR rate (95% CI) was 27.3% (10.7, 50.2), including 1 complete and 5 partial responses, noted May 23, 2024.",,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871
PFE,$28.30 ,Elranatamab - (MagnetisMM-9),Multiple MyelomaÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data from ASCO abstract reported that after a median follow-up of 7.4 mo, the most common (>50%) AEs were CRS (63.5%; grade â‰¥2, 15.3%) and neutropenia (54.1%; all grade â‰¥2), noted May 23, 20",,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871
PFE,$28.30 ,Sigvotatug vedotin (SGNB6A-001),Non-small cell lung cancer (NSCLC)Â ,Phase 1,5/23/2024,"Phase 1 data reported in ASCO abstract reported that the cORR was 19.5% (95% CI, 12.6-28.0) in all pts with NSCLC and 32.5% (95% CI, 18.6-49.1) in pts with non-squamous (non-Sq)/taxane-naive NSCLC. Ad",,162574.5502,27.096,29.6,28.69,28.2,-0.031225731,-0.048452383,0.036910267,0.035447868,1.10312,0.0254,1205.87871
MOLN,$3.81 ,MP0317,Solid TumorsÂ ,Phase 1,5/23/2024,"Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.",40,112.32136,51.8882,3.365,3.385,3.5,0.005925943,0.039335005,0.036910267,0.035447868,0,0.05974,0.05838
XLO,$1.07 ,XTX202,Solid TumorsÂ ,Phase 1/2,5/23/2024,"Phase 1/2 data from ASCO abstract reported that the DCR was 62% at the 1.4 mg/kg dose-level and 80% at the 4 mg/kg dose-level, with 19 pts ongoing and awaiting first response assessment, noted May 23,",51,39.49534,142.3294,1.15,1.07,0.9301,-0.072103294,-0.212225114,0.036910267,0.035447868,1.23676,0.00899,0.05665
VSTM,$4.12 ,AVMAPKI FAKZYNJA CO-PACK,Recurrent low-grade serous ovarian cancer (LGSOC)Â ,NDA Filing,5/24/2024,"NDA and accelerated approval application submitted May 24, 2024.",61,104.34127,166.7975,12.18,4.12,3.96,-1.083942099,-1.123551237,0.005500996,0.002129449,3.19708,0.07256,81.22537
IDYA,$37.71 ,Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM),Ocular MelanomaÂ ,Phase 2,5/24/2024,Phase 2 clinical efficacy update presented at ASCO abstract showed that monotherapy neoadjuvant treatment was generally well tolerated. Drug-related adverse events (AEs) were predominantly Grade 1 or,87,2854.14274,39.8969,38.45,37.71,36.55,-0.019433385,-0.05067751,0.005500996,0.002129449,14.64747,0.17227,80.20434
BLRX,$0.69 ,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC)Â ,Phase 2,5/24/2024,"Phase 2 data from ASCO reported that 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control , noted May 24, 2024.",3,193.05336,62.036,0.161,0.161,0.18,0,0.111552486,0.005500996,0.002129449,0,0.00464,0
CHRS,$1.91 ,CHS-114 - (SRF114),Solid tumorsÂ ,Phase 1,5/24/2024,Phase 1 preliminary results from dose escalation in an ASCO abstract shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors,116,219.12616,88.343,2.01,1.91,1.82,-0.05103148,-0.099298221,0.005500996,0.002129449,18.98862,0.05922,2.75926
BCTX,$1.44 ,Bria-IMT - (BRIA-ABC),Advanced breast cancerÂ ,Phase 2,5/24/2024,"Phase 2 data in an ASCO abstract resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double his",1,36.02055,89.9779,214.49989,215.99989,253.49987,0.006968673,0.167054085,0.005500996,0.002129449,0,0,2.85012
CGON,$32.71 ,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBCÂ ,Phase 2,5/24/2024,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.",76,2179.79931,0,29.99,32.71,32.58,0.086816849,0.08283461,0.005500996,0.002129449,4.2295,0.05336,29.0751
MRK,$127.88 ,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBCÂ ,Phase 2,5/24/2024,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.",,327973.0887,16.8929,131.09,129.49,125.54,-0.012280452,-0.043259677,0.005500996,0.002129449,0.80013,0.01813,774.84822
IPHA,$2.90 ,Lacutamab (IPH4102) - (TELLOMAK),"Mycosis Fungoides, SÃ©zary SyndromeÂ ",Phase 2,5/24/2024,"Phase 2 topline results reported that the ORR was 16.8%, with the median time to response was 1.0 months and median PFS 10.2m, noted May 24, 2024.",92,215.84811,71.6667,2.96,2.9013,2.74,-0.020030356,-0.077231348,0.005500996,0.002129449,0,0,0.05026
AZN,$78.06 ,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",,190616.8987,21.5572,124.04,122.96,121.9,-0.008744995,-0.017403058,0.005500996,0.002129449,0,0.18044,113.05779
IPHA,$2.90 ,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",92,215.84811,71.6667,2.96,2.9013,2.74,-0.020030356,-0.077231348,0.005500996,0.002129449,0,0,0.05026
ANL,$10.50 ,AN0025 + Keytruda,Solid tumorsÂ ,Phase 1b,5/24/2024,"Phase 1b data reported that the disease control rate (DCR) was 92% (11/12). The median progression-free survival (PFS) was not reached, with 6-month and 1-year PFS rates of 91% and 73%, respectively,",36,387.45281,106.3347,12.03,10.5,7.26,-0.136028273,-0.505023701,0.005500996,0.002129449,0.03261,0,0.18588
HCM,$18.73 ,Fruquintinib - (FRESCO),Metastatic colorectal cancer (CRC)Â ,Phase 3,5/24/2024,"Phase 3 data reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS and PFS, noted May 24, 2024.",174,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0,0.07989,0.04093
HCM,$18.73 ,Fruquintinib (HMPL-013) - (FRESCO-2),Metastatic Colorectal CancerÂ ,Phase 3,5/24/2024,"Phase 3 data reported at ASCO reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence, with similar magnitudes of benefit for OS (HRs 0.53â€“0.77) and PFS (HRs 0.25â€“0.3",174,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0,0.07989,0.04093
HCM,$18.73 ,HMPL-295,Solid tumorsÂ ,Preclinical,5/24/2024,"Preclinical data from ASCO reported that stable disease with tumor shrinkage was also observed in 2 pts with NSCLC on 50 mg QD and 75 mg QD 2w on/1w off cohort respectively, and 1 pt with pancreatic d",174,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0,0.07989,0.04093
HCM,$18.73 ,Stereotactic ablative radiotherapy (SABR) + fruquintinib and tislelizumab - (RIFLE),Metastatic colorectal cancerÂ ,Phase 2,5/24/2024,"Phase 2 data from ASCO reported 1 CR, 8 PR, 14 SD and 8 PD, noted May 24, 2024.",174,2526.81032,57.7116,3.04,2.96,2.95,-0.026668247,-0.030052345,0.005500996,0.002129449,0,0.07989,0.04093
INCY,$57.31 ,INCB099280,Solid TumorsÂ ,Phase 1,5/24/2024,"Phase 1 data to be presented at ASCO on June 1, 2024, with abstract data reporting that 96.6% of pts had â‰¥1 tx-emergent adverse events, and decreased ctCNA was seen in all complete responders (n=2) an",195,12886.41443,27.5766,57.45,57.31,57.79,-0.002439876,0.005900746,0.005500996,0.002129449,3.35364,0.17017,112.72052
INCY,$57.31 ,INCB057643,Myelofibrosis (MF) and Other Advanced Myeloid NeoplasmsÂ ,Phase 1,5/24/2024,"Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving â‰¥10 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.",195,12886.41443,27.5766,57.45,57.31,57.79,-0.002439876,0.005900746,0.005500996,0.002129449,3.35364,0.17017,112.72052
ALXO,$13.17 ,Evorpacept with PADCEV (enfortumab vedotin-ejfv) - (ASPEN-07),Urothelial Carcinoma (UC)Â ,Phase 1a,5/24/2024,"Phase 1a data from abstract reported an overall response rate (ORR) was 63% (1CR, 9PR), noted May 24, 2024.",53,686.15841,91.4641,14.69,13.17,10.63,-0.109225474,-0.323486798,0.005500996,0.002129449,6.44991,0.0764,6.93825
BNTX,$96.95 ,YL202/BNT326,Locally advanced or metastatic non-small cell lung cancer and breast cancerÂ ,Phase 1,5/24/2024,"Phase 1 data from ASCO abstract reported an ORR of 42.2% (19/45) and disease control rate (DCR) of 93.3% (42/45), noted May 24, 2024.",239,23395.84137,33.4316,99,96.95,100.6,-0.020924468,0.016032408,0.005500996,0.002129449,1.41897,0.07533,120.72718
GMAB,$28.00 ,Acasunlimab (GEN1046/BNT311),Non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data from ASCO abstract reported confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted May 24,",661,124368.6502,31.9785,2025,1926.5,1937,-0.049864815,-0.044429316,0.005500996,0.002129449,0,0.10611,827.3701
CGEN,$2.44 ,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancerÂ ",Phase 1,5/24/2024,"Data from abstract reported an ORR 2/17 (12%); disease control rate [DCR] 5/17 (29%) noted May 24, 2024,",93,218.45367,165.2338,2.27,2.44,2.17,0.072218208,-0.045052664,0.005500996,0.002129449,1.93067,0.04252,1.6432
NUVB,$3.08 ,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC)Â ,Phase 2,5/24/2024,"Phase 2 data from ASCO abstract reported that in TKI-pretreated patients, the ORR was 52% (95% CI: 40, 65) and IC-ORR was 75% , noted May 24, 2024.",342,761.2856,89.9542,3.08,3.08,3.1,0,0.006472515,0.005500996,0.002129449,1.34096,0.14163,2.40615
APLS,$40.61 ,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGNÂ ,Phase 2,5/24/2024,"Phase 2 data from NOBLE study demonstrated a rreduction in disease activity seen at 12 weeks was sustained at one year, 55% of patients showed zero C3c staining intensity, indicating that C3c deposit",126,4928.65519,67.034,39.68,40.61,39.25,0.023167059,-0.010895838,0.005500996,0.002129449,10.37072,0.01872,52.03587
MRK,$124.52 ,KEYTRUDA (pembrolizumab) - (KEYNOTE-522),Triple negative breast cancer (TNBC)Â ,Phase 3,5/28/2024,"Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.",,319361.5473,17.2992,129.49,126.09,128.71,-0.02660772,-0.006041846,0.015314235,-0.026001465,0.80013,0.01813,1294.10996
INSM,$48.06 ,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE)Â ,Phase 3,5/28/2024,"Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.",211,7141.93458,117.8407,22,48.06,57,0.781407777,0.952008814,0.015314235,-0.026001465,6.68184,0.07315,1605.69075
ARCT,$38.41 ,ARCT-032 - (LUNAR-CF),Cystic FibrosisÂ ,Phase 1b,5/28/2024,"Phase 1b data reported that the first four patients had an average improvement of 4% FEV1 after two administrations, noted May 28, 2024.",27,1034.45144,72.3561,30.41,38.41,41.42,0.233546341,0.308992354,0.015314235,-0.026001465,15.33095,0.29737,41.19415
UNCY,$0.84 ,UNI-494,Acute kidney injury (AKI)Â ,Preclinical,5/28/2024,"Preclinical model results of hyperphosphatemia demonstrated the relative potency of OLC Compared to tenapanor, noted May 28, 2024.",17,31.42782,95.6099,9.459,8.35699,8.056,-0.123868355,-0.160549514,0.015314235,-0.026001465,2.28622,0.00439,1.07219
ALLK,$1.39 ,AK006 (IV),Chronic spontaneous urticaria (CSU)Â ,Phase 1,5/28/2024,"Phase 1 trial in CSU initiated, noted May 28, 2024.",90,123.07682,0,0,0,0,#DIV/0!,#DIV/0!,0.015314235,-0.026001465,0,0,0
MRUS,$54.87 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 1/2,5/28/2024,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression",75,3220.18592,66.9549,59.99,54.87,50.36,-0.089211131,-0.174980672,0.015314235,-0.026001465,5.93469,0.18762,211.7205
GMAB,â€”,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid TumorsÂ ",Phase 1/2,5/28/2024,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression",661,124739.8216,31.7145,1955,1934.5,1937.5,-0.010541298,-0.008991711,0.015314235,-0.026001465,0,0.10611,229.69479
VERA,$37.13 ,Atacicept - (ORIGIN 3),IgA NephropathyÂ ,Phase 2b,5/28/2024,"Phase 2b 72-week data reported that participants who switched from placebo to atacicept also demonstrated stable eGFR, as well as similar reductions in Gd-IgA1, hematuria, and UPCR, noted May 28, 2024",63,2031.05619,93.7188,37.11,37.13,39.47,0.000538793,0.061654415,0.015314235,-0.026001465,11.81125,0.06407,39.32112
CORT,$31.61 ,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome)Â ,Phase 3,5/28/2024,"Phase 3 trial met its primary endpoint, noted May 28, 2024.",105,3290.9831,66.1659,27.52,31.61,32.87,0.138560513,0.177647375,0.015314235,-0.026001465,19.01861,0.02973,113.93268
ABBV,$152.69 ,ABBV-400,Colorectal cancer (CRC)Â ,Phase 1,5/28/2024,"Phase 1 preliminary data derived from ASCO abstract showed that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered o",,274309.9011,18.7191,157.06,155.34,162.14,-0.011011635,0.031832262,0.015314235,-0.026001465,0.90198,0.04121,859.56876
ABBV,$152.69 ,ABBV-706,Solid TumorsÂ ,Phase 1,5/28/2024,"Phase 1 data at ASCO abstract demonstrated that among a total of 48 efficacy-evaluable patients (23 SCLC and 25 NEN), the overall confirmed objective response rate was 43.8%. Within the SCLC group, th",,274309.9011,18.7191,157.06,155.34,162.14,-0.011011635,0.031832262,0.015314235,-0.026001465,0.90198,0.04121,859.56876
AZN,$76.15 ,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC)Â ,Phase 3,5/28/2024,Phase 3 trial data reported numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small,,186462.2688,21.6426,122.96,120.28,124.04,-0.022036741,0.008744995,0.015314235,-0.026001465,0,0.18044,264.24277
NVS,$99.68 ,Vanrafia (atrasentan),Proteinuria reduction in primary IgA nephropathy (IgAN)Â ,Phase 3,5/28/2024,"Phase 3 data reported a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks, noted May 28, 2024.",,1489.34759,56.9763,4.5,4.8,5.24,0.064538521,0.152244102,0.015314235,-0.026001465,0,0.00131,0.04877
NVS,$99.68 ,Fabhalta (iptacopan),C3 glomerulopathy (C3G)Â ,Phase 3,5/28/2024,"Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted",,1489.34759,56.9763,4.5,4.8,5.24,0.064538521,0.152244102,0.015314235,-0.026001465,0,0.00131,0.04877
PROK,$3.71 ,RMCL-002 - (REACT),"Type 2 diabetes, prevent/delay CKDÂ ",Phase 2,5/28/2024,"Phase 2 full results reported that patients s randomized to the deferred treatment arm experienced less decline in kidney function after rilparencel treatment versus standard of care , noted May 28, 2",294,237.15518,127.4935,3.37,3.71,3.21,0.096119132,-0.048641807,0.015314235,-0.026001465,15.47241,0.05632,2.20729
VANI,$1.66 ,OKV-119,ObesityÂ ,Preclinical,5/28/2024,"Preclinical data of proof-of-concept study in felines showed that a single OKV-119 implant effectively delivered therapeutic exenatide levels for the intended 3-month duration, achieving weight loss i",59,91.26425,204.7053,1.67,1.66,1.64,-0.006006024,-0.018127385,0.015314235,-0.026001465,1.23833,0.00329,0.96203
SRRK,$10.33 ,SRK-181 - (DRAGON),Solid TumorsÂ ,Phase 1,5/28/2024,"Phase 1 data from abstract continued to showed that study continues to be well tolerated in the dose expansion portion of the DRAGON trial (Part B), noted May 28, 2024.",96,823.85949,73.8471,10.67,10.33,9.8,-0.032383782,-0.08505368,0.015314235,-0.026001465,16.7081,0.01576,9.82309
XENE,$38.61 ,azetukalner (XEN1101) - (X-NOVA),Major depressive disorder (MDD)Â ,Phase 2,5/28/2024,"Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs",77,2913.85357,36.2397,38.37,38.61,38.1,0.006235406,-0.007061622,0.015314235,-0.026001465,3.73431,0.07207,12.78844
NRXP,$3.83 ,NRX-101,Bipolar Depression and Suicidal IdeationÂ ,Phase 2/3,5/28/2024,Phase 2b/3 trial results evaluating NRX-101 versus lurasidone in bipolar depression with suicidal ideation/behavior at ASCP 2024. The data showed NRX-101 achieved similar efficacy to lurasidone on dep,19,41.07672,158.3099,3.95,3.83,3.54,-0.030850776,-0.109588852,0.015314235,-0.026001465,4.54899,0.0629,0.51177
JAGX,$4.03 ,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio choleraeÂ ,Phase 1,5/28/2024,Phase 1 nnounced results from an investigator-initiated study showing that crofelemer led to statistically meaningful reductions in abdominal pain/discomfort and improved stool consistency compared to,2,19.70358,203.8104,115.75,100.75,98.5,-0.138790492,-0.161376145,0.015314235,-0.026001465,4.33199,0.00364,5.4802
APRE,$5.19 ,ATRN-119 - (ABOYA-119),Solid tumorsÂ ,Phase 1/2,5/28/2024,Phase 1/2a Safety Review Committee has approved opening enrollment for the 800mg once daily dosing cohort after reviewing favorable safety and pharmacokinetic data from the 550mg cohort. Initial signs,5,28.18282,95.7617,5.299,5.19,4.78,-0.020784426,-0.103077577,0.015314235,-0.026001465,0.59581,0.08002,0.1019
NLSP,$6.98 ,KO-874,Sleep and wakefulness disordersÂ ,Preclinical,5/28/2024,"Preclinical results results suggested that mazindol may modulate the orexin system through direct or indirect mechanisms. While lower 1 mg/kg doses were not effective, the dose-dependent response and",3,7.00484,124.7266,6.96,6.98,5.428,0.002869442,-0.248608732,0.015314235,-0.026001465,0.11307,0.00759,0.8827
AZN,$76.15 ,IK-930,"Solid tumors, non-small cell lung cancerÂ ",Phase 1,5/28/2024,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",,186462.2688,21.6426,122.96,120.28,124.04,-0.022036741,0.008744995,0.015314235,-0.026001465,0,0.18044,264.24277
IMA,â€”,IK-930,"Solid tumors, non-small cell lung cancerÂ ",Phase 1,5/28/2024,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",4,0,0,0,0,0,#DIV/0!,#DIV/0!,0.015314235,-0.026001465,0,0,0
IKNA,$1.33 ,IK-930,"Solid tumors, non-small cell lung cancerÂ ",Phase 1,5/28/2024,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",48,64.18328,0,0,0,0,#DIV/0!,#DIV/0!,0.015314235,-0.026001465,0,0,0
TELO,$6.23 ,Telomir-1,Age-related conditionsÂ ,Preclinical,5/28/2024,"Preclinical canine study dosing initiated, noted May 28, 2024.",32,184.46914,0,6.74,6.23,5.28,-0.078683592,-0.244133827,0.015314235,-0.026001465,0.13454,0.03581,0.48273
VTGN,$3.96 ,Fasedienol (PH94B) - (PALISADE-2),Social Anxiety Disorder (SAD)Â ,Phase 3,5/29/2024,Phase 3 results presented at the American Society of Clinical Psychopharmacology Conference reported that a single dose of fasedienol prior to a stressful PSC reduced anxiety levels as measured by SUD,30,107.01983,64.8884,4.06,3.96,3.9,-0.024938948,-0.04020642,0.001909148,-0.054474586,3.91512,0.00162,0.44107
AFMD,$4.02 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancerÂ ",Phase 2,5/29/2024,"Fast Track Designation granted May 29, 2024.",15,61.2144,0,0,0,0,#DIV/0!,#DIV/0!,0.001909148,-0.054474586,0,0,0
